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Basic and application-oriented research is carried out by the Institute of Bioinorganic and Radiophar- 
maceutical Chemistry as part of the research centre ~~rcchungszentrurn Rossendorf (FZR), a member 
of the research association Wi~enschafisgemeinsch~fi Gottfried Wilhelm Leibnitz. 
Committed to research into essential problems ~f our time, the Institute ~ O C U S ~ S  On investigations into 
radiotracers as molecular probes in Order to contribute to a better understanding 0f chemical proc- 
esses in the living organism on a nanomolar arid picomolar level. The all-embracing theme is the 
search for radionuclide-labelled tracer molecules which bind to specific targets in the body. 
When further developed into radiopharmaceuticals, the radiotracers permit medical research as well 
as diagnostic applications. Studies are performed in close cooperation with the Department of Nuclear 
Medicine of the Dresden University Hospital. For this purpose the Institute runs a centre for positron 
emission tomography (PET). A joint team of staff members from both the Institute and the Department 
of Nuclear Medicine work at this PET centre. 
The reports presented here Cover interdisciplinary research activities. The PET tracer group of the 
Institute studied the chemistry and radiopharmacy of "C and "F compounds. The bioinorganic group 
has dealt with the design, synthesis and characterization of radiometal-based radiotracers, prirnarily 
technetium and rhenium complexes. The biochemical group worked on the biological characterization 
of new radioactive compounds in cell and animal models and also On pharmacological and patho- 
physiological themes. Some first contributions from the joint medical group are also included in these 
reports. 
The main research activities of the Institute were devoted to radiochemical and pharmacological stud- 
ies of brain neurotransmitter-mediated processes and tumour targeting. 
Wiih respect to oncology, Progress in tracer development is highlighted by the proposed concept of 
using 3-U-rnethy~~- [ "~ ] f luoro-~-~0~~ for imaging brain tumours. Derived from biological studies of 
6 - [ ' s ~ ] f l u o r o - ~ - ~ ~ ~ ~  metaboliies and the development of an improved synthesis of 3-Crmethyl-6- 
[ ' 8 ~ u o r o - ~ - ~ ~ ~ ~ ,  the compound proved to be a substrate of an amino acid transporter and thus 
ablie to Cross the blwd-brain barrier with subsequent accumulation in brain tumours. 
In 1998 a European Biorned project started on twrnour-seeking receptor-binding peptides. The neuro- 
tensin molecule has meanwhile been modified and radiolabelled so as to maintain a high receptor- 
binding affinity. The structure is now being optimized in terms of optimal biodistribution by the groups 
collaborating on the project. 
The main subject of CNS receptor ligand research at this moment is to design technetium-based 
malecules that are able to overcome the serious hurdle presented by the blood-brain barrier and to 
achieve high, subnanomolar binding affinities. During the period covered by these reports, studies of a 
farge number of neutral mixed-ligand complexes confirrned the importance of the pKa value for trans- 
port of this class of compounds through the blwd-brain barrier and showed how the pKa can be ad- 
justed by appropriate substituents without impairing the receptor binding. 
The requirement of subnanomolar affinity was met by the synthesis and autoradiographic evaluation of 
a novel 9 9 m ~ ~  ligand for the serotonin 5-HT, receptor. 
The metallotricarbonyl concept, which was quite recently introduced by the chelator chemistry group of 
the Paul Scherrer Institute (PSI), Switzerland, in the design of CNS receptor irnaging agents based on 
technetium-99m, was successfully applied in cooperation with the PSI group. Ligands for the 5-HTZA 
and 5-HfiA receptors as welt as the dopamine transporter were prepared and characterized. 
The succecces a c h i i  so far have only been possible thanks to the dedication and commitment of 
the permanent and temporary staff, the Ph.D. students and coliaborators inside and outside the re- 
search centre Forschungszentrum Rossendorf. 
I would like to extend my thanks to all of them. 
Rousendorf, September 1999 
I. EDITORIAL 
Editorial 
Radiotracers for Tumour lmaging with Positron Emission Tomography 
P. Brust, J. Steinbach and B. Johannsen 
Positron emission tomography (PET) is a unique non-invasive diagnostic 
lntroduction 
tool offering the possibility of 
in vivo quantitative measurements. Depending on the radiotracer used it produces dynamic images of 
various physiological functions at the molecular level which can be used to quantify vital processes, 
such as glucose metabolism, blood flow and perfusion, receptor-ligand interactions and oxygen utili- 
zation. So far PET studies have made substantial contributions to at least four clinical disciplines: car- 
diology, neurology, psychiatry and oncology. 
A rapidly emerging clinical application of positron emission tomography (PET) is the detection and 
staging of Cancer with the glucose analogue 2-['8~]fluoro-2-deoxy-~-glucose (FDG). Early diagnosis in 
oncology is helpful for treatment by surgical intervention, which generally has the highest curative 
potential. Anatomic imaging modalities, such as C i  and MRI, are clinically important high-resolution 
imaging techniques that are well suited for revealing structural abnormalities. However, the differentia- 
tion of neoplasms as being benign or malignant is still problematic. PET can reveal biochemical pa- 
rameters of the neoplasms such as glucose, oxygen, or amino acid metabolism, or measure the re- 




Fig. 1. Uptake and metabolism of glucose compared with FDG. After being transported into the cell 
glucose is metabolized via the glycolytic pathway to provide energy in form of ATP. The FOG is only 
phosphorylated and trapped because the activity of glucose-6-phosphatase is much lower than the 
activity of the hexokinase. 
FDG for tumour imaging 
PET using FDG as a metabolic marker has the potential to distinguish malignant processes from nor- 
mal tissue by means of increased glucose metabolism (Fig. 1). Its higher spatial resolution compared 
with conventionat ccintigraphic methods ieads to the widespread application of FDG-PET in ancology. 
Functional imaging with FDG-PET provides relevant diagnostic information complementary to mor- 
phologic imaging. 
Knowledge of the normal physiological distribution of the radiotracer is required for the correct inter- 
pretation of FDG PET images. It has to be assured that benign pathological causes of FDG uptake are 
not confused with a malignant tumour. In a whole-body scan intense FDG activity can be seen in the 
brain, occasionally in the heart and due to the excretory route the urinary tract. Elsewhere, radiotracer 
activity is typically low. That allows sensitive demonstration of radiotracer accumulation in many tumor 
entities (Fig. 2). However, as a limitation one has to be aware that FDG uptake is nonspecific, which is 
related to the principle of FDG uptake and metabolism (Fig. 1). This offers the possibility of pitfalls that 
can be misinterpreted as cancer. Such pitfalls include variable physiological FDG uptake in various 
Organs, in healing bones, sites of infection and aseptic inflammatory response [I]. 
Fig. 2. FDG-PET image of a 
patient with tumour bulk and 
singular metastases of Hodg- 
kin's lymphoma in the medias- 
tinum as well as metastases in 
the lower part of the right lung. 
FDG accumulation is seen in 
the brain, heart and bladder as 
well. 
The clinical value of FDG-PET has been proved for a number af tumour entities and their metastases, 
e.g. bronchial, colorectal and pancreatic malignomas, nonsmall cell lung carcinomas, breast cancer, 
malignant lymphomas and others. General@, FDG-PET can be very useful in clinically and radiologi- 
cally "difficult-to-examine tumours," e.g., following tumour surgery. Qualitative assessment of the ex- 
tent of the tumour spread provides prognostic information and allows for selection of an appropriate 
therapy. The identification of tumour spread to the axillary nodes or to more remote nodal groups, i-e., 
internal mammary or supraclavicular nodes, is probably the most practical information that qualitative 
FDG-PET can offer. For routine use in oncology a detailed assessment of the specific efficiency of 
PET has been indicated by a panel of recognized experts in the framework of an interdisciplinary con- 
sensus conference [2]. 
in the PET Center Rossendorf a total number of 484 tumour patients were studied between 1. Jan. 
1998 and 30. Jun. 1999, among them 20 % with iymphoma and 20 % with squamous cell carcinoma 
as those with the highest incidence. Preliminary studies indicated that an early serial assessment of 
tumour metabolism by FOG-PET during an effective chemo- or radiotherapy may predict the subse- 
quent response to such a therapy. (Fig. 3). 
Another Iimitation of tumou~ imaging with FDG is the difficult visualization of gliomas because of the 
high uptake of thic radiotracer in the normal brain. Also for imaging neuroendocrine tumours FDG-PET 
is oniy of limited vatue [3]. 
From this point of view it would be most useful to develop radiotracers utilizing tumour specific proc- 
esses. Unfortunately the prerequisites for exploiting such processes are poor. The radiotracer accu- 
rnulation caused by such targeted processes is usually low and the quality of the images may there- 
fore be unsatisfactory. 
Before After chemotherapy 
Fig. 3. FDG-PET image of a patient with abdominal metastasis of a seminoma (left). After completion 
of chemotherapy, with [ ' 8 ~ ] ~ ~ ~ - ~ ~ ~  no vital tumour is detected, although on CT residual tumour is 
still present. 
To overcome this problem new radiodiagnostic tools for tumour imaging have to be considered. There 
are numerous new radiotracers whose particular distribution in the presence of Cancer in vivo serves 
to distinguish medically relevant properties of the tumour cells with which they associate. These radio- 
tracers include precursors of protein anabolism (e.g. amino acids), receptor ligands (e.g. peptides and 
steroids), substrates for enzymatic modification by the products of expression of specific genes (e.g. 
gancyclovir) and hypoxia markers (e.g. misonidazol). 
Amino acids for brain tumours 
New trends in PET applications for the study of brain tumours take the histological heterogeneity of 
these tumours into account and integrate PET data into their surgical management. The annual inci- 
dence of primary brain tumours is increasing. The prognosis for these tumours remains pmr, with an 
expected survival of oniy a few years. The ability to diagnose, monitor, and treat CNS tumours has 
been improved by newly developed radiotracers for PET such as amino acid radiotracers. 
The increased utilizaa'on of amino acids by tumours has been investigated for more than 40 years. 
Parameters such as membrane transport, metabolisrn and protein incorporation goversl the fate of the 
amino acids in living tissue. The possibiiities offered by PET of studying the amino acid metaboiism 
and protein synthesis have been evaluated within the framework of the European Cornmunity Medical 
and Public Health Research [4]. 
1 - A m i n o - 3 - ~ 8 ~ l u o r ~ y ~ I & u t i , ~ 1 ~ a r b ~ x y c  cid, r"FACBq111 
Fig. 4. '8~-labelled arnino acids developed and evaluated as tumour-detecting PET tracers. 
L-["~l~ethionine has already proved to be useful in delineating brain tumours [5, 61. However, this 
radiotracer has the disadvantage of a short half-life, which requires in-house radiosynthesis and re- 
peated radiolabelling for each single PET study. An "F-labelled arnino acid tracer is therefore desir- 
able for PET (Fig. 4). A number of such radiotracers have been developed and evaluated as tumour- 
detecting agents, e.g. 2-['8~]fluoro-~-tyrosine [i'], 4-['8~]fluoro-~-phenyl;alanine [8], 3-['8~]fluoro-~-a- 
rnethyl-tyrosine (FMT) [9], 0-['8~]fluoroethyl-~-tyrosine (FET) [I01 and 1-arnin0-3-['~F]fluoro- 
cyclobutane-1-carboxylic acid (FACBC) [I I]. 
COOH 
3@Mdhyl-&f'*~1uorddDOPA 
Fig. 5. The amino acid 3-~meth~l-6-['~~]fluoro- 
L-DOPA which may be used for tumour imaging 
with PET as proposed by the Rossendorf group 
n21. 
Rather ineffective radiosynthesis still lirnits the use of these radiotracers. An efficient synthesis of 3 - 0  
r n e t h y l - 6 - ~ 8 ~ ] f l u o r o - ~ - ~ ~ ~ ~  has therefore been developed in Rossendorf (Fig. 5). Some first in vivo 
studies dernonstrate the suitability of this radiotracer for turnour imaging [1 21. 
Tumour receptor imaging 
Turnour receptor imaging has great prospects for further PET investigations. The best-characterized 
Systems for receptor-based irnaging are estrogen-receptor irnaging of breast cancer, cornatostaün- 
receptor imaging of neuroendocrine turnours, and epidermal growth factor receptor imaging. The latter 
two Systems are only available for SPECT. 99m~c-labelled antihurnan epidermal growth factor receptor 
antibodies has been used in patients with turnours of epithelial origin [13-151. The '3'1-labelled epider- 
mal growth factor (EGF) has been used to localize squarnous lung carcinorna with SPECT [16]. EGF 
is also a potential peptide radiopharrnaceutical for the detection of brain turnours as rnany human 
gliornas overexpress the EGF receptor. For this purpose ["'I~IDTPA-EGF was coupled to a delivery 
vector to enable brain turnour irnaging [17]. Because of the higher spatial resolution PET imaging has 
an even greater potential. However, no suitable PET tracers are available so far. 
Peptides 
Bioactive peptides, such as peptide horrnones, imrnunomodulators and growth prornoters, have been 
found to rnodulate a wide variety of biological functions. Their effects are rnediated by high-affinity 
receptors located on the rnernbranes of the target cells. The widespread expression of high-density 
peptide receptors on the surface of turnour cells, which was recently dernonstrated, rnakes these bio- 
rnolecules attractive vectors for targeting those cells. Peptides may be used as tools for directing ra- 
dionuclides for either diagnostic or therapeutic purposes specifically onto rnalignant celjs. The devel- 
oprnent of the sornatostatin analogue ["'ln]octreoscan illustrates how advances in basic science are 
translated into health care [ I  8, 191. 
99m 123 Despite successful labelling of peptides with "'In, Tc, I and occasionally with 18F 13, 18, 20-261 
only a few of them have proved suitable for tumour receptor imaging. No PET tracer has as yet fulfilled 
the necessary criteria. Despite a high in vitro binding affinfty, certain unfavourable features (a high 
nonspecific binding in vivo, rapid degradation, unacceptable accurnulation in nontarget areas) pre- 
vented thern frorn being useful. 
One of the projects described in this annual report deals with the development of '8~-labelled neuro- 
tensin analogues for tumour imaging. The work is ernbedded in a BlOMED2 shared-eost action with 
five other Partners from European countries, which will hopefully ensure that the problems described 
can be solved. 
Steroids 
The use of PET with the estrogen analogue 16a-~8~]fluoroestradiol (FES) to rnonitor the receptos 
function and response to hormonal therapy Opens up intriguing new ways to rnonitor patients with 
breast cancer at a cellular level. Generaliy, 18~-labelled estradiol derivatives are suitable for in viv0 
irnaging of estrogen receptors, including functional receptor diagnosis. Their high specificity, estab- 
lished in animal experiments and in in vitro studies was reproduced in in viVo appiications in humans. 
However, estrogen receptor scintigraphy is oniy of lirnited use for turnour Screening or staging be- 
cause only 50 - 70 % of mammary carcinomas are receptor positive [27J. 
On the other hand, targeting the progesterone receptors found in seceptor-positive breast cancer pro- 
vides a means of diagnosing the disease non-inwasiveiy. The advantages of vicualizing the turnour 
through targeiing &ese receptors include PET imaging to follow the Progress of the tamoxifen therapy 
while the estrogen receptors are blocked [28j. 
Another therapeutic strategy is based on the assumption that the major source of estrogens in breast 
cancer cells is the conversion of estrone sulphate and dehydroepiandrosterone sulphate into estradiol 
and androstendioi by the enzymes estrone sulfatase and 17ß-hydroxysteroid dehydrogenase 129. 301. 
These estrogenic steroids deiivered by the sulphated transport form act as mitogens to stirnulate tu- 
rnour growth 130, 311. Inhibition of estrone sulfaphase is therefore expected to inhibii &so tumour 
growth. The concept has already proved its worth in vitro [29]. Highiy potent estrone sulfaphase in- 
hibitors were recently developed in cooperation with the Jena Hans Knöll Institute. They offer the po- 
tential of turnour irnaging after labelling with '*F [33]. 
Hypoxia markers 
Hypoxia occurs to a varying extent in a vast rnajority of rodent and human solid turnours. It results 
frorn an inadequate and disorganized tumour vasculature, and hence an impair4 oxygen delivery. A 
probe for the non-invasive detection of turnour hypoxia could be very useful in the selection of patients 
for therapy. Tumour hypoxia is an irnportant factor that lirnits the response to radiation in human can- 
Cers [34, 351. In addition, hypoxic turnor cells are also resistant to sorne cytotoxic drugs 135, 361. Ni- 
troirnidazoles and other compounds were designed to overcorne the hypoxic cell problern by specifi- 
cally sensitizing hypoxic cells to the effects of radiation. There has been considerable interest in im- 
aging hypoxia with radiolabelled derivatives of these cornpounds. A fluorinated 2-nitroirnidazole, N-(2- 
hydroxy-3,3,3-trifluoropropyl)-2-(2-nitrl-imidazolyl) acetarnide (SR 4554, CRC 94/17), was rationally 
designed for the measurernent of turnour hypoxia by magnetic resonance spectroscopy (MRS) and 
irnaging (MRI) 1371. Whole body "F-MRI in rnice dernonstrated that SR 4554 and related rnetabolites 
were rnainly concentrated in tumour, iiier and bladder. But rather high doses had to be administered, 
which rnay prevent the use of SR 4554 in hurnans on account of the possible toxiciiy. However, this 
cornpound also has a potential for use in positron emission tornography. 
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Fig. 6. Simultaneous investigation of P-glycoprotein (Pgp) expression and glucose metabolism in 
turnour cells. 
Left Schernatic representation of the principles: Uptake of MIBI and tetrofosrnin is caused by diffusion 
driven by the negatively charged rnernbranes of mitochondria. Excess of cytostatics saturates the 
capacity of Pgp and results in decreased efflux and intracellular accurnulation of the radiotracers MlBI 
and tetrofosmin. FDG is transported into the cell by a glucose transporter (glut) and is phosphorylated 
by hexokinase. The phosphorylated product is trapped within the cell. Effects of cytostatics on glucose 
metabolisrn are shown by increased or decreased accurnulation of glucose phosphate. 
Righf: Effects of various drugs on the accurnulation of MIBI and FDG by a Pgp expressing brain en- 
dothelial celI line. The typical effect of Pgp rnodulators. such as veraparnil and colchicine is shown by 
the increased accumulation of MIBI. Other compounds (cytochalasin B, valinornycine) influence pri- 
rnarily gfucose transport and metabolisrn. 
Several irnidazole derivatives have already been labelled with 1 8 ~ ,  such as ~ 8 ~ ~ f l ~ ~ r ~ r n i s ~ n i d ~ e  
(FMISO), ~8~]fluoroerythronitroirnidazole (FETNIM) and C'8~]fluoroethanidazole [38-401. Despite en- 
couraging prelirninary results these cornpounds are expected to be of lirnited use in routine clinical 
practice [35]. 
Monitoring drug resjstance 
Cellular resistance to cytotoxic agents is the major cause of treatment failure in many human cancers. 
Overexpression of the P-glycoprotein (Pgp), present in the plasma membrane of various tumour cells 
and in several normal cell types, contributes to the multiple drug resistance (MDR) phenotype of many 
human cancers (Fig. 6). The expression of Pgp has to be studied as a prerequisite for the therapy. 
Available clinical radiopharmaceuticals to sctdy the expression of Pgp include the lipophilic 9 9 m ~ ~  ca- 
tions MlBl and tetrofosmin [41-431. 
Many clinical studies from various institutions and trials, including a variety of malignancies, indicate 
that both tumour uptake and clearance of [ g Q m ~ ~ ] ~ ~ ~ ~  are correlated with Pgp expression and may be 
used for the phenotypic assessment of MDR 1441. There is still a lack of PET tracers suitable for clini- 
cal monitoring of multiple drug resistance. Recently the Pgp function was measured in vivo with PET 
and flC]verapamil as radiolabelled Pgp substrate in rats having a Pgp-negative small-cell lung carci- 
noma and its Pgp-overexpressing subline [45]. These results show the feasibility of in vivo Pgp func- 
tion measurement with PET under basal conditions and after modulation in solid tumours and in the 
brain. PET and radiolabelled Pgp substrates may therefore be useful as a clinical tools for selecting 
patients who might benefit from the addition of a Pgp modulator to MDR drugs. 
As was recently shown in cell culture and animal experiments, the combined use of various radiotrac- 
ers may be a tool for differentiating between individual tumours in terms of their sensitivity to thera- 





Fig. 7. Schematic representation of the principle of monitoring gene therapy with radiolabelled nucleo- 
side analogues that are not substrates for human kinases but are converted by 
herpes simplex virus thymidine kinase (HSV-TK) and subsequently by cellular 
kinases to antimetabolites (inhibitors of DNA synthesis). 
Tumour therapy 
One of the most promising new treatments for cancer are gene therapy approaches. Phase lfll clinical 
trials for brain, breast, colon and other tumours are under way 147-491. Cancer gene therapy hdudes 
gene detivery to tumour cells and the cellular expression of the specific transferred gene. Assessing 
the distribution and duration of gene expression is of prime importance for evaluating new gene ther- 
apy approaches, and PET provides a trernendous potential for improvernent over the currently used 
methods of monitoring gene transfer [35]. 
The herpes simplex virus thymidine kinase 1 ganciclovir systern is one of the most widely investigated 
gene therapy approaches which has also been used for PET imaging (Fig. 7) [50, 511. Several radio- 
tracers have been developed for this purpose (Fig. 8) [52-591. Generally, the in vitro and in vivo results 
obtained with these radiotracers demonstrated the validity of the concept. However it has been shown 
that the use of radiolabelled acyclovir and ganciclovir has lirnitations such as a poor sensitivity [51]. 
Other cornpounds lack selectivity. To overcorne these problems, new radiotracers have to be devel- 
oped. One of the most recent approaches is the synthesis and biological evaluation of [ ' 2 4 1 ] ~ ~ ~ ~  [60]. 
However, this radiotracer is only available on a lirnited number of sites, which cornplicates its routine 
use and encourages the search for other cornpounds. 
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Fig. 8. Radiolabelled nucleoside analogues as potential irnaging agents for rnonitoring gene therapy 
with herpes simplex virus thyrnidine kinase gene. 
Another strategy for tumour therapy which was developed by the GSI Darrnstadt with the support of 
the Rossendorf Research Center 161-651 is radiotherapy with heavy ions. Bearns of heavy ions such 
as carbon make it possible to cornbine two advantageous properties: beller targeting and higher bio- 
logical efficiency. Particfe bearns have an inverse depth dose profile, with the maximum dose in the 
deep-seated tumour, a finite range, srnall lateral scattering, and a drastically increased biological effi- 
ciency in the turnour. These properties rnaxirnize the deletion effects on tumour cells [%I. In addition, 
partiefe beams can be directed with great precision within one or two millimetres, and can be rnoni- 
tored using positron emission tomography (PET). 
In conclusion it can be said that PET has already been shown to contribute significantly to tumour 
research and clinical oncology. The development of new target-based imaging tools will provide even 
better possibilities for diagnosis and therapy in this field. 
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II. RESEARCH REPORTS 
TUMOUR AGENTS AND TUMOUR DIAGNOSIS 
1. Preparation of 3-0-Methy1-6-['~F'J~Iuoro-~-DOPA 
F. Füchtner, J. Steinbach, R. Lücke, C. Smuda, B. Johannsen 
lntroduction 
Since the middle of the ia990s we have been dealing with studies related to the dopaminergic System. 
6 - E ' 8 ~ ] ~ l u o r o - ~ - ~ O ~ ~  ([ FIFDOPA) was used as a radiotracer in our PET studies. In the analysis of 
the PET data 3-0-methyl-['~F]fluoro-~-~0~~ ( [ 1 8 ~ ] ~ ~ ~ ~ )  has to be treated as one of the main 
metabolites [I]. For simplification of the compartment model we synthesized and studied ["F'JoMFD. 
The substance is known to be rather stable in vivo [I]. 
By its chemical structure ~ 8 ~ ] ~ ~ ~ ~  belongs to the group of amino acids and shsuld have the 
potential of tumour affinity. Amino acids labelled with positron-emitting radionuclides play an important 
role as radiotracers in tumour imaging [2, 3, 41. Some useful '8~-labelled amino acids for tumour 
imaging are known [4, 5, 6, 71. Due to their potential for imaging tumour tissue, tumour rowth and 8 tumour staging, there exists a demand for a reliable and high-activity-level suppiy of F-labelled 
amino acids. The two procedures for ["F]OMFD synthesis described in the literature [8, 91 have the 
drawbacks of relatively low yields and complicated as well as time-consuming manufacturing 
processes. Here we describe an improved synthesis of ~'F]OMFD which provides the substance in a 
high yield after a relatively short preparation time. 
Experimental 
An apparatus for routine production based on an electrophilic reaction was set up. 
The schematic layout of the ["F]OMFD preparation unit is shown in Fig. 1. 
Fig. 1. Schematic presentation of the module for production of ~'FJOMFD 
Our synthesis starb with a new precursor, the N-formyl-3-0-mefiyl-4-Gm-6-trimethyistannyl-L- 
DOPA-ethyl ester synthesized by 80Z Chem, Canada, according b our specificatilrns. This 
compound is derived from the [ ' 8 ~ ] ~ ~ ~ ~ ~  precursor [10]. In contrast to the [ ' 8 ~ ~ ~ ~ ~ ~  precursor, the 
methoxy group is already contained in this compound and is kept stable during the whole procedure. 
[18F]~, is produced by the 20~e(d,a)'8~ reaction, using the 9 MeV deuterons from the Rossendorf 
cyclotron IBA 18/9 with Ne + F2 (100 pmol) as the target gas. The target gas is discharged un&$r its 
own pressure (1.2 MPa to Start with) through the transporting copper tube (about 500 m). The [ F]F2 
is transported to the synthesis unit using N2 as a carrier gas with a pressure of 0.5 MPa. 
To increase the efficiency of absorption, the f8FJF2 is absorbed in a special Vigreux absorption column 
containing a precursor solution of 45 mg N - f o r m y l - 3 - 0 - m e t h y l - 4 - 0 - b o c - 6 - t r i m e t h y w  
ethyl ester in 15 ml trichlorofluoromethane (CF& Freon 11). This arrangement also makes it possible 
to measure the starting activi with a dose calibrator. Under these conditions the reaction behveen the +X precursor and the gaseous [ F]F2 takes about 10 minutes. The volume of the solvent is reduced to 
about 5 ml by evaporation during absorption. 
H 
COOH 
- HO / \ 
14o0c, 10 Inin - 
After absorption of P8F]~, 2.5 ml 12 M HCI are added and this mixture is transferred into the reaction 
vessel. The temperature is increased to 70 "C while the remaining solvent is evaporated by blowing in 
gaseous Na. After evaporation the reaction vessel is closed and the temperature is increased to 140 
"C for 10 minutes to reach the conditions for hydrolysis. 
[ ' 8 ~ ~ ~ ~ ~  is separated from the cnide pro$uct by isocratic HPLC using isotonic acetate buffer as an 
eluent at pH 4.7 on an RP-8 column. The [ FIOMFD-containing radioactive peak is eluted after about 
19 minutes. After sterile filtration the product is ready for use as a radiopharmaceutical. 
Condifions for preparafive HPLC: 
- column: 
- guard column: 
- sample volume: 
- injection loop: 
- eluent: 
- Row rate: 
- pressure: 
- detection: 
LiChrosorb RP-8,7 pm, 250 mm X 10 mm, 
LiChrospher RP-8,5-20 pm, 30 mm X 9 mm, 
2.5 ml, 
10 ml, 
105.6 mM of CH3COONa and CH3COOH, pH 4.7, 
isotonic, prepared with steriiized water (aqua ad iniectabilia), 
3 ml/min, 
about 9 MPa, 
UV, 1 mm path length, 280 nm, 
radioactivity. 
According to the rules of good manufacturing practice (GMP), quality control of the final product is an 
essential part of quality assurance of radiopharmaceutical production. The quality of the product was 
characterized by HPLC, GC/MS and pharmaceutical data. 
Results 
The new precursor N-formyl-3-O-methyl-4-O-Boc-6-trimethylstannyl-L-DOPA-ethyl ester facilitates 
stereoselective radiofluorination with ["FIF~. As an advantage of this reaction only the desired isomer 
is generated, i.e. the 2- and 5-fluoroisomers do not occur. 
The protective groups are completely cleaved by the partial hydrolysis while the methoxy group is 
solely affected to a small extent. The kinetics of hydrolysis is demonstrated in Fig. 2. 
2 4 6 
time of hydrolysis [min] 
Fig. 2. Kinetics of the hydrolysis of ~-form~l-3-0-meth~l-4-0-~oc-6-[~ *F]fluoro-~-D~~~-ethylester 
The graph demonstrates that the maximum percentage of the desired product is achieved after 8 to 10 
minutes. A longer reaction time causes cleavage of the methoxy group, which leads to an increased 
amount of f 8 F ] F ~ 0 ~ ~ .  
The total preparation time of ~'FIOMFD after EOB, including radionuclide transport. taFfs abouut 50 
minutes. The total ["F~OMFD yield is between 20 and 25 % (decay corrected, related to [ FjF2) wifh a 
good reproducibility. The specific activity is 20 GBqlymol. Depending on the starting activity, up to 1.5 
GBq ["F]OMFD is available. 
The product ic characterized by the following quality parameters: 
Parameter Method Limit 
- Radiochemical purity: HPLC >95% 
- Chemical purity: HPLC [OMFD] > 95 % 
- Pharmaceutical 
Parameters: 
GC/MS [Freon 111 < 100 yglml 
[acetonittilel < 100 yglml 
[acetonef < 100 pglml 
PH 4-5 






< 25 yglml 
25 1.ig/rnl 
4.7 
300 - 33 0 mOsmoi/kg 
Conclusion 
As the improved synthesis procedure is simple and robust and the precurcor is commercially 
available, it can be adapted to existing [18F]FD0~~-modules. [ ' 8 ~ ] ~ ~ ~ ~  can thus be easily obtained. 
The easy preparation of [ ' 8 ~ ] ~ ~ ~ ~  and its biological behaviour make the compound seem promising 
for PET studies. 
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2. Metabolism of & [ ' 8 ~ ~ ~ ~ ~ r ~ - 3 - ~ ~ e t h y l - ~ - 3 , 4 - ~ i h y d r ~ x y p h e n y i a l a n i n e  in the Rat 
G. Vorwieger, R. Bergmann, R. Syhre , F. Füchtner, J. Steinbach, P. Brust, B. Johannsen 
Tumour diagnostics by tomographical tools makes use of the usually higher metabolic activii of neo- 
plastic tissue. Major metabolic processes include, first and foremost, protein biosynthesis and amino 
acid transport [l]. The xenobiotic L-amino acid OMFD (6-~8~]fluoro-3~methyl-~-3,4- 
dihydroxyphenylalanine ) is known as an undesirable, virtually inert side product within FDOPA-PET 
(See chapter "Piglet pharmacokinetics of FDOPA" of this monograph). We synthesized the compound 
OMFD and investigated in the rat whether or not this metabolic stability can be absolutely relied upon. 
This is one aspect of assessment for the elucidation of conceivable tumour tracer properties of OMFD. 
Methods 
Male Wistar rats (8 weeks old, weighing 200 g on average) were anaesthetized and i.v. injected 125 
MBqkg OMFD equivalent to 12 pmolikg. After tracer application the rats were left awake. Three ani- 
mals at a time were anaesthetised 30, 60 and 120 min after tracer application. Blood and urine were 
drawn by heart and biadder aspiration. Then the animals were decapitated and tissue samples of 
brain, gut and pancreas were prepared. 
Preanalytical processing of samples of the body fluids and tissues as well as HPLC separation with 
radiochromatography detection were performed as described in the chapter "Piglet metabolism of 
OMFD* in this monograph. 
The percentages of total ' 8 ~  for the metabolite substances were determined by integration of the ra- 
diochromatogramc. The analytical recovery of the metabolite substances was arbitrarily assumed to 
be identical with the OMFD recovery. 
The body distribution of the total ' 8 ~  activity was deterrnined by Wo approaches: 
withdrawal of an aliquot from the homogenate (before centrifugation) and determination of the 512 
keV gamma activity in the well counter; 
norrnalizing for each sample the total peak areas of the radiochromatography detector with the 
detector counting efficacy. 
The possible incorporation of OMFD-born activity into rnacromolecular ctructures was assessed on the 
basis of two pancreas samples. The pellets of those two samples were washed tree times with a vast 
excess of precipitation reagent and thereafter measured in the weil counter like homogenates. fhe 
total activities calculated in the two ways described above were moreover compared: the supernatants 
employed for HPLC separation were to contain only monorners and oligomers. 
Resuits and Discussion 
I I 1 
Fi. 1 a. Representative radiochromatogram of Fig. 1 b. Representative radiochromatogram of 
ticcue and plasma samples uiine sarnpies 
For the first time äIis work presents quantitative recults of äle QMFD tracer metabolisrn in l ~ n g  ani- 
rnais. Wfth the exception of urine, all the invesügated sampks revealsd mainiy N, producE; (WistA 
and HistB; See traces in Figs. l a  and lb). HistA and HistB are probably identical with the appropriate 
OMFD products in piglet plasma. The percentage relations between OMFD, HistA and HistB represent 
a tissue-specific metabolization Pattern (Figs. 2a - 2d). Two additional trace substances which never 
shared more then 2 % of the total "'F occurred predominantly in the gut. Neither they nor fluoride, 
which as an impurii or product instability accounted for about 5 mole percent of the OMFD prepara- 
tion, were taken into account in Fig. 2. 
Fig. 2a. Plasma 
M0SnWM ?bm60M 
Fig. 2c. Pancreas 
100 
Fig. 2b. Brain 
W 
OMFD 
Mean ffl mm Msin 120 rnn 
Fig. 2d. Gut 
Fig. 2. Distribution of 'F activity amongst OMFD and its main metabolites; 







Fig. 3a. Time course of total "F activify (mean + SD; n = 3), zoomed for low ac t iv i  details, 
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Fig. 3b. Time Course of total '*F activity (mean + SD; n = 3), determined from homogenate 
(upper columns) and total HPLC area (lower columns) 
HistA and HistB are probably first-degree products of OMFD belonging to the category of Phase I I  of 
biotransformation [CHIRAKAL, Chemist's view of imaging centers]. For identification of these Wo sub- 
stances we propose in the first place: HistA = OMFD glucuronide, HistB = 5-S-cysteinyl-OMFD. 
Phase I reactions of OMFD - decarboxylation, transamination, ß-hydroxylation are conceivable - did 
not occur due to a lack of oblique terminal products or intermediates such as homovanillic acid, vanil- 
lylmandelic acid and 3-methoxytyramine. 
80 
% total '*F 
, tn sample / Fluoride 
70T - I j 
Mean 30 min One sampie 60 min Mean 120 min 
Fig. 4. Distribution of 'F aMfy  amongst all detected substancec in urine; mean (n = 3) + CD 
(30 and 120 min p.i.); 60 rnin just one sampk avaiiable. 
We were able to confirm the long biological half life of OMD [2] for OMFD (see slow decrease of total 
activity in Fig. 3). The total activity plot (Fig. 3a) shows that among all the investigated tissues Pan- 
creas has the highest mass based activity content though still no enrichment compared with the whole 
body average (1 g body weight = 0,5 %). OMFD itself is responsible for the high pancreas values (see 
Fig. 2c). This finding Supports the suitability of OMFD as a tumour tracer. 
Kidney excretion obviously is the main excretion path. A typical urine chromatogram (Fig. 1 b) indicates 
that the activity is basically made up of 2 hydrophilic species which do not occur in tissues (UrinA and 
UrinB, presumably diierent OMFD sulphates). Interestingly, the fractions of OMFD and HistB increase 
in time (Fig 4). HistA is not found in urine. Three quantitatively insignificant substances (MinUrinl-3) 
each never exceed 5 per Cent each of the total urine activity. The impurity fluoride obviously under- 
goes a rapid enrichment in urine. lf we Want to consider only the OMFD metabolism as such, the urine 
columns in Fig.3 are overestimated by about 100 %. 
The following two arguments show that a possible invoivement of OMFD in the protein biosynthesis (t- 
RNA bonding, peptide bonding) cannot include more than 4.5 % of the administered tracer. 
(1) 4.5 or 3.3 % of the initial cample activity could not be desorbed from the protein pellet even by 
washing it three times with vast surplus volumes of the precipitation solution. 
(2) The congruent behaviour of the total activities determined by the two methods in the investigated 
tissues is shown cleariy by the data presented in Fig.3. The values in the supernatants applied to 
the HPLC, which are regulariy about 20 % lower (the radioactivity recovery of the HPLC System it- 
self is well documented at 100 %) have to be considered a systemic error of the conversion factor 
[well Counter / radiochromatography detector], i.e. they are due to imprecise calculation of the ef- 
fective dilution volume during the preanalytical procedure. 
The plasma kinetics of the piglet experiments (see chapter "Piglet pharmacokinetics" in this mono- 
graph; 2 - 50 min p-i.) and of this rat study (30, 60 and 120 min p.i.) can be combined without hesita- 
tion, they fit together. This indicates that differences between animal species are negligible. 
[ I ]  Wester H. J., Herz M., Weber W., Heiss P., Senekowitsch-Schmidtke R., Schwaiger M. and 
Stöcklin G. (1999) Synthesis and radiopharmacology of 0-(2-f8~]fluoroethyl)-L-tyrosine for tumor 
imaging. J. Nucl. Med. 40,205-212. 
[2] Rose S., Jenner P. and Marsden G. D. (1988) The effect of carbidopa on plasma and muscle 
ievels of L-Dopa, dopamine, and their metabolites following L-Dopa administration to rats. 
Movement Disorders 3,117-1 25. 
3. Metabolism of 6['8F]~luoro-3-0-~ethyl-~-3,4-~ihydroxyphenylalanine in Newborn 
Piglets 
G. Vorwieger, P. Brust, R. Bergmann, R. ~auer', 6. walte$, F. Füchtner, J. Steinbach 
1 Institut für Pathophysiologie, Friedrich-Schiller-Universität, Jena 
lntroduction 
Positron emission tomographic (PET) studies of the dopamine metabolism with the tracer 6-['sF$luoro- 
L-3,4-dihydroxyphenylalanine (FDOPA) are impaired by in vivo generation of the metabolite 6- 
~g~]fluoro-3-~-methyl-~-3,4-dihydroxyphenylalanine (OMFD). This labelled molecule, formed mainly 
peripherally by the action of catechol-O-methyltransferase on FDOPA, crosses the blood-brain barrier 
and contributes substantially to brain radioactivity. Especially with Carbidopa premedication, this 
drawback is the more pronounced the longer the scanning procedure lasts. Corrections for this radio- 
activity in the brain have been proposed. They are based upon the assumption that regional variations 
of OMFD pharmacokinetics within the brain are negligible. Studies in humans with OMFD have shown 
that this assumption is valid [I]. In that study the distribution volume of OMFD was close to unity, and 
a single, reversible compartment was adequate for modelling the measured time Course of OMFD. 
Analysis of human plasma samples for labelled metabolites [ I ]  showed that more than 95 % of the 
radioactivity was at all times associated with OMFD. In nonhuman primates a crude fractionation of 
the plasma metabolites revealed that only the negatively charged metabolites which should not Cross 
the blood-brain barrier (which are, for example, extractable with an anion exchange column) were 
found in the plasma in significant quantities ( 4 3  %) [2]. None of the studies rnentioned provided 
chromatograms of the Separations. There are no data available of the metabolism of OMFD in the 
brain or in peripheral Organs. 
Until now OMFD has thus been regarded as virtually not undergoing any further metabolism. It is 
therefore expected to be a good tracer for amino-acid transport processes in living subjects. We re- 
cently used OMFD to quantify the amino-acid transport at the BBB in piglets with PET 131. The blood- 
brain transfer constant of OMFD (K1) was estimated from the brain and plasma time activity curves. 
When there was a significant rnetabolism of OMFD, these data had to be corrected for the presence of 
labelled rnetabolites. 
We intended to examine mutual metabolism of OMFD in the plasma and brain of newborn piglets. 
Verification of the expected metabolic stability would promote (a) investigation of the LNAA trans- 
Porter, (b) judgement of its tissue distribution properties, and (C) differential identification of further 
"second-erdet'-FDOPA metabolites, all of this mainly with respect to the validation of the FDOPA PET 
model for the in vivo visualisation of catecholaminergic functionalities. 
Materials and Methods 
Animal experiments were perforrned as recently published [4]. After euthanasia by injection of satu- 
rated KCI Solution, the brain of the animals was removed within 30 s, stored on ice and immediitely 
dissected. Each brain tissue sample was submerged in 2.5 ml of the soivent CC14 which was pre- 
cooled to -20 "C. 
Metabolite anaiysis was carried out by gradient HPLC in the following configuration: Hewlett-Packard 
1050 quartenary gradient pump, autosampler (0.5 ml sample loop; injection volume 360 pl), UV do. 
tector (h = 280 nm), all parts of the Hewlett-Packard 1050 syctern, and a flow scintillation analyser 
(150 TR, Canberra Packard) with a PET Row cell(100 pi volume; energy window: 15 - 2000 keV). The 
analytes were separated on a C 18 reverse-phase column (250 X 4 mm, LiChrosorb, 7 um) fied with 
a guard column (4 X 4 mrn, LiChrospher 100 RP-18,5 pm), at a temperature of 30 'C. A binaty gradi- 
ent was chosen at a flow rate of 1.5 mVmin (start: 070 B, 4 rnin : 25 % B, 10 rnin 80 % B, 10.1 rnin 100 
% B, 11 2 min: 100 % B, 12.8 rnin 0 % B, 16 rnin : 0 % B; total method time: 16 min). Mobile phase A 
consisted of 70 rnM KH2P04, 1.5 mM sodium oc@t sulphate, 0.1 mM EDTA, adjusted to pH 3.4 witb 
HsP04. Mobile phase B was prepared by adding two parts (vovvol) MeCN to one part "A". After every 
30 samples the system was re-equiiibrated with water and MeCN. At the same tjme the guard col- 
umns were renewed and the flow direction reversed. The sequence af sample measurement was ran- 
domized. 
Resuits and Discussion 
The OMFD PET scans we accompanied by HPLC separations of brain extracts and plasma from three 
animals. No other substances were detected In the brain tissue extracts. This means that with our limit 
of detection the sum of possible metabolites is less than 2 % of the total activity. 
Fig.1. Representative radiochromatogram Fig. 2. Kinetics of the tracer OMFD (['*F]G-fluoro- 
3-0-methyl-L-3,4-dihydroxyphenylalanine) 
in piglet plasma. 
of a plasma sample 
Fig. 3. Kinetics of the two metabolites Fig. 4. Early p-i. kinetics of the two metabolites 
HistA and HistB in piglet plasma HistA and HistB. 
As opposed to those groups who previously checked the plasma for OMFD metabolism, we found 
significant amounts of metabolites. Only two substances occurred in the traces. We named them HistA 
and HistB (see trace in Fig.1). All available data are presented in Figs. 2 - 4. The values are normal- 
ized to the total activity at each time point and decay corrected. The ordinate Parameter [% of total 
''5 is thus plotted linearly against time p.i.. The resulting graphs correspond in good approximation to 
the monoexponential clearance (in the case of OMFD) and input function (HistA and HistB) even with- 
out cuwe fitting. A wmparison of the initial kinetics of both metabolites suggests that HistA is formed 
at a higher rate(Fig. 4). In all the following samples however the HistB concentration exceeds that of 
HistA. 
The identity of the Wo metaboiiies is discussed in a section "OMFD metabolism in the rat" of this 
monograph. Among other compounds, the giucuronide of OMFD (HistA) and 5-Cysteinyl-OMFD 
(HistB) are to be taken into consideration. 
Our results imply that in modelling investigations with OMFD the desired precision determines the 
campling frequency of the bkmd plasma. We suppose that in most cases a single anaiysis after PET 
scanning should be sufficient From this vafue the input function for the brain tissue can be extrapo- 
lated into lineariy extended graphs of the OMFD clearance (Fig. 2). This Suggestion does not apply to 
other tissues with significant metabolite fractions. 
The activii in the brain ROIs of the PET images can be exclusively attributed to OMFD itself. No 
OMFD metabolite wmpartment is necessary-for brain tissue. 
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4. First Results of 3-0-Methy1-6-[ '8~~luoro-~O~~ ( [ ' 8 F 1 3 - ~ ~ ~ ~ )  in Patients with 
Glioblastoma Multiforme 
W. Burchert, B. ~euthien-~aumann', H. Alheif, J. Bredowl, J. Steinbach, B. Johannsen, W.-G. 
Franke' 
TU Dresden, '~l inik und Poliklinik für Nuklearmedizin und 2~linik und Poliklinik für Strahlentherapie 
und Radioonkologie 
Introduction 
Patients with brain tumours such as glioblastoma multiforme generally face a grim prognosis. Even 
after intensive therapy such as tumour resection and postoperative radiotherapy, the incidence of tu- 
mour recurrence is high. For sorne patients one further therapeutic option in case of tumour recur- 
rence is stereotactic radiotherapy. For this treatrnent modality the confirrnation of the suspected recur- 
rence and the exact definition of the tumour borders is mandatory. In some cases this cannot be 
achieved with only CT or MRI, so that the application of additional imaging rnodalities is desirable. 
Some promising results in brain tumour diagnostics with positron emission tomography (PET) and 
radiolabelled amino acids have been published 12-41. The upregulation of amino acid transporters 
occurs as Part of the malignant transformation of the tumour cells 151. Since in normal brain tissue the 
amino acid uptake is low, a good tumour to non-tumour contrast can be expected. lncorporation of the 
PET data into treatment planning by image fusion could therefore be helpful for definition of the target 
volume for stereotactic radiotherapy. 
Since most of the radiolabelled amino acids applied for PET show limitations concerning synthesis 
(low yield of tracer) or the short half life of the radioisotope ("C, tln: 20 min), further research is been 
carried out for an optimized amino acid. 
One new amino acid without the above-mentioned limitations is 3-0-rnethyl-6-['8~]fluoro-~0~~ 
( [ ' 8 F ' J 3 - ~ ~ ~ ~ ) ,  a naturally occurring metabolite of dopamine [I]. Some first in vitro studies revealed 
promising results in terms of the tracer uptake in the cells of a human tumour cell line. Furthermore, a 
high tumour uptake and low tracer retention in the body was found for nude rnice bearing human 
squamous cell carcinomas (unpublished data, Biochemistry Dep.). 
These encouraging results of the in vifro and in vivo experiments seemed to justify the application of 
this substance to humans. Furthermore, [ ' 8 ~ 1 3 - ~ ~ ~ ~  is well known as a nontoxic metabolite occurring 
in [ ' 8 ~ ] ~ ~ ~ ~ - ~ ~ ~  studies. The first investigations were perforrned in patients with glioblastoma rnulti- 
forme in which the conventional diagnostic procedures were inconclusive and a stereotactic radiother- 
apy was considered because of a tumour recurrence was very likely. 
Materials and Methods 
Patients: 4 PET scans with [ ' 8 ~ ] 3 - ~ ~ ~ ~  were performed in 3 patients (2 fernale, 1 male; age 57 - 60 
years). All patients sufFered from histologically confirmed glioblastoma rnultiforme. In their medical 
history all of thern underwent neurosurgery and postoperative radiotherapy. Two of the patients un- 
derwent a second operation because of tumour recurrence, one patient already had a second Course 
of radiotherapy with a stereotactic approach. One patient was re-evaluated 3 months after stereotactic 
radiotherapy because of suspected Progress of the disease. 
lmaging procedure: PET imaging of the brain was performed, using a dedicated full-ring Scanner 
(ECAT EXACT HR*, Siemens /CTI, Knoxville, Tenn., U.S A.). Dynamic acquisition over 90 min. was 
started after intravenous injection of 330 MBq [ ' 8 ~ 3 - ~ ~ ~ ~ .  Following the dynamic sequence of the 
brain, a distribution study of the body from the orbits to the pehris was perforrned. 
The data were reconstructed by measured attenuation correction. They were visually and serniquan- 
titatively evaluated, using regions of interest. 
No adverse reactions were observed after tracer application. 
Resuk and Discussion 
fn all three patients the recurrence of the brain turnour was visualized with a high degree of contrast by 
[ ' 8 ~ ~ ~ ~ D - ~ ~ ~  (Fig. IA). A comparison of the radiotracer uptake in the tumour and the contralat- 
eral normal brain tissue revealed a tumour to non tumour ratio of 2.2 t 0.5. The maximal tracer uptake 
was observed between 12 min and 25 min p-i.. The F8~3-0MFD uptake is dependent on the arnino 
acid transport (unpublished data, Biochemistry Dep.) and is not integrated into proteins. Since f8f13- 
OMFD is not fiied wain the cells, a loss of tracer over time can be obsecved. This decline of ac t iv i  is 
more p r o n o u d  in turnour tissue than in normal brain tissue (Fig. 1 B). 
Fig. 1. Transaxial slice of a ["F]3-OMFD-PET brain scan of a patient with recurrent glioblastoma mul- 
tiforme. The tumour shows a high radiotracer uptake (RI) in the left temporal lobe. For quantitative 
analysis regions of inter,$st are placed in the himour region and in Contra lateral reference brain tissue 
(A). Uptake kinetics of [ F]3-OMFD in the tumour region (+) and reference brain tissue (*) (B). 
In addition to the tracer uptake in the tumour tissue, all patients 
exhibited a low tracer accumulation in the basal ganglia. 3-0- 
methy-6-DOPA, as a metabolite of dopamine, ceems to have 
some affinity to the basal ganglia. The physiology behind this 
phenomenon will have to be further investigated. In the whole 
body scan the tracer uptake in muscle and most of the internal 
Organs was low. The tracer accumulation in the kidneys and 
urinary tract is due to physiological elimination (Fig. 2). 
These first investigations with [ ' 8 ~ ] 3 - ~ ~ ~ ~  showed encourag- 
ing results with respect to tumour visualization and localization 
in glioblastoma multiforme. The diagnostic accuracy and the 
application to various tumour entities will have to be further 
evaluated in controlled studies. 
Fig. 2. Anterior-posterior projection of 
a [lBF]3-OMFD whole body scan 
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5. Reaction of Neurotensin (8-13) and its Partiaily Reduced Congener with Unlabelled 
and ' 8 ~ - ~ b e l l e d  N-Succinimidyl4-Fluorobenzoate (SFB) 
M. Scheunemann, P. Mäding, R. Bergmann, J. Steinbach, B. Johannsen, D. ~ourwe' 
1 Vrije Universiteit Brussel, Belgium 
introduction 
A promising approach for tracking tumours is the utilisation of radiolabelled peptides of specific affinity 
to receptors located on these tumours. Since neurotensin receptors were found in several tumour cell 
lines, such as small cell lung cancer [I], human colon [2] and pancreas cancer [3], the development of 
18 F-radiolabelled derivatives of neurotensin, which bind to these receptors with high affinity, attracted 
our interest. 
Investigation of the structure-affinity relationship of various neurotensin analogues showed that the 
hexapeptide NT (8-13) is the smallest biologically active fragment [4].We therefore started our label- 
ling experiments with this peptide fragment as well as smaller analogues containing either arginine or 
lysine as N-terminal amino acid (Arg-Tyr, Lys-Arg). 
HN-NH, / reduced peptide bond 
During the last decade only a few approaches to 18F labelling of proteins and peptides using the 
[18~fluorobenzoyl group have been denribed. Zalutsky and co-workers reported on their experience 
in the preparation of N-succinimidyl-C[ F'jfluorobenzoate ( P 8 q s ~ ~ )  and the subsequent labelling of 
the antibody F(abd)* [5]. In 1993 the Same group used this procedure to label a small peptide (HCO- 
Nle-Leu-Phe-Nle-Tyr-Lys) in order to develop a potential agent for PET imaging of infection or inflam- 
mation [6]. In both Papers the synthesis of the target molecule [~*F]SFB was described by a three-step 
procedure starting from 4-trimethylammonium benzaldehyde. 
Amang other prosthetic groups Stöcklin et al. investigated the labelling behaviour of the substituted 
benzoyl moiety for the introduction of ["F] into proteins F]. The authors used the triflate salt of ethyl 
4-trimethylammonium benzoate as the starting material for the preparation of f8F]sF~. 
Preparation of n.c.a. N-succinimidyl-4-['~fluorobenzoate 
The synthesis of the authentic N-succinimidyl-4-fluorobenzoate has been published F]. Radiosynthe- 
sis required a similar approach in which the 1 8 ~  was introduced at an early stage of the reaction Se- 
quence. Starting from trimethylammonium benzoate, which was wnverted into the 18~-labelled ester, 
a saponification step yielded the salt of the acid. Finally, the carboxylic group was activated by means 
of U(Wsuccinimidyl) N,N,N',Nr-tetramethyluronium tetrafiuoroborate in acetonitrile at 90°C. This 
method proved to be successful in achieving radiochemicai yields of up to 50% calculated for the 
three-step procedure (decay corrected). 
Peptide rnodification - Initial attempts at Iabelling of NT(8-13) and its smaller 
ana~ogues 
We began by examining the regioselectivity of nonlabelled SFB in its reaction with small peptides and 
(S)-arginine (I). The latter compound represents the Wterminal unit of the NT(8-13) sequence. 
The other goai at the start of our studies was to compare the reaction condiions for labeling the 
amino acid derivatives given in the Iiterature. Reaction of the activated fluorobenzoic acid derivative 
(unlabeffed SFB) with Wo equivalents arginine (I) in a mixture of water and dioxane at 22"C, followed 
by extractive workup by means of butanol, exclusiveiy afforded Ehe desired acylated amino acid 4. 
1 (R=OH) 
2 (R =Tyr) 
3 (R = Arg-Pro-Tyr-He-Leu) 
SFB = W l e d  or unlabelled SFB 
Proton NMR clearly demonstrates the success of a-Macylation, while no product was detected re- 
sulting from the attack of the guanidino function. 
For our initial labelling experiments of NT(8-13) with ["F]SFB we chose conditions similar to those 
described by Wesfer et al. [8]. Surprisingiy, the attempt to convert NT(8-13) (3) and even Arg-Tyr (2) 
following this protocol (borate buffer, pH = 8.8 - 9.1, 22°C) gave rise to a mixture of radioactive prod- 
ucts in each case. A similar complex product mixture was obtained by using unlabelled SFB. Appar- 
entiy, the acylation of an amino group located at a tertiary carbon by means of SFB is more affected 
than the corresponding reaction at an amino group connected to a secondary carbon atom. 
By contrast, the reaction of Lys-Arg both with labelled and unlabelled SFB yielded a predominant 
product together with smaller amounts of various unknown side products. In this case the kineticaliy 
preferred reaction presumabiy takes place at the E-amino group of the lysyl moiety. The better chemo- 
selectivity of the iysine-containing peptide is probabiy due to the lower steric hindrance and a c i d i  of 
the protonated E-amino group compared with the U-amino group in iysine. In fact, SFB has so far been 
described as a labelling agent soleiy for peptides containing iysine sequenoes. 
To enlarge the i i l d  of application we investigated the reactivii of nonradioactive SFB in vanous 
solvent Systems. We found that terminal Arg-peptides react with good chemoselectivii in an aprotic 
solvent such as DMF with triethylamine as a base or in buffered aqueous solutions with pH values 
lower than 8.5 at 22°C. Our labelling experiments then revealed that f 8 F ] s ~ ~  reacts with N-terminal 
Arg-peptides such as NT(8-13) or the metabolically stabilised pseudopeptide 
[ A ~ ~ ~ Y ( C H , N H ) A ~ ~ ~ N T ( ~ - ~ ~ )  with reasonableto good chemoselectivity in aqueous buffered solutions, 
preferabiy at pH 8.3. To shorten the period of time necessary for the complete consumption of 
f 8 f l s ~ ~ ,  we found it achrisabkt to heat the mixture to 35 - 40 "C for 20 min. 
The diluted reaction mixture was then subjected to chromatographic purification using semipreparative 
reversed-phase HPLC. The radioactivii corresponding to the desired product was collected and di- 
luted with water. The solution was concentrated on an RP-18 cartridge. After washing with water, the 
purified '8~-labelled peptide was eluted from the cartridge with a small amount of ethanol. 
The radioactive product was identied by chrornatographic comparicon with a reference compound. 
The reactions carried out with nonradioactive SFB were shown to yield the correcponding 4-FB pep 
tides. Their structural identity was confirmed by proton NMR and MS studies. 
Fig. 1. 
a) HPLC of the reaction product of NT(& 
13) and ['*F]sFB in phocphate birfter (pH 
8.3,40 rnin at 45*C). 
b) Purified product &TI the pnoduct mixture 
of a) 
C) Purified nonradiictive 4-FB-NT(&-'! 3). 
The forthcoming work will be focused on optimising the pH value for selective conversion within a 
smaller time range. 
This work is supported by the European Union (BMH4-CT98-3198). 
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6. Experiments of the Synthesis of ['*F]~luorornethyl Halides for Labelling Peptides 
P. Mäding, M. Scheunemann, J. Steinbach 
lntroduction 
Aiming at receptor-bindin neuropeptides for tumour diagnosis with PET, we are interested in labelling 
98 peptides by means of [ F]fluoroalkylation, especialiy ['8~fluoromethylation. The ['8~luoromethyl 
group (["F~FcH;) is the smallest prosthetic group for indirect labelling with "F. It is to be expected 
that a fluoromethylated peptide has only liffle change in the size and polarity in comparison with the 
starting peptide. The receptor affinity of the fluoromethylated peptide should be similiar to that of the 
starting peptide. Another advantage is the one-step procedure for synthesizing the fluorornethylation 
agent. 
But the fluoromethylation of peptides also has its risk: the selectivity of the fluoromethylation agent for 
amino graips of the peptide may be lower compared with fluoroacylation agents such as N-succinimidyl4- 
fluorobenzoate. The stability of the fluoromethyi-amino group is unknown. 
Experimental 
Materials 
Fluoromethyl bromide (98 %) was purchased from ABCR GmbH & Co., Germany, sodiurn fluoroaco. 
tate (pract. r 95 %) from Fluka, iodine (double-sublirnated) and sodium iodide (pure) from Labor- 
chemie Apolda, Germany. 
Analysis 
To determine the extent of conversion and the radiochemical purity and to identify the labelled prod- 
uct, an HPLC System (JASCO) was used, including a pump, a Rheodyne injector with a 20 p1 loop, a 
LiChrospher WP300 RP-18 column (5 pm, 250 mrn X 3 mm, Merck) and a UV detector coupled in 
series with a radioactivity detector FLO-ONRBeta 150TR (Canberra Packard). The HPLC analyses 
were carried out at a flow rate of 0.5 mVrnin with rnixtures of MeCN and water containing 0.2 % TFA. 
The gradient of the eluents was: 0 min - 10 % MeCW 90 % water; 10 min - 60 % MeCNI 40 % water; 
14 min - 100 % MeCW 0 % water; 20 min - 100 % MeCW 0 % water. 
Syntheses 
Siber salt of fluoroacetic acid 
A solution of sihrer nitrate (44 g = 259 rnmol) in 40 rnl water was added to a stirred solution of sodium 
fluoroacetate (25 g = 250 mmol) in 45 ml water, with a colourbss sait precipitating. After stirring for 1 h 
the salt was fiitered through a frit glass fiiter, washed with water and dried. Colouriess crystals, yieM: 
(40.7 g, 88.1 %). 
Conversion of siber fluoroacetate with iodine 
A mixture of the sihrer sait of fluoroacetic acid (10 g = 54 mmol) and iodine (34.2 g = 135 mmol) was 
slowiy heated in a special distillation apparatus under a slight helium stream. The decamxylation 
occurred at about 120 "C with iodine sublimating. When the reaction rnothire was then heated up to 
230 'C, iodine as well as a small amount of a strongiy acidii, water-soluble liquid was distilled from it, 
probably fluoroacetic acid. 
Fluoromefhyi iodide 
Fluoromethyl bromide (1.74 g = 15.4 mmol) was transferred from the storage vessel into a cooled 10 
ml via1 f- 78 "C) with Septum. A colution of sodiurn iodide (2.37 g = 15.8 mmol) in 2.9 ml acetone was 
added to the mied substance while stining. The reaction mixture was sbwty heated to room t€?m- 
perature and sodium bromide was separat&. After stirring for 3 h äie reaction mixtrrre was extFacted 
with water (3 X 6 rnl). The organic phase was dned with Na2S04. In tiiic way purified flworomethyl b 
dick was obtained. Pak yelbw iiquid, yieM: (1.3 g, 52.8 %). 
Radiosyntheses 
[18~fluoromethyl bromide 
A mixture of irradiated [ 1 8 0 ] ~ , ~  containing n.c.a. f8F]HF and K222/K2C03 solution (1.5 rnl of 86 % 
MeCN with 15 mg (= 40 pmol) kryptofix and 2.77 mg (= 20 pmol) K2C03) was dried by means of a 
vacuum and a nitrogen stream at 100 "C. The reaction mixture was carefully dried by repeated addi- 
tion and evaporation of abs. MeCN (3 X 1 ml). After addition of 1 ml abs. MeCN and 100 p1 dibro- 
rnomethane the reaction mixture was heated at 100 OC. By rneans of an Ng stream of 10 mVmin the 
['8~fluorornethyl brornide was driven into a cooled trap with an appropriate solvent. 
[ 7 8 ~ o r o m e t h y l  iodide 
A mixture of irradiated [ '80]~20 containing n.c.a. v8F'J~F and K222/K2C03 solution was carefully dried 
as mentioned above. After addiüon of abs. MeCN and diiodomethane the ['8~]fluoromethyl iodide 
forrned at roorn temperature or an elevated ternperature was driven (Na stream: 10 mllmin) into a 
cooled trap with a solvent. For detailed reaction conditions see Table 1. 
Results and Discussion 
Synthesis of [18flfluororneth 1 bromide Y Coenen et al. [ I ]  prepared [ 8~fluoromethyl brornide by nucleophilic substitution of ['8~]fluoride for one 
bromide of dibromomethane according to Scherne 1 : 
Scheme 1 
This reaction is very sensitive to moisture and other impurities. We tested this reaction in a closed as 
well as in an Open system. In a closed system it is not possible to obtain ['8~lfluoromethyl bromide in 
acceptable yields. We therefore optimized this conversion in an Open system with a special apparatus. 
The volatile ['8~]fluoromethyl bromide was driven by a nitrogen stream from the reaction mixture into a 
cooled trap. In this way the gaseous '8~-labelled product was obtained in radiochemical yields of up to 
53 %. The synthesis and purification of ['8~fluoromethyl bromide, especially the separation of the 
dibromomethane, have to be optimized to be used for labelling of peptides. 
Conversion of ~8~luoromethyl bromide with NT(8- 13) 
B ~ - c H ~ ' ~ F  + Arg-Arg-Pro-Tyr-He-Leu 
The arginine sequences of NT(8-13) contain two reactive guanidine functions in the pharrnacophoric 
group. 
Arginine (Arg): HN 
Because of the different pKa values of the a-arnino (9.04) and the guanidinyl group (12.84) of the 
Arg(8), it shouM be possible to label oniy the a-amino group (the N-terminal region) by pH-controlled 
['8F]Ruoro-methylation. 
But initial attempts at converting ['8FJfluoromethyl bromide with NT(8-13) in rnethanol using sodiurn 
acetate as a buffer failed at rwrn ternperature as well as at higher ternperatures (75 "C and 120 "C). 
The reason may be the low reactivity of ['8Flfluorornethyl bromide for arnino groups. At 120 "C the 
['8FJfluoromethyl brornide gradually began to decompose. 
For further ~F$iuoromethylation experirnents we wanted to use ['8Flfluoromethyl iodide, which has a 
better reactivii. 
Synthesis af [18fjfluoromethyl iodide 
The preparation of this labelling agent was described in [2] by nucleophilic substitution of the 
["FJfluoride for one iodide of diiodornethane according to Scheme 2 in yieldc of 35-40 %: 
[ ~ c 2 2 2 ] " ~ F  
I-CW2-I I8F-CH,-I Scheme 2 
Convercions of some rnodel cornpounds having an amino, rnercapto or carboxyl funcüon with 
["F]Ruorornettiyi iodide yieided the corresponding f8~fluoromethylated products [3]. The first use of 
[18FJfluoromethyl iodide to prepare a potential radiopharmacon was also carried out in [2]. In this way 
the so-called fluticasone propionate, a synthetic corticosteroid, was labelled with ' 8 ~  by [ 1 8 F ] f l ~ ~ r ~ -  
methylation of a carbothioacid function. 
We also tested the synthesis of ['8~fluoromethyl iodide according to [2] in a closed as well as in an 
Open System, but the radiochemical yields were ve low (about 2 %). The reason for that could be 17 impurities in the reaction mixture which react with [ FJfluoromethyl iodide. In addition to unconverted 
["F]fluoride a nonpolar 18~-labelled product in the reaction mixture was detected by HPLC. We tried to 
optimize the reaction conditions (see Table 1) such as reaction temperature (from room temperature 
up to 110 "C), reaction time, purity and amount of the sokent and the diiodomethane. So far these 
efforts have not been successful. 
Table 1. Results of experiments for synthesizing ['8F]fluoromethyl iodide under various reaction 
conditions 
No. Reaction Solvent Methylene iodide Reaction Total Radiochemi- 
vessel temperature yield cal purity 
[%I [%] 










1 ml MeCN 
1 rnl MeCN 
(dest.) 
1 ml MeCN 
(dest.) 
1 ml MeCN 
(dest.) 
1 ml dimethoxy- 
ethan (dest.) 
1 ml MeCN 
1 ml MeCN 
100 p1 MeCN 
100 PI (dest.) 
100 pI (dest.) 
1 00 pI (dest.) 
100 pI (dest.) 
100 pl (dest.) 




S A without sokent 100 pl 
S A without solvent 100 PI (dest.) 
addition at 100 
RT - 100 "C 
RT, 45 "C, 65 "C, 
80 "C 
RT, 60 "C, 100 "C 
RT, 60 "C, 100 "C 
RT 
60 - 100°C 
RT- 100 "C 
15 min RT 
5 min 100 "C 
2.5 min RT') 
9 rnin RT 
2.5 min RT') 
5 min RT 
10 min 100 "C 
10 min 100 "C 
SA = cpecial apparatus 
') without N2 stream 
Besides these attempts we also synthesized and tested the unlabelled fluoromethyl iodide. 
Synthesis of fluoromethyl iodide 
F-CH2-COONa + A$W3 -----* F-CH2-COOAg + NaNO, 
There are several methods to prepare this mmpound. 
One way to synthesize fiuoromethyl ibdide consists in the conversion of diiobarnethane wi?h mercury(1f 
Ruoride (yiekl: 15 %; [4]) or mrcury(ll] Auonde (yieM: 20 5%; 153). 
Another method of preparing fiuoromeöiyl iodide (yieM: 55 %) is described in 161 by wnversion of the 
ciiver satt 05 fluoroacetic acid with iodine under decarboxy1ation (Hundsdiecker reaction) acoording to 
Scheme 3. Tlie siiver sait of fluormcetic acid can be precipitated by reaction of sodiurn fluoroacetate 
with silver ni&ate in aqueous solution. 
We tested this procedure. The decarboxylation of the prepared silver salt of fluoroacetic acid was ob- 
served while heating this salt with iodine, but the desired fluoromethyl iodide was not obtained. Only a 
small amount of a strongly acidic, water-soluble liquid was distilled from the reaction mixture, probably 
fluoroacetic acid. 
Ws synthesized the fluoromethyl iodide using the Finkelstein exchange reaction of fluoromethyl bro- 
mide 
(b.p. 19 "C) with sodium iodide [7] according to Scheme 4. 
acetone F-CH2-Br + Na1 - F-CH2-I + NaBr Scheme 4 
The synthesis was improved as follows: The conversion was carried out in acetone as a solvent in- 
stead of MEK [7] at room temperature for 3 h. The reaction mixture was worked up by repeated ex- 
traction with water to separate the acetone and the inorganic salts from the final product. This con- 
venient procedure avoids the fractionated distillation of fluoromethyl iodide from the solvent. Fluo- 
romethyl iodide was obtained in yields of about 53 %. 
Conversion of fluoromethyl iodide with Arg-Tyr as model peptide 
Experiments of the conversion of fluoromethyl iodide with Arg-Tyr.HOAc were carried out in methanol 
- by means of tetrabutylammonium hydroxide as a base. The possible formation of a fluoromethylated 
Arg-Tyr was observed using Arg-Tyr.HOAc, BudNOH and FCH21 in a molar ratio of about 1 :3:3 at ele- 
vated temperatures (1 00 "C). 
Further investigations are under way. 
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7. Crystal and Solution Structures of the Rhenium(V) Gly-Gly-His Complex 
R. Jankowsky, W. seichter1, H. Spies, B. Johannsen 
1 Institut für Organische Chemie, TU Bergakademie Freiberg 
lntroduction 
In modern radiopharmaceutical research, 9 9 m ~ c  radiotracers basing on biologically active peptides are 
of growing interest for imaging of infections, inflammations, thrombi and tumors [I - 41. The successful 
design of peptide radiotracers decisively depends on the specific and stable metal binding to the pep 
tide. That can be accomplished by the use of peptidic chelators, which can be easily attached to the 
peptide by solid phase synthesis [5 - 91. Thus, the finding of specific metal binding peptide sequences 
remains to be a key task in basic radiopharmaceutical research. Previously, the rhenium(V) and tech- 
netium(V) binding properties of cysteinyl-containing model peptides were elucidated and successfuliy 
applied to the design of larger, biologically active Systems 110 - 131. Considering other peptidic donor 
groups, the histidine residue bearing an imidazole moiety can be expected to serue as a further an- 
chor group for metal complexation [14, 151. In the present study, we report on the rhenium(V) binding 
of the tripeptide Gly-Giy-His, which represents a model of the N-tetminus of the human Serum albumin 
(HSA) and is known to complexate other metals specifically [16]. The work deals with the crystal 
structure as well as the solution structures as studied by X-ray diffraction (XRD), capillary electropho- 
resis (CE) and X-ray absorption spectroscopy (EXAFS), respectively. 
Experimental 
The Re(V)-Gly-Gly-His complex was synthesized by common ligand exchange reactions starting from 
the Re gluconate precursor. Crystals were obtained from aqueous solution. The crystal structure was 
elucidated by XRD at the TU Bergakademie Freiberg, the solution structures were studied by a com- 
bined CE-EXAFS method as described previously [13]. EXAFS measurements were performed at 
HASYLAB, Hamburg, Germany at beamline X1.l using transmission techniques and analyzed as 
described [I 31. 
Results and Discussion 
Crystal strucfure. The crystal structure is marked by the formation of a dimeric system. It consists of 
two rhenium nuclei which are coordinated by tetradentateiy acting peptide molecules at each nucleus. 
Bridging of the molecular moieties is realized by the peptide carboql groups (Fig. 1). 
Fig. 1. Crystal smcture of the Re Gly-Giy-His complex. Left sketch, mnomeric nuckus moiety; 
right sketch, dimeric complex 
At each nucleus, the metai complexation is accomplished by a farmai M4 oootdination mode Of the 
amine, amide and imidazok nitrogens. The trans coordination OS' cadmxyl groups at each fiucleus 
leads to octahedral, neutral metal cores. Considering the bond lengths, deprotonation of the coordi- 
nating amide nitrogens takes place during metal complexation, while the coordinating amine and imi- 
dazole nitrogens remain protonated. Bond lengths are in good agreement with structural data from 
known rhenium complexes with similar donor atoms [I 1, 14, 151. 
Solution structure. For the elucidation of the solution structure of the complex, an electrophoretical 
mobility curve was recorded using the capillary electrophoresis technique. lt is shown with the corre- 
sponding pH-dependent UV spectra in Fig. 2. 
Wavelength (nm) 
Fig. 2. Electrophoretical mobility curve of the Re Giy-Gly-His complex with corresponding UV spectra 
Two steps were detected, where at each step the complex charge changes significantly. Furthermore, 
the UV spectra show diierent absorption Patterns over the pH range Wich gives rise to the assump- 
tion that the meta! surrounding is diierent at the three pH-values. The complex charge changes from 
cationic to anionic under acidic and alkaline conditions, respectiveiy. 
For the assignment of the electrophoretical mobilities to certain complex structures, EXAFS measure- 
rnentc were carried out at solid state, at pH 2.5 and at pH 12.4 (Fig. 3). At neutral pH, complex pre- 
cipitation prevented an EXAFS analysis in Solution. 
solid B 
0 1 2  3 4 5 . 6  
R + AR (A) 
Fig. 3. EXAFS Patterns and Fourier transforms of the Re Gly-Giy-His complex. A, experimental data 
and Fourier transforms with filtering windows; B, Fourier filtered data according to the filtering 
windows (dotted lines) and EXAFS fit data (solid lines) 
EXAFS analysis of the solid complex confirmed the dimeric stntcture as analyzed by XRD. At higher 
distances to the central atom, significant multiple scattering effects were detected which are obviously 
caused by both the coordinating peptide backbone and the imidzole ring System. Wiihin these back- 
scattering contributions, no resolution was possible by EXAFS fits. However, such a pattern may be 
considered as a fingerprint for coordinating peptide bacldiones and imidazoie rings. The EXAFS 
measurement at pH 2.5 showed some slight changes, which is in agreement with the complex &arge 
under acidic conditions. As a resuit of the EXAFS analysis, a formal N4 coordination of the 0x0 meta1 
core without involvement of a trans coordinated carboxyl oxygen atom could be concluded. Thus, at 
acidic pH a monomeric complex with a free protonated carboxyl group is existent. The plateau at pH 8 
in the electrophoretical mobility curve could not be analyted. However, due to the anionk complex 
charge, a complex structure similar to ü-ie crystal structure can be excluded. More probably, a hydroxyl 
group in trans position of the metal core is present under these conditions. At alkaline pH, Wo shortly 
bound oxygen atoms were detected at the metal core, which bebng to a rhenium dioxo oore. The 
ligand coordination mode doec not change at this pH, thus the second step in the ektctrophwetical 
mobility curve can be assigned to the formation of a rhenium dioxo core under basic cond' is .  With 
respect to the CE and EXAFS data, the folbwing scheme of the complex miution structure can t3e 
concluded. 
Scheme 1. 
(pK = 2.5) pK = 11.20 
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8. EXAFS Structure Analysis of a Rhenium Complex with Neurotensin Derivative 
ORP500 
R. Jankowsky, B. Johannsen 
ORP500, a peptide derived from the peptide horrnone neurotensin, consists of ten amino acids and 
has the sequence (dimethyl)-Gly-Ser-Cys-Giy-Lys-Lys-Pro-Tyr-Ile-Leu (Fig. 1). The N-terminal end of 
the peptide chain neurotensin(8-13) is attached to the tripeptide (dimethy1)-Gly-Ser-Cys, an analogue 
to the peptide Giy-Gly-Cys, which possesses strong coordination abilities to Re(V). 
Fig. 1. Sequence of the neurotensin derivative ORP500 
Extended X-ray absorption fine structure (EXAFS) spectroscopy was applied to investigate the com- 
plex coordination spheres. The sample was freeze-dried. Fluorescence detection was used because 
of the small sample amount. The EXAFS data and their Fourier transformation are shown in Fig. 2. 
Fg. 2. Left: Experimental EXAFS data (dotted) vs. fit data (solid) of the rhenium(V) 
0x0 OPR500 complex. 
Right: Fourier transformation corresponding to the experimental EXAFS data 
(dotted) vs. fit data (solid) and three filtering regions. 
Several coordination shells, parIiy cleariy resoived, are visible in the Fourier transformation of the ex- 
perimental EXAFS data. For the first filtered coordination sphere (Fig. 2), one oxygen atom at a dis- 
tance to rheniufn of 1.70 A, three nitrogen atoms at a distance of 2.06 A and a sulphur atom at a dis- 
tance of 2.33 A were found. The absorption edge position of the rhenium(V) 0x0 ORP500 complex 
was determined to be I 0  529 eV. These characteristic features indicate an oxidaüon state of + 5 for 
rhenium. 
Table 1. EXAFS fit results for the rhenium (V)oxo ORP500 complex 
Backscattering CN R ( 4  0' (A2) AEo 
atom 
CN: Number of coordinating atoms, R: distance to rhenium central atom, 
02: Debye-Waller factor, AEo: Energy shift, Energy shifts were linked during several fits, 
First filtered coordination sphere, 
Second filtered coordination sphere, 
3 Third filtered coordination sphere, 
Multiple scattering along the Re-N-C path, 
Multiple scattering along the Re-N-C-N path, 
C Multiple scattering along the Re-C-0 path, 
d Multiple scattering along the Re-C-0-C path, 
" CNs were constraint during fits. 
The detected distance of 2.06 A for the nitrogen atoms is likely a mean value for two amide nitrogen 
atoms and one amine nitrogen atom corresponding to the rhenium(V) 0x0 Gly-Gly-Cys compiex. This 
assumption is supported by an increased Debye-Waller factor for this coordination shell. 
The sulphur atom at 2.33 A resulted from the involvement of cysteinyl-SH in coordination of rhenium. 
Therefore, fonnal SN3 coordination is obtained with very similar binding parameters to the rhenium (V) 
0x0 Gly-Gly-Cys complex. 
The second filtered coordination sphere in the Fourier transform~tion of experimental EXAFS data 
shows six carbon atoms with a mean distance to rhenium of 3.00 A. This sphere was fitted with muM- 
ple scattering functions along the Re-N-C and Re-N-C-N pathes. Values were obtained show the in- 
volvement of the peptide backbone chain in the metal chelate ring. 
For the third filtered coordination sphere, multiple scattering along the Re-C-0 and Re-C-0-C pathes 
was found. This shows the involvement of amide nitrogen atoms of the peptide in coordination of rhe- 
nium. 
From EXAFS fit resuits, the structure of the rhenium(V) 0x0 ORP500 wmplex as shown in Fig. 3 can 
be concluded. This wmplex shows a coordination sphere analogous to the rheniump) 0x0 Gly-Gly- 
Cys complex respectively the rhenium(V) 0x0 (dimethy1)-Gly-Ser-Cys complex. 
Fig. 3. Structure of the rheniumfV) 0x0 ORf 500 cornpkx 
9. Syntheses and Characterization of the Sulphamates of 175-Estradiols 
and 1 Ga-Fluoroestradiol 
J. Römer, J. Steinbach, H. ~asch' 
1 Hans Knöll Institut, Jena 
lntroduction 
In the 1970s Papers about sulphamates of 3-hydroxy-estra-l,3,5(10)-trienes were published for the 
first time [ I  - 41. They related to sulphamates of artificial steroids with a contraceptive effect. 
Attention has now been focused again on estrogen sulphamates by some remarkable new insights. 
First, estrogen sulphamates were found to act as sulphatase inhibitors in the body [5]. Second, taken 
orally they were found to pass freeiy through the he r  and thus to offer a much greater oral bioavail- 
ability than the mother steroids [6]. 
These new insights are remarkable in two ways. The first discovery promises a new approach to com- 
bating Cancer [5] as sulphatase activity occurs particularly in placenta and mammary tumours. The 
second discovery Opens up new ways of hormone therapy [6] and of oral contraception F]. 
The first discovery could also be of significance in PET tracer chemistry. If, for example, 16a- 
['8~uoroestradiol can be routinely converted into sulphamates, a new tracer should become avail- 
able for the sulphatase receptor. This tracer could supply some first imaging agents for sulphatase 
activity in placenta and mamrnary tumours. 
Three sulphamates are conceivable for 16a-fluoroestradiol. These three sulphamates, their properties 
and conditions of formation have to be known for successful sulphamoylation of 16a- 
[78~fluoroestradiol. It was therefore necessary to work out production processes. Estradiol (la) and 
17a-estradiol (2a) were available as commercial standard steroids. These unsubstituted diols and 
16a-fluoroestradiol(3a) as well as the relevant sulphamates are compiled in Schemel. 
Scheme 1 
Resutts and Discussion 
Using sulphamoyl chloride (SCI), the first preparatory sulphamoyiation experiments were carried out 
W& estrone (4) according to a rnethod specified by Howarth et al. [8]. Estrone-3-sulphamate (5) was 
obtained according to Scheme 2. We found confirrned [2] that the formation of the 3-amido- 
sulphonytoxy-estra-1,3,5(10)-triene stnicture is accornpanied by a hypsochromic SM of the absoip- 
tion maximum of the 3-hydroxy-estrogens by about 10 nm. The absorption rnaximum of 5 was found 
at 270 nm. In all the follovving syntheses the hypsochrornic shift was useful for identifying the 3-amido- 
sulphonyk,xyestra-l,3,5(10)-triene structure. 
Scheme 2 
Howarth et al. [8] sulphamatized 4 in DMF and used NaH as a deprotonation agent. In our case this 
procedure required a great excess of reagents and was too time-consuming. Because of its high boil- 
ing point DMF was not a suitable solvent for an automatic synthesis apparatus, Mich was to be used 
later. We therefore replaced it by MeCN and tested Spillane's solid-liquid phase transfer process 191. 
We were able to show that a few 3-amido-sulphonyloxy-estra-1,3,5(10)-trienes which are not accessi- 
ble through [8] can be favourably synthesized in this way. The process was used for all sulphamates 
mentioned in Scheme 1. 
Table 1. Physical data found for all steroids from Scheme 1 
Steroid Melting point ["C] Rf value a' RT (spec.) b' UV, [nm] 
1 a 177 - 179 0.27 1 .000 284 
3d 160 - 166 0.21 0.651 270 
a) Silica gel plates as carners and toluene I ethyl acetate (3:1) as solvent 
b) RT (@C.) = RT (steroid) 1 RT (la) 
C) Became rearranged during heating and showed the metting point of the 
rearranged product (see [1 01) 
The sulphamoylation of estradiols always yielded product mixtures which had to be separated by an 
efficient process. HPLC proved to be the rnethod of choice. We used a preparative RPI8 column. Elu- 
tion was by pure MeCN at a flow rate V = 7 mVrnin. The retention times found in this system for ia, 2a 
and 3a and for the sulphamates obtained from thern are compiled in Table 1. The tongest retention 
time (12.9 min) was found for estradiol (la). It was equated to 1. All other retention times in Table 1 
were related to 12.9 min. 
In addiion to HPLC, #in-layer chromatography (TLC) on silica gel plates was used to check the purity 
of the synthesized sulpharnates. The solvent was toluene/ethyl acetate (3 : 1). The Rf values found are 
aiso included in Table 1. In addition, Table 1 cornprises the rrtelting points of ail compounds frorn 
Scheme I and their UV maxirna. 
Sulphamoylation of estradiol (la) 
After addition of the stoichiometric amount of SC1 and doubfe the stoichiomelric amount of anhydrous 
Na&%, vigorous stirring of a solution of estradiol (la) in anhydrous MeCN yietded three reaetion 
products as weil as unreacted l a  after a short reaction time at room ternperature, Une of them was 
produced in a distinctiy bigger yield than the other Wo. It proved to !X? estradioE1Jf3-sulphamte (ic). 
Schwarz ef al. [l I] were aiso surprised by this because äieir eariier experiments wiih 17a-ethinyl es- 
tradioi [3] bad aiways shown that suiphamoyiation was strköy confined to äie phendic QH group. 
With the stoichiometric amount of SC1 the yield of sulphamates was small. It grew along with the 
amount of SCI. The amount of estradiol-3,17ß-disulphamate (Id) increased in particular. The yield of 
estradiol-3-sulphamate ( I  b) always remained the lowest. 
To obtain I c  in amounts of about 50 mg, reaction batches of 100 mg of estradiol (la) and the treble 
stoichiometric amount of SC1 were needed. With the tenfold amount of reagent the formation of I d  
finally predominated. Sulphamoylation of estradiol (la) did not offer favourable conditions for the 
preparation of I b. 
In an alternative process for the preparation of I b according to Schwan and Elger [7] estrone sul- 
phamate (5), which was easy to prepare from estrone (4), was reduced in THF/MeOH with NaBH4. 
The reaction sequence is shown in Scheme 2. 
The retention times of the estradiol sulphamates increased in the order I d  C I c  C Ib. But the se- 
quence of the fi values indicated by TLC differed from the retention times: I b  < I d  c Ic. 
Sulphamoylation of 17a-estradiol(2a) 
When the same sulphamoylation conditions were used for 17a-estradiol (2a) as for la, three reaction 
products were again obtained in addition to unreacted 2a. The elution sequence was the same as 
above, i.e. 2d C 2c < 2b, and the main product was 17a-estradiol-17a-sulphamate (2c). Excessive SC1 
caused the quantitative reaction of 2a with the formation of 2c and 2d afier only 1 hour's stirring. Dif- 
ferent reaction conditions (CH2CC instead of MeCN as reaction medium, higher temperature, long 
reaction time) also yielded a non-polar by-product at R, = 15.8 min [10]. This by-product was not 
formed when the sulphamoylation occuned in MeCN at room temperature. 
While the sulphamates Ib, Ic, I d  as well as 17a-estradiol-3-sulphamate (2b) and 17a-estra@ol- 
3,17a-disulphamate (2d) were stable compounds, 17a-estradiol-17a-sulphamate (2c) proved to be 
very delicate. Studies showed that 2c forrned the above-mentioned non-polar by-product [ I  01 on mere 
exposure to air. By boiling in MeCN 2c was completely transformed into the non-polar product [10]. 
TLC again showed a sequence of the Ri values which differed from the retention times. With 2b C 2d < 
2c, the sequence was the same as above. TLC showed further that the above-mentioned by-product 
was also formed on the TLC plate. 
Suiphamate of I&-fluoroestradiol(3a) 
The required 16u.fluoroestradiol (3a) was prepared according to a specification by Lim et al. [ I  21 and 
purified by preparative HPLC. 
At first glance sulphamoylation of 3a only seemed to yield two products. lt turned out, however, that 
16a-fluoroestradiol-3-sulphamate (3b) and 1 Ga-fluoroestradiol-l7ß-sulphamate (34 had the came 
retention time (9.0 min). The latter dominated to an extent that the abcorption maximum of 3b (2, = 270 
nm) was not even noticed in the mixture, i.e. predominantly 16a-fluoroestradiol-3,17ß-disulphamate 
(W) and 16a-fluoroestradiol-17ßsulphamate (3c) were found. No formation of non-polar products was 
observed. It was therefore not necessary to restrict the production conditions to room temperature and 
MeCN as in the case of 17a-estradioi (2a). 
Some experiments conducted for optimization are compiled in Table 2. While the amount of substrate 
remained the same, the amounts of reagent and of anhydrous Na2C03 were varied. The solvent was 
dichloromethane. Each batch was stirred in a bath of 50 "C. Samples were taken afier 2 and 4 hours 
and analysed by HPLC. Table 2 shows the peak distribution after the second sampling. It has to be 
taken into account that the peak of 3c contained a small amount of 3b. 
Table 2: Optimum reaciion conditions for the synthesis of 16a-fluoroestradiol-17ßsulphamate (3c) 
and 16a-fluoroestradiol-3,17ßdisulphamate (3d) 
Reaction wnditions Product distribution Experiment 
.- - -_ ---_----- *-- ---* ----- ------ --- -- --------- --- ---- -- --- --- ---------- ----- --- 
Substrate 3a §CI Na2C03 3d 3c Rest of 3a 
[mg] / fmmol] [mg] 1 [mmol] [mgf I [mmol] [%] [%] 
1 15 I 0.052 62 J 0.54 10010.94 80 9 0 
In experiments 1, 2 and 3 about the same amount of substrate 3a and excessive reagent (m(SCI) : 
m(3a) = 10 : 1) was used. When there was also sufficient alkali as in experiment 1 (m(soda) : m(SCI) = 
2 : I) ,  16a-fluoroestradiol (3a) was completely converted and a high yield of disulphamate 3d ob- 
tained. When there was not enough alkali (experiment 2), only part of 3a was sulphamatized, chiefly to 
1 Ga-fluoroestradiol-l7ß-sulphamate (3c). A partial conversion occurred even without alkali (experi- 
ment 3). Disulphamate was practically not formed in this process. When only double the molar amount 
of reagent was used for sulphamoylation (experiment 4), 3a was only partially sulphamatized in spite 
of the presence of excessive alkali, and a similar result as that of experiment 2 was obtained. 
The conditions of experiment 1 were suitable for preparation of disulphamate 34 while sulphamatiza- 
ton in the absence of alkali was useful for preparation of 3c, although with qualifications. First, 3c was 
never obtained pure but always contained small amounts of 3b. Second, it was advisable to recover 
the unconverted 3a. Third, the yield of 3c was not increased by addition of further SCI.. 
The conditions of experiments 2 and 4 are unsuitable for sulphamoylation. This is due to the fact that 
SC1 and Na2C03 can also react with each other (see Eq. (1)) so that after a certain reaction time the 
deficient reactant is used up. The results of experiments 2 and 4 were therefore between the resuks of 
experiments 1 and 3. 
Two alternative processes were devised for preparing the pure monosulphamates 3b and 3c, starting 
from 1 Ga-fluoroestradiol-l7ß-sodium sulphate (6) or from 3-0-methoxymethyl-16a-fluoroestradiol (8) 
(see Scheme 3). The starting material 6 was obtained from 16a-fluoroestradiol-l7ß-hydrogensulphate, 
an intermediate compound in the synthesis of 3a [ I  31, by treatment with a cation exchanger in the Na+ 
form. 
Sulphamoylation of 1 Ga-fluoroestradiol-l7ß-sodium sulphate (6) yielded 3-0-amidosulphonyl-l6a- 
fluoroestradiol-17ß-sodium sulphate (7). The reaction was sluggish. The following hydrolysis was car- 
ried out according to an elegant procedure [12] by refluxing a Solution of 7 in anhydrous MeQH in the 
presence of an H+-charged cation exchanger. All available sulphamate 7 was wnverted into 3b. Unre- 
acted 6 yielded 3a. 
3-0-Methoxymethyl-l6a-fluoroestradiol (8) was synthesized from 3a. The sulphamoylation of 8 W- 
curred in a quantitative process, yielding 3-0-methoxymethyl-16a-fluoroe~tradiol-17ß-sulphamate (9). 




Aldrich, Fluka and Sigma were the suppliers of commercial reagents and solvents. SC1 was prepared 
according to [14] from chlorosulphonyl isocyanate, 16a-fluoroestradiol (3a) according to a modified 
specification [ I  31 from estra-1,3,5(1O)-trieneB,16ß,17ß-triol. 
Equipment 
The melting points were determined using a " ~ a l e n ~ ~ l l l "  microheating Stage (Reichert Division of the 
Vienna Leica AG) with a digital temperature measuring system. 13c NMR spectra were recorded with 
a DRX 500 spectrometer (Bruker). A Merck-Hitachi HPLC system was used for the chromatographic 
analyses. It comprised an L-6200A gradient pump, a Rheodyne injector with a 500 yI loop, an RP col- 
umn SP 250121 Nucleosil 100-7C18 (Macherey & Nagel) and an 1-4500 DAD diode array detector. The 
eluent was pure MeCN, the flow rate was 7 m l l  min. UV absorption was measured at h = 275 nm. 
General sulphamoylation specification 
The chosen substrate ( l a  or 2a or 3a) was dissolved in a suitable solvent (MeCN or CH2CI2), adding 
freshly heated and recooled Na2C03 (anhydrous, the tenfold molar amount related to the substrate) to 
the solution. SC1 (at least the double and not more than the 8fold molar amount related to the sub- 
strate) was added while stirring vigorously. Stirring was then continued for a few hours at room tem- 
perature or a higher temperature. The end of the reaction was determined by HPLC control. Process- 
ing: The batch was stirred into diluted HCI, followed by double extraction with ether, washing of the 
combined organic phases, evaporation of the ether, take-up of the residue in a suitable amount of 
MeCN. HPLC: The injection volume depended on the efficiency of separation. Per 0.1 mmol of sub- 
strate about 1 ml of MeCN was added to the extracted substance mixture. The injection volume was 
chosen in the range from 0.2 to 0.5 ml. Obtaining the product: The peaks of interest were separately 
collected in beakers. MeCN was boiled down to 10 ml on the heating plate. The MeCN solution of 2c 
was an exception. This solution was carefuliy boiled down in the rotary evaporator at not more than 
45" C, then covered with a layer of argon and the sealed flask kept in the refngerator. The solutions of 
the other peaks were left to stand Open overnight and the solid crystalline product was weighed the 
following morning. 
Syntheses 
1) Estradiol-3-suluhamate ( I  b). estradiol-l7ß-suluhamate (I C) and estradiol-3.17Bdisul~hamate (I d) 
(a) l a  (85 mg, 0.3 mmol) was dissohred in MeCN (anhydrous; 15 ml) in a round-bottomed flask. 
Addition of Na2C03 (anhydrous; 265 mg, 2.5 mmol). After setting a high stirring speed, SC1 
(1 16 mg, 1 mmol) was added. Stirnng time at room temperature: 2 hours, reaction control by 
HPLC. Procecsed as usual and taken up in 2 ml of MeCN. Preparative HPLC with 8 times 0.25 ml 
injection solution, separate collection of the peaks of Id, I c  and Ib, product obtained as usual. 
White crystals. Weighed products: I d  (11 mg = 25.6 pmol), I c  (38 mg = 108 pmol), I b  (6 mg = 
17 pmol). 
(b) 500 mg of Na2C03 (4.7 mmol) and 350 mg of SC1 (3 mmol) were added to a similar-sized batch 
of l a  in MeCN, which was otherwise treated as above described. HPLC indicated no l a  and very 
JMe Ib. Weighed products: I d  (68 mg = 158 ymol), I c  (25 mg = 71 ymol). 
2) Estradiol-3-suluhamate (Ib) from estrone (4) 
4 (135 mg, 0.5 mmol) was d i i h r e d  in MeCN (anhydous, 15 ml) in a round-bottomed flask and 
Ma2C03 (anhydrous; 510 mg, 5 mmol) and SC! (310 mg, 2.7 mmol) were added to it. The colution 
was stined vigorously for 6 hours at room temperature. Procecsed as usual, preparative HPLC, 
product obtained as usual. Weight of estrone sulpharnate (5): 92 rng = 0.26 mmol; yiefd: 52 %. The 
whiie product 5 was dissobed in a mucture of THF (2.5 ml) and EtOH (2.5 ml). NaBH4 (20 mg, 
0.5 mmol) was added to this batch in an ice bath and stirred for 2 hours. HPLC control, processed 
as usual, HPLC purification with 5 times 0.25 ml, produd obtained as usual. Weight of I b: 52 mg 
(0.15 mmol). Yieki related to estrone (4): 30 %. 
3) 17a-estradiol-3-sulohamate (2bA l7a-estradiol-l7a-sulohamate (2c) and 17a-estradiol-3.17a- 
disulohamate (2c) 
(a) 2a (90 mg, 0.33 rnmol) was dissolved in MeCN (anhydrous; 15 ml) in a round-bottomed flask. 
Addition of Na2C03 (anhydrous; 370 rng, 3.5 mrnol). After setting a high stirring speed, SC1 
(230 mg, 2 mmol) was added. Stirring time at roorn temperature: 1 hour, reaction control by HPLC. 
Processed as usual and residue taken up with 2.5 ml of MeCN. Preparative HPLC with 10 times 
0.25 rnl injection solution, separate collection of the peaks of 2d, 2c and 2b. Product distribution: 
2d (14 %), 2c (42 %), 2b (10 %), remainder of 2a (34 %). Processed as usual and products 2d and 
2b obtained as usual. Weighed products: 2d (17 rng = 39.5 pmol), 2b (9 mg = 25.6 pmol). The 
MeCN solution of 2c was boiled down to 2 rnl at 45 "C in the rotary evaporator. The remaining 
MeCN was dispelled with argon. A tan coloured product was obtained. Quick weighing showed the 
product to be 48 mg (136.7 pmol). 
(b) A batch of 83 rng (0.305 rnmol) of 2a, 10 ml of MeCN, 507 rng (4.8 mmol) of Na2C03 and 
290 mg (2.5 mmol) of SC1 was vigorously stirred at roorn temperature for 2 hours. HPLC indicated 
only the 2 peaks of 2d and 2c. Product distribution: 2d (70 %), 2c (30 %). Processed and products 
obtained as above described. Weighed products: 2d (81 mg = 188 pmol) and 2c (20 mg = 
57 pmol). 
4) 16a-fluoroestradiol-3.17ß-disulohamate (3d) 
3a (1 10 mg, 0.38 mmol) was dissolved in CH2C12 (40 rnl) in a 100 ml round-bottomed flask, and 
anhydrous Na2C03 (600 mg, 5.65 mmol) was added to it. SCI (480 rng, 4.15 mmol) was added 
while stirring vigorously, and stirring was continued for 4 hours in a bath of 50 "C. Reaction control 
by HPLC. The solvent was dispelled in the rotary evaporator. Processed as usual, residue taken'up 
in 5 rnl of MeCN, then preparative HPLC with 10 times 0.5 ml injection solution. Only the peak of 
3d was collected. Product obtained as usual. Weight of 3d: 108 rng (251 pmol) of a white crystal- 
line product. Yield: 66 %. 
5) 1 Ga-fluoroestradiol-178-sul~hamate /3c) 
3a (87 mg, 0.3 rnmol) was dissolved in THF (anhydrous; 5 mi) in a 15 ml round-bottomed flask. 
NaH (60 % suspension, 30 rng, 0.75 mmol; freed from mineral oil by means of hexane, then sus- 
pended in 3 ml THF) was added to it. Methoxymethyl chloride (0.04 ml, 0.5 mrnol) was added to 
0.5 ml THF and this reagent solution stirred into the batch. HPLC showed good conversion after 
2 hours' stirring. Processed as usual by ether extraction. The residue was 3-0-methoxymethyl- 
l6a-fluoroestradiol(8) as a yeliow oil. 
To the oil were added CH2C12 (anhydrous, 5 ml), anhydrous Na2C03 (150 mg, 1.42 mmol) and SC1 
(1 10 rng, 0.95 rnmol). The batch was vigorously stirred for 2.5 hours in a bath of 50 "C. HPLC 
showed almost complete conversion to 3-O-methoxyrnethyl-l6a-fluoroestradiol-l7ß-sulphamate 
(9). The batch was fiitered, fiiter and d a  were washed with CH&i2. The filtrate was boiled down 
in the rotary evaporator. 
Four tirnes 1 ml of 0,1 M hydrochloric MeCN solution was added to the residue of sulphamoylation 
with its content of 9 and the rnixture evaporated to dryness in the rotary evaporator 1161. The solid 
residue was processed as usual, the residue taken up in MeCN (2.5 ml). Preparative WPLC wiih 10 
times 0.25 ml injection solution, peak collection and preparation of the product as usual yieMeti 
55 rng of W i e  crystalline 3c equivalent to 150 prnol. The yieM was 50 % related to 3a. 
6) 1 Ga-fluoroestradiol-3-sul~hamate 13bl 
A batch of 16a-Ruoroestradiol-17ß-sodium sulphate (6) (93 mg, 0.237 mmol), MeCN (30 ml), anhy 
drous Na2C03 (510 mg, 4.8 mmol) and SC1 (510 mg, 4.4 mmol) was vigorously stirred at rwm 
temperature for 1 hour. The MeCN was dispelled in the rotary evaporator, 10 rnl of besh MeCN 
was added and again d ' i l l ed .  This was repeated five times, each time adcling 10 rnl MeCN. Each 
time a white, caked residue remained on the inside of tbe ftask. The cation exchanger (CAT; H+ 
form, washed neutral, 12 mmol capacity) was treated with 4 portions of Mi3OH (anhydrous, 10 ml 
each) and then put into the abve flask W'& 3 poportions of M&M (10 rnl each). The batch was re- 
fluxed for 2 hours in a bath of 95 - 100 "C. The methanoiii solution was ihen a vwy pale yellow 
and clear. It reacted acid and contained 3b and 3a in the ratio 1 : 2. The mthanolic soiution was 
fiitered off, The fiiter witS'i the CAT was washed severat times w h  a iittle M H .  The combined fiC 
trates were WiM down in the rotary svaporator. After ihe usual p r w s s  3 ml of MeGN wem add& 
to the residue of the concentrated ether extract. HPLC with 6 times 0.5 ml injection solution. Only 
3b was collected. Product obtained as usual. Weight: 21 mg of a white product. This is equivalent 
to 60 pmol of 3b. The yield was 25.2 %, related to 6. 
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Introduction 
In the preparation of sulphamates of 17a-estradiol [ l ]  a non-polar product was observed, which occur- 
red in particular when the reaction batches had been heated. This non-polar product was formed from 
1701-estradiol-17a-sulphamate (1) and was a stable compound. Its stnicture was chiefiy determined by 
'H NMR and 13c NMR. It proved to be 17-methyl-gona-l,3,5(10),13(17)-tetraene-3-ol(2). 
Experimental 
The 13c NMR spectrum was recorded with a DRX 500 spectrometer (Bruker). A 'H NMR spectrum 
was also prepared, and the two-dimensional methods COSY, HSQC, HMBC and NOESY were used 
to clear up its structure. 
Synthesis: 
MeCN (5 ml) was added to 17a-estradiol-l7a-sulphamate (1) (HPLC purified, 13 mg, 39pmol). The 
clear solution was slowly boiled down to 1 ml on the heating plate and then restored to 5 ml by adding 
MeCN. HPLC indicated the complete conversion of 1 and the formation of a non-polar product with a 
retention time of 15.6 min. Evaporation of MeCN at room temperature yielded a fine white produd. 
Weight: 8.5 mg. This is equivalent to 33.5 pmol of 2. The yield was 86 % related to 1. 
Results and Discussion 
17-Methyl-gona-l,3,5(1 O), l3(l7)-tetraene-3-ol (2) was first prepared by Aninachalam et al. [2] by re- 
fluxing 17a-lodestra-l,3,5(10)-triene-3-01 (3) for 24 hours (!) in 2-propanol in the presence of Nal. The 
meiting point indicated by the authors was 95 "C. But we found a quick and complete conversion of 1 
+ 2 and 132 - 135" C for the chromatographicaliy pure product. That is to say, comparsd with the 
substituent 17a-I, the 17a-0-SO2-NH2 group is a much better leaving group. 
The 'H NMR spectrum also contradicted 
structure I as there were no additional olefi- 
nic protons. But it contained a methyl group 
at 1.65 ppm as a singlet. Its location, the fact 
that there was no cleavage and the HMBC 
suggested a methyl group at a double bond. 
Structure II was in agreement with this resuit. I II 111 
The assumption of structure II and the che- 
mical shifts found in the 13c NMR spectnim indicated the assignments shown in Table 1. 
Table 1. Assignments suggested for the chemicai shifis of the non-polar produd 
C atom 6 fppml C atom 6 @Pm1 C atom 6 [W>m3 
1 127.9 7 28.4 13 129.1 
As expected, a comparison of ahe chemical shifts of the six Ring A cartxn? a t m  of TaMe I with the 
values of the 3-ttydroxyestra-1,3,5(10)-trienes shows good agrwment. Tbe values also agreed for 
C@) and C(7). On tt\e basis of this certain refationship it was possiMe to ciearfy define the assbnment 
of the protons ta ca- chains 7 - 8 - 14 - 15 - 16 and 9 - 1 1 - 12, ugng the two-dimensiwKiI 
spectrurns. The definite assignrnent of the protons also pointed to a A ' ~ ( ' ~  structure II .  The as- 
signrnents of the protons of compound 2 are cornpiled in Table 2. 
Table 2. Assignment of the chernical shifts of the H atorns in the 'H NMR spectrurn of compound 2 
H atom 6 [ P P ~ ]  H atorn 6 [ P P ~ ]  H atorn 6 [ P P ~ ]  
1 -H 7.18 8ß-H 1.00 14a-H 2.30 
7ß-H 1 -94 12ß-H 2.67 
a) Location of centroid; it holds that 6(6ß) > 6(6a) 
b) Location of centroid 
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All sulpharnates b c, d shown in Scheme 1 were described in the above paper [I]. They were cleariy 
characterized by "C NMR spectroscopy. 
R ~2 
Scheme 1 a H H 
b H2N-SO2 H 
C H SO2-NH2 
d H2N-SO2 SO2-NH2 
Experimental 
The NMR spectra were recorded using a DRX 500 spectrometer (Bruker). 
Results and Discussion 
The chemical shifts found for estradiol (la) and its three sulpharnates, 17a-estradiol (2a) and its thrse 
sulphamates and 16a-fluoroestradiol(3a) and its three sulphamates are compiied in Tabie 1. 
A 3-O-sulphamate group influences in particular the chemical shifts of the Ring A carbon atoms. We 
found a distinct high-fild shii for the signal of C(3) and distinct low-fieid shifts for the signals of C(2) 
and C(4). The signals of the atorns C(1) and C(5) were hardly influenced at all. But the unshielding 
effect on C(10), Wich led to the signals of C(5) and C(10) lying side by side, was remarkable. This is 
a characteristic feature of the presence of a 3-amidosulphonyloxy-estra-l,3,5(10)-triene. 
A 175-O-sulphamate group mainiy influenced oniy the chernical shift of C(17), but unlike the 3-0- 
sulphamate group it did this by causing a bw-field shifl of the sgnat. The above-rnentioned infiuences 
were all present in the 3,175-disulphamates. 
A cornparison of the spectra of estradiol (Ja) and I6a-fluoroestradiof (3a) shwed that Ruorine ac a 
substituent influences in particular the Ring D carbon atorns. The coupling constants strmgiy confir- 
med the 16a orientation. It was to be expected that the signals of the Ring D carbon atoms are cpli 
into doubiets in the spEtctra of the Ruorosteroids 3s - 36. The coupling constant 'J(c,F) was found ta 
be - 178.5 Hz, which agrees wiär the value for Ruorocyckpentane quoted in the literature (- 173.5 Hz) 
121. The coupling constants 'J(C,F) were 21.7 Hz for C(17) and 23.1 Hz for C(l5). ?he cwpling con- 
stants 3 ~ ( ~ , ~ )  for C(14) turned out to be 4.9 Hz and for C(13) 6.1 Hz. Because of the greater dihedrai 
angle the !arger value of C(13) can aniy be expiained by I&-F in the Karplus equation. 16ß-F wouM 
have caused a larger value for C(14). 
Table 1. 13c chemical shifts of estradiol (la) and its sulphamates, of 17a-estradiol(2a) and its 
sulphamates and of 1 Ga-fluoroestradioi (3a) and its sulphamates 
atom 
1 126.0 126.9 127.2 127.0 127.1 127.6 127.1 127.1 126.0 126.4 126.0 126.3 
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In an effort to develop radiopharmaceuticals useful for diagnostic imaging of steroid receptor-positive 
breast tumours, several progesterone receptor ligands containing a bulky N2S2 (e-g. BAT, MAMA) 
rhenium and technetium chelate have been explored. The complexes obtained represent stereoico- 
mers which were not completely separable. The remarkably high receptor affinity of some of these 
conjugates is compromised by a high nonspecific binding due to high Iipophilicity [I]. 
To extend our current research aimed at technetium tracers capable of binding to steroid hormone re- 
ceptors, we explored the usefulness of small-sized neutral mixed-ligand complexes, thioether-carbonyl 
complexes and organometallic complexes. In our preliminary investigations, rhenium was used as a 
model for the radioactive technetium. Starting from 21 -hydroxyprogesterone (deoxycorticosterone), we 
prepared various progesterone-rhenium chelates containing the rhenium meta1 at the oxidation states 
+5, +3 and +l. 
Experimental 
Starting from commercially available deoxycorticosterone, the 21-hydroxy group was converted into a 
thiol group, N-formyl amine group and dithioether unit required for the formation of rhenium complexes 
according to the "n+lS mixed-ligand design and dithioether-carbonyl design. The attachment of a cy- 
clopentadienyltricarbonylrhenium(l) moiety was accomplished by an ester formation invohring the 21- 
hydroxy group. 
Results and Discussion 
21-Mercaptoprogesterone 1 was subjected to standard conditions 121 for äle formation of ,fe '&1* 
mixed-ligand complexes 2 and 3 by means of two dierent oxorhenium(V) precursorc 4 and 5 (Fa. 1). 
Me 6 3 
Fig. 1. Synthecis of "3t J * mixed-ligand complexes 
The reaction of the chlorine containing oxorhenium(V) precursor 4 with thiol 1 in refluxing acetonitrile 
gave the "SSS" mixed-ligand complex 2 in a good yield (67 %) as brown crystals. The alternative 
"SNMeS" complex 3 was obtained by the reaction of the oxorhenium(V) precursor 5 with the mono- 
dentate thiol ligand 1 and tridentate "SNMeS" ligand 6 in refluxing 1 N methanolic NaOAc. 
Suitable crystals of 2 for X-ray single crystal analysis were obtained by slow crystallization of 2 from 
acetoneln-hexane solution at room temperature. The X-ray structure of complex 2 is shown in Fig. 2. 
Fig. 2. X-ray structure and selected bond lengths [AI of complex 2 
The four sulphur donor atoms are arranged in a square-pyramidal geometry around the oxorhe- 
nium(V) core as is typical of "SSSn-cwrdinated "3+lU mixed-ligand complexes. The square-pyramidal 
chelate moiety exhibiis an anti-like orientation with respect to the ß-orientated methyl groups at posi- 
tions 10 and 13 of the progesterone molecule. 
Alternatively, a *4+ln mixed-ligand design [2] is based on rhenium and technetium in the oxidation 
state +3. The tetradentate ligand N(CH2CH2-SH)3 fills four of the five coordination sites of the 
metal(1ll) core, the remaining position being occupied by a monodentate isocyanide ligand. The %+Iu 
complex 9 was convenienüy prepared in one step by reaction of the phosphane-containing tripodal 
rhenium(ll1) precursor 8 with an isocyanide generated in situ. Starting from forrnamide 7, we used 
POCl~diisopropylamine as a dehydrating agent to prepare the corresponding isocyanide. The isocya- 
nide immediately undergoes a substituüon of the phosphane ligand in 8. This procedure avoids the 
isolation of the free isocyanide, and gives complex 9 in a modest yield (53 %) as an olive-green solid 
(Fig. 3). 
Fig. 3. Synthesis of "&I mixed-ligand cornplex 9 
A bromotricarbonylrhenium(l) moiety was attached to the dithioether 10 as inaugurated by Alberto et 
al, [3]. The two soft donor sulphur atoms of the dithioether unit replace two of the three bromine atoms 
of precursor 11, to give the neutral rhenium(1) complex 12 in a good yield (79 %) (Fig. 4). 
Fig. 4. Synthesis of complex 12 
1 H NMR analysis of complex 12 reveals the formation of a 1:l diastereomeric mixture. The attachment 
of the tricarbonyl bromo rhenium(1) core through the thioether sulphur leads to a rhenium(1) chelate 
where the rhenium is a stereogenic centre (Fig. 5). Furthermore, the coordination of the thioether sul- 
fur also results in the formation of chiral sulphur donor atoms. 
Fig. 5. Diastereomeric rhenium complexes 
An organometallic cyclopentadienyltricarbonylrhenium(l) complex 15 was synthesized in an excellent 
yield (96 %) by coupling 21-hydroxyprogesterone 13 with cyclopentadienyi tricarbonyl rhenium(1) Gar- 
boxylic acid 14 by means of 1-ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) as the dehydrating 
agent and DMAP as the cataiytic base (Fig. 6). Rhenium(1) precursor 14 was easiiy obtained by a 
central meta1 exchange reaction starting from ferrocene dimethylester [4]. 
Fi. 6. Synthesis of cyclopentadienyWarix,nyi~enium(J) complex 15 
The complexes were used in a competitive receptor-binding assay (rat uterine qtosof, O 'C) t0 deter- 
mine their binding to the progesterone receptor (PgR) (Tabie 1). 
Table 1. Relative binding affinities (RBAs) of 21-substituted progesterone rhenium complexes for the 
progesterone receptor @BARU 5020 = 100). 





The best affinity of 9 % (RU 5020 = 100 %) was obtained with "3+1" mixed-ligand complex 3 contain- 
ing a NMe group as the central donor atorn in the tridentate ligand part. This value reflects a relative 
binding affinity of 75 % compared with the parent molecule progesterone. 
We described the preparation of several new PgR binding ligands labelled with rhenium by four differ- 
ent means - three inorganic complexes and one organometallic complex - and we have shown that 
some of these have substantial binding affinity for the progesterone receptor. Further investigations 
concerning the in vivo stability of all complexes are planned using the corresponding technetium-99m 
complexes. 
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The synthesis of metal-containing complexes capable of mimicking the steric structure of steroids re- 
presents an alternative integrated design for the synthesis of steroid receptor-binding ligands. Here 
the characteristics of the metal-containing complex are acsociated with the steric and functional con- 
tours of the receptor ligand. 
Studies of the potent nonsteroidal estrogen diethylstilbestrol (DES) showed that the ER can accom- 
modate a second phenol ring that mimics the 17ß-hydroxy-substituted D-ring. DES has been shown to 
possess a trans-stilbene structure and the distance between both oxygen atoms, which plays an im- 
portant role in receptor binding, is 12.13 A. This distance is close to that of 3,17ß-estradiol(10.9 - 11.0 
A) [I, 21. 
The further expansion of metal-containing steroid rnimics on oxorhenium(V) and oxotechnetium(V) 
compiexes according to the *3+lm rnixed-ligand concept and knowledge of the structural requirements 
for binding to the ER [I, 21 resulted in the design of an oxometal(V) complex (Fig. 1 .) as a DES rnimic. 
M = Re, Tc 
Fig. 1. "3t lm mixed-ligand complex as a DES mimic 
Results and Discussion 
In our preliminaty investigations we sirnplified the structure of the target molecule by removing the hy- 
d r o ~  group of the pyridine ring. Thus, commercially available 2,6-dimethanolpyridine 1 could be used. 
Its conversion into the corresponding tridentate "SN9 ligand 2 is shown in Fig. 2. 
Chlorination of the alcohol 1 by means of thionyl chkride in chloroform generated the conesponding 
chioro derivative. Treatment of the dichloro compound with thiourea in refiuxing EtOH yielded the 
isothiuronium satt, which was then saponified with NaOH to release ätiol2 in a total yieM of 50 %. 
1 2 
Rg. 2. Synthecic of the tridentate "CNS-iigand 2 
The formation of the "3+1" mixed-ligand complexes 6 - 8 was achieved by the common reaction of the 
oxorhenium(V) precursor 6 with the monodentate thiols 3 - 5 and the tridentate "SNS" ligand 2 (Fig. 
3.). The complexes 7 - 9 were obtained in moderate yields of 48 % - 57 %. 
R = O H  3 
OMe 4 
H 5 
R =  OH 7 (57%) 
OMe 8 (48%) 
H 9 (51%) 
Fig. 3. Complex formation of the steroid mimics 7 - 9 
For compound 8 crystals suitable for an X-ray single crystal analysis were obtained. The X-ray structu- 
re of complex 8 is given in Fig. 4. 
Fig. 4. X-ray structure of complex 8 and selected bond lengths (A) 
Compkx 8 exhibiits the usual square-pyramidal arrangrnent of the four donor atoms (SNS-S) around 
the [Re=0]* core. The tridentate Iigand part used represents a novel set of donor atoms capable of 
foming "3tf mixed-ligand cornpiexes, being Wo benzylic sulphur atoms and a pyridine nitrogen. The 
pyndine nitrogen is iess basic #an the centai tertiary amine nitrogen of the "SNMeS' ligand, which is 
othetwised empbyed. 
In an even more simpfiied structure according to the lntegrated Design compiex 10 is uced. Simple 
reacäon of 4hydroxy thiophenol 3 with the chlorine-containing oxorhenium(V) precursor 6 afforded 
complex 10 in a 33 % yieM (Fig. 5.). 
Fig. 5. Synthesis of complex 10 
All complexes display the characteristic Re=O stretching band in the IR-spectra, being 961 cm-' for 10, 
965 cm-' for 7,965 cm-' for 8 and 968 cm-' for 9. 
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Diagnostic nuclear medicine provides valuable information on a variety of disease states. In recent 
years there has been an increasing interest in tracers able to visualise biochemical reactions in vivo. 
For imaging the various redox processes occurring in the organism the development of redox-active 
radiotracers is needed. The search for Tc tracers in this field is in its infancy. First technetium mm- 
plexes with 2-nitroimidazoles that are enzymaticaliy reducible in the organism and accumulate in hy- 
poxic tissue and in tumour cells were studied in vivo some years ago [I, 21. Recently *CU-labeled 
complexes based on bis(thiosemicarbazone) and bis(salicylaldimine) ligands were prepared and 
tested for cell uptake under norrnoxic and hypoxic conditions [3J. Looking for technetium chelates 
bearing a pyridinium saltidihydropyridine moiety by analogy to the NAD'INADH redox s stem we de- 
veloped a mixed-ligand rhenium pyridinium mmplex [4]. Re serves as a Surrogate for &Tc and de- 
scribes the reduction with sodium dithionite to the dihydropyridine compound. in the present paper we 
report the synthesis of a "TC pyridinium salt complex according the "3+ln principle and its characteri- 
sation by 'H NMR-, NMR spectroscopy and X-ray structure analysis. After conversion to the corre- 
sponding 14-dihydropyridine compound the stability of the "TC dihydropyridine complex in buffer, tis- 




HPLC-investigations were carried out with an analytical RP18 column (Lichrospher 100 RP-18, 5pm, 
MERCK) and a semi-preparative RP column (Uitracarb 5 ODS, 20 , PHENOMENEX) using a 3:1 mix- 
ture of iso-propanovphosphate buffer (10 mmol, pH = 7.0) as eluent with a flow rate of 0.2 mllmin or 
0.8 mVmin respectiveiy. The products were determined by UV absorbance at 254 nm and by ß- 
detection with a scintillation detector (Ramona 90 , RAYTEST). The NMR spectra were recorded on 
an FT-Spectrometer ARX 500 (BRUKER) in DMSO-d6.The UVNlS spectroscopic measurements were 
carried out with a diode array spectrometer with 1024 diodes (J & M ANALYTISCHE MESSTECHNIK). 
The X-ray structure analysis was performed on a Image Plate Detector System (STOE) with MoK, X- 
rays (71.07 pm) and calculated with the programs Stoe Expose, Stoe Cell and Stoe Integrate. 
Reparation of PTc](l -~ethyl-3-pyridinyl-ethylcarbamoyl-ihioaio)(ihiantan- 1,5-diihio1ato)oxo- 
technefium(V)-iodide 2. 
54 ml of an aqueous N H ~ ~ C O ~  solution (C = 4.64 mmoV1,250 pmol) was added to 5.45 g (25 mmol) 
sodium d-gluconate dissolved in 10 ml water. Reduction to gluconate was carried out by addition 
of 15 m10.02 M solution of stannous chloride (20 mmol) in 0.1 M HCI. After complete reduction 486 mg 
(1.5 mmol) 3(2-mercaptoethyl carbamoy1)-1-methylpyridinium iodide 1 dissolved in 5 ml water was 
added followed by 25 ml acetonitrile after 25 minutes and 39 mg (250 pmol) 3-thia-16-pentanedithiol 
dissolved in 5 ml acetonitrile. The reaction mixture was evaporated to 5 ml and the product was puri- 
f i i  by preparative HPLC. Yield: 96 mg (163 pmol, 65 %), M.p. 190 - 194 "C. 
'H NMR (DMSO-G) qpprn]: 2.26 (2H, td), 3.03 (2H, td), 3.67 (2H, q), 3.86 (2H, t), 4.08 (2H, dd), 4.30 
f2H, dd),4.39 (3H, s), 8.22 (IH, t), 8.88 (IH, d), 9.09 (1H,d),9.30 (IH, t), 9-39 (IH, s); 
I3c NMR (DMSO-ds) G[ppm]: 34.94 (CH2), 42.64 (CH2), 43.04 (2xCH2), 45.74 (=H2), 48.22 (CH3), 
127.33 (C,), 133.29 (C,), 142.63 (Cu), 145-45 (Ca), 147.07 (Car), 161 -19 (CO). 
Preparation of ~ ~ c ] ( f - ~ e t h ~ 1 - 3 - ( 1 , 4 ) d i h ~ d r o p y r i d i n ~ l - e ~ ~ l ~ - 1 , 5 d i t h i o -  
laio)oxoiechneffium(V) 3 
8.0 ml diethyl ether was added to 0.6 g (3.45 mmol) sodium diiionite and 0.48 g (3.45 mmol) sodium 
~arbonate dicsoived in 2.0 ml water. To this biphasic System 10 mg (17 pmol) 2 dicsohted in 0.5 ml 
water was added and the m'kture was refluxed for 20 minutes with vigorous ctirring. After cooling the 
organic layer was separat& and at -18 'G wncentrated in vacuum to 1.0 ml. This ethereal soiution of 
the product 3 is stable for one day at -18 "C and was used for the UVNlS spectrometric investigations 
without purification. 
UVNlS spectrometric investigations of kinetic and stabilily of the 3 in buffer and tissue homogenate 
For investigation of the kinetics of 3 in different media 0.1 M phosphate buffers at pH 6.7 - 7.6 were 
used. The homogenates of kidney, her  and brain were diluted with phosphate buffer pH = 7.4. Blood 
plasma and cerebrospinal fluid were used without dilution. The measurements were performed at 20 
"C and at 37 "C with 1.0 cm standard cuvettes in a temperature-controlled cuvette holder. For the ki- 
netic measurements 100 pI of the ethereal colution of 3 was added to 2.0 rnl buffer in the cuvette and 
the diethyl ether was removed by passing a stream of argon. The sarnples were measured at regular 
intervals of 10 seconds over a period of 15 minutes. The decrease in the abcorption at 365 nm served 
as the criterion for the decay of the dihydropyridine complex. 
Results and Discussion 
The synthesis of the (1-methyl-3-pyridinyl ethylcarbamoyl thiolato)-(3-thiapentan-l,5-dithio1ato)oxo- 
technetium(V) iodide 2 was carried out acwrding to the "3+1" principle by reaction of "TC gluconate 
with the monodentate ligand 3(2-mercaptoethyl carbamoy1)-1-methyl pyridinium iodide 1 [4] and the 
tridentate 3-thia-1,s-pentanedithiol (Fig. 1). The corresponding 4:l complex of monodentate ligand 
and technetium is obsewed as intermediate [4]. After addition of the tridentate the resulting compiex 2 
was purified by HPLC. 
Fig. 1. Reaction pathway for the synthesis of the "TC complexes 2 and 3. 
The molecular süucture of complex 2 was established by crystallographic means. The X-ray stnicture 
reveals that the monodentate and the tridentate ligand form a Square pyramid with distorted basal 
surface and the oxygen in an axial position (Fig. 2). The Tc-0 bond distance was found to be 1 .W A, 
the average T& bond distance is 2.32 A whilst the thioether metal bond has a distance of 
2.37 A because of the coordinative character of this bond. 
The reduction of 2 to the complex 3 with sodium dithionite in pure 0.1 M potassiurn carbonate was not 
a cuccessful way to icolate the dihydropyridine because the basic condiins kad to rapid decomposi- 
tion of the complex. So we looked for an alternative procedure that was realiced by using a biphasic 
System diethyl ethedwater according to a iiierature p r d u r e  [6]. After vigorous stirring the iipophilie 
dihydropyridine complex 3 accumulated in the organic phase and wuld be separated. UVNlS investi- 
gations chowed that the dihydrupyridine in ethereal solution ic stabb for 24 hours Yvhereas in alkaline 
Solution it rapidly decomposes. 
Fig. 2. Molecular structure of 2. Selected bond length [AI and angles P]: Tc-01 1.680(6), Tc-SI 
2.320(3), Tc42 2.288(3), TC-S3 2.372(3), TC-S4 2.294(3), 01 -TC-SI 1 O5.3(3), 
Ol-TC-S2 1 l4,6(3), 01-Tc43 101.8(3), 01  -TC-S4 1 l4,8(3) 
For the kinetic investigations of the stability the UV spectrum of the dihydropyridine complex 3 was re- 
corded in phosphate buffer at various pH's. The samples were measured at regular intervals of 10 
seconds over a period of 15 minutes. Dihydropyridines are characterized by a strong UV absorption at 
360 nm [7] that decrease with oxidation to the pyridinium salt. Figure 3a shows a typical UVNIS spec- 
trum of 3 at pH = 6.97 and 20 "C. The declining absorption at 360 nm was used as a basis for the de- 
cay of the dihydropyridine complex. The increasing band at 270 nm is characteristic of the pyridinium 
salt that had a maximum absorption at 265 nm. The appearance of an isosbestic point at 315 nm may 
serve as proof of a pure two-compound System. The drop in the absorption at 360 nm over time de- 
scribed an exponential function and in this way the half iiie of the re-oxidation was established as a 
criterion for the stability. In Figure 3b the decay of the dihydropyridine complex 3 depending as a func- 
tion of time is shown and it is obvious that 600 seconds after start of the measurernent mostiy all of the 
dihydropyridine had decomposed. 
Fig. 3a. UVNIS spectrum of cornplex 3 at FQ. 3b. Exponentiai decrease in the a b  
pH = 6.97 over 10 minutes, the arrows show sorption of 3 at 360 nm at pH = 6.97 over 
the course of measurement. the time. 
To investigate the stability of 3 as a functian of pH and temperature 0.1 M phosphate buffers were 
used wEäi äie physiological relevant values between pH = 6.7 - 7.6 at 20 "C and at 37 "C. The tissue 
hornogenates of kiiney, Wer and brain were diiuted with 0.1 M phosphate buffer (pH = 7.4) and tested 
at 37 OC. £%xauce of the t u rb i i i  of the biibgkal materlak caused by suspended particles Ihat coukl 
not be removed by centrifugation, the probes bad a high background UV abapthn. The absorbance 
at 360 nm was near 2.0 and the decreasing extinction values can only show tendencies. Table 1 gives 
an overview of the half-lives of the complex 3 in various media and selected temperatures. 
Table 1. Half-life times of complex 3 in various media and selected temperatures 











l ie r  homogenate 
brain homogenate 
blood plasma 
Considering the half-life times it is remarkable that the stability decreases with increasing pH, whereas 
at room temperature the relationship is inverted. In Iiver homogenate a significanüy faster decomposi- 
tion than in other tissue homogenates was 0bse~ed and in blood plasma the dihydropyridine is more 
stable which is in accordance to previous work by Bodor et al. [8]. In cerebrospinal fluid the wmplex is 
notably more stable than in all other media. No exponential Course of decomposition was observed 
here, the concentration of 3 declines linear@. 
As a result of the studies of the stability of the dihydrop ridine wmplex 3 in buffer and tissue ho- 
mogenate it must be concluded that the dihydropyridine & C-mixed-ligand m p l e x  3 wiöi half-hes 
between 40 and 400 seconds is not stable enough for further bioiogical experiments and preparation 
of the corresponding m~~ derivative is not useful. Future work will focus on improvements to the sta- 
bility of the dihydropyndine by introduction of electron withdrawing substituents such as benzyl or iso- 
propyl at the pyridinum nitrogen. Bromine substitution in the 5-position of the pyriiinium ring and the 
utilisation of the chinolinium sattldihydrochinoline system also has a stabilising effect [5]. Another op- 
tion might be to employ a tetradentate ligand system where a higher stability of the chelate against the 
reducing media sodium dithionite/alkali is expected. 
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15. Evaluation of the In Vitro and In Vivo Properties of a Potential Tc-Labelled Inhibitor 
of the MDR Gene Product P-Glycoprotein 
R. Bergmann, P. Brust, H.-J. Pietzsch, M. Scheunemann, S. Seifert, B. Johannsen 
lntroduction 
Resistance of malignant tumours to chemotherapy is a major cause of treatment failure [ I  - 31. One of 
the important mechanisms is overexpression of the human muttidrug resistance gene (MDR1) [4]. On 
the other hand, MDR gene transfer and expression in bone marrow cells followed by autologous bone 
marrow transplantation in patients with advanced cancer is Seen as a strategy to minimize the risks of 
high-dose chemotherapy [5]. Monitoring the functional expression of the gene products or the suc- 
cessful gene transfer may be a prerequisite for the therapy, i-e. it is required to study the functional 
expression of the gene products. Its overexpression has been demonstrated to contribute to the multi- 
drug resistance (MDR) phenotype of many human cancers. The gene product P-glycoprotein (Pgp) is 
present in the plasma membrane not only of tumour cells but also of several normal tissues, including 
the brain endothelial cells forming the blood-brain barrier (BBB) and the intestinal epithelium [6]. It acts 
as an energy-dependent efflux pump which allows the transport of a wide range of structurally and 
functionally unrelated cytotoxic drugs out of tumour cells, including doxorubicine, vincristine, vinblasti- 
ne and many others (for review See [i']). These substances tend to be lipophilic, cationic compounds 
[8]. Additionally, a number of drugs called MDR modulators have been identified that are non-toxic in 
themselves (calcium channel blockers, anti-arrhythmics, antidepressants and many others) but can 
reverse Pgp-mediated MDR. These drugs, such as verapamil, quinidine and cyclosporin-A, make 
MDR tumour cells sensitive to coadministered cytotoxic agents. However many of them are of limited 
clinical use due to side effects in the relevant doses [9]. On the other hand they may be of potential 
use for the development of radiopharmaceuticals for PET and SPECT imaging. Thus, 
["cldaunorubicin and r~]verapamil both have potential for in vivo probing of Pgp with PET [10, 111. 
The only available clinical radiopharmaceuticals for studying the expression of P with SPECT are 9%P the lipophilic ""'TC cations hexakis(2-methoxy-isobutyl-isonitrile)technetium(l), [ Tclsestamibi, [12, 
131 and transdioxo-bis(diphosphine)-technetium(V), [99m~c]tetrofosmin, (for review see [14]. Some 
99m Tc (111)-complexes of the Q-series are currenüy under investigation 1151. 
It was recentiy suggested that a Set of structural elements was required for an interaction of drugs with 
Pgp. The recognition elements were formed by 2 or 3 electron donor groups with a fiied spatial 
separation [16]. The investigation of neutral and monoprotonated forms of a large number of 
compounds revealed that, in parallel with the commoniy recognized critical sites (such as polycyclic 
ring Systems and N-substituted moiety), the molecular profile of hydrophobicity is a specific structural 
determinant for the anti-MDR activity of these drugs [17]. 8ased on these findings we examined 
various 3+1' mixed-ligand technetiumo and rheniumw) complexes containing electron donor groups 
such as protonable nitrogen and aromatic moieties as prerequisites for MDR modulation [18 - 201. We 
demonstrate that one of these novel complexes shows a strong inhibition of Pgp-mediated transport 
function in vitro (immortalized rat brain endotheliai cells) and in vivo (organ distribution in rats). These 
experiments were perforrned in comparison with classical MDR modulators. A muttitracer approach 
was used to investigate simuitaneously the effects of Pgp modulators on the function of Pgp and basic 
physiological and metabolic parameters such as the glucoce metabolism. Toxic effects resulting in 
disturbances of the cell rnetabolism may thus also be obsewed in these in vitro and in vivo studies. 
Experimental 
Prepara fion of Be complexes and fracers used 
Synfhesis of the ligandc, the preparation of the oxorhenium(V) and the Tc-99 complexes (Fg. I), the 
compiex purification, and the qwalii control technique were based on the previousiy described general 
methods after minor modification 11 81. The preparation of the n.c.a. -TC compiex 3-thiipentane-13- 
di#iolato)(~-(J-phenSpropyl)-N-2(~uin~oline2,4dbnyl~thyl]amin~th~thiolato~xotechnetium~~ 
usiw a ligand-exchange reaction followed by HPLC purif i t ion was described in detail [22j. 
[3~]vinblastine (670 GBglmmol) an$ T~lvincristine (370 GBqlmmol) were obtained from hersham 
BuchIer, Braunschweig, Germany. [ HJcold'ricine (2.73 ißq/mmol) was purchased from NEWDuPont, 
Gemny. 2 - [ ' 8~ luoro -2 -deoxy -~+ i~~  was kindly provided by tbe Rossendorf PET Center [21], 
p"rc]sestamibi (Cardiolite, Du Pont Pharma GmbH, Gerrnany) and [~cltetrofosmin (Myoview, 
Amersharn, Germany) were prepared from wmmercially availabfe kits according to manufacturer's in- 
structions and added to the control solution (see beiow) at a final concentration of 1 M w m i  ( 4 0  nM 
in all experiments). 
Fig. 1. "3+1" mixed-ligand m~~ complexes 
Tracer uptake studies 
lmmortalized rat brain microvessel endothelial cells (RBE4) (23,24) were plated on tissue culture pla- 
tes 24-well flat bottom ~el l+@ (Sarstedt, Inc., Newton, USA). Cells were grown in cuiture medium mn- 
sisting of a-minimal essential medium (a-MEM)Mamls F10 (GIBCO, Eggenstein; Germany) (1:1 
vol/vol), supplemented by 2 mM glutamin, 10 % heat-inactivated fetal calf Serum (Sigma, Deisenhofen, 
Germany)l nglml of basic fibroblast growth factor (bFGF) (Boehringer Mannheim) and 300 pglrnl of 
geneticin (6418) (Sigma, Deisenhofen, Germany) in humidied 5 % COS95 % air at 37 OC. In the 24- 
well cell culture plates the cells reached confluence afier 3 - 4 days. The experiments were conducted 
at confluence with cell densities between 10' - 106 cells per well (equivalent to about 100 - 150 pg 
protein) of Passage 30 - 40. 
The solution used for the transport experiments was a modified culture medium consisting of a- 
minimal essential medium (a-MEM)IHamls F10 (GIBCO, Eggenstein; Germany) (1:1 vohol), supple 
mented by 2 mM glutamin, and 1 % (VIV) albumin. The wash solution for clearing the extra-cellular 
space was phosphatebuffered solution mntaining Mg* (0.5 mM) and Ca* (0.9 mM). The lftake stu- 
dies were performed using various tracers with up to four different isotopic labels, (%, F, g9m~c, 
-C). The experiments were initiated by washing each of the 24-welk in the plate with a-MEM and by 
loading them with a-MEM containing the Pgp inhibitor under review (10 UM). After a preincubation pe- 
riod of 60 min the soiutions were aspirated from the welk and replaced by 0.5 ml per well of the ra- 
dioactive incubation medium to initiate transport. In additisn to the radiotracers the media mntained 
various drugs or -c(v) mmplexes in concentrations ranging from 1 nM to 10 mM. At ththe end of the 
incubation period (after 60 min) the well plates were transferred onto ice (4 OC). Aliquots of the incuba- 
tion medium from each well were used to calculate the free tracer concentration in the supernatant. 
The remaining medium was then aspirated and the cells were carefully rinsed four t ims  with 1 rnl of 
ice-cold washing solution. The remaining cells were solubilized by shaking them with 500 pl of Wi- 
fied 0.1 N NaOH with 1% sodium dodecyl sulphate. Aiiiuots were obtained for r and &counting and 
for protein determination by the method of Lowry. All sampies (aliquots of the stock incubation medi- 
um, of the supernatant after incubation and of the solubilised cells) were transferred to 4 rnl vials con- 
taining Ultima Gold counting solution (Canberra-Packard, Dreieich, Gennany). These viais were as- 
sayed for gamma activ'ily in a multichannel wefi-type sodium Mine  gamma munter (COBRA 11, Pack- 
ard Instrument Company, Meriden, USA) using two energy windows (110 - 180 keV and 450 - 15QO 
keV). After a minimum of 10 half-lies of the short-mied isotopes userJ ("F, 9 g m ~ ~ ) ,  the m n t  viais weri; 
assayed in a multichannel well-type beta munter (TRICARB, Packard instniment Corrip;nny, Meriden, 
USA) using Wo energy uvindows to determine the 3~ (0-20 W )  as well as % contenlts (262000 
keV) in the sampies. 
Anima1 experiments 
Animi experiments wse carried out according to the relevant national regutatbns. 0.5 M&1 of -C 
complex was injected into the tail veins of 5-6 weeks oId Wistar raff. At 30 min p.i. the rats were sad- 
ficed by heart puncture under ether anaesätesia. Selected organs were isofatrtd for weighing and 
counting. 
Calcula tions 
All data were corrected for background, spill over, and decay. The amount of accumulated tracer in 
the cells was presented as a percentage of the total radioactivity per mg cell protein. The data (means 
I S.D.) were obtained in quadruplicate from preparations of the Same cell culture in at least two inde- 
pendent experiments. Statistical analysis was performed using the two-tailed t-test with equal varian- 
Ces. Values of pc0.05 (*), pe0.01 (**), pc0.005 (**) were considered significant. 
Results and Discussion 
In this study we describe the in vitro and in vivo properties of the complex 3-thiapentane-1,5- 
dithiolato){[N-(3-phenylpropyl)-N-2(3-quinazoline-2,4-dionyl)ethyl]aminoethylthiolato]oxotechnetium(V) 
(=TCI) and structurally related compounds as potential inhibitors of Pgp. As shown in Fig. 1 all 
these complexes contain a tridentate S,S,S donor ligand and a monodentate thiolato ligand of variable 
structure. Fig. 2 shows the effect of these compounds and of various known Pgp modulators on the 
accumulation of [99m~c]sestamibi n RBE4 cells, an imrnortalised cell line of brain endothelial cells. 
Arnong the complex compounds only those with a higher frequency of the electron donor groups in the 
molecule ("~cl-3) show a considerable inhibition of Pgp as revealed by an increased accumulation of 
[99m~c]sestamibi (see Fig. 2). Complex -CI was further characterized using also ?H]vinblastine, 
[3~]vinaistine, FH]colchicine, ~9m~c]tetrofosmine and the n.c.a. -CI itself as substrates for the Pgp. 
As shown in Table 2 *CI significantiy increases the accumulation of all these radiotracers with the 
exception of its 9 9 m ~ ~  congener which was competitively decreased. 
Table 1. Effects of Pgp modulators and various coordination compounds on the accumulation ' 
of '-TC sestamibi in RBE4 cells (% of control). 
Substance Mean S.D. P Substance Mean S.D. P 
Control 100.0 31.4 
*** 
(-CI) 312.6 25.1 ** 
Vinblastin 321.2 20.1 ( 3 ~ 2 )  277,8 5,8 *** 
Veraparnil 312.6 11.3 *** 
** 
(Y&) 231,O 10,8 ** 
Cytochalasine B 233.6 12.0 ( 9 ~ 4 )  101,8 3,1 n.s. 
Reserpine 365.0 15.5 ** (-6) 95,7 4,7 n.s. 
Table 2. Effects of Pgp modulators (10 PM) and complex (1) (10 PM) on the accumulation of various 
Pgp substrates in RBE4 cells. 
%Dfmg -TC- 99m~c- 99m~~l 3 ~ -  3 ~ -  3 ~ -  
protein sestamibi tetrofosrnin colchicine vinblastine vincristine 
Control 31 -9 I 3.3 8.1 I 1.5 50.4 I 3.7 30.7 I 0.7 53.2 I 5.5 45.4 I 5.6 
Veraparnil 54.4 I 4.6 17.5 I 0.2** 60.3 12.3'" 47.0 13.7* 80-716.0" 72.4 +8.8** 
Reserpine 62.4 I 5.7*** 21 -0 I 2.1** 66.3 I 2.2** 49.0 I 4.4*** 93.9 I 9.5** 76.6 I 11.8* 
=Tc1 45.116.4* 22.311.8*** 33.11.5**" 36.811.3** 79.4 I 1 0.6* 81 -0 I 2.5*** 
To study poccible side effectc of I On the cell metabolism a multitracer approach was used. The celis 
were sirnuitaneousiy incubated with [Bg"rcJsestamibi or ?CI and ["FJFDG. Two-dimensional scatter 
plots of both gR"rc tracer accumulations vs. E"'F]FDG accumulation show typical changes of known 
Pgp inhibiors including 98190mTcl (Fig. 2). They show that the side effects of compounds may be sepa- 
rated from the dir& effectc On Pgp. Valinomycin increases oniy the accumulation of Ogmicl but de- 
creases tfie accumuiation of ~Tclsestamibi. iiowever, it strongiy increases the accurnulation of 
[ ' 8 ~ ~ ~ ~ ,  fhe effects of *cl on the in vive distnbution of ~Tc]sestarnibi and I'~F]FDG in rats are 
also comparabfe with the effectc of verapamil, an established Pgp inhibitor and Cachannel blocker. 
(Fg. 3). After preheatrnent with both verapamil and *CI, an increase in üie [Bgm~c]sestamibi accu- 
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Fig. 2. Effects of various Pgp modulators on the accumulation of accumulation of ~Tc]sestamibi (left) 
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Fig. 3. Effects of verapamil(5 mgkg body weight) and complex g Q ~ c i  (5 w k g  body weight) on the 
accumulation of ~Tc]sestarnibi and ['$FJFDG in ratc 
Up to now the clinical radiopharmaceuticals available for studying the expression of the Pgp have 
been the iipuphilic -TC cations (~~c]sestamibi,  ~Tcftetrofosmin) as well as fPgm~cp5'7, 
[ 9 9 m ~ ~ ] ~ 5 8 ,  and f e g m ~ c ~  [I 3 - 151. A l  these complexes are transported by Pw. 
In this study, we have shown that the structuralty diierent complex (3-thiapmtam+l ,tTciiiiolatc,)f[N- 
(3-phenylpropyl)-N-2(3-quinaz~line-2,4di0nyf)ethyI~aminoeäiy~ti'~1lato)oxo~hnetium(v) ~l) 
also serves as a substrate and inhibitor of Pgp. 
The RBE4 cetls used for the in vitro studies express Pgp, wtiich is functionaliy active i25, 261. The 
cellular accumuiation of Pgp substrates after inhibion of Pgp is commoniy used as a meinsure of the 
capacity of Pgp [27J. It has been suggested that Pgp afFects both äte inRux and efflux [28]. In addition, 
the amount of this accumuiation may not oniy depend on Pgp but also M the type of ti.re intxacelluW 
t a w t  of the dtug (e.g. mitodiondniat inner membrane, tubwlin or DNA) and the tightness of binding. 
In the present stuciy, we usecl drugs Hntti variais t a r ~ e t s  to exclude the possibility of unyle~ific effecb. 
Two of them ~ic]ceskirnibi and ~~c] te&ofosmin are nonrnetabdized metallopharmaceuticais with 
a nontitratable detoca!ized manocatiwi'i charge which have been shmm to be transpacted by P- 
gtycoprotein [12]. They iack the uwal siructural Matures which wert4 previousty thaught impotMnt for 
recognition by P-glycoprotein, such as basic nitrogen atoms, titratable protons, or aromatic residues. 
As classical substrates of ~gp,tH]vinblastine, [3~]vincristine, and FH]cholchicin were used in the ex- 
periments simultaneously with "'TC. Under normal conditions the direct and linear correlation of the 
uptake of the three tracers at different levels of PGP inhibition may be interpreted as a sign of the 
strong influence of the PGP on the drug accumulation process in the cells. 
Complex ' ' ~c i  was selected in our study from a number of other coordination compounds on account 
of its ability to increase the accumulation of [99m~c]sestamibi, which was expected to have an effect on 
Pgp. In addition, this compound significantiy increased the accumulation of all the other Pgp radiotrac- 
ers studied, which is strong evidence of a direct interaction with Pgp. The various radiotracers are ex- 
pected to bind to different binding sites. There is evidence from photoaffinity labelling and from binding 
studies with [3~]vinblastine [29] that Pgp has at least two allosterically coupled drug acceptor sites. 
One of the drawbacks in studying the function of Pgp is the lack of specificity of the classical Pgp in- 
hibiors. The drugs commonly used to inhibit Pgp may thus also influence the metabolism of the cells. 
Since ATP is needed as a CO-substrate for the transporter disturbances of the energy metabolism may 
indirectly influence its function. Using a multi-tracer approach (CO-administration of [99m~c]sestamibi 
and [18F]~D~), we demonstrate in this paper that the inhibition of Pgp by our novel complex *cl 
does not influence basic metabolic Parameters of the cells which is important for the suitability as ra- 
diopharmaceutical. Valinomycine, which is also known to interact with the Pgp, was used as a positive 
control (30). It dramatically increases the accumulation of [ ' 8 ~ ] ~ ~ ~  and f3Hlvinblastine (data not 
shown) without changing the accumulation of ~m~c]sestamibi. It also increases the accumulation of 
99m Tcl, suggesting various intracellular targets for this complex and for [99m~c]sestamibi. 
[3~]valinomycine serves as an ionophor for K' ions at the mitochondria and depolarizes the mitochon- 
drial membrane potential causing a decreased cellular accumulation of [99m~c]sestamibi 1311. In our 
study it also inhibii Pgp, as revealed by the increased accumulation of [3H]vinblastine, resulting in un- 
changed [99m~c]sestamibi accumulation as the net effect. 
In Summary, was shown to have biochemical and pharmacological properties of a Pgp sub- 
strate and inhibitor of the Pgpmediated efflux of sestamibi, vinblastine and colchicine. It may therefore 
be considered as a candidate reversal agent and could serve as a template for the development of 
nonradioactive Re(V) analogues as Pgp inhibitors. The in vivo distribution of the -CI is similar to 
[99m~c]sestamibi. However, further experiments are needed to show the potential of 99m~cl  as a radio- 
pharmaceutical for monitoring the function of Pgp in vivo. 
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Fig. 1 .  Reaction route of the preparation of the PET precurcor and the inactive reference compound 
Analysis of metabolites 
For determination of metabolies, urine and plasma samples are checked by thin-layer chromatogra- 
phy on RP-18 (Merck) aluminium sheets and methanol / water (9:l) as the eluent. The chromatograms 
were evaluated by measuring the radioactivity (the urine and the shoit-time plasma sampies) on a 
linear anaiyser (Berthold) and the chromatograms with the lowest activity levet (long-time plasma 
samples) on a FUDJl BAS 2000 device. The F$ value of 9[(3-['8~-ffuoro-l-hydroxy-2-propoxy~ 
methyllguanine is 0.7. With sufficient diierences in Rf it was possible to separate both gamiclovir and 
fluoroganciclovir on this TLC System. 
Resutts and üiiussion 
The nonradioactive reference ccimpund fluorogancicWr was obtained in a high PU*. The prodg  
was characterised by 'H NMR, elemental anaiysis and mass spectromtty. The irfentity of Zi7e F- 
fabelled ganciclovir with the nonradioactive reference compound was detenined by HPLC. n ie  radio- 
chemhi purity of the '8~-labeiled ganciclovir exceeded 99 % and ttte yield of ttte radihamiaceuticai 
preparation amounted to 12 % (time corrected). 
The diiibution of E'~F]GCV in the various tissues of mate Wistar rats is summrired in Tab& 1. 
Table 1. Biodistribution data of ['8~]ganciclovir in male Wistar rats at 5, 60, and 120 min 
post injection (p-i.). 
%Dose/g 5 min 60 min 120 min 
Blood 0.65010.049 0.05610.008 0.02010.004 
Brain-total 0.04410.016 0.00910.002 0.005+0.001 
Pancreas 0.92310.092 0.06610.002 0.04210.013 
Spleen 1 -378I0.105 0.13010.023 0.05110.017 
Adrenals 0.87910.031 0.1 0210.009 0.07410.035 
Kidney 3.685I0.467 0-28710.048 0.1 1510.015 
Fat 0.20310.026 0.03410.022 0.02010.017 
Muscle 0.25810.018 0.14810.033 0.051 10.008 
Heart 0.52410.019 0.06210.005 0.01 810.002 
Lung 0.90910.092 0.08510.003 0.036I0.009 
Thyrnus 0.655I0.034 0.060I0.010 0.02210.003 
Liver 1 S8110.134 0.1 1710.017 0.044I0.006 
Femur 0.471 10.039 0.08910.015 0.04310.008 
[ ' 8 ~ ~ ~ ~  shows a relatively fast blood clearance. The erythrocyte binding of the tracer was negligible 
(5 min: 6.73 i 0.92 %, 60 min: 6.83 * 1.93 %,I20 min: 8.44 I 3.73 %). An initial high uptake of the 
tracer was found in the spleen, kindney and liver, which decreased rapidly in time. The lowest uptake 
was found in the brain, indicating a negligible penetration across the blood-brain barrier. The absence 
of metabolites both in the plasma and in the urine is in accordance with the resub obtained with gan- 
ciclovir in a clinical study concerning its antiviral activity 161. 
The rapid blood and Organ clearance and the in vivo stability of [ ' 8 ~ ] ~ ~ ~  is expected to be advanta- 
geous for in vivo monitoring of the gene transfer in tumours. After transfer of the Herpes simplex virus 
thymidine kinase gene into tumours metabolization and trapping of ["FIGCV should occur. Thus, a 
reasonable target-to-background ratio may be expected within the physical half-life of the tracer. 
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17. The Diagnostic Value of [''QFDG Positron-Emission lmaging for Detection and 
Treatment Control of Malignant Germ Cell Tumours 
P. ~satalpas', B. ~euthien-~aumann~, T. S ie ell, J. uropp2, A. ~anseck', C. ~ ie~oW' ,  P O. ~akenberg', W. Burchert, W.-G. Franke , M. P. wirthl 
TU Dresden, 'Klinik und Poliklinik für Urologie und 2~l inik und Poliklinik für Nuklearmedizin 
lntroduction 
The role of positron emission tomography (PET) with 2-['8FJfluoro-2-deoxy-~-glucose (["F'JFDG) is 
currently under evaluation in genitourinary tumours 11, 2, 7-10, 131. Recent studies showed that in 
many tumour types the uptake of ["FJFDG is increased compared with normal tissue [4,11]. Effective 
chemotherapy was found to reduce the [ ' 8 ~ ] ~ ~ ~  uptake prior to volumetric changes in morphological 
imaging techniques such as computed tomography (CT) 15, 6, 121. In this study the potential of 
['*F]FDG-PET for the detection and therapy control of testicular gerrn cell tumours was investigated. 
Materials and Methods 
Patients: Twenty-three consecutive patients with histopathologically confirmed testicular germ cell 
tumours were included in the study from June 1997 to July 1998. The histological diagnosis was 
seminoma in ten patients (43 %), a combined turnour in nine (39 %), embryonic carcinoma in three 
(13 %), and one patient (4 %) had a combined testicular tumour. Tumour staging was assessed ac- 
cording to the international workshop on staging and treatment of testicular cancer in Lugano 1161. 
Eleven pts. were classified as stage 1 (48 %), six pts. as stage 11 (26 %), and six pts. as stage III 
(26 %). 16 patients received chemotherapy, six patients underwent retroperitoneal lymphadenectomy. 
One patient received a bone-marrow support in addion to high-dose chemotherapy and one patient 
underwent mediastinal lymph-node dissection with recection of pulmonal residual tumour masses after 
chemotherapy. Four of seven patients with a Stage I seminoma received an adjuvant radiation therapy 
(26 Gy), two an adjuvant monochemotherapy with two series of carboplatin. A total of 32 PET scans 
were carried out. The scans were performed either after initial diagnosis (n = 21) andor within 3 to 45 
days after chemotherapy was completed (stage II-IIII patients snly, n = 11). 
PET irnaging PET studies were carried out after the patients had fasted for 6-12 hours. Plasma glu- 
cose levels at the time of the f 8 f l F ~ G  injection were within physiological limits. Patients Yvith diibetes 
mellitus were excluded. [ ' 8 ~ ~ ~ ~  was produced in-house by a modiied method as described by [3]. 
330 MBq ["FJFDG per patient were intravenously injected. Fiieen of the tvventy-one initial scans and 
all scans after chemotherapy were carried out using an ECAT EXACT HR+ PET scanner (Siemens 
ICTI, Knoxville, Tenn., USA). The reconstructed image resolution was about 6-7 mrn FWHM. Attenua- 
tion correction was perfonned by a 10 min transmission scan in selected bed pocitions (BP);g min 
after injection the emission scan was acquired for 10 min per BP. Six of the twentysne W a l [  FJFDG 
scans (185 Müq per patient) were performed using a dual head coincidence gamma camera (Solus 
EPlC MCD, ADAC Laboratories, Milpitas, Calif., USA). Iteratively reconstructed images had a recolu- 
tion of about 15 mm. The visual analysis was graded as positive, indeterminate or negative for malig- 
nancy. In studies performed with the dedicated PET scanner quantitative image analysis of tumour 
uptake was perforrned by calculating the standardized uptake values (SUVs) in seiected areas [14]. 
CT irnaging Thirty-four CT scans (23 initial and 11 after chemotherapy) were acquired with a third or 
fourth-generation CT scanner corresponding to all PET studies (10 mm slice thickness; oral and intra- 
venous contrast medium). CT scans for initial staging were interpreted as suspicious of metastatic 
lymphatic cpread, when the iymph node was larger than 1.5 cm and of Organ metastases when char- 
acteristic radiological signs such as contrast enhancernent after intravenous wntract medium applica- 
tion were Seen. 
Tumor markers: Turnour marker levels of AFP and bHCG were avaiiable in all patienb entered into 
the study. AFP > 9 ngml and b-HCG > 5 Uh were considered pathologit. 
Validation and sfatistics: Validation was canied out either by histoiogy (n = 7) or by dinical blbw-up 
for 6 to 11 months (n = 16). The absence of disease after therapy was assumed if W patitsnts wert3 
wittiout progrecsion in CT and tumour rnarkers were negative for at keast 6 months without furäter 
therapy. Tissue for histology was obtained by retroperitoneal lymphadenectomy (n = fil and thoracot- 
orny (n = I). Serrsitiirty, specificity, positive and negative predictive values and aauracy wer@ deter- 
mined for PET and CT. Differences between PET and C i  for parameters of diagnostic value were 
evaluated by the chi-square test. The accepted limit to indicate statistical significance was p < 0.05. 
Results and Discussion 
Pathological accumulation of ~*F]FDG was detected in 9 of 21 (43 %) of the initial PET studies. All 
lesions with pathological findings represented metastatic lesions confirmed either by histology or clini- 
cal follow-up (Fig. 1). Twelve of 21 primary PET studies (57 %) were graded as negative in accor- 
dance with clinical and CT findings. 
Fig. 1. A 54 year-old patient with left sided seminoma. CT transversal slices (left), corresponding PET 
slices (middle) and PET projection images (right) are shown (upper row prior to therapy, bottom row 
after chemotherapy). Before chemotherapy the mediastinal lymph node metastasis showed intensive 
accumulation of labelled glucose, while the CT was inconclusive with respect to the dignity of the mass 
(arrow), After Wo cycles of chemotherapy no viable tumour tissue was detected with PET. 
Pretherapeutic PET (Table 1) was more sensitive (0.90 vs. 0.60) and had a higher negative predictive 
value (0.92 vs. 0.73) than CT. However, these differences did not reach statistical significance. Speci- 
ficity and positive predictive value were comparable to the CT resuits. 
Table 1. Overall diagnostic value of PET versus CT 
Sensitiiity Specifii PPV NPV 
Before therapy 
(n = 21) 
PET 0.90 1.00 1.00 0.92 
CT 0.60 1.00 1 -00 0.73 
After therapy 
(n = 11) 
PET 1.00 0.60 0.20 1 .OO 
CT 1 -00 0.60 0.20 1.00 
PET = positron emission tomography; CT = X-ray computed tomography; PPV = positive predictive 
value; NPV = negative predictive vafue 
ARw chemtherap~ 5 of 11 pa6ents (45 %) showed a pathological accumulation of ['*F]FDG. In one of 
the patients the QFDG accurnulation represented persistent disease. In the 4 other cases, new 
lesions were found in the posttherapeutic PET (iung and neck), whereas the initial lesions had com- 
pletely disappeared. These new f8~]FDG accumulations were due to inflammatory reactions proved 
by histology after thoracotomy (1 of 4 cases), antibiotic treatrnent and clinical follow-up (3 of 4 cases). 
Six-of the eleven (55 %) PET scans after chemotherapy showed no accumulation of [ 1 8 f l ~ ~ ~ ,  al- 
though in four of these six patients residual tumour masses were identified by CT. After retroperitoneal 
lymphadenectomy in three cases, these masses were shown by histology to be scar tissue and an 
ectopic seminal vesicle without vital tumour cells. One patient with a residual retroperitoneal tumour 
mass is still without progression after 8 months. The other two patients with negative PET scans after 
chemotherapy also showed a complete remission with respect to control CT and serologic turnour 
markers. They are still in remission after a follow-up period of 8 to 11 months. 
After chemotherapy no significant differences were found between PET and CT results in the overall 
tumour detection rate. Considering infradiaphragmatic lesions only (Table 2), PET was shown to be 
superior to CT in specificiiy (1.0 vs. 0.60; p C 0.05) and positive predictive value (1.0 vs. 0.20; n.s.). 
Regarding supradiaphragmatic lesions (Table 3) CT was found to be more specific ( 1 . 0 ~ ~ .  0.60; 
p C 0.05) and to have a higher positive predictive value (1.0 vs. 0.20; n.s.1 than PET. 
Our preliminary results demonstrate [ ' 8 ~ ~ ~ ~  positron imaging to be a useful diagnostic tool for initial 
staging and treatrnent control in patients with germ cell tumours. The possible advantages compared 
Table 2. Diagnostic value of PET versus CT in infradiaphragmatic tumour lesions 
Sensitiity Specifii PPV NPV 
Before therapy 
(n = 21) 
PET 0.85 1 .OO 1.00 0.93 
CT 0.71 1.00 1 .00 0.87 
After therapy 
( n = i i j -  
PET 1.00 1.00 1.00 1.00 
CT 1.00 0.60 0.20 1.00 
PET = positron-emission tomagraphy; CT = X-ray computed tomqraphy; PPV = positive p r e d i i e  
value; NPV = negative predictive value 
Table 3. Diagnostic value of PET versus CT in supradiaphragmatic tumour lesions 
Sensitivii ~pecifiity PPV NPV 
Before therapv 
. - (n = 21) 
PET 0.80 1.00 1.00 0.94 
CT 0.60 1.00 1.00 0.89 
After thewv 
(n= 11j - 
PET 1 -00 0.60 0.20 1.00 
CT 1 .W 1 .OO 1 -00 1.00 
PET = positron-emission tomography; CT = X-ray computed tomqraphy; PPV = positive predictive 
value; NPV = negative predictive value 
wiäl CT are not yet clearly defined due to the tirnited number of investigald patients. A limitation of 
this method seern to be supradiaphragrnatic inflamrnatory processes after chemotherapy resusng in 
false positive PET findings. However, in infradiaphragmatic lesions PET proved Zo bt. superior to CT. 
The combined use of both irnaging methods should therefore be preferred at the moment in clrder to 
achieve maximal diagnostic accuracy. Further investigations are needetf to improve ffie irnaging 
ccheme for PET to avoid false positive resuits caused by inflarnmato~ chamyes post chemoälempy. 
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lntroduction 
In patients with differentiated thyroid cancer, positron emission tomography (PET) using [''V 
fluorodeoxy lucose (FDG) has been demonstrated to provide additional diagnostic information com- 
pared with "'I whole body scanning. It was found to be particulariy useful in cases of suspected local 
recurrence, regional lymph node metastases or distant metastatic spread [I, 21. 
The availability of PET for routine clinical use is limited by the great expense of a full-ring tomograph. 
The coincidence gamma camera was therefore proposed as a cost-effective alternative for FDG im- 
aging. In spite of the technical limitations of gamma camera coincidence imaging, some first results 
indicate the usefulness in clinical settings [3,4]. The aim of this study was to investigate the diagnostic 
accuracy of coincidence imaging and PET with regard to the staging of patients with differentiated 
thyroid cancer. 
Materials and Methods 
Patients: Twenty-three patients with differentiated thyroid cancer with positive 1311 whole body scans 
(n = 20) andlor elevated thyroglobulin levels (n = 20) were included in this study. All patients had un- 
dergone thyroidectomy and at least four radioiodine treatments for metastases. At the time of initial'the 
diagnosis, 17 patients had lymph node or distant metastases verified by chest X-ray, computerized 
tomography, or by histology. 
Study design: All patients were investigated with both dedicated PET and coincidence camera on the 
Same day. Prior to the injection the patients fasted for at least 4 hours. The reference scan with a 
dedicated ring tomograph was performed 60 minutes after the intravenous injection of 300-370 MBq of 
["FIFDG. Then coincidence imaging with the dual head gamma camera was carried out 210-240 min- 
utes after tracer application. Due to a radioiodine whole-body scan being performed at roughiy the 
same time, 11 patients were off levothyroxine when the FDG scan was performed. 
PET imaging: We used an ECAT Exact HR+ (Siemens/CTI) with BGO detectors and an axial field of 
view of 15.2 cm. Six bed positions overlapping by 1 cm were acquired in 2D mode for 10 minutes 
each. 
Coincidence gamma camera imging: A Solus EPlC MCD (ADAC Laboratories) with a 518 inch Na1 
crystal and an axial field of view of 38 cm was used. Two to three bed positions covering head, neck 
and chest and overlapping by 35 % were acquired in three-dimensional(3D) mode with 32 angles of 
40 s each. 
13'1 whole body scannin . An 13'1 whole body scan was performed 72 hours after oral administration of 
a therapeutic dose of %-Na1 (3,700 MBq) for treatment of metastases using a dual head gamma 
camera equipped with high-energy collimators (Genesis, ADAC Laboratories). 
Data analysis: Images obtained with both modalities were read by two experienced investigators (GT, 
BB-B) who were blinded to the FDG-PET results when evaluating the coincidence gamma camera 
scans. The size of each lesion was derived from the PET images, applying a 50 % intensity isocontour 
as the outline of the tumour. 
Resuits and Discussion 
By the combined use of ~ 'F~FDG and 13'1-~al 123 lesions were detected (1 W %). 551123 (45 %) k+ 
sions were visualized with l3  1 whole body scan, 661123 (54 %o) wiih coincidence imaging, and 101f123 
(82 %) with dediited PET. 
A lesion-by-lesion comparison between the images obtained with dediited PET and the coincidence 
camera showed concurrence in 65 % of cases. The analysis of various anatomical areas shoy$ 
61 % agreement in the head and neck and 73 % in the chest. Of 23 bone metastases detected by 1 
whoie bocty scan, 14 lesions were revealed by dediited PET, but onIy 6 by caincidence imaging. 
The anaiysis according to size showed that the coincidew wmra detected 98 % of the lesions 
larger than 1.5 an and 56 % of the lesions between 1 and 1.5 crn that were seen wittL the PET W n -  
ner. Lesions smalier than 1 cm (n = 16) could oniy bo imam with the dod'ited PET scanner. 
Compared with 13'1, ["F]FDG showed additional lymph node metastases in 6 patients when imaged 
with the coincidence camera, and in 8 patients when imaged with the PET scanner (Fig. 1). 
The therapeutic strategy was changed as a result of the additional diagnostic information provided by 
the [ ' 8 ~ ~ ~ ~  scan in 2/23 patients. In these cases both the dedicated PET scanner and the coinci- 
dence camera showed radioiodine negative lymph node metastases which were subsequently re- 
moved by surgery. 
Two patients who had known metastases dernonstrated by the I3'l whole-body scan were misstaged 
as MO by both imaging modalities employing ['*F]FDG. 
The sarne N stage as with the PET scanner was obtained with the coincidence camera in 21/23 pa- 
tients (Fig. 2). The same M stage was assigned to 21/23 patients, resulting in an overall agreement of 
coincidence carnera and PET scanner in 19/23 patients. Those metastases that were rnissed by coin- 
cidence irnaging but were relevant to TNM staging were small (< 1.5 crn) mediastinal lymph nodes in 
two cases (in one of which the PET scan was the only diagnostic procedure showing evidence of dis- 
ease activii), small (< 1.5 crn) metastases in the lung in one patient, and a lesion in the thoracic spine 
in another patient. The misstaging of 4 patients by coincidence irnaging did not, however, alter thera- 
peutic management of these patients. 
Coincidence imaging using a modified gamrna carnera offers a cost-effective alternative to a dedicated 
PET scanner for imaging oncological patients with f8F]FDG. This new technology has, however, not 
been fully evaluated in clinical Settings. 
This study showed a relative sensitivity of 65 % for coincidence imaging compared with dedicated 
PET. This is slightly more than the results published by Shreve et al. who found a relative sensitivity of 
55 % in 31 patients. For lesions located in the chest an identical relative sensitiiity of 73 % was re- 
ported. The overall lower sensitivity may have been caused by the low detection rate for abdominal 
lesions (23 %) in this heterogeneous patient population [5]. 
Wiihout attenuation correction it proved difficult to assign lesions located at the border between lung 
and mediastinum to one or the other anatomical structure. Due to the lower usable spatial resolution, 
this effect was rnore pronounced with the coincidence gamrna camera imaging than with the dedicated 
PET system. A study of Shreve et al. reported similar results [5]. Furthermore, the generally poorer 
image quality of the coincidence camera makes the distinction of pathological frorn physiological FDG 
uptake more difficult [5f. As attenuation correction improves geometric distortion as well as edge defi- 
nition of lesions, it will lead to a better visualization and localization. An increased sensitivity can 
therefore be expected [6]. 
Taking into account the severe technical limitations of coincidence imaging outlined above, it seerns 
encouraging that 19/23 patients in our selective cohort were staged correctly according to the TNM 
system with dedicated PET as a reference. The incorrect staging of four patients was due to chest 
lesions srnaller than 1.5 Cm. 
Fig. 1. A 67-year-old man W& metastatic differentiated thyroid cancer. Coronal irnages frorn the coin- 
cidence camera (left) and PET (right) showed an increaced uptake in medi ina !  iymph node metas- 
tasrrs. Whereas the contrast in the PET image was qua1 in al1 lesions, in the coincidence image it was 
lower in the srnalier lesions. One lesion (in the teft jugular region) was not recognizable in the coinci- 
dence irnage without knowledge of the PET resutts. 
Patient rnanagernent changed as a result of the FDG scan in Wo cases with raised serurn thyroglobu- 
lin and lymph node rnetastases, which showed no uptake of radioiodine. These lesions were detected 
with both PET and the coincidence gamma camera. 
Although the accurate detection of lesions with coincidence imaging is limited to a size larger than 
1.5 crn, the staging was affected in 17 % of the patients in this population. Due to technical limitations, 
FDG scanning with a coincidence gamma carnera is at present not suitable for clinical imaging of pa- 
tients with thyroid cancer. For future applications it is expected that the application of attenuation cor- 
rection will improve the clinical accuracy of the coincidence gamrna camera. 
Fig. 2. A 60-year-old man was investi ated with ' 8 ~ - ~ ~ ~  h a u s e  of raised thyroglobulin and a (false) 8 negative l3'l whofe body scan. The [ FIFDG irnages obtained with the coincidence camera (left) and 
the PET scanner (right) clearly showed an increased uptake in the paratmcheal region. Surgery and 
histology confirrned this finding. 
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19. The Pharmacokinetics of FDOPA in Newborn Piglets 
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Introduction 
Positron emission tomography (PET) after i.v. application of FDOPA provides, among other things, 
information about the enzyme kinetics in dopamine metabolism (for review See [4]). Its application to 
newborn piglets represents a new animal model which requires chemical quantification of radiotracer 
metabolism in the brain target tissue as well as in plasma. The results of this quantification are shown 
here on a temporary level and discussed with regard to commonly accepted FDOPA PET modelling. 
Methods 
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Fig. 1. Representative HPLC radiotraces of brain extract and plasma. 
Colours and abbreviations as in Fig. 3. 
Five brain regions (cerebellum, frontal cortex, mesencephalon, nucleus caudatus arid putamen) were 
Chosen for tissue metabolite analysis after euthanasia at different times p.i.. Preanalytical preparation 
and HPLC of that tissue and of blood plasma were accomplished by an application [T] speyfliy 
developed specially developed for the purpose, aimed at fast sample throughput (short half life of F), 
recovery of all the potential FDOPA metabolites and low detection limit. Further sample throughput 
enhancement was achieved by simultaneous use of two analytical columns coupled by a switching 
valve. Fig. 1 shows representative chromatograms of brain extract and plasma with the individual 
peaks coloured as in the pathway scheme (Fig. 3). 
Resuiis 
The plasma total activity soon after injection passed a brief rnfximum and then approximated a steady 
state at a 111 plasmahrain ratio (Fig. 2). In the brain the F activity never covered more than six 
substances. Their relative kinetics, together with the plasma kinetics of the identical substances, are 
arranged according to the generally accepted pathway and biodistribution succecsion (Fig. 3). 
i 
1 ' rnin p.i. i I - 1 
Fig. 2: Normalised total "F activity of the plasma and brain versus time (ordinate: 1000x(%dose/g)). 
Graph colours as in Fig. 3. 
Among the fiie extracted brain regions we suggest to classify three types of metabolism (table + Fig. 
3). Since we worked without peripheral AADC inhibition, we obtained a cornplex plasma metabolite 
pattern: the plasma activity was rnainly formed by four substances (FDOPA, 3-0-M, FDOPAC, FHVA). 
FMT and FDA belonged to the minor plasma metabolites the sum of which never exceeded 15 % of 
total "'F. 
Table 1. Brain metabolism classification 
TYPe Region FDOPA turnover FDA Storage 
I cerebellum / cortex slow negligible 
I l  mesencephalon fast negligible 
I11 Nucleus caudatus / putamen intermediate significant 
Discussion 
During the first few minutes p.i. the FDOPA brain metabolism showed considerable dynamics with 
quantitative changes higher than during all the remaining PET acquisition time (total 120 min). In the 
piglets this contradicts prolonged data acquisition procedures yielding the diagnosticaliy discriminating 
variables (such as k).  The rapidly accumulating major metabolite FHVA as well as FMT and FDOPAC 
are by definition regarded as non BBB diffusible. We emphasise that FMT accounted for as much as 
35 % of total brain activity (peak at 4 rnin p.i.). Expressed as total activity this implies that the most 
concentrated 1 8 ~  species wcurring in piglet brain are FHVA, FDOPAC and FMT. 
- - -  33-1 %18F 
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Fig. 3. Plots of the ' 8 ~  activity fractions 1% of total tissue ' 8 ~ j  of the metabotites in the investigated 
tissues versus time. 
In recent PET modelling FMT has been generally neglected on the assumption that it represents less 
than 5 % of total activity. In endogenous metabolism methoxytyramine may be indicative for 
dopamine release into interstices [I]. 
The rapid pathway Passage does not meet substantial postulates of slope-intercept plots (that is: FDA 
and its acidic metabolites are trapped in the brain target regions; brain clearance processes of 
FDOPAC and FHVA do not significantly alter tissue activity because of their low percentage up to 50 
min p-i.. For review See [4]). The metabolite Pattern changes dunng the first few minutes p.i. are 
possibly part of a qualitativeiy distinct episode that describes xenobioticum detoxification (violation of 
tracer principle by the injected FDOPA amounts; 181) rather than endogenous turnover rates. 
As against the results in adult animals, the Same magnitude of metabolism was found in reference 
regions (cerebellum, cortex) and target regions (nc. caud., putamen). However, this might have been 
expected from experiments on the ontogenesis of CNS AADC activity [3] and tissue extract analysis 
revealing high endogenous HVA contents[5]. The contribution of an immature BBB has to be 
considered as well. Nevertheless, we found small but partially significant differences in normalised '*F 
contents of FDOPA, FHVA, the sum of amines and the sum of AADC products between the three 
metabolic types with plausible signs (t = 8 min p.i.; n = 7; data not shown). These differences may 
reflect the only specific volume of transmitter metabolism and thus the appropriate ontogenetic 
maturation level of the dopaminergic system (dopamine Storage [6], precursor and terminal product 
accumulation of the transmitter). 
Conclusion 
Without peripheral AADC inhibition in neonatal piglets, there emerge two features which interfere with 
the use of FDOPA PET for striatal AADC investigation: (1) The properties of the much higher 
concentrated FDA products conceal the desired target process. (2) The widespread distribution of 
AADC in the brain does not leave a well suitable PET reference region. Feature (1) is treated by 
implementation of compartment models which take FDA metabolites into account (k4, describes the 
loss of tissue activity by FDOPAC and FHVA diffusion). Feature (2) is treated by the choice of the 
plasma slope-intercept plot instead of the tissue slope-intercept plot together with properly 
performed plasma metabolite analyses. 
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lntroduction 
In preceding Papers, we have dernonstrated that it requires, not the unidirectional blood-brain clear- 
ance constant (Kl ), but two Michaelis-Menten constants to describe blood-brain transport of glucose 
[I]. The two constants, relative r n a x i ~ l  transport of OMG (T;,) and the half-saturation constant of 
glucose (K,), can be obtained when K, is rneasured with PET at a range of plasrna glucose levels. In 
the study, the two constants were estirnated in a group of subjects, assurning cornrnon values arnong 
individuals. It is necessary, however, to estirnate the two constants in a single individual and in a sin- 
gle region in order to exarnine changes in the constants in neurological conditions in which pathologi- 
cal changes in the constants are expected. 
Blood-brain transport of large neutral arnino acids (LNAAs) is also shown to obey the Michaelis- 
Menten equation [2, 31. Recently, Miyagawa et al. [4] dernonstrated an up-regulation of LNAA trans- 
port in brain turnors. 
In this study, we introduced a new rnethod for estirnating the Michaelis-Menten constants of blood- 
brain LNAA transport in a single subject with one PET study with [ ' 8 ~ ] f l u o r o - ~ - r n e t h y l - ~ - ~ ~ ~ ~  
(OMFD), a specific tracer of the transport. 
Theory 
In the following, we present a theoretical basis for rneasuring Parameters of blood-brain transport of 
LNAAs in one OMFD-PET study. In the proposed experirnents, concentrations of LNAAs are in- 
creased gradually when OMFD is in a near steady-state following an intravenous injection (e.g., 40 
rninutes after injection). In such experirnents, rate constants which describe the kinetics of individual 
LNAAs and OMFD are time-variant. In addition, the fact that a number of LNAAs cornpete for the 
same facilitated transport makes equations complicated. For this reason, oniy critical equations will be 
presented in this paper. Details can be found elsewhere [5]. According to the Michaelis-Menten equa- 
tion, Kl of i-th LNAA (denoted by suffix i) is give by: 
where K1i, Kti, and C, (0 are the maximal transport, half-saturation constant, and concentration in 
plasrna of the i-th LNAA. The equation for k2i, the brain-blood clearance rate constant of the i-th LNAA, 
can be obtained by replacing C, (0 by M, (0, the content of i-th LNAA in the brain in the equation. 
(Strictly speaking, the concentration and the content shoulb be discriminated. However, we treat thern 
equaliy in this paper for the sake of simplicity). Sirnilarly, Kl of OMFD is given by: 
where f „  and f(. are the maximal transport and half-saturation constant of OMFD. The K; - k2 ratios 
are common among LNAAs and the OMFD tracer. Thus, the ratio, denoted by V,(t) is given by: 
It is likeiy that the utilization of the i-th LNAA rernains constant (c;S despite the gradual increace in 
plasma concentrations of LNAAs during the experirnent. The utilization is gken by: 
as the differente between the amount of the LNAA which enters the brain (the first term) and the 
amount of the LNAA which returns to the circulation (the second term). The equation is divided by 
Kli(t)' Kti to obtain: 
In the right-hand side of the equation, Kli(t)' Kti is replaced by T ~ , ,  /(I + C* C ( t ) /  K ) , according to 
1x1 ‘3 ' j
Equation (1 ), to obtain: 
The equation for each LNAA is added across LNAAs to obtain: 
The left-hand side of the equation can be modified as follows: 
The first Wo terms cancel each other, according to Equation (3). Thus Equation (7) can be rearranged 
to: 
Further more, Equation (9) can be modified as follows using Equation (2): 
l l ~ , ( t ) = l + C  1=1 [ C ~ I T ~ ~ ~ ] - [ T ~ I K ~ I I K ~ *  (1 0) 
Since V,(tj is common among LNAAs and OMFD, Equation (1 0) is multiplied by K,* (0 to obtain: 
k; ( t )  = K; ( t )  + I=I [Ci I Tmmi I . [T, I X,*] (11) 
Separately, the kinetics of OMFD is described by the following differential equation: 
dM ,* ( t )  1  dt = K,* ( f )  - C: ( t )  - k; ( t )  . M: ( t )  (1 2) 
In this equation, k2* (4 is replaced by Equation (1 1) and K~. (0 by Equation (2) to obtain: 
There are Wo constants to estimate by least Squares optimization, namely T' lK:and 
x = l c i  /Tmc . Practical application of the equation will be discussed in Methods. 
Methods 
We studied 5 pigs (-6 weeks old, body weight-20 kg) in this project under isoflurane anesthesia. Each 
pig was studied with OMG twice at least 4 hours before the OMFD study. We confirrned that the pigs 
were norrnoglycernic at least one hour before the OMFD study, although plasrna glucose concentra- 
tion was rnodified in the OMG experirnents. At time 0, a bolus of -300 Bq (two thirds of the total dose) 
was given intravenously over one rninute and PET data acquisition was started. Starting at 20 rnin- 
utes, the remaining one third dose of OMFD was continuousiy infused throughout the study. Starting 
at 40 rninutes, either physiological saline (n = 3) or arnino acid solution (n = 2) were infused at a con- 
stant rate throughout the study. A total of 38 frarnes were recorded with the Siemens ECAT EXACT 
HR+ PET. There were 6 thirty-second frarnes, 7 one-rninute frarnes, 5 two-rninute frarnes, and 20 five- 
rninute frarnes. Arterial blood was sarnpled frorn the femoral artery using an HPLC fraction collection 
System at a constant speed for the first 20 rninutes. Blood samples were collected into a tube every 20 
seconds for the first 6 rninutes then every rninute thereafter. Blood sarnples were taken rnanually 
every 5 rninutes after 20 rninutes. Sarnples were irnrnediately placed on ice. The radioactivity in 
plasrna was deterrnined with the Wallac 1480 Wizard 3" autornatic garnrna Counter which was cross- 
calibrated with the PET. Concentrations of LNAAs were deterrnined on arterial plasrna taken at 10 rni- 
nute intewals after 35 rninutes. 
All data were processed as described in detail in a separate paper. The radioactivity was corrected for 
physical decay to time 0. The radioactivity in arterial plasrna was expressed in nCürnl as a function of 
time. Regional radioactivity data sets were also obtained as functions of time and expressed in nCig. 
The regionc includeg left and right frontal, temporal, parietal, and occipital lobes, and cerebellurn. We 
obtained K1 and k2 of OMFD in the 12 brain regions for each anirnal using data obtained during the 
first 40 rninute~. In the amino acid infusion experirnents, we assurned that regional estimates of .Kl 
represenfed Kl for plasrna LNAA concentrations at 35 rninutes (i.e., pre-infusion) of the regions. Re- 
gional K1 estirnates were used later as described below. 
We found that rneasured radioactivity was subject-to error due to relatively low Counts toward the end 
of study. In order to rninirnize the uncertainty, M, (0 was fitted by a surn of two exponentials as fol- 
lows: 
M: ( t )  = A* (t)  - V, - C: ( t )  = X3 1=1 e-G .Iibi 
where V, is the effective vascular volurne to subtract intravascular radioactivity (V,= 0.035 rnVg). The 
derivative of M,' (0, d ~ ~ *  (I)/&,was obtained by differentiating Equation (14) as follows: 
Since the values of Kfor individual LNAAs are not known for young pigs, we used values reported for 
the rat brain [2,6] after averaging, assurning that the pig values were proportional to the rat values F]. 
Thus: 
where ß is a factor to account for the proportionality. Si  LNAAs were considered in this ctudy. The K, 
values used were 0.42 for valine, 0.1 15 for rnethionine, 0.193 for isoleucine, 0.0895 for leucine, 0.1 12 
for tyrosine, and 0.0655 for phenylalanine (unk are prnoVrnl). The sum was also fitted by a sum of WO 
exponentials as follows: 
Equation (1 3) can be re-written as: 
where a is T,IK;, and y is [T& 1 K : ] .  x i l c i  /T„ . In a preliminary study, we found that the resid- 
ual Square sum changed little when ß was changed in step wise from 0.1 to 7.2. Thus, we chose re- 
gional values of ß which minimized the difference between calculated values of K,., given by 
aI( l+ ß - ~ ~ = 1 ~ ,  (35)), and the estimates of the regions. We assumed that concentrations of LNAAs 
in plasma remained constant before amino acid solution infusion started at 40 minutes. 
Resuits and Discussion 
The radioactivity in arterial plasma is shown in Fig. 1 a for one experiment with saline infusion (marked 
with X) and one experiment with amino acid infusion (0). The present infusion method kept Ca (0 rela- 
tively constant throughout the experiment in all studies. The radioactivity in the right temporal lobe is 
shown in Fig. 1 b for the two fxperiments. In the experiment with saline infusion, A ( T )  increased con- 
stantly over time because Ca (9 also increased slightly over time in this experiment. However, the dis- 
tribution volume (A-(T) over Ca (0) remained constant as shown in Fig. 1 C. 
When A*(7) changes relativeiy liffl? over time as is the case with this experiment, the distribution vol- 
ume must be close to the KI - k2 ratio (Equation (12)). In the experirnent with amino acid infusion, 
A (T) decreased slowiy over time despite C, (0 remaining constant afier 40 minutes. The distribution 
volume decreased from 0.7 at 40 minutes to 0.3 at 120 minutes. 
The sum of the concentration-half saturation constant ratios, given by Equation (16), remained con- 
stant in saline infusion experiments. One example is shown in Fig. 2 with X. The sum of the ratios in- 
creased rapidly from 6 at pre-infusion (35 minutes) to 18 at 120 minutes in this arnino acid infusion 
experiment (shown by o in the figure). In another amino acid infusion experiment, the sum increased 
somewhat less from 6.5 at 35 minutes to 14.4 at 120 minutes. The curve in the figure indicated the 
best fit by Equation (1 8). 
As described in the Method, ß was fixed to estimate a and y of Equation (18). The value of ß was 
changed step wise from 0.1 to 7.2 (step size: 0.1) and a and y were estimated for each ß. KI' was cal- 
culated by Equation (2) as a/(l+ B. z6 Ca, (35) 1 4  ). in Fig. 3a, calculated K,* was plotted against 
F 1  
ß. The calculated K,- should represent K,* before amino acid infusion and should be equal to the esti- 
mate of K1'using the data obtained during the first 40 minutes (shown by the doZted line in the figure). 
It was noted, however, that the choice of ß rnay suffer uncertainty because the paths of the two K,' 
crossed where calculated K,' approached an asymptote, as evidenced in the figure. For this reason, 
we chose the mean ß across regions. The values were 3.5 for one experirnent (shown in the figure) 
and 2.2 in the other experiment. In Fig. 3b (right panel), measured d ~ , '  (f)ldt (strictiy speaking, calcu- 
lated d ~ , '  (Qldt using Equation (15)) where shown by circles and predicted d ~ , '  (Qldt (calculated by 
Equation (18)) by the curve. In all regions, the two were close to each other. The best estimates of 
T„'IK (=U) averaged 0.87 1: 0.15 (glml) in one amino acid infusion experiment and 0.26 1: 0.06 in the 
other. The values were quite different between the two animals. The value from the second animal 
was close to the value for the human striatum (0.22 ghl) we obtained in a previous expriient [7]. In 
the human study, T-*/&<;' was obtained as the best estimate across 6 subjects using [ F]fluoro-L- 
DOPA. The estimates of /T=, (= Y/ a) averaged 0.034 i 0.010 (ratio) in one animal end 0.057 
f 0.010 in the other. These values indicated that only about 0.6-0.9 % of LN- were used in the pig 
brain relative to the maximal transport. If values of individual Kt change in parallel in a pathological 
condiiion, estimates of ß should change accordingly. However, it is not certain whether such changes 
in ß can be detected by this method at this point. 
Summary 
We introduced the theory for regional measurements of the Michaelis-Menten constants of blood- 
brain transpoit of LNAAs. 
We demonstrated thatth? theory described actuai data. 
The estimates of Tm/& for the pig brain was close to the value we obtained tor the human 
striaturn using [I 8Fffluoro-L-DOPA. 
The current study indicated that only about 0.6-0.9% of LNAAs were used in the pig brain ~@laWe 
to the maximal transport. 
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21. Regional Distribution of Cerebral Blood Volume in Newborn Piglets - Effect of 
HypoxiaIH ypercapnia 
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lntroduction 
Cerebral blood volume (CBV) is an important factor in cerebral hemodynamics as weil as a key pa- 
rameter in brain tracer studies. The newborn piglet has been shown to be a good model for the study 
of brain blood flow and metabolism and this model has now been well standardized (for review see 
[I]). However, apparently up until now an estimation of regional CBV has not been performed. In order 
to establish in vivo tracer studies for further investigaüons of normal and disturbed brain functions in 
newborn piglets, knowledge of regional distribution of CBV is necessary. 
The aim of this study was to determine the regional distribution of CBV that occur under normal condi- 
tions and under conditions of vasodilatation induced by hypoxialhypercapnia. 
Material and Methods 
The animal experiments were performed according to the German Law on the Protection of Animals. 
The study was approved by the committee of the Saxon state government for animal research (75- 
91 85.81-4.6195). 
Fourteen newborn piglets (aged 5 to 7 days old, body weight 2373 I 381 g) of both sexes were utilized 
in this study. All animals were anesthetized with 0.25 - 0.5 % isoflurane in 70 % nitrous oxide and 30 
% oxygen. Body temperature, heart rate, mean arterial blood pressure (MAP), arterial and brain ve- 
nous pH, pCO„ and pO„ oxygen Saturation and hemoglobin values were monitored. A central venous 
catheter was introduced through the lefi extemal jugular vein and was used for tracer injection and for 
volume substitution (Ringerllactate solution: 5 mlh). A poiyurethane catheter (PU 3.5 Ch, Sherwood, 
England) was advanced through the right femoral artery into the abdominal aorta 1 Cm above the aor- 
tic bifurcation for blood sampling and for arterial blood pressure monitoring. Seven animals were held 
under unchanged conditions and served as sham operated control (normoxic group). Another w e n  
animals underwent a change in their inspired gas composition (Fa2 was lowered from 0.35 to 0.1 1 in 
exchange for nitrogen and about 10 % CO2 was added) and served as the hypoxianiypercapnia grwp. 
At thel5* minute of hypoxialhypercapnia the animals were injected with 30 - 40 MBq -TC% intraw 
nously.. Five minutes later the animals were killed by decapitation immediiteiy following intracardil 
injection of about Iml  saturated KCI solution, which stopped myocardial function. The brain was re- 
moved within 90 seconds and further dissected for CBV measurements. In blood samples obtained 
immediateiy before death and in brain tissue samples radioactivity of P g m ~ ~  was measured in a weil 
Counter (COBRA 11, Packard Instrument Company, Meriden, CT, and U.S.A.).Cerebral blood v o l u ~  
(CBV) was calculated using the following formula: CBV = (tissue radioactivity 2 blood weight) / (blood 
radioactivity tissue weight) and expressed as percentage of sample weight. 
Data are reported as rneans I SD. Comparisons between both animal groups were perf0mEd using 
the t-test for independent samples and Bonferroni correction for multiple use. üifferences Wre Gon- 
sidered significant when P < 0.05. 
Table 1 summatizes the values for MAP, heart rate, arterial bZood gases, and catechoiamines dufing 
baseline conditions and afier fifteen minutes of hypoxiaypercapnia. fhe baseline ~alueS are within 
the physiological range and consistent with other data obtained from anesthetized and arüfiiially ven- 
tilated n e h m  piglets [2]. The supposed degree of moderate hypoxiaßlwrcapnia, i.e. a r&uctio* 0f 
arterial p02 of about twenty five per cent of baseline value in %MI 20 nearly dOubling amrkd &02, 
ied to a significant increase d MAP and heart rate together witfr a severat foM increase of epinephrine 
and riorepinephrine @ < 0.05). Moreover, arterial oxygen Gontent and also brain AVDB2 wer@ r@duW 
to a b u t  one third (p 0.05). Howeyer, under this condition of hypoxialhyp?erc;tpnist brain oxidative 
metabolism has obvbusiy not been ;compromis&. Regional C W  was sQniMnäy higher in ffte bwer 
brain stem and cerebeilum compartrd with the values from thalarnus and white matter Ip < 0.05). 
Table 1. Physiological values and blood catecholarnines of newborn piglets obtained during baseline 
conditions and in the 15'~ minute of hypoxidhypercapnia. 
Control group Hypoxidhypercapnia group 
n = 7  n = 7  
baseline baseline hypoxidhypercapnia 
Heart rate 217 I 25 201 I 23 261 I 19 * 
(rnin-') 
MABP 68 I 3 68 I 9 7 9 1  4 *  
(rnrnHg) 
Arterial pH 7.42 I 0.04 7.46 I 0.02 7.23 I 0.05 * 
Arterial pCOp 39 + 3 36 I 1 6 8 1  5 *  
(mm Hg) 
Arterial p02 120 I 12 128 + 8 32 i 5 *  
(mm Hg) 
Arterial O2 content 4.1 I 0.7 4.2 rc 0.9 1.4 I 0.3 * 
(p mollml) 
AVD02 2.5 I 0.4 2.5 I 0.4 0.7 I 0.2 * 
(rnrnol/l) 
Epinephrine 175 I 40 217 I 169 1239 i 979 * 
(pglml) 
Norepinephrine 504 + 315 481 I 442 7807 I 5245 * 
(pg/mI) 
Dopamine 204 I 38 145 I 68 262 I 94 * 
(pglrnl) 
(Values are means I SD. AVDO, indicates difference of arterial and brain venous blood content of 
oxygen. * P C 0.05, cornparison between baseline stage and the stage of hypoxidhypercapnia.) 
Hypoxidhypercapnia induced a considerable change in CBV. There were considerable differences 
among different regions in the brain. The increase in percentage of the CBV was higher in structures 
with lowest baseline values; i.e. the thalamus (66 % increase) and white matter (62 % increase). How- 
ever, absolute values rernained significantly higher within the lower brain Stern, cerebellum and cere- 
bral Cortex (p 0.05). 
Discussion 
The newborn piglet has been shown to be an appropriate model for the study of cerebral blood flow 
and metabolism [I]. However, to the best of one's knowledge rneasurement of regional CBV has not 
been done before in newbom piglets. A considerable nurnber of studies which presented parameters 
of cerebral oxidative metabolism under different experimental conditions, including vanous sedation 
states have been performed in newborn piglets [3 - 91. Usually the CBV is rneasured by determining 
the brain distribution space for nondiffusible red cell and / or plasrna rnarkers. Typical tracers include 
"~ r - ,  55~e-, *TC-, or c150 labelled red cells, or ""'TC- or radioiodine-labeled alburnin. Recenüy, as a 
new principle paramagnetic contrast rnedia like Gd-cornplexes are used to deterrnine quantitatively the 
intravascular volume by using contrast MRI techniques [10, 1 I]. The obtained magnetic resonance 
imaging of cerebral blood volurne (CBV) estirnates correlated well with values obtained by '0 labelled 
carbon rnonoxide ( ~ ' ~ 0 )  PET. However, PET CBV values were approximateiy 2.5 times larger than 
absolute MRI CBV values, supporöng a hypothesized sensitivity of MRI to small vessek 11 21. In addi- 
t im to their expenses, these attraciive approaches appear to be of Iimited value for use in srnaller 
mamrnais because of the limited possibility to determine exacüy the input (arterial) function in MRI and 
in difficulty to diierentiate intracraniaf blood volurne cornpartments and the extracranial cornpartrnent 
with appropriate exactness due to a reduced spatial resoiution (> 5-8 mm) in PET [12], accordingly. In 
regard to the chocen method of intraparenchyrnal CBV we used a rnethwl based on labeling plasma 
and red cells together, which allows calculation of blood volume without any correction. Therefore, this 
method avoids hematocrit sourcec of error because all methods based on separate red blood ceil or 
plasma labelling alone require a correction for the difference between large-vessel and cerebral he- 
matocrit [I 31. 
Table 2. Cerebral blood volume (CBV) of different brain regions obtained during baseline conditions 
and in the 15" minute of hypoxiahypercapnia in newborn piglets. 
l ndex 
Regional CBV ( m l ~  1009-') 
control group n = 6 HM group n = 7 
1 lower brainstem 2.23 I 0.22 3.29 I 0.34* 
2 cerebellum 2.60 I 0.60 3.55 I 0.39* 
3 thalamus 1.55 I 0.40' '. 2.58 I 0.42*'ls2 
4 cerebral cortex 2.01 I 0.31 3.07 I 0.31* 
5 white matter 1.50 I 0 . 3 7 ' ~ ~ ~  2.43 I 0.36*§'.~.~ 
(Values are means I SD. * B P C 0.05, * indicates the comparison between baseline stage and the 
stage of hypoxia/hypercapnia; ' indicates the comparison between different brain regions, given by the 
index column.) 
Since we obtained brain tissue samples just after induction of cardiac arrest by intravenous potassium 
chloride and subsequent brain removal, parenchymal blood volume was measured. We used 99m~c- 
pertechnetate as a blood marker because evidence exist that both red blood cell membranes and se- 
rum proteins could bind 99m~c-pertechnetate with a similar degree of afFinity and kinetic stability 1141. 
Moreover, 99m~c-pertechnetate distribution between red blood cells and plasma is suggested to be 
finished within a few seconds 1131. Unbiased CBV estimation is based on the prerequisite that tracer 
amount and distribution (e.g. in this study 99m~~-pertechnetate bound on erythocytes and Serum pro- 
teins) has not been affected either by the procedure of the killing, brain removal and brain sample 
processing. No separate study was carried out to determine if a secondary mismatch occurred, but it 
has been assumed that through the method, sequence, and timing such mismatch can be largeiy ex- 
cluded. In detail, the procedure to gain brain tissue samples was initiated by intracardial injection of a 
small volume of saturated KCI solution, which led immediately (within 2 - 3 seconds after onset of KCI 
injection) to a simuitaneous arrest of both ventricles. Simultaneously, decapitation was performed after 
tipping the forwards by about 75" so that effluence of blood from the head was largely prevented. 
Therefore, a dilution of the head blood by the injected KCI solution can be virtualiy excluded because 
dissection of all cervical vessels occurred irnmediateiy after intracardial KCI injection. Moreover, head 
repositioning by incline forwards after removal greatiy prevents blood congestion as well as blood ef- 
fluence. Indeed, using the procedure of decapitation should aid reduction of transmural pressure 
within cerebral circulation making arterial branches reduce in diameter. The effects on capillary beds 
and venous branches should have been rather small if not abolished becauce the head repositioning 
in order to prevent blood effluence resulted in a positive hydrostatic pressure similar to in viv0 condi- 
tions of intracerebral venous pressure. Therefore, the normal filling of the venous branches and of 
park of the capillary bed should not have been changed due to the procedure of brain removal. Fur- 
thermore, considering that the change in capacity of arterial branches due to the reduced transmural 
pressure would have been counteracted by a dilation of the resistive vessefs due to terminal anaxia 
and acidic waste accumulation, a conuption of CBV estimation by procedure used here WOUM seem t0 
be minimal. 
We chose to determine intraparenchymal blood volume as that part of &tat cerebral blood V O ~ U ~ ? .  
which deals mainly with microcircuiation [13, 151. Therefore, the appruach U& here provides unbi- 
ased data of intraparenchymai CBV, which are of particular concern ior instance in studies ~Sing 
tracer kinetics methods in newbom piglets 11 61. 
We found under norrnoxidnormocapnic condiions considerabie regional differencec of CBV with the 
highest vaiues in the brain stem and the Iowest values in the forebrain white matter (p c: 0.05). CBV 0f 
the cerebral Cortex was found to be similar to data measured in aduit rat forebrain afkr in viv0 micro- 
wave fixation 1171. Other studies, however, reported considerably lower parenchymal CBV values 
(about half) in adult rats [13, 15, 181. In these studies CBV measurements were done after decapita- 
tion. Estimation of CBV in young rats after killing by saturated potassium chloride and brain dissection 
yielded CBV values, which were slightly higher than in adult rats [1 91. As extensively discussed meas- 
urement of CBV in brain tissue samples after brain removal is markedly influenced by the methods, 
which were used. Todd and CO-worker pointed out when the CBV is measured in small samples of 
brain tissue obtained after animals are killed either by drug overdose or decapitation, the resultant val- 
ues would be lower than those obtained from in vivo methods or those obtained when the brain was 
fixed in situ before removal because of tracer loss from the tissue during processing [ I  71. Keyeux et al. 
argued that a higher CBV value after in situ fixation by focussed microwave irradiation could be due to 
the absence of bleeding during decapitation and dissection and also to the brain sample contamina- 
tion by extraparenchymal components, since microwave fixation makes peeling off the meninges im- 
possible [20]. We used brain tissue samples, which were carefully stripped of their meningeal cover- 
ings so that penetrating arterial branches, capillaries and intraparenchymal veins are included into 
CBV estimation. Extracerebral contamination appears almost excluded. Therefore in newborn piglets 
the parenchymal CBV seems to be somewhat higher than in adult animals. 
Two different mechanisms appear to be responsible for cerebral vasodilatation under hy- 
poxialhypercapnia. Hypoxia per se induces pial artery dilation by neuronal derived nitric oxide (NO) in 
newborn piglets via formation of cGMP and the subsequent release of opioids [21]. Hypercapnia- 
induced cerebral vasodilation is prostanoid-associated [22] and NO independent [23] in the newborn 
pig. Studies in cerebral microvascular smooth muscle cells derived from newborn pigs suggest that 
arteriolar dilation in response to hypercapnia requires the presence of an intact endothelium and is 
accompanied by an indomethacine-sensitive increase in cortical adenosine 3, 6-cyclic monophos- 
phate (CAMP) [24]. We assume that under hypoxid hypercapnia used here a maximum dilation of 
cerebral resistive vessels occurred in newborn piglets. 
As a consequence of this vasodilation, hypoxialhypercapnia induced a moderate increase in CBV in 
all brain regions studied (36 to 66 %) (p < 0.05). The moderate increase in intracerebral CBV may re- 
flect predominantiy the enlargement of the resistive vessel branches. However, minor increase of 
cerebral venous pressure as might result from upstream basil dilation cannot be excluded, because 
cerebral venous pressure has not been measured in this study. A capillary recruitment obviously does 
not exist in the adult brain during the high flow situation of hypercapnia [25], and the brain circulation 
appears to be different from peripheral vascular beds by having a continuous capillary perfusion. Ac- 
cording to our data derived from newborn piglets it seems also to be true for the immature brain, con- 
sidering that only a moderate CBV increase resulted under hypoxidhypercapnia in comparison to a 
tremendous CBF elevation (see following report). 
One study was reported where cerebral erythrocyte volume (CEV) was monitored together with other 
Parameters of cerebral oxygen delivery and uptake in newborn piglets during normal conditions and 
various stages of blood gas manipulation [26]. CEV was measured by erythrocytes labeled with ""'TC- 
pertechnetate and scintillation detection over the head. Surprisingly, no significant changes in CEV 
were detected throughout this study. This was obviously caused by methodological problems in regard 
to the used CEV measurement procedure since extracranially counted radioactivii as a measure of 
Cerebra1 erythrocyte volume is contaminated by radioactivity emitted by labeled red blood cells from 
vessel beds outside the brain, mainiy from venous plexus at the base of the skull and from adjacent 
extracranial tissue, e-g. nasal mucosa. The authors stated that despite all their efforts to reduce extra- 
contamination, e.g. shielding within the oral cavity and animal body surface by lead, about 30 
% of the detwted radioactivity was assumed to be resulted from Compton scatter from the subdural 
venous plexus at the base of the skull and from adjacent extracraniai tissue. However the assumption 
that extraCerebra1 erythrocyte volume varied parallel to CEV throughout the various experimental 
states remains rather unlikeiy. Changes in blood gas compocition which induce a marked redistribution 
of circukting blcmd which is accompanied by gradual increase in sympathetic tone should lead to o p  
re-nses of cerebral and adjacent extracerebral blood volume, e.g. vasodilatation of brain 
ve-1~ (W above) and vasoconstriction of respecüve extracerebral vessels especialiy within the ad- 
jacent nasal mucosa, particularly the nasal venous sinusoids since nasal mucosa blood flow and tone 
of the capacitance vessels are strictiy controlled by sympathetic tone [18, 271. 
In Summary, newborn piglets under normoxic and normocapnic conditions exhibit a comparatively en- 
larged intraparenchymal CBV. Moderate h w x i a  and hypercapnia induced a increase in CBV caused 
by vasodilation of cerebral vessels. 
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22. Effect of Hypoxiakiypercapnia on Cerebral Blood Flow in Newborn Piglets 
R. ~auer', P. Brust, B. walte$, R. Bergmann 
'Institut für Pathophysiologie, Friedrich-Schiller-Universität Jena 
lntroduction 
Cerebral blood flow (CBF) is an important factor in cerebral hemodynamics as well as a key parameter 
in brain tracer studies. A linear relationship is suggested between CBF and cerebral blood volume 
(CBV) according to the fundamental equation derived by Meier and Zierler [I]. This equation states 
that the mean transit time (MTT) of a tracer equals the ratio between the volume of distribution of the 
tracer in the organ and the blood flow rate through the organ. Therefore it has to be assumed that the 
relation between CBV and CBF is a continuously changing function which is predestined by momen- 
tary metabolic requirements and that one parameter alone cannot be used as a reliable index for the 
other [2]. 
The newbom piglet has been shown to be a good model for the study of CBF and metabolism and this 
model has now been weil standardized (for review See [3]). 
The aim of this study was to determine the regional distribution of CBV, CBF, and MTT that occur un- 
der normal conditions and under conditions of vasodilatation induced by hypoxialhypercapnia. We 
tested the hypothesis that the marked inerease of regional cerebral blood flow is predominantly 
caused by reduced MTT rather than increased regional GBV during hypoxialhypercapnia. 
Material and Methods 
The animal experiments were performed according to the German Law on the Protection of Animals. 
The study was approved by the committee of the Saxon state govemment for animal research (75- 
91 85.81-4.6195). 
Fourteen newborn piglets (aged 5 to 7 days old, body weight 2373 ir 381 g) of both Sexes were utilized 
in this study. All animals were anesthetized with 0.25 - 0.5 % isoflurane in 70 % nitrous oxide and 30% 
oxygen. Body temperature, heart rate, mean arterial blood pressure (MAP), arterial and brain venous 
pH, pC02, and p02, oxygen saturation and hemoglobin values were monitored. A central venous 
catheter was introduced through the left extemal jugular vein and was used for tracer injection and for 
volume substitution (Ringernactate solution: 5 mVh). The left ventricle was cannulated retrogradely via 
the right common carotid artery with a polyurethane catheter (PU 3.5 Ch, Sherwood, England) for col- 
ored microsphere (CMS) injection and placement was verified by pressure tracings and at autopsy. A 
polyurethane catheter (PU 3.5 Ch, Sherwood, England) was advanced through the right femoral artery 
into the abdominal aorta 1 cm above the aortic biurcation for blood sampling, for withdrawing the ref- 
erence sample of CMS method and for arterial blood pressure monitoring. 
Seven animals were held under unchanged conditions and served as sham operated control (nor- 
moxic group). Another seven animals underwent a change in their inspired gas composition (Fi02 Was 
lowered from 0.35 to 0.1 1 in exchange for nitrogen and about 10 % CO2 was added) and served as 
the hypoxiakypercapnia group. Physiological measurements were performed at thel5th minute of 
hypoxiakypercapnia. Five minutes later the animals were killed by decapitation immediately following 
intracardial injection of about 1 ml saturated KCI solution, which stopped myocardial function. 
Regional CBF was measured by means of the reference sample color-labeled microsphere technique- 
Absolute flow to tissues measured by colored microspheres were calculated by the fomula: flowti, = 
number of microspheresti, q (flowrefe- I number of micr~spheres,~~,). Flows are expressecl in 
milliliters per minute per 1009 of tissue by normalizing for tissue weight. Cerebrovascular resistanm 
(CVR) was calculated as the quotient of mean arterial blood pressure diwided by forettrain biood ROW. 
Assuming the oxygen capacity of hemoglobin to be 1.39 ml Odg hemoglobin in piglets 141, bbod 0 2  - 
content was calculated as equal to g hemoglobinlml r 1.39 ml Odg hemogtobin % -Saturation and 
expressed in pMoVmin * 100 g. Discohred oxygen was added by calculation, using the measured W2 
and the temperature-corrected solubi1i.y coefficient of oxygen. Because the sagittal sinus drains the 
cerebral cortex, cerebral white matter, and some deep gray struckrres (basal ganglia, hippocampusJ, 
blood flow measured to the Cerebrum included these structures. CMR02 was obtained by mu&plying 
blood flow to the cerebrum by the cerebral arteriovenous 0, content difference (avD0,). Cerebral 0, 
delivery (cD02) was calculated as the product of cerebral blood flow times the arterial O2 content. 
Data are reported as means I SD. Comparisons between both animal groups were performed using 
the t-test for independent samples and Bonferroni correction for multiple use. Differences were con- 
sidered significant when P .c 0.05. 
Resuits 
The values for MAP, heart rate, arterial blood gases, and catecholamines during baseline conditions 
and after fifteen minutes of hypoxidhypercapnia are shown Table 1 of the previous report. Under this 
condition of hypoxidhypercapnia brain oxidative metabolism has obviously not been compromised. 
Because of an unadapted cerebral blood flow increase to the forebrain (p < 0.05) due to a consider- 
able reduction of CVR (p 0.05) an elevated brain oxygen delivery occurred (p < 0.05) whereas 
CMRO, remained unchanged (Table 1). 
Table 1. Forebrain cerebral blood flow and parameters of brain oxidative metabolism of newborn pig- 
lets obtained during baseline conditions and in the 1 5 ~  minute of hypoxidhypercapnia. 
Control group Hypoxidhypercapnia group 
n = 7  n = 7 
Baseline Baseline Hypoxidhypercapnia 
Forebrain CBF 64 + 1 1  70 I 13 274 I 74* 
(ml 100g" min-') . 
Forebrain CVR 1.08 I 0.15 0.99 I 0.19 0.30 I 0.08* 
(mmHg 1bOg min ml-') 
Cerebral 0,-delivery 274 I 90 303 I 70 364 I 60* 
(pmol 1009-I min-') 
CMRO:, 164% 54 182 I 39 183 I 45 
(pmol 1009-' min-') 
Oxygen extraction ratio 0.58 I 0.03 0.61 I 0.09 0.52 + 0.17 
vaiues are means I SD. CMR4 indicates cerebral metabolic rate off oxygen. 
* P C 0.05, comparison between baseline stage and the stage of hypoxidhypercapnia.) 
The levels of regional CBF and MTT were considerably different during baseline conditions (Table 2). 
The highest perfusion rate was found in the lower brain stem and cerebellum, whereas white matter 
exhibited the lowest values, which was about 38 % less than those of brain stem and cerebellum (p < 
0.05). Under baseline conditions MTT was significantly prolonged within the cerebral cortex compared 
with the thalamic MTT (p < 0.05). Hypoxidhypercapnia induced a considerable change in brain perfu- 
sion with a vast increase of CBF and marked shortening of MTT. However there were considerable 
differences among different regions in the brain. The strongest increase of perfusion rate was found in 
the lower brain stem with an improvement of 6.7 fold, which resulted in a significantly higher rCBF in 
comparison to those of the cerebral cortex and white matter (Table 2, p < 0.05). MTT shortening was 
pronounced in alt regions - between 22 % of baseline value in the lower brainstem and 49% in white 
matter (p 0.05). 
Table 2. Cerebral blood flow (CBF), cerebral blood volume (CBV) and mean transit time (MTT) of dif- 
ferent brain regions obtained during baseline conditions and in the 1 5 ~  minute of hypoxialhypercapnia 
in newborn piglets. 
Index 
Regional CBF (ml 1009-I min-') Regional MTT (s) 
Control group HIH group Control group H/H group 
n = 6 n = 7  n = 6  n = 7  
1 lower brain- 69 t 1 1  460 I 131* 2.09 t 0.50 0.46 t 0.14* 
stem 
2 cerebellum 70 t 10 369 I 104* 2.22 I. 0.31 0.61 t 0.17* 
3 thalamus 62 I 9 393 t 107* 1.53 ir 0.38 0.42 I 0.14* 
4 cerebral cortex 56 I 4 258 1: 72* 2.34 + 0 . 4 2 ~ ~  0.79 I 0.27*§~ 
5 white matter 43 7§ 1.2.3 150 I 42*§ 12.3 2.06 I 0.52 1.05 I 0.35*~'".~ 
(Values are means t SD. * § P C 0.05, * indicates the comparison between baseline stage and 
the stage of hypoxialhypercapnia; ' indicates the comparison between diierent brain regions, given 
by the index column.) 
Discussion 
The newborn piglet has been shown to be an appropriate model for the study of cerebral blood flow 
and metabolism [3]. Therefore, a considerable number of studies which presented Parameters of 
cerebral oxidative metabolism under different experimental conditions, including various sedation 
states have been performed in newborn piglets [5 - 81. Mild sedation by volatiie anesthetics and anal- 
gesia by nitrous oxide (used here) has no detectable influence on cardiovascular response in newborn 
piglets [9]. Furthermore, pancuronium administered in newborn piglets for neuromuscular blocking 
while ventilation is controlled does not alter systemic hernodynamic status [10]. Cerebral blood flow 
and cerebral O2 uptake values presented in this study were similar to values obtained from newborn 
piglets which were treated with other drugs for general anesthesia whkh were indicated to not alter 
brain oxidative metabolism and therefore the accompanying cerebral blood flow [I I]. However studies 
in awake and unrestrained newborn piglets chowed considerabiy higher regional perfusion rates in the 
brain and also higher cerebral oxygen uptake 1121. The reason for that could be the reduced sensory 
input and abolished rnotor function due to immobilization and artificial ventilation. There is, however, 
no evidence that cerebrovascular responce to hypoxia and hypercapnia under gensral anesthesia 
used here is basically different to that in unbiased conditions [13]. Therefore the study design is ap- 
propriate estimating regional CBF, and MTT under baseline normoxic and normocapnic state arid 
during conditions of cerebrovascular dilation induced by combined moderate hypoxia and hyperwnia 
which is able to effect a compensatory blood flow increase in order to maintain an adequate brain 
oxygen uptake under compromised condiiians. Indeed, systemic hpxiaJhypercapnia induces a cir- 
culatory redistribution even in immature mammals which favors the blood flow towards the heart, brain 
and adrenals in expense of the other Organs and tissues. This is mainly affected by an increase in 
sympathoadrenal activity. However, in contrast to older animals cardiivascular r e s p s e  in newborns 
is mainly caused by circulating catecholamines because of delayed central sympathetic t2'taturii$. In- 
deed, Lee and Downing have shown that hypoxia-induced cardiovascular responss were obsewd in 
intact and ganglionic blockade piglets, but no changes occurred in adrenalectomired piglets [14]. Di- 
rect stimulation of adrenal medulla and extramedullar chromaffin cells by redum arterial @Z is 
mainly responsible for increased catecholamine release in newborn rats eariy after birttt 1151. Neuro- 
genic activation via increased efferent sympathetic tone appears to be rather unlikdy since peripheral 
chemoreceptors remain insensitive shorüy after birth. Resetting takes several days wen in p r m d a l  
animals like newborn lambs [l€i].Therefore, syrnpathetic acWQ is mainly reflected by changes in cir- 
culating catecholamines and may serve as a relevant indicator for an adequate response of G%dio- 
vascular reguiation due to systemic hypoxialhypercapnia in newboms. 
We used the colored microsphere method for regional cerebral blood flow rneasurement, which was 
evaluated in this lab for use on newborn piglets [25]. This method enables a multiple quantitative esti- 
mation of the nutritive circulation during a short period of time (e.g. 2 to 3 minutes after intracardial 
microsphere injection). In contrast to CBF deterrnination by diffusible tracers the use of particles as 
indicators of nutritive flow has been shown to be appropriate even during high perfusion states [17]. 
Moderate hypoxemia combined with hypercapnia, which sirnulates blood gas changes typical for respi- 
ratory distress in newborns, leads to an exceeding CBF increase so that cerebral oxygen delivery sur- 
passes baseline value but cerebral O2 uptake remains not altered (Table 2). The reason for this high 
increase in non-adapted cerebral blood flow should be a dilation of cerebral resistive vessels, which 
appeared to be not more cornpletely controlled by rnetabolic demands since cerebral oxygen metabo- 
lism remained obviously unchanged, but cerebral 02-delivery was inadequately increased (p 0.05). 
This assumption is supported by findings in parallel studies on newborn piglets. We studied effects of 
hypoxic hypoxia alone and of combined hypoxidhypercapnia on CBF and the cerebral oxidative me- 
talbolism. We found that hypoxia alone induced a balanced CBF increase of about 160 %, whereas 
cerebral 02-delivery and CMR02 remained constant. In contrast, combined hypoxidhypercapnia led to 
a further CBF increase with a concomitant increase of cerebral 02-delivery, but CMR02 remained un- 
changed [l8]. 
Two different mechanisms appear to be responsible for cerebral vasodilatation under these conditions. 
Hypoxia per se induces pial artery dilation by neuronal derived nitric oxide (NO) in newborn piglets via 
formation of cGMP and the subsequent release of opioids [19]. Hypercapnia-induced cerebral vasodi- 
lation is prostanoid-associated [2O] and NO independent [21] in the newborn pig. Studies in cerebral 
mlcrovascular smooth muscle cells derived from newborn pigs suggest that arteriolar dilation in re- 
sponse to hypercapnia requires the presence of an intact endothelium and is accornpanied by an in- 
domethacine-sensitive increase in cortical adenosine 3', Ei'cyclic monophosphate (CAMP) [22]. We 
assume that under hypoxid hypercapnia used here a maximum dilation of cerebral resistive vessels 
oecurred in newborn piglets. 
A capillary recruitment obviously does not exist in the adult brain during the high flow situation of hy- 
percapnia 1231, and the brain circulation appears to be different from peripheral vascular beds by hav- 
ing a continuous capillary perfusion. According to our data derived from newborn piglets it seems also 
to be true for the immature brain, considenng that only a moderate CBV (see previous report) increase 
resulted under hypoxidhypercapnia in cornparison to the tremendous CBF elevation. According to the 
law of continuity of flow, in the case of continuous capillary perfusion, blood flow regulation is under 
unique control of vasomotion. Because the cerebral arteries, as well as pial arteries and arterioles rep- 
resent the main part of cerebral resistive vessels [24], cerebral perfusion is mainly regulated outside 
the parenchyrna itself. Therefore, under conditions of marked vasodilation like combined hy- 
poxialhypercapnia with concomitantiy marked CVR decrease, an increased pressure gradient 
throughout the microcirculating branch has to be assumed because pressure decrease along the re- 
sistive vessels was considerably reduced. As a consequence, perfusion velocity through intraparen- 
chymal vessels, mainly shaped by the capillary network, must be increased, as shown in this study by 
a considerable shortening of MTT. In regard to the disproportionate shortening of MTT in cornparison 
to the changes in intraparenchymal CBV increase there is no prediction about the behavior of extrapa- 
renchymal CBV which represents about 75 per cent of total CBV [17] and includes main branches of 
resistive vessels which are predominantly enlarged due to hypoxidhypercapnia. Nevertheless, MTT 
shortening appears to be a direct consequence of cerebral vasodilation. Furäier influences, like in- 
creased cerebral perfusion pressure may be additional factors influencing perfusion velocity within 
cerebral microcirculation. However, the observed small but significantly increased arterial blood pres- 
Sure of 117i13% obviously did not seriousiy affect the marked CBF increase to 393 f 79 % and MTT 
shortening to 32 + 11 % due to hypoxialhypercapnia. Indeed, there was no correlation between arterial 
btood pressure and forebrain CBF during norrnoxic condiions (I?' = 0.092) as well as at hy- 
paxidhypercapnia ( R ~  = 0.056), as expected, since arterial biood pressure was in all cases above the 
autoregulatory threshold considerabiy lower in newborns than in ofder animals 125,263 bot only insub- 
stantiafk increased. 
More reievant for rnicrocirculatory exchange function should be that parenchymal MTT was considera- 
bfy reduced which reflects a marked increase in blood fiow velocity within the microcirculation. There- 
fore, the contact time for substance exchange within the capillaries couid be criücaliy reduced and 

[23] Göbel U., Klein B., Schröck H. and Kuschinsky W. (1989) Lack of capillary recruitment in the 
brains of awake rats during hypercapnia [see comments]. 
J. Cereb. Blood Flow Metab. 9,491 499. 
[24] Bauer R., Hoyer D., Walter B., Gaser E., Kluge H. and Zwiener U. (1997) Changed systemic and 
cerebral hemodynamics and oxygen supply due to gradual hemorrhagic hypotension induced by 
an external PID-controller in newborn swine. Ekp. Toxic. Pathol. 49,469-476. 
[25] Hernandez M. J., Brennan R. W. and Bowman G. S. (1980) Autoregulation of cerebral blood flow 
in the newborn dog. Brain Res. 184, 199-202. 
23. A New Tropane-Derived Rhenium Complex with High Affinity for the Dopamine 
Transporter 
A. Hoepping, M. Reisgys, P. Brust, S. Seifert, H. Spies, R. ~lberto', B. Johannsen 
1 Paul Scherrer Institut, Villigen, Switzerland 
lntroduction 
Parkinson's disease is characterized by a significant loss of dopaminergic neurons in the basal gan- 
glia. A decreased specific striatal uptake may therefore indicate early pathological states and allow a 
diagnosis, preferably by a radiotracer [I]. Considerable efforts have been made to incorporate a 9 9 m ~ ~ -  
containing unit into a CNS receptor-targeted agent [2 - 71. 
Here we describe the synthesis of the new DAT-binding ligand 4,7-dithiaoctanoic acid (3844- 
fluoropheny1)tropan-2ßyl)-methyl ester and its coordination reaction with the tricarbonylmetal(1) centre 
of Re and 99m~c-forming complexes of the common formula [MX"S2"(C0)3] ("Si2" = RS(CH2)2SR). We 
also report in vitro competition binding studies of 3 and the rhenium complex 4 with DAT, the serotonin 
transporter (5-HTT) and the norepinephrine transporter (NET). 
Experimental 
Starting from CFT, the new chelating ligand 3 was prepared by introduction of a dithioether unit into 
the 2ß-position. The synthesis route is shown in Scheme 1. The desired product 3 was obtained in a 
quantitative yield. 
Scheme 1. Synthesis of ligand 3 and the complexes 4a,b. 
Reagents: a DIBAL, toluene, 0 "C, 85 - 95 %; b EDCI, DMPA, CH2C12, 25 "C, quant.; 
C (NEt&[MX3(C0)3] (M = Re, X = Br; M = ""'TC, X = CI), MeOH, 25 "C, 
The synthesis of the rhenium complex 4a was performed by reaction of 3 with (NEt)2 iReBr3 (C0)31 in 
methanol[16]. After work-up 4a was obtained in a 83 % yieid. 
Elemental anafysis, mass specüa and IR spectra cleariy indicate the popoced stnicture of 4a. The 
tricarbonyl rhenium core is characterized by the strong vibration bands at 2032, 1940 and 1904 cd'. 
An additional C=O band at 1728 cm-' beiongs to öie ester group. The mass Cpectmrn (FAB') S ~ O W  
the molecular peak at miz 762. The synthesis of the corresponding *TC compiex 4b was carried Out 
by reaction of 3 with ihe anakylue *TC precursor according to 1173. Pur"rficatim and charactefization 
of the cornplex was completed by HPLC (R, = 6.2 min). The complex was Otttained in a 60 - 65 % 
yield of 97 % radiochernicai punty. 
Results and Discussion 
The binding affinities of the compounds 3 and 4a for DAT, NET and 5-HTT, determined by competi- 
tive binding assays using [ 3 ~ ] ~ ~ ~ ,  [3 ]nisoxetine and P~lparoxetine as radioligands [21, 221, revealed 
a high affinity for cloned human DAT and a moderate affinity for NET and 5-HTT. Most remarkably, the 
dithioether-containing CFT3 has an affinity higher by one order of magnitude than CFT, and this high 
affinity is not diminished by complexation. Rese~ing poor statistics, the rhenium complex 4a binds 
even more strongly to the high affinity site than the chelator 3 (Table 1). 
Our ICS0 values obtained on cloned human DAT expressed in CHO cells are about four times lower 
than those found by Pristupa et al. [251, using COS-7 cells. Because of inconsistencies in the literature 
in describing one or two binding sites, we also calculated the affinities assuming only a single binding 
site and found a higher affinity f0r 4a (lC50 = 1.5 nM I 0.4 nM) than for 3 = 3.2 nM I 0.3 nM). It is 
known that CFT also binds to 5-HTT and NET. Our data (Table 1) shows that the introduction of rhe- 
nium into the chelating tropane derivative 3 decreases the affinity towards 5-HTT but, interestingly, 
increases the affinity towards NET. 
Table 1. Binding data (C50 values) of RCFT, 3 and 4 to the monoamine transporters. Data are 
means f S.E.M. (n = 3 - 4). 
DAT high affine (nM) DAT low affine (nM) NET (nM) 5-HTT (nM) 
Considering the high affinities of 3 and the complex 4a, it is assumed that the chelating group of 3 or 
the chelate in 4a are active parts in the ligand-transporter interaction. The increased lipophilicity of 3 
and 4a compared with 1 may enhance the interaction of the ligand rnolecule with the transporter, 
which is characterized by hydrophobic interaction and an assumed hydrogen bond. This argument is 
consistent with the previously reported resuits by Kozikowski regarding a 2-vinyl substituted cocaine 
analogue [26] and by Carroll regarding 2-heterocyclic substituted derivatives [27]. 60th reports also 
soggest that hydrophobic interaction may contribute to the binding to the DAT. 
Conclusions 
The results show that the M(I) carbonyvdithioether ligand System is a valuable tool for the design and 
synthesis of receptor-affine technetium and rhenium complexes. In the present case the introduction 
of a diithioether chelator into the tropane moiety causes an increase in affinity in the subnanomolar 
range which is further enhanced by complexation. 
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24. lnvestigations for an lmproved Synthesis of TRODAT 
1. Heimbold, A. Hoepping, S. Seifert 
Introduction 
Recent publications by Kung and coworkers described [ 9 9 m ~ ~ ] ~ ~ ~ ~ ~ ~ - 1  1 to be a uceful imaging 
agent in the evaluation of the Status of CNS dopamine transporters in humans [ I  - 41. 
The authors describe a sequential synthesis of TRODAT starting from 2ß-carbomethoxy-3ß- 
phenyltropanes [ I ]  as shown (Scherne I). 
Scheme 1. 
Deprotection of the thiof functims occurs w2h Hg(OA& foilowed by radiolabelling with sodium 
[*~c@?rtechnetate. 
The interest of our group in further investigations of TRODAT made it attractive to look for an im- 
proved synthetic route to &&in this compound. 
Resuits and Discussion 
In our opinion some modifications of the original synthesis would be favorable. Therefore we devel- 
oped the following new synthetic strategy (Scheme 2). 
Varying the synthesis by Kung and co-workers we investigated the combination of the complete 
MAMA ligand with the tropane molecule and we tried to find protecting groups for the thiol functions of 
the MAMA ligand which give the possibility to carry out the deprotection reaction simultaneously with 
the 99m~c  labelling reaction. Good experiences in this case were made in our group with trityl groups . 
Scheme 2. 
H&-N COOCH, WOOEt U0 LiBH, 80 
CI + 
C1 
The 2ß-carbomethoxy-3ß-(4-chlorophenyl)tropane 2a was prepared following previousiy described 
methods [SI. Protection of the tropane amine function of 2a occurs by refiuxing it in ethylchloroformate 
(98 % yield). In the next step the methylester 9 was reduced to the alcohol 10 in 96 % yield, using 
LiBH4 in diethylether at room temperature. 
It is not possible to prepare 2~-(hydroxymethyl)-3ß-(4-~hlorophenyl)trq)ane [q and protect the tropane 
amine function in the next step because of the reaction of ethylchloroforrnate with the hydroxy group 
(Scheme 3). 
Scheme 3. 
Treafing 10 wilh trifiuoromethansuifonic anhydride in methylenechloride at -10 'C yieMs the con'e- 
sponding trifiate, which reacted - without Separation - with the MAMA K i n d  and was stirred at room 
tempersure for one day. Purifikation o&urs by iysh chromatography on silica get wiäi first 
etherImethvlenechlonde/methanol f 1 D : 5 : 0.1 1 and second etherletti~ce~telmetfianoVNH~0H (10 : 
8.5 : 1 : 0.6). YieMs between 50 % and 70 % of 1 I wwe reached. 
Reduction of trityl-protected 11 to 8a with LiAIH4 was not possible because of instability of the trityl 
roups against the reducing agent. Therefore we had to look for another useful protecting group. 
b c  labelling investigations with p-methoxybenzyl-protected 8a (yielded by Kung synthesis) in a 
strong acidic medium showed that it is possible to carry out deprotection simultaneously with the la- 
belling reaction (yield about 50 %). Now we study the coupling reaction of the p-methoxybenzyl- 
protected MAMA ligand with the triflate of 10 and the following reduction. First encouraging results 
were reached but yields must be improved. 
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25. Potentially Dopamine Receptor-Binding Technetium and Rhenium Tracers: 
Synthesis and Characterisation of Ligands Derived from Partial Structures of Epidepride 
M. Scheunemann, H.-J. Pietzsch, H. Spies, P. Brust, B. Johannsen 
lntroduction 
During the last four decades numerous substituted benzamides have been developed as potential 
antipsychotic agents due to their ability to block dopamine D-2 receptors [I]. 
Amongst this class of compounds the 2-methoxy or 2,3-dimethoxybenzoic acid amides are highly po- 
tent and selective D-2 receptor antagonists. Especially amides having a 2-pyrrolidinylmethyl side 
chain, such as raclopride, sulpiride or epidepride, attracted attention because of their good penetration 
through the blood-brain barrier and an exceptionally good receptor-binding profile [2]. 
As part of a project concerned with the synthesis of Tc complexes for in vivo imaging of neurorecep- 
tors by SPECT, we decided to apply the structure of epidepride and its bromo-analogue FLB 457 as 








Ki: 14.5 nrnd 
Previous studies by Hall and CO-workers showed that steric bulk at the side chain of the pynolidine 
nitrogen may affect the receptor-binding potency [3]. Furthermore, the stereochemistry at the 2'- 
position is crucial for its neuroactivity, as oniy the Senantiomer exhibi  the desired picomolar affinity 
to the D-2 receptor. In an attempt to attenuate the detrimental effect of the fluoro alkyl substituent On 
the pyrrolidine amino group, Mukherjee reported on a new class of fluorinated neuroleptics CIS candi- 
dates for use as radiotracers for PET [4]. 
FPMB (ref. 141) 
In these derivatives, which show a high affinity to the 0-2 receptor, the fiuonne atom is incorporated as 
a 3-fluoropropyl group on the benzene ring. 
These disclosures prompted us to choose the 5-position at the benzene ring rather than the 1 '-pOSiti~n 
of the pyrrolidine ring for linkage of a suitable Tc-chelating unk 
(S)-2-Aminoneth~)-N-ethSpyrrolKline was prepared following a procedure descnbed in the tierature 
[5]. Natural (S)-proline was both esterified and simuttanesusty N-efhyiated by treatment af W amino 
acid with iodo ethane in dry DMF. Then the ester (1) was transfomed into ttre amide (2) in %he prec- 
ence of rnethanolic ammonia in a closed via1 at 50°C for 20 hours. Final& tbe reduction of the amide to 
the desired amino compound (3) was aceomplished by reaction witli tithium aluminium tiydnde in THF. 
iodoethane 
K,CO„ DMF NH3, MeOH LiAIH„ THF 
14h reflux, 14h 
H 
OH / NH2 
For the preparation of an appropriately derivatized benzoic acid we started frorn cornrnercially avail- 
able 2-hydroxy-3-rnethoxy benzoic acid. After its esterification with methanol in the presence of sul- 
phuric acid, the resulting ester (4) was alkylated by means of 3-brorno-1-propene in DMF at room 
ternperature to yield the allyl ether (5). Claisen rearrangernent was effected by heating the allyl ether 
at 210 - 220°C for 3 hours 161. 
3-bromo-1-prqxne 
KO-tert-butylat, DMF 
20 - 30oC, 8h 
______, 
87 % 
For the methylation of the phenolic hydroxy group with iodornethane we used reaction conditions 
similiar to the aliylation step. Finally the ester (7) was saponified to yield the sustituted benzoic acid (8) 
in a 61 % overall yield. 
R-SH 
9 (R: H3CSC2H& 
10 (F?: CH3CO) 
_L_+ 
(-> 1 I, 95%) 
(-> 12,9%) 
1. oxaiyi chloride, CHCI, 
OH 2.3 (-> 13) 
3. NaOcH3(-> 14) 
S 
CH3 (-> l3,72%) R 
0 (-> 14.65%) 
11 (R: H,CSC,H4) 
12 (R: CH3CO) 
f 3 (R: H3CSC2H4) 
14 (R: H) 
2,3-Dimetho~-5-al&l-benzoic acid (8) represents a valuable starting material for a number of reac- 
tions leading to appropriate cheiators for technetium in various oxidation stages. 
For our purpose we selected on the rnain two transfomtions. A chelating unit containing Wo sulphur 
&mors was at first attached to the olefinic group of 8 by radical addition of Pmethyt-thioethyl thiol (9). 
The intermediate benzoic acid (1 1) was äien coupled to the pyrroiidine derivative (3) by its carboxylic 
acid chloride, wbich was obtained by treatment with oxafyl chioride in chloroform. 
In a simiiiar rnanner heating of 8 with a surplus of thiol acetic acid (10) yieMed the Sacetyl-protected 
derivative 12. Again tbe carboxyt'c group in 12 was acthated by the oxalyi chloride under mild condii 
tions (C 20°C). Wiout  jsolaa'ng äie acid chloride intermediate, the S-acetyl derivative of 14 was ob- 
tained in a 73% yieM after reaction with 3 at 20°C for 10 h. Deproteciion proceeded efficiently ( W h  
yieid) and ckanfy in MeOH in the presence of sodium methanoiate at 0 - 18°C for 2 h. 
The H and ' 3 ~  NMR q m t m  of 7 , s  and 11 - 14 cleatfy confirm the success of the a d d i n  step, the 
coupling to amine 3 and removal of the protecting group from the precursor of 14. 
With 13 and 14 in hand, we have already started to prepare neutral Tc complexes both on a c.a. and 
n.c.a. level. 
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26. lmplementation of the Catecholamine Analysis and Precolumn Technique in 
Amino Acid Determination with the Fluorescence Label Naphthalene-2,3- 
dicarbaldehyde 
G. Vorwieger, R. Bergmann, P. Brust 
Various projects currently under investigation necessitate measurement of extracellular indicator 
molecule concentrations, many of them being primary amines (Table 1). In the past decades, neuro- 
chemical research generally included brain microdiaiysis as a suitable tool for such tasks. Surgical 
know-how and standard amino acid analysis were established in our group as early as in 1994 [5]. 
Table 1. lmplication of primary amine solutes in recent research subjects 
Subject lndicator solutes Function of indicator solute 
role of dopamine metabolism in glutamate, taurine, glycine, modulator of aminergic trans- 
the pathogenesis of asphyxia- y-aminobutyric acid (GABA) mission~, excitatory and inhibitory 
induced brain injury amino acids (excitotoxic index) 
role of dopamine metabolism in dopamine (DA), neurotransmitter, marker for DA 
the pathogenesis of asphyxia- 3-methoxytyramine. norepineph- release and catalyst of radical 
induced brain injury rine, DOPA genesis 
["flfluoro-DOPA Positron Emis- fluoro-DA, fluoro-DOPA, etc. inactive carrier of radiotracer: 
sion Tomography kinetics and metabolism 
fluorinated peptide-receptor neurotensin fragments visualization of receptor densi- 
tracers ties, undesirable cleavage prod- 
ucts 
I 
serotonergic System and de- 1 serotonine I neurotransmitter 
pression 
brain trauma citrulline marker for nitric oxide synthesis 
Since 1995 trace analysis of primary amines by derivatization with naphthalene-2,3dicarbaldehyde 
(NDA) and HPLC separation/fluorescence detection of the resulting cyanobenzisoindole (CBI) deriva- 
tives has been consistentiy appiied. Components of the application ensuring a desirable high sensitiv- 
ity and reproducibili have already been developed and described 141- 
In this work the inclusion of catechol analytes as additional modules in the application and the ex- 
tended HPLC-configuration wreconcentration of the CBlderivatives on a precolumnn will be verified. 
The reconcentration, aiong with the benefits mentioned in the discussion, is a prerequisite for experi- 
mental manipulations such as dilution with catechol protection colution and removal of excessive rea- 
gents by precipitation. 
Methods 
A compromise was to be found between the high reactiv'i of the catechol group in alkaline solutions 
and the alkaline pH optimum of the derivatization reaction. In orientating trials with DOPA and DA we 
found undesirabie side reactions leading to spontaneous browning (oxidation, condensation producing 
mefanines) which were visible to the naked eye. A catechol protection solution CPS (yet to be pub- 
Iished) was aerefore inn.oduced. As an alternative to the automatized reactions described in 141, all 
derivatizations mentioned in this report were peFformed by the following manual procedure: 
mix 1 vol. a c K f W  samplelstandard with 0.25 vol. CPS + cyanide and 0.5 vol. methanolic NDA, allow 
for rea&n (1 min), add the stopping reagent (0.5 vol., tryptamine excessive to NDA; containing CPS), 
aHow mother 5 min for reaction, centrifuge at 12,000 X g for 5 min. A tightly seaiable giass microvial 
that wiärstands centrifugation was chosen to prevent adsorption and NDA recrystaliiition due to 
nethanal evaporation. 
All other conditions were the Same as described in the experimental section in 141. 
For the precolumn/reconcentration experiment the following modiiications were introduced: precolumn 
Waters SENTRY guard 3.9 mm diameter X 20mm length, Symmetry C18 5 p, mobile phase un- 
changed, load of 200 p1 sample at a flow 0.3 mllmin. Backflush onto the analytical column (4.6 X 
150 mm high-speed column packed with Symmetry C18 3.5 p, Waters) with a steep MeCN gradient 
beginning with a high elution power, pH adjusted to 6.4, flow 1.5 mllmin. Switching valve: 6 port 
(Valco cheminert) with microbore port diameter, pneumatic actuator with high-speed switching assem- 
bly. The temperature of both columns was maintained at 30 "C within a Jetstream 2 (Eppendorf 
BIOTRONIK) column oven. 
derivatised sample ( 
after 5 days of Storage 
0 5 10 15 20 25 30 35 40 mit 
Fig. 1. Fluorescence traws of one and äie same sample (d(depr0binised human piasma) 
immediateiy after derivatisation (top) and alter 5 days of Storage 
at room temperature in ihe dark (bottom) 
Resuits and Discussion 
CBI derivatives of (deproteinized) human plasma amines were rendered stable for 5 days of storage at 
room temperature in the dark. Even within such a complex sample matrix there is no significant 
change in peak areas (Fig. 1). 
10 20 30 40 50 60 70 80 min 
I . . . ' * . . . . , . . . . , . * . . * * * . . , . . . . , . . . . & . .  
10 20 30 40 50 60 70 min 
F@. 2. Fiuoreccence traces demonstrating the results of DOPA derivatisation by the conventional 
procedure (top) and by addion of GPS (bottom). 
This stability allows measurement of large sample sequences, i.e. at least one autosampler tray (34 
samples, their measurement takes about a day) also without autosampler cooling devices. The stabil- 
ity of CBI-dopamine and CBI-DOPA was verified in separate experiments with standard com- 
pounds(data not shown). 
Fig. 3. Fluorescence trace of CBI derivatives of proteinogenic amino acids and DA on line recon- 
centrated from a large sample volume and backfiushed with a steep gradient. 
The trace in Fig. 2 (top) is the resuR of DOPA anaiysis without CPS. The multitude of polycondensa- 
tion products gives raise to a broad signal agglomerate which moreover exhibits a strong memorjt 
phenomenon on the column (the latter is not shown). W i  CPS there remains just common peak tail- 
ing as compared to neutral amino-acid CBIs (Fig. 2 bottom). We assume that this remaining Problem, 
which of Course impairs the detection limit, can be abolished by a lower pH of the rnobife phase. 
The catecholamines are commoniy determined by HPLC with elecbcxhemical detection ECD. Wih 
ECD the only selectivity critenon is the oxidation potential, which of wurse is not group SPXik. A 
noisy background and restrictions in gradient use are ECD chatacteristicc. T0 our knowfedge 
have been just 3 Papers until now reporting on the contempotary Ruorescence anaiysis of amino acidc 
and catecholamines by derivatisations with NDA or the reiated oräro-phthakidehyde OPA 11, 2,3$ 
Two of them [2,3] are restricted to oniine (to CE) derivat'aations. 
Here we demonstrate the integration of catechoiamines into an amino-acid protwl. lt is o jonger W- 
essary to split the samples volumes, which are anyway rninute, into an amino acid and a catechola- 
mine anaiysis. The Ruorescence detection of &e derivatives is moreover mors m s W e  than eIeCtr0- 
chemical detection. 
Fig. 3 is the result of a precolumn/reconcentration experiment with a commercially available amino 
acid standard solution stocked up with DA. Though we used just a rather short precolumn, all solutes 
but aspartic acid (15 %) and glutamic acid (60 %) were quantitatively recovered. These acidic species 
can probably be included in the range of quantitative recovery by lowering the pH of the loading mo- 
bile phase, adding to it basic ion pairing reagents, and elongating the precolumn. 
The in viv0 experimental procedures can thus be performed quite independently of any analytical de- 
mands, keeping the benefits of low limit of detection [4 1. 
The capability of quantitative reconcentration abolishes handling difficulties because n * microlitre 
sample volumes can be taken up immediately in convenient volumes of stabilization solution. 
The analytical column receives the sample via backfluch in an optimized manner (within its own mo- 
bile phase, guaranteed free of particles, the only dilution being the dispersion of the valve void vol- 
ume). Thus, as in the demonstrated case, the employment of high-speed columns becomes possible. 
Difficult separating processes, e-g. CBI-arg and CBI-citrulline, can be carried out by all available spe- 
cific tools of HPLC, regardiess of any matrix problems. 
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27. Characterization of the Impaired Brain Function in Persistent Vegetative State: 
Evaluation of Perfusion and Glucose Metabolism with Emission Tomography 
Techniques 
B. ~euthien-~aumann', W. ~andricp, T. ~chmidt?, W. Burchert, G. ~chacke$, W.-G.   ranke' 
'TU Dresden, '~l inik und Poliklinik für Nuklearmedizin, '~linik und Poliklinik für Neurochirurgie, 
3~ehabilitationsklinik Pulsnitz 
lntroduction 
The persistent vegetative state is characterized by a comatose state with a preserved sleep-wake 
cycle, but without detectable awareness [I]. Most often this syndrorne is due to a severe brain injury. 
For many patients this state is irreversible, but some of them show improvement after intensive reha- 
bilitation efforts [2]. To further characterize the extent of functional brain damage we evaluated brain 
perfusion and cerebral glucose rnetabolism in this patient group. 
Materials and Methods 
PaSients:16 patients (3 female, 13 male, age 18-67 years, median age 47.5 years) with persistent 
vegetative state and dilated ventricular System were investigated. The persistent vegetative state de- 
veloped after a head trauma or cerebral haemonhage. The time intewal between the initiil brain injury 
and the scanning procedure was 2.5 to 11 rnonths. Blwd glucose levels at the time of investigation 
were within physiological limits, none of the patients was diabetic. 
lmaging procedures: Brain perfusion was assecsed with Single Photon Emission Computed Tomogra- 
phy (SPECT) using a Sheaded gamma carnera (Multi SPECT III, Siemens). Ten minutes after injec- 
tion of 750 MBq Tc-99m-ECD (Neurolite, DuPont) a static tomographic acquisition was performed. 
The cerebral glucose metabolism was measured with dynamic Positron Emission Tomography (PET) 
using a dedicated full-ring PET Scanner (ECAT EXACT HR+, Siemens ICTI, Knoxville, Tenn., gSA). A 
dynamic data acquisition over 60 min was performed after intravenous injecüon of 300 MBq [ FJFDG 
(in-house production [3]). Several pseudo-arterial blood samples were taken at the Same time to de- 
temine the input function of the tracer. The actual blood glucose level for quantitative analysis of the 
cerebral glucose metabolism was measured 20 min and 40 min after the Start of the scan. Quant'rtative 
parametric images of the regional metabolic rate of glucose were derived using the Gjedde-Patlak 
approach [4 - 61. 
After reconstruction of both data Sets, image fusion of PET and SPECT data was perf0rt-W 
(MPITOOL, [7, 81. Differences in glucose metabolism and perfusion were qualitatively evaluated by 
visual analysis. Furthermore, quantitative data were derived from anatomically defined 'regions of 
interest' (ROI) according to the vascular territories of the main brain artenes. 
For a direct comparison of perfusion and MRGlc, the values derived by R01 analysis were nomlized 
to the total Counts (SPECT) and MRGIc (PET) of grey matter. 
Statistical data evaluation using the paired and unpaired t-test was performed with commercial soft- 
Ware (StatView, SAS Institute Inc.). A pvalue of < 0,05 was used as level of significance. 
Resutts and Discussion 
Visual analysis of the data revealed that all patients showed substantial defects of regional Perfusion 
and metabolism. The cerebral glucose metabolism was impaired even in brain areas not flmanly 
affected by the trauma. In the lesion area the defect of #e glucose metabolism was m e  extensive 
than the perfusion defect (Fig. l).Quantitative anaiysis of the absolute cerebral metabolic rate of glu- 
mce (MRGlc) revealed signifiintiy lower values in the cortical and subcortical areas than W Mxrnal 
controls (Fig. 2). This difference was not significant in the areas of äle brain stem and #e vermis af 
the cerebellurn. These findings are in accordance wi# the literature, in Mich reduced values of the 
Cerebra1 glucose metaboiism are described in patients with a persistent vegetative state [9 - 1 I]. 
Fig. 1. A 46-year-old patient 3 months after brain trauma. Upper row ["FJFDG-PET, lower row 
S 9 m ~ c - E C ~ - S ~ ~ C ~ .  Regional hyperperfusion (arrow) with relatively low glucose metabolism. 
Fig. 2. Comparison of MRGlu in various brain regions in vegetative state and controls. 
Concerning the relative glucose metabolism and perfusion, the glucose metabolism of cortical regions 
was more severely impaired than the perfusion (Table 1). In lesions and even more cleariy in their 
hrder zones, perfusion was better preserved than the glucose metabolism (Fig. 3). No significant 
differences betvveen normalized MRGlc and normalized perfusion were found in subcortical areas, 
brain stem and vermis of tbe cerebellum. 
Under physiological conditions there is a close correlation between brain perfusion and cerebral glu- 
cose metabolism [12]. A dissociation of these two Parameters in cortical areas was found in this study. 
The higher perfusion indices in cortical areas seem to represent changes in the sense of 'luxury per- 
fusion'. Therefore, the evaluation of the viability of brain tiscue seems to be more predictive with 
[ ' 8 ~ ] ~ ~ ~ - ~ E T  than with B R " ~ c - ~ ~ ~ - ~ ~ ~ ~ ~ .  
Nevertheless, to assess the prognostic value of both imaging modalities with respect to the clinical 
outcome a longer follow-up of the patients is needed. 
Table 1. Comparison of norrnalized PET and normalized SPECT in various brain regions 
Region Mean f SD Mean f SD P =  
Anterior * 0,83 f 0,28 0,91 t 0,31 < 0,05 
Media 0,88 t 0,23 
Posterior * 0,85 f 0,21 
Basal ganglia 1,10 f 0,34 
Thalamus 0,81 f 0,23 
Cerebellum 0,86 f 0,20 
Brain ctem 0,80 f 0,11 
Vermis of cerebell. 1,15 f 0,35 
n.s. = not significant 
* territories of the main brain arteries 
lesion borderzone 
Fig. 3. Comparicon of normalized PET and nomalized SPECT in brain lesions and their border zones 
References 
[ I ]  Fuechtner F., Steinbach J., Maeding P. and Johannsen B. (1996) Bacic hydroiysis 0f 2- 
[18~luoro-l ,3,4,6-tetra-0-acetyl-D-glucose in the preparation of 2-~8~uoro-2deoxy-Dgluco~ 
Appl. Radiat lsot 47,61-66. 
121 Gjedde A. (1982) Calculation of cerebral glucose phosphorylation from brain uptake of glucclce 
anaiogs in vivo: a re-examination. Brain Res. 257,237-274. 
131 Levy D. E., Sidtis J. J., Rottenberg D. A., Jarden J. O., Strother S. C., Dhawan V., Ginos J. Z., 
Tramo M. J., Evans A. C. and Plum F. (1987) Dierences in cerebrai b W  fbw and gkicose uti- 
lization in vegetative versus iocked-in patients. Ann. Neuro!. 22,6731682. 
[4] Patiak C. S. and Blasberg R. G. (1985) Graphical evaluation of blood-to-brain transfer ~0nstank 
from mutüple- time uptake data. Generafizations. J, Cer& B W  Flow MeW. 5,584-590. 
[51 Patiak C. S., Blasberg R. G. and Fenstermacher J. D. (1983) Graphicai evaluation 0f bkxlcl-t* 
brain transfer constants from muttipk- time uptake data. J. Cer&* BIood Fbw Metab. 3,1-7. 
[6] Pietrzyk U., Herholz K., Fink G., Jacobs A., Mielke R., Slansky I., Wurker M. and Heiss W. D. 
(1994) An interactive technique for three-dimensional image registration: validation for PET, 
SPECT, MRI and CT brain studies. J. Nucl. Med. 35,201 1-2018. 
[7] Pietrzyk U., Herholz K. and Heisc W. D. (1990) Three-dimensional alignment of functional and 
morphological tomograrns. J. Comput. Assist Tomogr. 14,51-59. 
[8] Pilon M. and Sullivan S. J. (1996) Motor profile of patients in minimally responsive and persistent 
vegetative states. Brain Inj. 10,421 -437. 
[9] Rudolf J., Ghaemi M., Ghaemi M., Sobesky J., Haupt W., Szelies B., Grond M. and Heiss W.-D. 
(1999) Alterations of cerebral glucose metabolism and benzodiazepine receptor binding in acute 
and persistent vegetative state. J Cereb Blood Flow Metabol. 19, S839. 
[I01 Rudolf J., Ghaemi M., Haupt W. F., Szelies B. and Heiss W. D. (1999) Cerebral glucose metabo- 
lism in acute and persistent vegetative state. J Neurosurg Anesthesiol. 1 l, 17-24. 
[I 11 The multi-society task force on PVS. (1994) Medical aspects of the persistent vegetative state 
(First of two park). n Eng1 J Med. 330,1499-1 508. 
[I 21 Wienhard K., Wagner R. and Heiss W.-D. (1 989) PET - Grundlagen und Anwendungen der Po- 
sitronen-Emissions-Tomographie. Springer-Verlag Berlin, Heidelberg, New York. 
BRAlN SEROTONERGIC SYSTEMS 
28. Synthesis of Enantiomerically Pure Thioester Precursors of ["C]McN-5652 
P. ~ucker', J. Zessin, S. M. ~metamey', J. Steinbach 
1 Center of Radiopharmaceutical Science, Paul-Scherrer-Institut Villigen (Switzerland) 
lntroduction 
The radioligand ["c]~cN-5652 (trans-1,2,3,5,6,1 0b-hexahydro-6-[4-(["C]methylthio)-pheny1]pyrro1~ 
[2,1-a]-isoquinoline, ["CI-I) is a potent tracer for imaging serotonin uptake sites with positron emission 
tomography (PET) [I, 21. In viv0 investigations in baboons and humans have shown that satisfactory 
target-to-non-target ratios (hypothalamus to cerebellum ratio) of 1.5 - 1.8 are oniy obtained using the 
biologically active (+)-enantiomer [3,4]. 
["C](+)-MCN-5652 is prepared by methylation of the normethyl compound 2 with [1'C]rnethyl iodide [5]. 
The normethyl precursor 2 can be prepared by demethylation of 1 by treatment with sodium 
thiomethoxide [5]. The stability of the thiol 2 was increased by conversion into a thioester as thiol 
acetate 3 or butyrate [6]. The demethylation using sodium thiomethoxide is accompanied by a confor- 
mational change which reduces the portion of the desired trans diastereomer to about 40 %. This iso- 
merization reaction is avoided by demethylation using sodium amide in liquid ammonia m. 
(+)-McN-5652, the starting compound for the precursor synthesis, is not commercialiy availabk. The 
known preparation method of (+)-I is based on resolution of racemic 1 by recrystallization of the 
(+)-tatrate [8], but this procedure gives no satisfactory resuits [9]. 
This problem can be prevented by a stereoconse~ative synthesis utilizing the 6-(4-bromophenyl) 
analogues of 1 as key intermediates [9]. However, this procedure requires time-consuming prepara- 
tion of the bromophenyl compound. 
In this paper we describe a route for preparation of the enantiornericaliy pure thioester precursors (+)- 
3 and (-)-3 starting from racemic McN-5652. The preparation is based on the resolution of racemic 1 
by crystallization with (+)- and (-)di-p-toluoyltartaric acid. The S-demethyiation was performed by 
treatment of (+)-I or (-)-I with sodium amide (cee Scheme 1). 
Scheme 1. Synthesis of the thioester precurcor for ["CIMCN-5652 
Experimental 
Reagents and solvents were obtained from commercial suppliers and were used without purification. 
Racemic McN-5652 was prepared starting from 2-phenylpyrrolidine and 4-methylthiomandelic acid 
according to literature procedures 18, 101. 
1 H NMR spectra were recorded with a Varian INOVA 400 NMR spectrometer. The chemical shifts are 
expressed in ppm relative to tetramethylsilane. CDCb or benzene-d6 were used as solvent and inter- 
nal standard. The enantiomeric purity was determined by NMR spectra of the (+)-Mosher's acid salts 
((+)-a-methoxy-a(trifluoromethyl)phenylacetic acid, (+)-MTPA) of 1 as described by Villani et al. [I 11. 
Optical rotations (589 nm) were obtained by using a JASCO Digital Polarimeter DIP-370. 
HPLC anaiyses were petformed with the following chromatographic Systems: 
Chemical purities were determined with a Purospher RP 18 column (125 mm X 3 mm, 5 pm) eluted 
isocraticaliy with acetonitrilelwater (50150) containing 0.1 M ammonium formate at a flow rate of 
0.5 mlfmin. The enantiomeric purity was determined with a Chirobiotic T column (250 mm X 4.6 mm, 
5 pm) eluted isocratically with methanoilacetic acidltriethylamine (100/0.1/0.05) at a flow rate of 
I milmin. 
Resolution of racemic trans- l,Z,3,5,6,l Ob-hexahydro-6-[4-(methy1thio)-phenyl]pyrrolo- 
[2,1 -a]-isoquinoline 
Racemic McN-5652 as a free amine was dissolved in acetonitrile, filtered and added to a solution of 
(+)-dip-toluoyltartaric acid in acetonitrile. The combined solutions were left to stand at ambient tem- 
perature for 24 h. The precipitate was separated, dried, dissolved in hot ethanol, and lefi to stand at 
room temperature for 3 days to give off-white crystals. 
A sample was converted into the (-)-tartrate, which showed an optical rotation of [a121D -51 -90 (MeOH, 
C 0.236). 'H NMR of the (+)-MTPA salt showed an enantiomeric excess (ee) of (-)-I > 98 % 
The mother liquors of previous crystallizations were evaporated. The residue was partitioned between 
aqueous NaOH and dichloromethane. The resulting oil was dissolved in acetonitrile, combined with a 
solution of (-)-dip-toluoyltartaric acid in acetonitrile, and left to crystallize at ambient temperature for 
1 day to produce off-white crystals, which were enriched with (+)-I (determined by HPLC of the (+)- 
MTPA sak, ee > 98 %). A sample was converted into the (+)-tartrate: [a ] "~  +50.50 (MeOH, C 0.221). 
Trans- l,2,3,5,6, $Ob-hexahydro-6-[4-(acevthio)-phenylpyrrolo-1 -a]-isoquinoline ((+)-3, (-)-3) 
The thioesters (-)-3 or (+)-3 respectiveiy were prepared by demethylation of (-)-I or (+)-I with sodium 
amide in liquid ammonia and subsequent reaction of the resulting thiol wiü~ acetyl chloride as reported 
in [73. 
ßadiosynthesis of (+)- and (-)-trans- l,2,3,5,6,l~hexahydro-6-[~-(["~]meth~&hio)-~hen~1]~~~olo-[~, 1 -
a]-isoquinoline ([+" C](+)-1, [+"C](-)-I) 
["C](+)- or T C ] ( - ) - M C N - ~ ~ ~ ~  were prepared by hydrolysis of the thioester precursor (+)-3 or (-)3 fol- 
lowed by methylation of the resulting thiol with ["Clmethyl iodide according to the literature procedure 
[Ql. 
Resuk and Discucsion 
The parent McN-5652 ((&)-I was prepared starting from Pphenylpyrrolidine and 4-methylthiomandelic 
acid in a five-step synthesis as reported in [8,10]. Initialiy, we tried to resolve the racemic product by 
repeated crystallization of th (+)-tartrate fr0m ethanol or acetonitrile similar to 181. These operations 
produced no enrichment of any enantiomer, which confirms the results of Huang et. al. [9] 
In an alternative method, we tested the reerystallization of racemic 1 with (+)di-ptoiuoyiiartaric acid. 
Unexpectedfy, ö-re initial crystallization from acetonitrile yielded (-)-I in an enatiomeric purity of about 
W s. Opticaliy pure (-)-1 (ee > 98 %) was obtained after an additional recrystallization from ethanol. 
The mother liquors of the initiai crystallizations were enriched with the (+)-enantiomer (ee > 90 %). 
hather  crystallizaäon of tfre fecovered Emine with (-)-di-ptoluyltratraic acid from acetonibile produced 
opticalfy pure (+)-I (ee > 98 %). 
The enantiomeric pur@ was determined by 'H NMR spectra of the McN-5652 enantiomers with 
(I-)-MTPA. In addion to 'H NMR, anafysk of the enantiomeric composition was pedormed by chiral 
HPLC. A separation of (+)-I and (-)-1 was achieved using the glycopeptide teicoplanine as chiral sta- 
tionary phase. 
The separated enantiomers of 1 were converted into the related thiols 2 by treatment with sodium 
amide in liquid ammonia as described in a former report [i']. The thioesters (+)-3 or (-)-3 respectively 
were obtained by reaction of the intermediate thiol enantiomers with acetylchloride. 
A sample of (+)-3 was converted into McN-5652 by hydrolysis with potassium hydroxide and subse- 
quent methylation with methyl iodide. The product was identified as optically pure (+)-McN-5652 by 
chiral HPLC analysis. In case of (-)-3, an analogous result was obtained. These results established 
that no racemization occurred during S-demethylation of enantiomerically pure 1 by treatment with 
sodium amide. 
The thioester precursors (+)-3 or (-)-3 respectively were used for "C-labelling of (+)-McN-5652 or 
(-)-McN-5652 in a similar procedure as reported [9]. ["C](+)-1 or flC](-)-I were obtained in an overall 
radiochemical yield of 22 % (corrected for decay, related to ["cIco~). The radiochemical purity was 
>98 %. The products were identified by chiral HPLC as enantiomerically pure ["C](+)-1 or ["C](+)-1, 
which confirms that no racemization occurred during the thioester synthesis and the labelling step. 
Conclusion 
Enantiomerically pure thioester precursor of [ "C](+)-~~~5652 and [''C](-)-~c~5652 can be prepared, 
starting from racemic McN5652. The key step is the resolution of (*)-I by recrystallization with (+)- and 
(-)-di-p-toluoyltartaric acid, yielding (+)-I and (-)-I in an enantiomeric purity > 98 %. 
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29. lmproved Synthesis of ['8q~ltanserin, a Radioligand for lmaging 5-HT2A Receptors 
with PET 
J. Zessin, K. ~amacher', F. Füchtner, H. ~üttich', N. Dohn, J. Steinbach 
'~orschungzentrurn Jülich GmbH, Institut für Nuklearchernie; '~entralabteilung Neue Beschleuniger 
Introduction 
Serotonin (5-HT) receptors are involved in the regulation of several brain processes as weil as in vari- 
ous neurological or psychiatric diseases. PET investigations of the receptor conditions, using suitable 
radiotracers, therefore improve understanding of the causes of such diseases. A special PET tracer 
for investigation of the 5-HT, receptors is ['8~]altanserin because of its high affinity (Ki 0.13 nM) and 
high selectivity for the 5-HT2 receptor [I]. The structure of altanserin (Scherne 1) is related to ketanse- 
rin and characterized by the fluorobenzoyl rnoiety. 
Scheme 1. Structure of ['8~]altanserin 
['*F]~ltanserin is prepared by nucleophilic substitution of the nitro group of nitroaltanserin with 
['8~lfluoride (Scheme 2) [I]. The radiochernical yield depends on the reaction conditions and on the 
amount of precursor used. ['8~]~ltanserin was obtained in a yield of 2 - 20 % (using 5 - 15 mg nitro- 
altansenn) with conventional heating (30 min, 135 "C) [I]. The radiochemical yield was increased to 
50 % by fiuorination in a microwave oven [I]. 
The purification of ['8~altanserin was perforrned by solid phase extraction followed by preparative 
HPLC. The HPLC eluent was rernoved by solid phase extraction using an RP18 cartridge. 
Scheme 2. Synthesis of ['8flaltanserin 
Due to the lack of a suitable microwave oven for radiochernical conversion, we were forced to use the 
preparation of [78~]altanserin by conventional heating. Our investigations led to an improved synthesis 
method, which is described in the present report. 
Experimental 
Most of the reagents and coivents were obtained from comrnercial suppliers, altanserin was a gift from 
Jannsen Pharmaceuüca. 
HPLG analyses of the chemicaf and radiochemical purity were petformed with a LiChrospher 60 se- 
lectB column (250 mrn X 4 mm) isocratically eluted with acetate buffer (pH 4.4)/THF/methanol 
(5!%/%?4/ 126) at a ff ow rate of 0.8 mümin. 
Purification by sernipreparative HPLC was carried out by using a LiChrospher 60 s e h t  B column 
(250 mm X 10 mm). The column was isoc~aticaliy eluted with phosphate buffer (pH 5.6)iTHF/meffianol 
(55Q/324/126) at a Row rate of 5 mümin. 
Purification of nitroaltanserin 
Nitroaltanserin (300 mg) was suspended in THF (8 ml). The resulting suspension was refluxed for 
30 min and filtered hot. The filter cake was washed with hot THF (4 ml). The collected filtrates were 
evaporated to yield a beige solid. 
Yield: 195 mg (65 %) 
Melting point: 201 - 206 "C 
ßadiosynthesis of [78~]altanserin  a microwave oven 
A solution of Kryptofix 2.2.2 (15 mg) and K2C03 (3 mg) dissolved in a mixture of water (0.2 ml) and 
acetonitrile (1 ml) was added to water (0.1 ml) containing f8~lfluoride. The water was evaporated by 
heating the resulting solution at 120 "C in a nitrogen stream while repeatedly adding several portions 
of acetonitrile (0.5 ml). The dry residue was dissolved in dry DMSO (1 ml) containing nitroaltanserin 
(nonpurified, 3 - 5 mg). The sealed reaction vessel was placed in the microwave oven and heated 
several times. 
Samples of the reaction mixture were analysed by HPLC to determine the Course of the reaction. 
ßadiosynthesis of r8f]altanserin by conventional heating 
The aqueous solution of [18~]fluoride was evaporated in the presence of Kryptofix 2.2.2 and potassium 
carbonate as described above. The nitroaltanserin solution (3-5 mg of purified nitroaltanserin in 1 ml 
DMSO) was added to the resulting residue.The reaction mixture was heated at 140 "C for 25 min and 
diluted with HPLC eluent. It was purified by semipreparative HPLC as described above. The eluent 
containing [Is~]altanserin was collected and diluted with water (eluentlwater ratio 1:2). The solution 
was passed through a C18 cartridge (Chromafix from Macherey & Nagel, 200 mg, prewashed with 5 
ml ethanol and 10 ml water). The cartrid e was washed with water (10 ml). The product was eluted B with absolute ethanol (1 ml). For use of f Flaltanserin in biochemical studies, saline (9 ml) was added 
and the resulting solution was filtered through a 0.22 Pm sterile filter. Chemical and radiochemical 
purity was determined by the described methods. 
Results and Discussion 
lnitially we carried out the synthesis of  altanse ans er in by using a modied home microwave oven. The 
heating cavity of the oven was reduced to a size suitable for a 2 ml reaction vessel. The reaction mix- 
ture (1 ml) was irridiated with a microwave power of 30 W. Under these conditions nitroaltancerin was 
completely decomposed within 20 s during the fluorination step without fonnation of f8F]aitanserin. 
Further experiments using the microwave-assisted synthesis of [Is~altanserin were not carried out 
because regulation of the power of the microwave oven proved to be very expensive. 
Radiofluorination of nitroaltanserin by conventional heating proceeded without complete decomposi- 
tion of the precursor. After fluorination, the resulting reaction mixture contained about 15 % 
["8~]a~anserin (decay-corrected, determined by HPLC). 
Nitroaltanserin is very slightly soluble in most common solvents, which makes purification very difficuk 
In the original procedure this precursor was therefore used as a crude product [l]. We found that ni- 
troaltanserin can be purified by extraction of crude nitroattanserin with hot THF. Using puraied nitrml- 
tanserin, the yield of the Ruorination step increased to 25 - 35 %. Under thece conditions the amwnt 
of nitroaltanserin can be reduced to 3 - 4 mg. By contrast, Lemaire et aL [I] obtained radiochemicaf 
yields of 20 % with 9 mg crude nitroaltanserin. 
Furthermore, the synthesis time was reduced by simplifying purification of f8f]attanserin, Wich W S  
performed by semipreparative HPLC. The retention time of f"f1altanserin was reduced from 55 min t0 
17 min by using a smaller HPLC column. 
The improved synthesis of f8F@ltanserin was completed after 85 min. The overalf fadiihemical yieki 
ranged from 12 to 27 % (decay-wrrected, related to fsF]Ruoridef. 
[I] Lemaire G., Cantineau R., Guillaume M., Plenevawc A. and Christiaens L. (1991) Ffuorinel& 
altanserin: A radiiligand for the study of serotonin receptars Hnth PET: Radidabling and in vnIo 
biologica! behavior in rats. J. Nu&. Med. 32,2266 - 2272. 
30. Serotonin Receptor-Binding Technetium and Rhenium Complexes 
21'. Synthesis and Characterization of a Novel High-Affinity Tc-99m Ligand for the 5-HT, 
Receptor 
H.-J. Pietzsch, M. Scheunemann, S. Seifert, P. Brust, H. Spies, B. Johannsen 
introduction 
In contrast to the successful development of p m ~ ~ ] ~ ~ ~ ~ ~ ~  as a ligand for the dopamine transporter 
[ I ]  the search for Tc-99m complexes with affinity for post-synaptic CNS receptors have not yet re- 
ached the Same Stage of development. The differences in the topology and structural features of the 
receptors as opposed to the dopamine transporter [2] as well as the at least 10fold lower concentra- 
tions in the brain may be recognized as the principal factors for these difficulties [3]. 
As one of the consequences for the design of ~erotonin-5-HT~~ receptor binding Tc-99m complexes 
we have dealt with for some years [4 - 61, an affinity of < 1nM is believed to be a prerequisite for 
further Progress. Aiming at such a high affinity, we have pursued our design concept starting from the 
selective, high affinity ~ - H T ~ A  receptor antagonist ketanserin as lead structure for 5-HT2A receptor 
binding ligands. 
Here we report on the synthesis of a new high-affinity Tc-99m ligand that meets the requirement of 
subnanomolar affinity. The complex has been evaluated by several in vitro receptor binding assays 
(radioligand binding and functional experiments) [7]. 
Results and Discussion 
Previous studies have shown that already quite simple technetium hybrid molecules of type I (Figure 
1) may exhibit nanomolar affinity for the ~ - H T ~ A  receptor [4, 51. These ketanserin-derived complexes 
combine an aromatic moiety and a protonable nitrogen in an appropriate spacer distance with a neu- 
tral technetium chelate representing a mked ligand "3+lU unit. 
M=Tc(Tcl)  
Re (Re 1) 
Fig. 1. Serotonin-5-HTZA receptor binding Tc complex I derived from ketanserin as lead structure and a 
novei Tc-99m ligand Tc 1 with subnanomolar affinity for the ~erotonin-5-HT~~ receptor. 
The new technetium complex Tc 1 has resulted from modiiication of spacer length and tridentate li- 
gand of the chelate uns. The 4-(4-fluor0)benzoyl piperidine portion derived from ketanserin, which 
contributes much to an effective binding of 5-HT2~ receptor antagonists, has been conserved. 
The rhenium complex Re 1 has been synthesized as a Surrogate for the Tc-99m complex for use in 
receptor binding assays and for complete structural characterization. Elemental analysis as well as 
NMR data ciearly indicated the purity and composition of the compound. Co-injedions of ~ C ] T C  1 
and Re 4 into HPLC under various elution condiiions showing similar retention times confirm the 
structural identity of both substances. 
Synthesis of ffie monodentafe tfiiol ligand 6 
The synthesis of monodentate thiol ligand 6 was performed by a new method using a ring opening 
reactian of 2-thianone 3 as the key step (Scheme 1). 
Prior to this ring opening reacüon C(4-fluoro)benzoyl piperidine 1 was protected by 1,2-ethanediiol, 
using a three-sfep procedure to give fhe ketal2. The aminolysis of 2-thianone 3 with 2 was carried out 
in chforofom at ambint temperahire for 3 h. The convenience of the purification of the resulting a m  
* fw part 20 see RR-Annual Repr t  1997, pp. 18-20. 
-submitted fw pubiication in Nuci. MBd. W. 1999 
ide 4 is mainly due to its nonbasic properties. Thus, simple washing of the reaction mixture with diluted 
acid removes any basic starting material. 
Reduction of the amide group is accomplished with lithium aluminium hydride. The 13c NMR spectrum 
of the product obtained indicates no contamination by unreacted amide. Finally, the ketal intermediate 
5 was deprotected by treatment with 4 N HCI for 1 hour at 45 "C to give the monodentate thiol 6. The 
isolated compound was homogeneous on TLC and showed satisfying elemental analysis in the form 
of its oxalate salt. 
Scheme 1. Synthesis of the monodentate thiol ligand 6 via ring opening reaction of 2-thianone 3 as the 
key step 
{[3-N-methyl-azapentane-I ,5dithiolato][5-(434-fluorobenzoyl}piperidin-1 -yl)pentyl-1 -thiolato]}-oxorhe- 
niurn(V) (Re 1) 
Thiol 6 (104 rng, 0.26 mmol) and 3-(N-methyl)-azapentane-l,5-diihiol oxalate (58 mg, 0.24 mmol) 
were dissohred in MeOH (8 ml) at 50 "C. After addition of a methanolic solution of sodium acetate (1 
M, 4 ml) and ReOC13(PPh3)2 (208 mg, 0.25 mmol) the suspension was stirred and heated under refiux 
for 2 h. 
After cooling to room temperature, the reaction mixture was evaporated. The residue was partitioned 
between CHCI, (1 5 ml) and 5 % aequeous solution of NaHCO, (10 ml). The organic phace was dried 
(MgS04), evaporated and purified by liquid chromatography on silica gel with CHCI&leOH (18:l) as 
solvent to give the product as a green coloured fraction. The solvent of the separated ffaction was 
removed and the residue was Witurated with MeOH to afford the compiex as dar% green C W S ~ ~ ~ S :  ykM, 
53.9 mg (34 %); m.p. 135 - 137 "C. 
1 H NMR (400 MHz, CDCI3): 6 = 1.49 - 1.57 [m, 4H, N-CH2-(C&)2-CH& 1.80 - 1 .W [m, 6H, C&-C%- 
S, Pip-3-H, Pip5Hj 2.0 - 2.14 [m, 2H, Pip-2-H„ Pip-6-H& 2.36 [m, 2H, N-C&-(CH2)3], 2.62 [m, 2H, 
(CH&-CU&], 3.00 [m, 2H, Pip-2-H„ Pip-6-Hd, 3.35 [s, 3H, NCH3J, 3.10 - 3.20, 3.50 - 3-58 arid 
3.72 [2m and br, 9H, Pi@-H, N(CH2-CHTS)2]i 7.13 and 7.96 [AA'BBC-part of AA'BB'X-system, 4H, 
Ha-I- 
13c NMR (1 00 MHz, CDC13): 6 = 26.77,27.20,28.77,32.?4,41.52,43.88,44.81,52.59,53.23, 58.96, 
68.70, 115.69 (d, J = 22.2 Hz, 2C, C3), 130.83 (d, J = 9.2 Hz, 2C, C2), 132.48 (d, J = 2.8 HZ, 1C, Cl), 
155.54 (d, J = 253.9 Hz, 1 C, C4), 201.10 (CS). 
Elernental anaiysis: Found: C, 39.97; H, 4.72; N, 4.13; S, 14.66. 
requires: C, 40.04; H, 5.19; N, 4.25; S, 14.66 %. 
Preparation of the technetium-99 complex PTC]TC I 
"TC(V) gluconate was prepared by gradual addition of stannous chloride to an aqueous solution of 
99~~0; (2 pmollca. 5 MBq) in an excess of sodium gluconate. 
1 ml of the 9 9 ~ c  gluconate solution was diluted with 1 ml of ethanol. A solution of 2 pmol of 3-(N- 
methy1)azapentane-1,s-dithiol (HS-NMe-SH) and 2 pmol of the monodentate thiol 6 in 0.2 ml ethanol 
was added. The colour of the mixture turned to reddish-brown. After stirring for 30 rnin and adding 2 
ml of water, the Tc compound was isolated by extraction of the reaction mixture with 2 ml of chloro- 
form. The organic phase was washed twice with 1 ml of water and dried over Na2S04. 
The yields are in the range from 75 to 80 percent (related to technetium gluconate). 
The radiochemical purity (98 %) of the technetium complex was determined by HPLC: Perkin Elmer 
250 binary pump gradient elution, Hamilton PRP 1 reversed phase column (250 X 4 mm, 10 pm), mo- 
bile phases: acetonitrile and ammonium acetate buffer (0.05 M, adjusted to pH 4.0 with acetic acid), 
initial elution: for 2 rnin with 50 % acetonitrile and 50 % buffer, within 20 rnin the eluting solution was 
100 % acetonitrile, flow rate: 2 mllmin. 
For receptor binding studies a stock solution of the complex was prepared by evaporating the organic 
solvent under nitrogen and redissoiving the residue in 1 ml of DMSO. 
No carrier added preparation of the Tc-99m complex PTC]TC I 
0.5 mg of an aqueouslethanolic solution (200 PI) of the monothiol ligand 6 and 0.05 mg of the triden- 
tate ligand dissoived in ethanol (10 PI) are added to a mixture of 1.0 ml pertechnetate eluate (100 - 
500 MBq) and 0.5 ml propylene glycol. After increasing the pH of the solution with 150 PI 0.1 N NaOH 
the reduction of pertechnetate was performed by addition of 20 p1 stannous chloride solution (1.0 - 2.0 
mg SnCI2 2 H20 dissoived in 5.0 mlO.l N HCI) and heating for 20 rnin in a water bath at 50 "C. . 
Radiochemical purity: 90 - 95 % determined by HPLC (Hypersil ODS (250 X 4 mm), flow rate 1.0 
mVmin, isocratic gradient mixture of 80 % methanol and 20 % 0.01 M phosphate buffer of pH 7.4). 
For the separation of ligand excess the reaction mixture is loaded onto a semi-preparative PRP-1 col- 
umn. The complex is eluted with a Rt value of 11.5 rnin and well separated from the ligands (R, = 6.5 
rnin and 13.9 min) using a linear gradient system of acetonitrilel0.1 % trifluoroacetic acid (A) and 0.1 
% trifluoroacetic acid (B); [t(min)lA(%)]: [5/30], [10/80], [5180], flow rate 3.0 mVmin, UV detection at 254 
nm and y-detection. 
After neutralization of the complex fraction and adding of 200 PI propylene glycol the acetonitrile is 
evaporated under vacuum. The radiochemical purity of the final solution is :, 95%. For the autora- 
diographic studies the solution is diluted with Saline. 
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lntroduction 
Alterations in serotonergic neurotransrnission have been implicated in various neuropsychiatric disor- 
ders, e.g. anxiety, depression and Alzheimer's disease. Changes in the density of the 5- i i - r~~ receptor 
were demonstrated in vitro on postmortem human brain [6, 151. Modern imaging technology, such as 
positron ernission tomography (PET) or single- photon computed tornography (SPECT), allows the 
visualization and quantification of these receptor-binding sites in Iiving patients. f8f]~etoperone and 
p8~altanserin were developed as PET tracer and are currently used for in viv0 human application [ 2, 
3,4, 121. 
In contrast to this achievement and in spite of the efforts many groups, the search for 9 9 m ~ ~  complexes 
with an affinity to post-synaptic CNS receptors for the application of SPECT have not yet reached the 
Same Stage of development [10]. 
Aiming at a high-affinity serotonin-5-HT2~ receptor-binding -TC mmplex, we pursued our design 
concept, starting from the selective, high-affinity 5-HT2A receptor antagonist ketanserin [21] as lead 
structure for 5-HT2A receptor-binding li ands. 
The synthesis of a new high-affinity "TC ligand (Tc 1) that meets the requirement of subnanornblar 
affinity was described in an accompanying report [17]. This study evaluates the compiex and its rhe- 
nium congener (Re 1) by several in vitro receptor-binding assays (radioligand binding and functional 
experirnents) and by in vitro autoradiography. 
Experimental 
Receptor-binding assays : 
A. Brain homogenates 
Binding assays using the m c ] ~ c l  and Re 1 compounds for the 5-HT2A receptor, the ~-HTIA reCeptOr 
and Dg receptor were performed as previously described 1181. The procedures for the binding assays 
for the 5-HT and DA transporters were published recentiy [8,9 1. 
B. Functional receptor assays on isolated Organs 
The ~ - H T ~ A  receptor assay On the rat tail artery using the Re 1 compound was petformed as Pub- 
Iished [16, 171. Assays for histamine H, and muscarinic M3 receptors of the guinea-pig whole ileal 
Segments, adrenergic a , ~  receptors of the rat thoracic aorta, histamine Hz and adrenergic P1 recep- 
tors of the spontaneously beating guinea-pig right atrium, 5-HTle receptors of the guinea-pig iliac ar- 
tery were carried out On the model of Pertz and Elz [16]. Histamine H3 receptors were measured On 
the field-stimulated guinea-pig ileal longitudinal muscle wläl adhering myenteric plexus 1191 and 5-HT3 
receptors on quiescent guinea-pig ileal longitudinal muscle with adhering myenteric plexus and 5-HT4 
receptors of rat oecophagal muscular mucous membrane E7j. 
In vifro autoradiogaphy 
Maie Wistar rats (210-230 g) and male piglets (1.8-2.9 kg) were used in tfie studiis, Aiter euth$nacia 
the brains were removed and quickiy frozen by immersion in isopentaneldty ice solution at -50 C. 20 
pm horizontal and sagittal sections were sliced on a cryostat microtome, thaw-mounted Onto pro. 
treated slides and kept at -20 O C until use. Prior to the experiment, the slides were dried at room tem- 
perature and pre-incubated for 30 min in buffer containing 50 mM Tris-HCi (pH 7.4) and 120 mM MC3. 
Ac described above the s l i s  were then incubated for 1.5 h in buffer mtaining mcfrc 1 Wm- 
pound ( 0.008 MBqlml= 216 nCiimlf. After incubation, the siides were washed twH=e 10 min in - 
cold T& buffer, rinced in cold distilled water, and dtied by cold air. Nonspecific binding was deter- 
mined in the presence of 1 PM mianserin. 
in order to detetmine the pharmacological specifiiity and scl.lectiGi of ~ C F G  I receptor binding, 1 
tfM of various drugs was added to the incubation buffer, s a h  as ttie 5-HTa rweptor antagonist ko. 
tanserin, the 5-HTl~ receptor agonist &OH-DPAT, ttie dopamiw mcqtor antagonict hakw3ridol and 
the a,pl adrenergic receptor agonist (t) norepinepbrine. 
As a reference for the ~ - H T ~ A  receptor distribution in the brain, additional slides containing the high- 
affinity 5-HTZA receptor ligands [3~]ketanserin (1 nM) or [18~]altanserin (10 nM) were incubated in the 
Same buffer. The nonspecific binding of these ligands was also determined in the presence of 1 pM of 
mianserin. 
For autoradiography the method of radioluminography was used. The 9 9 m ~ ~  and 18~-labelled sections 
were apposed to standard imaging plates for approximately 18 h whereas 3~-labelled sections were 
apposed to triiium- sensitive plates for 11 days. The imaging plates were scanned in the bio-imaging 
analyser BAS 2000 (FUJI photo film Co,Tokyo). The evaluation was carried out with the TINA 2.09 g 
program (RAYTEST, STRAUBENHARDT). After exposure the brain sections were stained with cresyl 
violet to match anatomical with functional information. 
Results and Discussion 
ßeceptor-binding assays 
The Tc 1 and Re 1 were used in various receptor-binding assays to determine the affinity and selec- 
t i i ty of these ligands for the S-HT~A receptor. As shown in Table 1, both compounds have a similarly 
high affinity for this serotonin receptor subtype . They also display a high selectivity for the the 5-HTqA 
receptor, the 5-HT transporter (5-HTT) and the dopamine transporter (DAT). The selectivity for the 
dopamine D2 receptor is much lower. However, for extrastriatal regions Tc 1 meets some of the crite- 
ria of a good imaging agent. This lack of selectivity is not a general problem for brain imaging. It has 
been shown with "C-3-N-methylspiperone (NMSP), a ligand with high affinity to 5-HT2A and Dg re- 
ceptors, that these Wo receptor types can be simultaneously measured with PET [22]. 
Table 1. Inhibition constants (F tr SD) of [~CITC 1 and Re 1 for serotonin and dopamine receptors 
(5-HTIA, 5-HTzA, D,) and transporters (SHTT, DAT). 
Complex ~ - H T ~ A  ~ - H T ~ A  5-HTT D2 DAT 
The subnanomolar 5-HT2~ receptor binding of Re 1 was confirmed by functional in viu.0 antagonism of 
contractile effects evoked by 5-HT in rat arterial tissue. The vascular contraction of the rat taii artery 
elicited by 5-HT and related tryptamines is mediated by 5-HT~A receptors [5]. This effect was antago- 
nized by Re 1 (10 - 1000 nM). The Re llreceptor dissociation constant was similar to the & value ob- 
tained from inhibion of the radioligand binding in rat cortex under various experimental conditions 
(0.83 nM versus 0.25 nM). The selectivii of Re 1 for some other 5-HT receptor subtypes was >I200 [lq. In a series of selectivity experiments vis-a-vis histamine, acetylcholine, and adrenergic receptors, 
Re 1 showed a moderate competitiie antagonist affinity for H1 receptors of guinea-pig ileum and a l ~  
receptors of rat aorta. This behaviour is shared by ketanserin, which blocked the H1 and a l ~  receptors 
to a similar extent [I61 and thus dispiayed similar selectiv'i ratios for these receptors (10 and 36) as 
Re I [I 71. 
In vifro autoradiagraphy 
The regional in vitro distribution and accumulation of r "Tc ]~c  1 was measured in sections of rat and 
pigiet brains. Autoradiograrns of brain slices are shown in Fig. 1. Obviously, the 99m~c radioactivity 
accumulates predominantfy in the frontal cortex, anterior olfactory nucleus and caudate putamen, ar- 
eas known tu have a high density of 5-HT2~ receptors [I 1, 12,13,14]. 
An almost identical regional labellin pattem of the brain sections was found with [3~]ketanserin (Fig. 
2). ['8~altanserin [I] (Fig. 3) and k c n c  1, Wah the exception of the tracer accumulation in the 
thaiamus. Larger amounts of -TC radioactivity were measured in this region. 55 % of the total binding 
in äie thalarnus of the rat was displaced by miancerin (Fig. 4). lhe displacement of f3~1ketanserin was 
oniy 35 %. En the piglet too a higher binding of $ " r c ~ c  1 was found compared with T~jketanserin 
(Fii. 4). lt is possibie that the -TC mrnpfex occupies binding sites in the thalarnus other than 5-HTZA 
receptors. ds was shown using the functionat receptor assays, the Re congener has a rather high 
affinity also for the a , ~  and histamine H1 receptors [17j which are found at reiatiiely high densities in 
the älaiarnw [12,20]. For exampie in our studies the adrenergic agonict (I) norepinephrine dis- 
placed 15 % of the total [ @ g m ~ c ] ~ c  1 binding in the thalarnus (Fig. 5).A slightly higher accurnulation od 
[ 9 g m ~ c ] ~ c  1 was also found in the white matter (corpus callosurn, internal and external capsula) and in 
the rnedullary substance of the cerebellum. The accumulation in these lipid-rich areas rnay be caused 
by the considerable lipophilicity of the compound. 
Fig.1. In vitro autoradiograms (above) and histological image (below) of sa ittal (A, C) and horizontal 
(B) brain sections of piglets (A) and rats (B, C) showing the distribution of k c ] T c  1. A - C: control 
sections without displacer, A' - C consecutive sections after displacement by rnianserin. Cx = frontal 
cortex, cpu = caudate putamen, th = thalamus, cb = cerebellum, aon = anterior oiiactory nucleus. 
Fig. 2. In vitro autoradiograrns ( above ) and histological image fbelow) of sagittal A, C) and horizon- s, tat (B) brain sections of piglets (A) and rats (B, Cf showing äie distribution of Iketanserin. 
A - C: control sections without dispiacer, A' - C': consecutive sections after displacemsnt 
by rnianserin. Cx = frontal Cortex, cpu = caudate putamen, th = 3kralamus. 
cb = cerebellum, aon = anterior olfactory nucleus. 
Fig. 3. In vitro autoradiograms ( above ) and histological image (below) of sagittal (A, C) and horizon- 
tal (B) brain sections of piglets (A) and rats (B, C) showing the distribution of [ '~laltanserin. 
Cx = frontal cortex, cpu = caudate putamen, th = thalamus, cb = cerebellum, 
aon = anterior olfactoty nucleus. 
The binding of [ ssm~c]~c  1 in the various brain regions can be inhibited by the 5-HT, antagonists mi- 
anserin (rat: between 55 and 32 %; piglet: between 47 and 10 %) and ketanserin (rat: between 41 and 
6 %; piglet: between 37 and 0 %) (Fig. 5). 
WBS Cx CPU Th Cb 
I iiiPmTc] TCI +mianserin rat B P~TCJ TCI + mianserin pigiet I 
Fig. 4. Comparison of the inhibition of [3~]ketanserin binding (specific 5-HT2A receptor binding) and 
~ T C ] T C  1 binding by mianserin in various regions of the brain of rats (n = 5) and 
pigtets (n = 3). WBS = whoie brain section, Cx =frontal cortex, 
Cpu = caudate putamen, Th = thalamus, Cb = cerebellum 
The dopamine receptor antagonist haloperidol also significantly inhibited the binding of [gPm~c]~c  1 in 
various brain areas (Fig. 5). This result is in agreement with the skidies by Leysen et al. [I31 who 
Sound that the g3t-l]ketanserin binding was displaced by haloperidol (Ki = 22 nMf in the rat prefrontal 
cortex. With the 5-HT„ agonist SOH-DPAT no inhibition of binding was observed in most regions of 
the brain (Fig. 5). These results agree with the noticeable binding affinity to the dopamine D2 receptor 
(K, = 7 3  nM) a s  well as  with the relatively low 5-Hf receptor-binding afFinity (Ki = 142 nM) found in the 
receptor-binding studies. (Table 1) [I 71. 
Fig. 5. Effect of the equimolar administration of several drugs on in vitro [ ~ C J T C  1 binding in vanous 
rat (left) and piglet (right) brain regions (percentage of total complex binding ) 
In conclusion, it was shown that among the '"'TC compounds studied so far the new [ ~ ~ ~ T c I T c  1 li- 
gand exhibits the highest affinity to the ~erotonin-5-HT~~ receptor in the subnanomolar range with ob- 
vious visualization of the in vitro binding in areas of the brain known to have a high density of seroto- 
nin-&HTp~ receptors. 
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introduction 
Organometallic complexes exhibit unique features, which make them very attractive mainly in catalysis 
but, more recently, their application in life science has bewme a field of growing interest as well [I]. 
Beside investigations on the metabolical behaviour of pure organometallic compounds, bioorganomet- 
allic chemistry, as introduced by Jaouen and coworkers [2] stands for the wmbination of an organo- 
metallic moiety and a bioactive molecule which targets different type of receptors. For the latter pur- 
poses, the metal complex should be "innocent" but provide major advantages in metabolical stability 
and interference with binding properties of the biomolecule. 
We present herein the first example where the organometallic tricarbonyl moiety " ~ ~ C - [ ~ ~ ~ T C ( C ~ ) E J + "  
was successfully applied for the straight forward labelling of a biomolecule designed for binding to the 
serotonergic receptor 5-HT1~ in the central nervous System 133. 
Resuits and Discussion 
Bioorganometallic chemistry comprises the combination of an organometallic transition metal complex 
and a targetting biomolecule. If ever such a combination should be applied in nuclear medicine, the 
synthesis has to be convenient, fast and requires one or two steps only. A useful precursor is repre- 
sented by the organometallic aquo-complex [ 9 9 m ~ ~ ( ~ ~ 2 ) 3 ( ~ 0 ) 3 ] +  1 for Mich we recently presented a 
convenient one step ki procedure directly from saline in high yield [4]. 
Potential 9 9 m ~ ~  complexes attached to CNS receptor ligands have to be neutral in charge and lipophilic 
to Cross the blood-brain barrier. Thus, we have focused our interest on neutral bidentate amine ligands 
(NAN'). The occupation of Wo coordination sites by such a set of donors entails the mrdination of 
charge neutralizing CI- at the third pocition. Whereas aliphatic diamines were found to be weak (or 
slow) chelators, all combination of nitrogen donors containing an aromatic amine group were extrem& 
efficient. In particular Schiff Base ligands can be prepared just by reacting an aliphatic amine, which is 
a frequent functionality in biomolecules, with a corresponding aromatic aldehyde of choice. 
To examplify this, we have derivatized a receptor ligand from the class of atylpiperazinec, which be- 
longs to the most thoroughly studied molecules for the ~-HT,A subclass of serotonergic receptcxc "1. 
In particular, 4-(3-aminopropy1)-1-(2-methoxypheny1)piperazine 1 was reacted with 2-pyridine carbal- 
dehyde 2 to yield compound 3, a Schiff Base type ligand attached to the bioactive moiety (Scheme 1). 
Labelling was achieved by incubating the precursor 1 with the corresponding amount of 3. After 10 
min at 90 OC the radiolabelled biomolecule 4 was formed in almost quantitative yield. 
Scheme 1. Preparation of the derivatized aryl piperazine 3 from 4-(aminopropy1)-1-(2-methoxy- 
pheny1)piperazine 1 and 2-pyridine carbaldehyde 2 
To get unambigous evidence for the compesition of ä?e compounds, we have synthesized the con* 
cponding complex with bng-iied ?C. Formation of äle compkx 4 was ~ r r i e d  out by the reaction 0f 
[ 9 9 ~ ~ ~ 1 3 ( ~ 0 ) 3 ] 2 -  in methanol [6] with 1 eq. of ligand 3 at r. t.(Scheme 2). Crystals could be grown di- 
rectly from the solvent and the structure was elucidated by X-ray analysis. HPLC comparison of the 
cold, macroscopic complex and the material prepared on the n. C. a. level finally established their 
identity. 
Scheme 2. Synthesis of complexes 4 by the reaction of [MX~(CO)~]~- in methanol with 1 eq. of ligand 3 
[MX,(W,I,- + 3 - 
methanol 
' 'CO OC 
4 (M = 99T~,  X = CI 
M = Re, X = Br) 
The molecular structure of 4 is given in Fig. 1. The technetium acts as a chirality center. Conse- 
quently, two enantiomeric forms of the labelled compound exist with ""'TC. Since the complex isfar 
away from the effective binding site of the optically inactive receptor ligand, it can be anticipated that 
interference and decrease of affinity should not be initiated by this chiral center. 
Fig. 1. Molecular structure of the 5-HT1~ receptor binding 9 9 ~ c  cornplex 4 
In vitro receptor binding assays 
To assess the retention of biological acüvity and selectivity, the in vitro binding affinities of 4 with cold 
rheniurn instead of Tc were tested. The affinity (IC, values) to the 5-HTIA receptor was 5k2 nM (com- 
petitor [ 3 ~ ] & ~ ~ - ~ ~ ~ ~ ) .  
The selectiity (cornpetitor in brackets) was investigated with the following other receptors: 5-HT2. 
(F~lketanserin), dopamin-D2 (r~~spiperone) 5-Hf-transporter (P~lparoxetine) and D-transporter 
(fHJW1~35,428). In all cases the affinity was found to be > 1 mM. The rheniurn labelled compounds 
revealed, thus, a very good seiectivii for the 5-kiTt~ receptor. Due to the chernical relationship be- 
tween Re and Tc, the values for the latter one are not significanüy different m. The good selectivity 
justifies further invesb'gations on the in viv0 behaviour and in parücular the brain uptake of CNS re- 
ceptor ligands labelled with the "fac-~fc(CO)$' moiety. 
Conclusion 
In conclusion, it was shown for the first time, that organometallic complexes such as 
~ g m ~ ~ ( ~ ~ 2 ) 3 ( ~ 0 ) 3 ] '  can be applied in purely aqueous systems for the labelling of derivatized bioactive 
molecules under retention of their receptor affinity. Thus, the concept of bioorganometallic chemistry 
could be established on a routinely applicable base. Unique advantages in comparicon to other con- 
cepts emerge from the partially organometallic coordination sphere of the label. In particular, very low 
biomolecule concentration, high kinetic stabilities and flexibility in the choice of ligands make this type 
of precursor very attractive for routine use. 
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RADIOPHARMACEUTICAL CHEMISTRY 
33. Automated Production of [ " ~ l ~ e t h y l  Iodide 
J. Zessin, P. Mäding, H. ~rug' ,  S. ~ornmlich', B. Jung, E. Lösel, N. Dohn, F. Füchtner, J. Steinbach 
1 Zentralabteilung Forschungs- und lnforrnationstechnik 
lntroduction 
["Cl~ethyl iodide is one of the most important precursors for syntheses of "C-labelled tracers used in 
investigations with positron emission tomography (PET). Studying regions with a low density of the 
target such as brain receptors requires radiotracers of a high specific radioactivity. A prerequisite for 
the production of ["Clrnethyl iodide of a high specific radioactivity is a large quantity of starting radio- 
activity. Under these conditions the preparation has to take place in hot cells with a remote-controlled 
system or an automated synthesis apparatus. 
A synthesis apparatus for automated preparation of ["C]methyl iodide was developed in our PET 
centre. The preparation is based on the reduction of ["C]CO~ to ['l~]methanol by using lithium alu- 
minium hydride, followed by conversion of the released methanol into ["clmethyl iodide by treatment 
with hydroiodic acid [l]. 




The automated apparatus for preparation of ["clmethyl iodide consists of a synthetic unit, a control 
unit based on SlEMATlC S5 blocks and a control PC. The apparatus was controlled by using the 
InTouch software from Wonderware. A schematic picture of the synthetic unit is shown in Fig.1. 
["C]CO~ was produced by the 14~(p,ol)"~ reaction on an IBA Cyclone 1819 cyclotron. For most ex- 
periments the nitrogen target (nitrogen 99.999 % with 0.2 % oxygen) was irradiated with a beam cur- 
rent of 5 pA for 4 min giving, on average, 3.9 GBq of ['l~]carbon dioxide (EOB). Production of 37 GE3q 
["c]co~ required an irridation of 25 pA for 12 rnin. 
Hydroiodic acid, 2-thionaphthol, dimethyl formamide (DMF) and tetrabutyl ammoniurn hydroxide 
(methanolic solution) were purchased from cornmercial suppliers and used without purification. THF 
was dried by distillation over lithium aluminium hydride in a nitrogen atmosphere as reported by Ha- 
rada and Hayashi [2]. The lithium aluminium hydride solution was prepared by dissolving solid LiAiH4 
in dry THF. The saturated solution was diluted with dry THF in a ratio of 1:19. These prepaprative 
steps were carried out in a glove box under nitrogen. 
[ l '~]~ethyl iodide 
["Clcarbon dioxide was trappecl in a Carbosphere (Alltech) loop at ambient temperature and released 
at 110 "C. ["C]CO~ was transferred by a nitrogen stream into the LiAIH4 solution (7.3 ml). The THF 
was evaporated by heating the reaction vessel under reduced pressure. After cooling the reaction 
vessel, hydroiodic acid (1.7 ml) was added. The reaction mixture was heated to 165 "C and the 
[''C]methyl iodide was distilied over NaOH on charcoal and Sicapent (Merck) into a cooled vial. 
2-[l l~JVethylthionaphthol 
["Cl~ethyl iodide was trapped in a solution of 2-thionaphthol (5 rng, 31 pmol) and tetrabutyl amrno- 
nium hydroxide (40 pnol, as 1 M rnethanolic solution) in dimethyl forrnarnide (0.4 ml) while cooling 
with dry icelmethanol. Then the reaction mixture was warmed to room temperature. 
A small sample of the reaction mixture was analysed with HPLC (Purospher 125mm x 3 rnm, 5 Pm; 
water/acetonitrile (5050) with 0.1 M amrnoniurn formate as eluent, fiow rate of 0.8 mlfmin) to deter- 
mine the specific radioactivity. 
Resuits and Discussion 
In the first experiments the reaction Parameters and process times for adsorption of ~ C ~ C O ~  on the 
Carbosphere loop, desorption, evaporation of THF and release of ['IIC]methyl iodide by treatment wi* 
hydroiodic acid were optimized. The synthesis 05 ["C]methyl iodide using the optimized parameter Set 
was completed after 7.7 rt 0.1 min (without transfer of ["c]co~ from the cydotron to the automatic 
synthesis system). 
- . .. -- 
Start 
Fig. 1. Scheme of the synthetic unit for automated production of ["c]methyl iodide 
Starting from 3,900 MBq ["cICO~, 1,450 - 1,750 MBq ["clmethyl M i e  were produced. The repro- 
ducible radkhemical yield of ["CICHBI in relation to TC]CO:, was 66 f 5 % (decay-corrected). An 
exact determination of the loss of radi ict ivi i  was not possible. A loss of radioactivity was observed 
during evaporation of THF (I - 5 % of the starting radiictivity). After the release of ["~lmethyl iodide, 
the hydroiodic acid solutiin in the reaction V ~ S S ~  contained about 1 % of the starting radioactivity. The 
detection of the residual radioactivii in the Carbosphere toop and in the gaseous waste was not pos- 
sible. 
The radiahemical pirity of r~ lme thy l  iodide produced using the automatic synthesis apparatus was 
about 98 %. The [ 'c]methyl iodide was converted into 2-[' Clmethylthionaphthol as this compound 
has a stronger UV absorbance than methyl iodkk?, which is useful for determination of the specific 
radioactivity. At the end of the synthesis, the rnean specific radioactivi was 125 mcilpmol. 
In single experiments the preparation started with 37 GBq ["c]co~ (EOB) yielding 16 GBq ["clmethyl 
iodide. The cpecific radioactivity of ["clrnethyl iodiie was 1.7 Cilpmol. 
In summacy, it can be said that the new synthesis apparatus is suitable for automated preparation of 
[ "~ jmeth~ l  iodjde in good radiochemical yields and specific radictivities in short synthesis times. 
[I ] Crarzef C., L&ngsa.bm B., Pike V. W. and Coenen H. H. (1987) Recommendatiins for a practical 
prodoction of jl'C]rnethyl iodide. Appl. Rad. Isot. 38,6431-603 
&?I Harada N. and Wayashi N. (1993) Measurement of the carbon source which is responsibk for 
dilution in carbon-1 1 labelling reacfions. Rad, lsot. 44,629-630 
34. Synthesis of 5-~ethoxy-[2-"~]lndole by Reduction of 5-Methoxy-ß,2-Dinitro- 
[ß-"C]Styrene 
J. Zessin, J. Steinbach 
The indole ring is the basic structure of many biologically active compounds. Many of these sub- 
stances labelled with a positron ernitter such as "C or '*F may be potential radiotracers for the posi- 
tron emission tomography (PET). In particular the application of "C-labelled tracers requires efficient 
preparation methods on account of the short half iiie (tE = 20.38 min). The reduction of ß,2dinitro-[ß 
"~lstyrene with titanium(1ll) chloride was recognized as a first practicable method of synthesizing "C- 
ring labelled indole [I]. 
In this paper the synthesis of a 5-substituted indole derivative utilizing this method is described. 
5-~ethoxy-[2-"~]indole 1 was prepared by reduction of 5-metho~~-ß,2dinitro-@-~'~]styrene 4 with 
titanium(ll1) chloride. The intermediate 4 was obtained from condensation of 5-methoxy-2- 
nitrobenzaldehyde 2 with nitro-["~[methane 3 (Scheme 1). 
Scheme 1. Synthesis of 5-methoxy-[2-"Clindole 1. Reaction conditions: i, ammonium acetate, glacial 
acetic acid, 140 "C; ii, titanium(1ll) chloride, glacial acetic acid, room temperature 
Experimental 
General 
Glacial acetic acid, ammonium acetate, titanium(ll1) chloride and 5-hydroxy-2-nitro-benzakiehw w r e  
purchased from commercial suppliers and were used without purification. ~itro-rCJmethane was 
prepared via flC]methyl iodide according to the method of Schoeps et al. as describod in [2]. 
'H NMR spectra were recorded on a Varian NOVA 400 NMR spectrometer. 
HPLC anaiyses were performed on a JASCO System with a PUROSPHER RP 18 eolumn (125 mm X 
3 mm, 5 pm) isocraticaiiy eluted with acetonitrilefwater (40:60) containing O.1M ammonium formte at 
a flow rate of 0.5 mllmin. Semipreparative HPLC was perforrned with a NULEOSIL 120 RP 18 Wl~mn 
(250 mm X 10 mm, 7 pm) isccratically eluted wiih acetonitrilehater (5050) at a flow rate of 4 mi/min. 
5-Methoxy-2-niirobemaidehyde ('2) 
5-Hydroxy-2-nitrobenzaldehyde (5.0 g, 30 mmol) was dissohred in a potassium hydmxXkk sdution 
(2.73 g in 30 ml water). Dimethyl sulphate (4.1 g, 32.5 mmol) was added to äis sM&n. Then the 
reaction mocture was heated at 100 "C for 30 min. The methoxy cornpound was e x t r a d  with dich& 
romethane. The organic layers were washed with sodium hydroxide solution and water, dnod uMtti 
sodium sulphate and evaporated to yield a lightbrown solid. 
Yiekl: 2.3 g (42 Ob) 
Meiting point: 77 - 79 "C 
NMR data: 6H (400 MHz, sohrent CD&, standard: SiMe,): 3.90 fW, s, OCW& 7.10 [$X, m, W, 7.21 
[IH, m, CsH], 8.10 [IH, m, C4H], 10.42 [1H, s, CHO] 
5-Meth0@24inifm@-~'~&@~ne (4) 
5-Methoxy-2-nittobenzaldeyhde (10 mg, 55 pml)  and ammnium acetate (25 mg, 325 
dissoived in glacial aoetic a d  (230 vif- Niio-["C]mthane was 'trapped in tts so9utian. Ttie saikd 
reaction vessel was bat& at 145 "C for 10 min. The reaction mixtum was d i l W  W 1 mf HPLC 
eloent and purified by semipreparative HPLC. The eluent containing 3 was d i i W  with WixW (10 ml) 
and passed through a C18 cartridge. After washing with water, compound 3 was eluted with glacial 
acetic acid (1 ml). 
5- ~ethoxy-[2- " ~lindole ( I )  
Titanium(lll) chloride (6 mg, 40 vmol) was placed in a sealed reaction vial, which had been purged 
with nitrogen. The eluate from solid phase extraction containing 3 was added to this vial. After 6 min at 
room temperature a sample of the reaction mixture was dissolved in the HPLC eluent, filtered and 
analysed by HPLC. 
Results and Discussion 
The procedure of preparing 5-methoxyp"C]indole 1 is illustrated in Schem:J. The two-step synthe- 
sis involves the condensation of 5-methoxy-2-nitrobenzaldehyde 2 with nitro-[ Clmethane 3 to yield 5- 
rnetho~y-ß,2dinitro-[ß-~~~]ctyrene 4. After purification the intermediate 4 was converted into 1 by re- 
duction with titanium(lll) chloride. 
The preparation of 5-rnethoxy-ß,2-dinitr~-[ß-~~~]styrene 4 being investigated here ic a modification of a 
procedure earlier published for synthesis of ß,2-dinitro-[ß-"clstyrene [I]. The condensation reaction 
was carried out in glacial acetic acid catalysed by ammonium acetate (10 min, 140 "C). Under these 
conditions 27 % of 3 (determined by HPLC, decay-corrected) were converted into 1. In comparison 
with the preparation of unsubstituted ß,2dinitro-[ß-"Clstyrene [I], the 5-methoxy group causes a less 
incoporation of nitro-flc]methane. 
The reduction of ß,2-dinitro-[ß-llc]ctyrene with titanium(ll1) chloride in the presence of the catalyst 
ammoniurn acetate proceeded without formation of indole. The dinitrostyrene was completely decom- 
posed [I]. Ammonium acetate was therefore removed by solid phase extraction, using a C18 car- 
tridge. Reduction the of purified compound 4 with titanium(l1l) chloride in glacial acetic acid (6 min, 
roorn temperature) yielded a product mixture which contained the desired 5-methoxy-12-"clindole in a 
percentage of 7 % (determined by HPLC, decay-corrected). The parent 4 was almost completely con- 
verted. 
The yield of 1 increased when the purification of 4 was performed by semipreparative HPLC. The ra- 
diochemical yield of 4 after HPLC purification and removal of the HPLC eluent by solid phase extrac- 
tion was 14 % (decay-corrected, related to compound 3). In addition to ammonium acetate, unreacted 
5-methoxy-2-nitrobenzaldehyde was removed in the Course of this purification procedure. The reduc- 
tion reaction can therefore be carried out with a smaller amount of the reduction agent titanium(llll) 
chloride. The resulting product mixture contained the 5-methoxy-[2-"~]indole 1 in a percentage of 26 
% (determined by HPLC, decay-corrected), which is equivalent to a decay-corrected radiochemical 
yield of 4 % (in relation to 3). The synthesis of 1 starting from 3 was completed after 40 min. 
in conclusion it shall be pointed out that the reduction of ß,2dinitro-[ß-"~]styrenes with titanium(lll) 
chloride can be provide a practicable route to "C-ring labelled indole derivatives with substituents at 
the benzene ring. This was demonstrated by the preparation of 5-methoxy-[2-"~lindole 1. 
[I] Zessin J. and Steinbach J. (1998) "C-~abelling of Heterocyclic Aromatic Compounds in Ring 
Positions: Synthesis of [2-"~llndole. J. Labelled Compd. Radiopharm. 41,669-676. 
[2] Schoeps K.-O., Stone-Elander S. and Halldin C. (1989) On-line synthesis of C"~]nitroalkanes. 
Appl. Radiaf. fsot 40,261 - 262. 
35. Synthesis of 3-0-["CIMethyl-D-~lucose 
P. Mäding, H. Kasper, J. Zessin, M. Gnauck, F. Füchtner, P. Brust, J. Steinbach 
lntroduction 
Unlike the established radiopharmaceutical 2-~8~]fluoro-2-deoxy-~-glucose ( r 8 F ' J ~ ~ ~ ) ,  
3-0-["C]methyl-D-glucose (["CIMG; 4) is not metabolized in the living body [I, 2].6oth tracers share, 
however, the Same transport in the tissue via the glucose transporter [3]. Therefore, the "C-labelled 
radiotracer 4 is especially suitable for investigating glucose transport and its alteration under patholo- 
gical conditions. For PET animal experiments in this field, we had to work out a more convenient 
procedure to prepare ["CIMG based on the known synthesis process [4]. 
Experimental 
Materials 
Diacetone-D-glucose (1; purum, 2 98 %) was purchased from Fluka, and potassium hydride (35 % in 
paraffin oil) from Merck. As reference substances were used: 3-0-methyl-D-glucose 97 % (Aldrich) 
and D(+)-glucose waterfree for biochemical use (Merck). 
Analysis 
To determine the extent of the reaction conversion, the radiochemical and chemical purity and the 
specific radioactivity of PCIMG, an HPLC System (Hewlett Packard) was used, including a gradient 
pump (series 1050), an autosampler (series 1050), a CarboPac PA 1 column (4 X 250 mm, Dionex), 
an electrochemical detector (ECD) coupled in series with a radioactivity detector (A 100, Canberra 
Packard). The mobile phase consisted of 0.1 M NaOH at a flow rate of 1 mümin. This method is based 
on an anion-exchange separation mechanism and allows isocratic separation of carbohydrates 
(further details are given in 151). 
The osmolality was determined by an Osmomat 030-D from Gonotec, Berlin, Germany. The measu- 
rements of the pH values were performed by the microprocessor pH-Meter pH 3000 from WMI, Weil- 
heim, Germany. 
Synthesis of the precursor solution of the pofassium sait of diacetone-D-glucose (2) 
A suspension of 35 % potassium hydride in paraffin oil (lg; 8.7 mmol) was washed with Pentane and 
then with freshly distilled THF to remove the paraffin oil by decantation of the sokent. A solution of i 
(150 mg; 0.58 mmol) in 5 ml THF was added to a stirred suspension of the puriiied KH in 10 ml THF. 
This mixture was stirred at room temperature for 1.5 h and then refluxed for 30 min. After cooling to 
room temperature the suspension was filtered through a frit glas filter. The ckar yellow precurcor so- 
lution of 2 was stored at 4 "C for use within 4 weeks. 
Radiosynthesis ["c]co, was produced on the cyclotron Cyclone 1819 (BA) by the '4~(p,a)'1~ nuclear rEaction. 
[1'C]~ethyl iodide was prepared by the classic one-pot method [6J invoiving the reduction of [ CJC02 
w-m LiAIH4, hydrolysis of the intermediate organometallic complex and subsequent iodization uf the 
["C]methanol formed with Hl. 
["CIM~I was trapped in a cooled 2 ml vessel (- 78 "C) containing the precursor solution of 2 (250 PI). 
For methylation the welkealed vessel was heated at 120 OC for 3 min. Then the THF was evaporatd 
by means of a stream of nitrogen gas. 0.5 M HCI (0.6 ml) was added to the recidue. The mixture was 
heated at 120 "C for 2 min. After cooling to room temperature the solution was neutralked by a;ddition 
of 0.5 M NaOH (0.6 ml) and a solution of physiobgical phocphate buffer (pH 7.2; 0.7 ml). The rie~ufting 
solution was transferred to a 10 ml syringe. The readon vecsel was washed with water (2.8 ml) and 
this solution was aiso drawn up into the 10 ml syringe. The radiieactive sotution was put äirough a 
steriie filter into a seaied steriie iksk containing an aqueous solution of 5.85 Q/a NaCl(0.37 ml). 
Resutts and Discussion 
["CIMG (4) was synthesized according to Scheme 1 by methylation of the potassium salt of diaceto- 
ne-D-glucose (2) with E"~]methyl iodide followed by acidic hydrolysis of the ketal groups of the 
[llC]methyl-diacetone-D-glucose (3) forrned. 
Scheme 1 I * E "CI 
The preparation of 4 in this way is described in [4]. But we have modified this procedure for our purpo- 
sec: 
- changing the solvent for preparing the precursor 2 and for the methylation reaction, i.e. substitution 
of THF for diethyl ether; 
- preparation of the precursor 2 from compound 1 using KH instead of K; 
- reduction of the methylation time from 6 min to 3 min, reduction of the hydrolysis time from 6 min to 
2 min; 
- using 0.5 M aqueous HCI instead of 0.5 M aqueous methanolic HCI for hydroiysis; 
- simple working-up of the reaction mixture without HPLC purification. 
We performed 34 production runs for animal experiments which yielded 686 I 212 MBq ["CIMG. The 
["GIMG was obtained in radiochernical yields of 56.1 -t 11.2 % (decay-corrected) with specific ra- 
dioactivities of 12 - 42 mCi/pmol(450 - 1550 MBqIpmol) within 16 min, starting from ["CIM~I. 
Qualitv Darameters of T"C~MG: 
radiochemical purity > 96 % 
content of D-glucose 0.47 + 0.22 mglml 
content of 3-0-methyl-D-glucose 0.0244 I 0.01 7 mglml 
PH 7.1 -t 2.2 
osmolality 335 I 30 mOsmoVkg 
The excellent analytical assistance by Mr. C. Smuda and Mrs. R. Hüller is gratefully acknowledged. 
[I] Seider M. J. and Kim H. D. (1979) COW red blood cells. I. Effect of purines, pyrimidines, and 
nucleosides in bovine red cell giycolysis. Am. J. Physiol. 236, C255-61 
P] Pesquero J., Albi J. L., Gaiiardo M- A., Planas J. and Sanchez J. (1992) Glucose metabolism by 
trout (Salmo trutta) red blood celis. J. Comp. Physiol. .[8] 162,448-54 
[3] Johnson J. H., Newgard C. B., Milbum J. L., Lodish H. F. and Thorens B. (1990) The high Km 
glucose transporter of islets of Langerhans is functionaliy simiiar to the low affinity transporter of 
liver and has an identical primary sequence. J. Biol. Chem. 265,654.8-51 
[4] Kloster G., MüHer-Platz C. and Laufer P. (1981) 3-["~l~ethyl-D-glucose, a potential agent for 
regional cerebral glucose utilization studies: synthesis, chrornatography and tissue distribution in 
mice. J. LabeIled C~mpd. Radiopharm. 18,855-863 
E51 Füchaier F., Neuberf K. and Steinbach J- (1994) Determination of the chemical and radiochemical 
purity and specific radioactfvity of ~'~F-]FDG by HPLG. Annual R e m  1993, Institute of Bioinorga- 
nie and Radiophamraceuticat Chemistry, FZR-32,17-23 
f6] Crouzel C., tcingström B., Pike V. W. and Coenen H. H. (1987) Recommendations for a practical 
production of ff~]metf-tyt Mi&. AppL ßadiat.  OE, 38,601-603 
36. '3+1' Mixed-Ligand Oxorhenium(V) Complex with 1,2,3,4-Tetrahydroisoquinoline 
A. zablotskal, I. segall, E. ~ukevics', H.-J. Pietzsch, T. Kniess, H. Spies 
1 Latvian Institute of Organic Synthesis, Riga 
It has been reported that some tetrahydro(iso)quinoline-containing ligands display affinity to serotonin 
(5HTlA) and dopamine receptors [I, 21. In addition, we found earlier that some tetrahydro-, tetrahy- 
droiso- and tetrahydrosilaisoquinoline derivatives exhibied the sedative action 13-51. One may there- 
fore expect that the tetrahydro(iso)quinoline moiety may serve as an anchor group in the design of 
receptor-affine rhenium and technetium complexes. As an access to such compounds we synthe- 
sized the first Prototype of '3+1' mixed-ligand oxorhenium(V) complexes with 1,2,3,4- 
tetrahydroisoquinoline-containing monodentate (Scheme 1). 
Scheme 1. Reaction pathway for synthesis of tetrahydroisoquinoline containing oxorhenium(V) com- 
plex 4 
N-(2-hydroxyethyl)-l,2,3,4-tetrahydroisoquinoline obtained by condensation of 1,2,3,4- 
tetrahydroisoqui-noline witti Biodoethanol in the presence of triethylamine was further converted into 
N-(2-mercaptoethyl)-1,2,3,4-tetrahydroisoquinoline suitabie for complexation. Thus, ihe reactibn 0f 
aminoalcohol 1 with thionyl chloride produced the aminoalkyl chloride 2 in a 59% isolated yield. The 
subsequent treatment of 2 with sodium thiophosphate dodecahydrate in dimethyiformamide 161 fbl- 
lowed by acid hydroiysis resulted in mercaptane 3 in a 30 % yield (after isolation). 
N-(2-mercaptomethyl)-1,2,3,4-tetrahydroisoquinoline 3 was further uced for complexation with (3- 
thiapen-tane-1,5dithiolato)oxorhenium(V) chloride to obtain the desired mixed-ligand cornplex 4. The 
newiy prepared complex was characterized by elemental anaiysis, 'H and 13c NMR and 1R spc3ctroS- 
copy. Fig. 1 shows the infrared spectrum with the Re=O band at 967 cm*'. 
The molecular structure, brain receptor-binding in vitro, psychotropic ac t lv i  and acute toxicity in 
of compound 4 are under investigation and the results will be published in ihe subsequent paper. 
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37. Tc-99m Labelled Fatty Acids on Basis of "n+lU Mixed-Ligand Compiexes ? 
H. Spies, H.-J. Pietzsch, J. ~ropp', T. Fietz, C. ~ u n ~ ~  
1 TU Dresden, Universitätsklinikum Carl Gustav Carus, Klinik und Poliklinik für Nuklearmedizin 
2 Universität Marburg, Fachbereich Kernchemie 
lntroduction 
Although some efforts have been made to develop Tc-99m-labeled fatty acid analogues, poor recog- 
nition of those compounds as substrates for beta-oxidation has prevented their application 11-31. Rea- 
sons for failure may come from the nature of the chelate, that is has been chosen to attach at the 
Omega position of a fatty acid and in the nature of this fatty acid itself. The majority of previousiy 
known chelates used for binding technetium to a fatty acid moiety are almost without exception 
square-pyramidal oxotechnetium(V) complexes of tetradentate complexing agents, in which the prog 
erties, and thus the in vivo behavior, is strongly influenced by the coupling to the polar Tc=O una (Fig. 
1)- 
Fig. 1. Tc complexes intended as fatty acid analogues showing no uptake in myocardium [l - 31. 
lntended working strategy 
It is to be expected, but remains to be proven, that ligands that allow extensive shielding of the metai, 
rnay particularly suitable to be combined with fatty acids. We Want to appiy the *n+lM mixed-ligand 
approach [4, 51 (Fig. 2), with emphasis on the "4+1"-version [6], to the synälesis of new types of TC- 
99m-labelled fatty acid analogs in the hope to make them acceptable as substrates ior energy prOdUC- 
tion in living cells. 
Fig. 2. *%I* and W l "  m p l e x e s  as Wo versions of the "n+l "ooncept 14 - 61. 
Concerning the nature of the fatty acid sequence, "modified" fatty acids as used to be labeled with '*F 
and lZ3l will preferably be used. Fig. 3 shows schematically the intended working program that aims at 
"thian acids bearing a lipophilic mixed-ligand chelate unit at the omega-position. 
fast metabolism 
"C-palmitate for PET 
'=I: planar imaging 
inhibited metabolism 
l *~ ,  1231 
PET, SPECT 
inhibition of the beta-oxidation by: 
- insertion of hetero atoms, e.g. S 
- phenyl substitution 
- insertion of a methyl group in beta-position 
In H,-CWH PHlP 3-10 
strongly modified faiiy add 
(faiiy add + coordinaiion compound) 
slow metabolism ?? 
99mT~ 
SPECT 
potential Tc-labeled fatty acids 
Fig. 3. lntended development of Tc-99m-labelled fatty acid analogs; from ['231]iodine "native" fatty ac- 
ids to [-TCITC coupled "modified" fatty acids 
Preliminary results 
To become familiar with synthesis and handling of this class of high-lipophilic acids, 1 was synthesized 
as a representative of omega-mercapto substituted fatty acids and used for the preparation of "3+1" 
mked ligand complexes 2 according to Figi 4 [7]. Both species were obtained in moderate yields and 
were characterized by elemental analysis, H NMR and IR spectroscopy. LipophilicityIpH profiles (de- 
termination of PHpl= at different pH values as described in [8]) show the form expected for highiy lipo- 
philic carboxylic acids. 
COOH 
H S ~  
2 
Fig. 4. ReaGtion scheme for the synthesis of long-chain fatty acid "311 ' Re compiexes p"J. 
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38. '86''88Re Labelling of Stents for the Prevention of Restenosis 
B. Noll, H. Goerner, L. ~inckelborg', C. S. ~ilger', E. ~ichter" 
1 Research Laboratories of Schering AG, Berlin 
2~orschungszentrum Rossendorf, Institut für lonenstrahlphysik und Materiaiforschung 
lntracoronary implantations of stents allow an improved revascularization of obstructive coronary ar- 
tery disease compared to the conventional balloon angioplasty. Despite this Progress restenosis is still 
significant. The use of ionizing radiation is a promising approach to prevent restenosis after stent im- 
plantation. 
There are several approaches for delivering radioactive gamma or beta rays to decrease the prolifera- 
tion response by coronary irradiation. One way is the use of liquid filled balloons containing solutions 
with beta- and gamma-emitting radionuclides [I]. Another approach, catheder-based vascular brachy- 
therapy, uses wires or wire coils of radioactive metals, which are centred within the vessel lumen. The 
very high activity level of sources for vascular brachytherapy needed because of the short exposure 
time being available during the treatment leads to a significant radiation exposure for both the patient 
and the laboratory staff [2]. 
An attractive concept for irradiation of the vessel wall is the use of stents impianted with low activities 
of a P-emitting radioisotope to inhibit the proliferative process in arteries [3]. For this purpose, pre- 
loading of the stents with a radioisotope can be carried out, e.g. by implanting 3 2 ~ .  This, however, has 
to be done by means of accelerator facilities remote from the site of stent application. To overcome 
this and other limitations, we searched for a convenient method to label stents with the rhenium iso- 
topes lE6Re and lE8Re directly at the site of application. The labelling procedure should allow individual 
reparations with easily adjusted radiation doses as well as the preparation in a similar easy way as 
'"Tc radiopharmaceuticals are prepared in a hospital. 
Results and Discussion 
Several methods for the labelling of stents were developed in cooperation with the Research Labora- 
tories of Schering AG. Because of intellectual property reasons they are not disclosed in detail in this 
report. 
0 5 10 15 20 25 30 
time [min] 
Fig. 1. Dependence of the '*%e uptake on the labelling time 
Using this technology, the 18%e deposition on the stent surface increases with the time (Fig.1). Within 
a labelling time of ten minutes no significant rnodification of the metallic grain was observerd by e h -  
tron microscopy (500 fold scale-up). 
Furthermore, the amount of bound I8%e in dependence on the activity in the labelling solution was 
investigated. Up to 2 MBq/mg stent in the labelling solution a linear increase of I8%e uptake was ob- 
served (Fig.2). 
Labelling solution [MBqImg stent] 
Fig. 2. '%e uptake on stents in dependence on the activity of the labelling solution, 
n = number of labelled stents. 
Because of the strong linearity between the amount of activity in the labelling solution and the 18%e 
uptake on the stent we consider this as the preferred control variable in the labelling process. 
Thus, a reproducible method for labelling of stents was developed. There is, however, still an increase 
of the tenacity of the deposited radioactivity to achieve. In preliminary studies, the stability was inves- 
tigated by incubation of the labelled stents in isotonic saline solution and in human blood at 37 "C. 
Under these condiions, 1 8 6 ~ e  was released from the Stent surface. After 24 h incubation about 50 - 
60 % of the start activity remains deposited. In further experiments the stability of the deposited 18%e 
on the stent will be improved by e. g. coating the stent with an organic polymer. 
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39. Synthesis and Molecular Structure of Chloro(3-Thiapentane-1,s-Dithio1ato)- 
Oxotechnetium(V) 
B. Noll, P. ~eibnitz', H. Spies 
1 Bundesanstalt für Materialforschung und -prüfung Berlin 
Tetrachlorooxotechnetate(V) [TCOCI~]~ and the tridentate ligand HS-CH2CH2-S-CH2CH2-SH (H2S3) 
react in acetonitrile to produce the (chloro)oxotechnetium(V) complex rcO(S3)CI] according to the 
following reaction scheme: 
The new Tc complex is an analogue to the neutral Rew) complex that was described earlier [l]. The 
chlorine at the Tc core can be replaced by monodentate thiols in a subsequent step forming "3i1" 
complexes. A new precursor for the synthesis of derived mixed-ligand Tc complexes has thus become 
available. 
Synthesis: 
132 mg (CGHE,)~ASPTCOCI~] (0.2 mmol) are dissolved in 10 ml acetonitrile. 0.2 mmol 3-thiapentane-1.5- 
dithiol dissolved in 2 ml acetonitrile are slowly added to the reaction mixture while stirring and cooling 
to -20 "C under argon. The colour changes from yellowish green to dark green. After stirring for 30 min 
the completeness of the reaction is controlled by TLC (silicagel / acetone), the Rf is 0.6. After reducing 
the volume of the solution by slow evaporation in an argon stream, yellowish green prismatic crystals 
are recrystallized from acetonitrile. The yield is about 70 %. 
The complex was identified by elemental analysis, infrared spectroscopy, and X-ray crystal structure 
determination. 
Elemental analysis: (found C, 16.01 ; H, 2.72; S, 31.21, TCOC~H~S~CI requires 
C, 15.92; H, 2.67; S, 31.88 %) 
IR absorption: A,Jcm-' 956 (TcO) 
Melting point: >340 "C (decomp.) 
U 
Fig. 1. CELLGRAPH drawing of the TcOCIS3 
The structure was confirmed by X-ray crystallography. The X-ray data were collected at room tem- 
perature (296 K) with an ENRAF-NONIUS CAD 4 diffractometer, graphite monochromatized Mo K, 
radiation (A = 0.71 073 A) 
Crystal structure analysis shows the square-pyramidal arrangement, where the the tridentate H2S3 
ligand and the chloro atom form the Square. The bond lengths of Tc=O(l), Tc-0(2) and Tc-S in 
ncOCIS3] are found in the region expected. This complex can be used as a precurcor for preparation 
of a varieiy of Tc complexes by analogy with the corresponding rhenium precursor. 
[I] Fietz T., Spies H., Pietzsch H.-J. and Leibnitz P. (1995) Synthesis and molecular structure of 
chloro(3-thiapentane-l,5-diihiolato)oxotechnetium(V). 1norg.Chim.Acta 231,233-236. 
40. Synthesis and Molecular Structure of ~c(CN-CH~COOCH~)~]TCO~ 
B. Noll, P. ~eibnitz', H. Spies 
1 Bundesanstalt für Materialforschung und -prüfung Berlin 
Organornetallic hornoleptic isocyanide cornpounds of technetium are described both at c.a. and n.c.a. 
level [I, 21. They were prepared either frorn the rc(diph~sphine)~Cl~]' precursor in organic solution or 
directly by reduction of pertechnetate in the presence of isocyanides under while heating the reaction 
rnixture. 
We observed an uncornmon forrnation of a Tc(1) hexakisisonitrile cornplex [Tc(CN-CH2- 
COOCH&]Tc04 when Tc(V) gluconate in aqueous solution was heated in the presence of the isoni- 
trile ligand. The cornplex was extracted into rnethylene chloride, purified by column chrornatography 
on silica gel and crystallized frorn rnethanol. The resulting cornpound contained the pertechnetate 
anion as a counter ion. A possible explanation is that Tc(V) disproportionates to the oxidation states 
+1 and +7 when Tc(V) gluconate is attacked by the isonitrile. 
The structure was confirrned by X-ray crystallography. The X-ray data were collected at room tern- 
perature (296 K) with an ENRAF-NONIUS CAD 4 diffractorneter, graphite rnonochromatized Mo K, 
radiation (A = 0.71 073 A). Crystal structure analysis shows the syrnmetric coordination of the six car- 
bon atorns of the isonitrile ligand at the technetium central atorn. The bond length of Tc-C is found in 
the region expected (2.033 A) 131. The geornetry around the Tc central atom is octahedral. The per- 
technetate counter ion is fixed within the molecular packing of the Tc cornplex. 
Fig. 1. CELLGRAPH drawing of öle fTc(CN-CW~-CooCH&lT~~ 
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41. Crystal Structure of the Nitridorhenium(V) Complex 
[ReN{CMe2PPh Me2}(DMSMe2)d 
S. Seifert, P. ~eibnitz', H. Spies 
1 Bundesanstalt für Materialforschung und -prüfung Berlin 
The preparation and partial characterization of nitridorheniurn(V) cornplexes with DMSA and 
DMSdirnethylester as ligands were described sorne years ago [I]. By elernental analysis and NMR 
studies it was found that a phosphine rnolecule rernains in the cornplex after the ligand exchange 
reaction of ReNC12(Me2PhP)3 with the DMS ligands and that a solvent acetone reacts with the ReN 
core. However, the formulation [ReN(C(CH3)2)(PMe2Ph)(DMSMe2)2] was still rather speculative and 
had to be clarified by rnas spectrornetry and X-ray analysis. 
Mass spectrornetric analyses show that in addition to the DMS ligands and the phosphine molecule a 
cornponent with the rnass of 42 (CH3-C-CH3) is patt of the molecule ion (m/z = 795, 797). A reaction 
product with condensed acetone was not found [2,3]. 
When methylethylketone is used as solvent instead of acetone, the forrnation of a sirnilar cornplex of 
the mass m/z = 810,812 is observed. The resulting cornplex [ReN{C(CH3)(C2H5)PMe2Ph}(DMSMe2)2] 
is forrned by addition of CHS-C-C~H~ to the ReN core. Moreover, an additional cornplex 
[ReN{C(CH3)(C2H5)CH2C(0)C2H5PMe2Ph)(DMSMe2)2] of the rnass m/z = 881, 883 is found by FAB- 
MS. As deccribed for other ReN cornplexes [2, 31 this complex is forrned by acid condensation of two 
solvent rnolecules and addition of the reaction product to the ReN core. 
The X-ray analysis of the cornplex [ReN{C(CH3)2PMe2Ph)(DMSMe2)2] leads to a surprising result. 
The phosphine molecule is bound to the central C atorn of the added solvent molecule and not, as 
expected, directly to the Re atorn (Fig. 1). 
Fig. 1. X-ray crystal structure of the cornplex [ReN{C(CH3)2PMe2Ph)(DMSMe2)2] 
The resufüng chain Re=N-C-P has never been described before and shows an angle NI-C13-PI of 
99.5 ". The Re-N bond Iength of 1.697 A is in the range of a double bound nitrogen atorn. The Re-S 
distances are of the order generaliy found for these complexes. 
The exceptional configuration found by X-ray analysis can possibly be explained by the reductive 
attack of a free phosphine molecule on a solvent molecule and following forrnation of a carbonium ion 
and phsphine oxide. The resulting electrophilic agent is added onto the nitndo atom and the unusual 
Re-N-C-P configuration is formed by the nucleophilic a W k  of a second phosphine (Scheme 1). 
Scheme 1. 
CH,-C(0)-CH, 
ReNCI,(PMe,Ph), + 2 DMSMe, r ReN(C(CH,),P(Me,Ph)(DMSMe,), 
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42. Reactions of Hydroxy-Group-Containing 3+1' Mixed-Ligand Oxorhenium(V) 
Complexes. 
Part 3*. Synthesis and Physico-Chemical Investigation of 0-Organosilicon-Containing 3- 
Thih, 3-Oxa- and SMethylazapentane-l,5-Diihiolato-Oxorhenium(V) 
A. ~ablotska', I. segall, A. Kemme, E. ~ukevicsl, R. Berger, H. Spies 
1 Latvian Institute of Organic Synthesis, Riga 
To investigate the influence of substituents on the physico-chemical and biological properties a series 
of neutral oxorhenium(V) complexes 1-10 was synthesized in which the oxorhenium(V) core ~ e 0 ~  is 
coordinated with a tridentate 3-thia- [ I  ,2], 3-oxa- and 3-methylazapentane-l,5-dithiolate as well as 
with a hydroxy- or triorganylsiloxy-containing monodentate thiolate. In the synthesis of novel O- 
silylated oxorhenium complexes 6-10 silylation experiments were performed, starting from '3+1' 
mixed-ligand rhenium complexes 1-5 in which the monodentate ligand Part contains a hydroxy group. 
A ligand containing the hydroxy group was first fixed at the complex core first and then the silyl group 
was introduced by silyl halogenides in the presence of triethylamine (Scheme 1). 
The structure of the synthesized compounds was proved by the elemental analysis, 'H and 2 9 ~ i  NMR
spectroscopy. The molecular structures of complexes 5, 8 and 10 was established by X-ray analysis. 
No additional coordination of the silicon atom in organosilicon oxorhenium complexes was observed. 
But the resonance for (2-tn'methylsiloxyethanethiolato)[3-(N-methyl)azapen-tane-l,5-dithiolato]- 
oxorhenium(V) 10 is shifted strongly down-field, suggesting the deshielding anisotropic effect of 
rhenium on the silicon atom in solution. 
X-ray analysis revealed the precence of Wo crystallographic independent molecules per unit cell for 
(2-hydroxyethanethiolato)[3-(N-methyl)azapentane-1,5-dithiolato]oxorhenium(V) 5 (Fig. 1). A disorder 
of C atoms in a-position to the N atom of the tridentate ligand with its occupation factors ratio of 
approximately 2:3 was observed in one of them. 
Fig. I .  Molecular shchires of two conformers of 
(2-hydroxyethanethiolato)~3-azapentane(~I ,5-diiolato~xorhenium(V) 5 
Scherne 1 
To evaluate the difFerence between the siiylated and parent compounds, aeir lipophiticity was 
determined by a HPLC procedure (Tabk 1). The data obtained adequateiy describes (a) the effect of 
the organosilicon-substituent intraduction, (b) the sequence concerning 3-thia-, Wxa- and 3-(N- 
methy1)aza ligands, and (C) the side chain iength. For unsiiylaied complexes 1 and 3-5 log P values 
are under 1. For the siiylated ones these values vary from 2.4 to 5.4 and depend an the increase in 
the steric bulk about the s i i i in  atom. The maximal value, 5.4, was found for (3-tnphmyIsibxy- 
propanethioiato)(3-~iapentane-l,5-ditt.liolato)oxorhenium(V) 8. Log f for (3-bimethytsilox~,rry>ane- 
thiolato)(3-thiapentane-l,5-d'itt.lio-lato)oxohenium(v) 9 is about Wo times smalier (Table 1). 
For bOfh silylated and unsiiylated complexes the tendency of log P to increase from aza ta toxa and 
further to thia is consistent with the electronic effect caused by by, O and N atorns of ttie tridentate 
ligands. 
The influence of %e c a h n  chain imgth of monodentate ligands for the compiexes 3-4 and 6-7 is also 
reasonable. 
The synthesized compounds are tested in vPvo for psychotrop& actMty ~aused W~austy by the 
introduction of ttte siiyl group. 
Table 1. Lipophilicity data 
Denotation Structure PHPLC 
* Part 2 has been published in Annual Report 1997, FZR-200, pp. 116-1 17. 
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43. Artificial Guanidinium Hosts for Binding Pertechnetate 
H. Stephan, F. P. schmidtchen1, H. Spies, B. Johannsen 
1 Institut für Organische Chemie und Biochemie, Technische Universität München 
lntroduction 
Noncovalent binding of pertechnetate may be of considerable interest as a new approach to labelling 
organic compounds with technetium without any reduction step, and for removal of pertechnetate as 
an environmental contaminant. Special requirements have to be met in the first envisaged area of 
application, particulariy as specific irnaging agents, including 
high kinetic stability of the host-pertechnetate cornplex in the presence of competitiie anions such 
as chloride and bicarbonate 
adjustment of the shape, charge, redox properties and Iipophilicity of the complex 
host-guest complex rnay be conjugated to targeting molecules in order to govern the 
biodistribution. 
This objective should be realizable on the basis of modular assernbled supramolecular receptors that 
can provide multi-point fixation of pertechnetate as shown in Fig. 1. 
Thus, the receptor should have a 
framework that is cornplementary to 
the charge and topology of tetrahedral COORDINAilON pertechnetate. The receptor may be COORDlNATlON 
ditopic, with the coordination centre 1 CENTRE I CENTRE P 
designed for charge compensation and 
both coordination groups operating by 
ion-dipole binding. In the latter nexus 
hydrogen bonds are the most 
prominent and prototypical 
representatives of dipolar elernents. 
The spacer rnoiety rnakes it possible to 
adjust the stability and lipophilicity, and 
most irnportant, to introduce 
biomolecules without disturbing the 
coordination centre. 
Recently we developed ditopic 
CIuanidiniurn receptors as selective Fig. 1. Conception for the complexation of pertechnetate 
extractants for tetrahedral oxoanions 
[I]. In this paper we report the binding behaviour of guanidinium compounds towards pertechnetate. 
Liquid-liquid partition of ' ' ~ ~ 0 4  in a CHClJaqueous buffer systern was chosen to characterke the 
binding properties of various host compounds. 
Experimental 
All chernicals were reagent grade and used as obtained. Cornpound 1 was received from Fiuka, the 
bicyclic guanidinium hosts 2 - 4 were synthesized as described eariier 121 and used as chbrides. 
The extraction studies 
were perforrned at 
25t1°C in 2 rni 1: If microcentriiuge tubes by 
mechanical shaking. The 1 2 3 
phase ratio V(w):V(„ was 
1:l (0.5 rnl each); the 
shaking penod was 
30 rnin. The extraction 
equilibriurn was achieved 
during this period. All 
samples were centrifuged 4 
after extraction. The 
pertechnetate concentration in both phases was deterrnined radiornetrically using the P-radiation 
rneasurements of ''TCO~ (Arnersharn) in a liquid scintillation Counter (Tricarb 2500, Canberra- 
Packard). The aqueous solution was adjusted using 0.05 M 4-(2-hydroxyethy1)piperazine-1- 
ethanesulphonic acid (HEPES)/NaOH buffer. 
Resuits and Discussion 
Fig. 2 shows the results of pertechnetate extraction with the guanidiniurn hosts 1 - 4. It can be Seen 
that the rnost lipophilic cornpounds 3 and 4 are capable of transferring pertechnetate with high 
efficiency frorn water into trichlorornethane. The distribution ratios DTcO4 are of the Same order of 
rnaanitude as obtained for extractants that are rnainly used for pertechnetate such as 
tet~phenylarsoniurn [3 - 51, 
tetraphylphosphoniurn [6] and trioctyl- 
rnethylamrnonium chloride (Aliquat 
336) [7,8]. The extractability is 
lowered with decreasing lipophilicity of 
the guanidiniurn hosts (cf. 1 and 2), 
but even the highly hydrophilic 
derivative 1 extracts pertechnetate 
with unprecedented efficiency. This 
finding points to the reinforcernent of 
binding caused by using two hydrogen 
bonds in addition to electrostatic 
aitraction. As expected, the 
guanidiniurn hosts investigated form 
clean 1:1 cornplexes with 
pertechnetate in the organic phase [9]. 
In the presence of the cornpetitive 
anions chloride and bicarbonate the 
pertechnetate extraction decreases. 
But even at a huge excess of these 
anions pertechnetate is still extracted 
with high efficiency. Thus, rnore than 
60% of pertechnetate is transferred 
into trichlorornethane with guanidinium 
host 4 (cqorg) = 1.1 0-3 M in CHCI3) at a 
concentration ratio = 1 : 1 OOO for 
T a ,  : Cl-(Hco;). 
Fig. 2. Extraction of pertechnetate with bicyclic guanidiniurn 
compounds 1 - 4 
[rcrco,] = 1.10" M; pH = 7.4 (HEPEStNaOH buffer); [ligand] = 5.1CY4.. 
1 .1V2 M in CHCI, ; points represent the experimental data; lines correspond 
to 1 :1 complex formation. 
Summary 
Guanidiniurn hosts rnay serve to cornplex pertechnetate. Lipophilic derivatives transfer this tetrahedral 
anion frorn water to lrichlorornethane with high efficiency. A remarkable selectivity of pertechnetate 
over chloride and bicarbnate was obtained. Structural rnodifications of host rnolecules in terms of 
complex stabiiii and lipophilicity are under way. 
We conclude that suprarnolecular recepetors having at least one guanidiniurn unit are very promising 
for dir@ complexation of pertechnetate. 
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44. EXAFS Analysis of a Rhenium(1) Carbonyl Complex 
S. Seifert, J.-U. Künstler, H.  unke', A. ~oßberg', C. ~ennig', T.  eich', G. ~ernhard', B. Johannsen 
1 Institut für Radiochemie 
lntroduction 
After joint EXAFS experiments at the Hamburger Synchrotronstrahlungslabor (Hasylab) and the 
Stanford Synchrotron Radiation Laboratory (SSRL), EXAFS measurements of various rhenium 
complexes were performed, using for the first time the sophisticated Rossendorf Beamline (ROBL) 
facility at the European Synchrotron Radiation Facility (ESRF) in Grenoble. Being a collaboration 
between the Institute of Radiochemistry and the Institute of Bioinorganic and Radiopharmaceutical 
Chemistry, this analysis serves as a stepping stone towards preparing future EXAFS experiments with 
9 ?C carbonyl complexes. 
Rhenium and technetium carbonyl complexes of the general formula [M(CO),XL] (M = Re, Tc; X = Br-, 
CI'; L = bidentate thioether or Schiff base ligand) are at present under investigation for the 
development of neutral receptor-affine complexes which are able to Cross the blood-brain barrier and 
to bind to receptors of the central nervous System. Some of the rhenium cairbonyl thioether complexes 
are fully characterized by X-ray analysis and other chemical methods, the data of which may be used 
for comparison with the EXAFS results. 
Experimental 
The EXAFS spectra of the Re LI,, and Br K-edges of the Same sample were measured in transmisiion 
mode, using the Si(ll1) double-crystal monochromator in fixed-exit mode. 
The sample consists of 20 mg of the foilowing rhenium complex: F 
This complex was mixed with Teflon powder as matrii material 
and pressed into a pellet. The EXAFS spectra were evaluated, 
using the program package EXAFSPAK [I], and phases and F 
amplitudes were calculated with the scattering code FEFFG. CO CO CO 
To obtain a satisfactory fit result for the Re spectra, the individual scattering paths Re-C, Re-S, and 
Re-Br and the multiple scattering path along the carbonyl group, i.e. Re-C-0, have to be included 
(sec? Fig. 1 and Tab. 1). 
Fig. 3 .  Re LfI1 edge EXAFS spectrurn and Fourier transform of the rhenium(1) carbonyl complex 
(sotid line: expetimental data, dotted iine: fit). 
Table 1. Comparison of bond distances obtained by EXAFS measurement 
and X-ray analyses data of similar complexes (AREx~~s < 0.02 A) 




" Re(CO)3Br(CH3-S-C2H,-S-CH3GCH), [2] 
2' Re(C0)3Br(C1-C2H4-S-C,H4-S-C2H,-CI), [3] 
3' Debye Waller factors in 10.~ AZ 
4' The degeneracy of 2 was taken into account 
The EXAFS scan of the Same compound with Br as the central atom produces a more complicated 
spectrum dominated by the heaviest possible back-satterer, rhenium. Apart from the main scattering 
path Br-Re, the nearly linear multiple scattering paths Br-Re-C and Br-Re-C-0 make the main 
contributions to the radial distribution function (Fig. 2). The evaluated bond length is 2.6 A. 
Fig. 2. Br K-edge EXAFS specbum and Fourier transfom of the rhenium[l) carbonyl ~ m p l e x  
(solid line: experimental data, dotted line: fit). 
Measurements of the inner coordination spheres of rhenium carbonyl complexes with different 
dithioether ligands, using X-ray crystal-structure methods, show Re-Br distances between 2.61 and 
2.64 A [2,3]. The EXAFS-results presented are consistent with these data. 
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45. First XANES and EXAFS Measurements of Technetium Model Compounds at the 
Rossendorf Beamline ROBL 
T.  eich', H.   unke', C. ~ennig', A. ~oßberg', H.-J. Pietzsch, S. Seifert, J.-U. Künstler, G. Bernhard' 
'lnstitut für Radiochemie 
Technetium K-edge EXAFS measurements on rnodel compounds demonstrate the superb quality of 
the radiochemistry endstation of ROBL for X-ray absorption spectroscopy. 
Experimental 
The structure of novel Tc complexes has been studied successfully in the frarnework of a collaboration 
between the Institute of Radiochernistry and the Institute of Bioinorganic and Radiopharrnaceutical 
Chemistry over the last few years [I, 21. 
In order to evaluate the possibilities of the new Rossendorf Beamline (ROBL) for Tc EXAFS studies, 
we prepared four sarnples for a first experiment with 9 9 ~ c  at ROBL. The samples were 127 mM 
NaTc04(aq), 1.3 mM NaTc04(aq), KTc04(s), and TcO2mnH20(s). Except for the 1.3 mM Tc solution, 
the amount of Tc in the samples yielded an edge jurnp of -1 across the Tc K absorption edge at 21 
keV. These samples were measured in transrnission mode using the Si(ll1) double-crystal 
monochromator in fixed-exit rnode with an additional feedback System to minimize beam intensity 
fluctuations. The Tc K-edge EXAFS spectrum of the dilute solution was recorded using a four pixel Ge 
fluorescence detector. The energy scale of the XANES scans was calibrated with a Mo metal foil (Mo 
K-edge at 20004.3 eV). For the EXAFS analysis, the first inflection point of the pre-edge absorpqon 
peak for the NaTc04(aq) sarnple was defined as 21044 eV [3f. 
Results and Discussion 
Fig. 1 displays the raw Tc K-edge k3-weighted EXAFS spectrum of MaTc04(aq). The spectrum of the 
127 mM Tc solution was recorded in a single sweep up to k = 21 ,kl. Dunng this sweep the counting 
time per data point was gradually increased frorn 2 to 20 sec. To our knowledge, this is the first Tc 
EXAFS spectrum of a liquid sample where it was possible to obsewe the fine structure of the X-ray 
absorption spectrum over an energy range of 1700 eV. In addition, this spectrum is an impressive 
demonstration of the superb quality and stabil i  of all beamline components. It follows from the bect 
theoretical fit to the data (Fig. 1) that Tc is surrounded by 4 oxygen atoms (N = 4.1a.1) at a distance 
of 1.7210.01 A (C? = 0.001310.0004 A2). The EXAFS spectnim of the 100 tirnes more dilute 
NaTc04(aq) sample is also shown in Fig. 1 and represents an average of four sweeps rneasured in 
fluorescence rnode. The intensiv of the Tc Ka fluorescence line was 1.2 X 105 countslsec. The total 
Count rate processed by the fluorescence detector was 6.4 X lo5 countslsec. Under these conditions, it 
was possible to analyze the Tc K-edge k3-weighted EXAFS spectrum of the 1.3 mmol Tc coiution up to 
k = 15 A-'. The structural Parameters obtained are the same as for the TcOi ion in the concentrated 
solution, i-e., N = 3.910.2, R = 1.72I0.01 A, and C? = 0.001W.0003 A2. Our structural parameters 
agree with a previous Tc K-edge EXAFS measurement of a 0.2 M NH4Tc04(aq) sarnple 131. 
Fig. 2 displays the Tc K-edge XANES spectra of KTc04(s), and TcOpnH20(s). The energy of the m i n  
absorption edge defined by the first-derivative method increases from 21061.6 eY to 21065.8 @V as 
the Tc valence increases from IV to VI1. This energy shi i  of 4.2 eV is in qualitative agreement with 
previous measurements [3]. The shape of the Tc K-edge XANES spectra reflects the symmetry of the 
oxygen atoms surrounding Tc. The rnost distinct feature of the Tc04 ion, which has T& Jymmetry, ic 
the pre-edge peak at 21050.8 eV. The XANES features can been used as a probe to detemine the 
speciation as it has been shown, for example, in cernent waste forrnc [3]. 
In Summary, the Tc K-edge X-ray absorption measurements on Tc modei mpounds chomrd älat 
highquality data can be obtained for liquids and solkis at the new Rossend& Beamtin@. W@ csnclude 
that ROBL provides excelknt experimentai conditions to study the structure of solid and liquid TC 
compiexes with a large vanety of organic and inorganic I i n d s  covering a Tc cx+mentrati~n rang@ ~f 
at least Wo onlers of magnitude. 
Fig. 1. Raw k3-weighted Tc K-edge EXAFS spectra (left) and corresponding Fourier transforms (right) 
of experimental data (solid line) and theoretical fits (dots) for 127 mM (top) 
and 1.3 mM (bottom) NaTc04(aq). 
Energy (eV) 
Fig. 2. Raw Tc K-edge XANES spectra of Tc@nH20(s) (top) and KTc04(s) (bottom). 
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46. Challenge Experiments with "3+1" Mixed-Ligand 99mT~ Complexes and 
Glutathione: lnfluence of Structural Parameters on the Complex Stability 
A. Gupta, S. Seifert, R. Syhre, B. Johannsen 
lntroduction 
"3+lW rnixed-ligand ""'TC cornplexes, containing a tridentate ligand and a rnonodentate ligand, are of 
particular interest in the developrnent of new technetiurn-99m radiopharrnaceuticals. An important 
point is the stability of these cornplexes in the various biologically relevant fluids. The "3+11' rnixed- 
ligand ""'TC cornplexes proved to be stable in saline, phosphate buffer of pH = 7.4 and in plasrna. 
In blood, however, the cornplexes are converted. The assurnption of a ligand exchange in terrns of 
replacernent of the rnonodentate ligand by GSH is quite reasonable as recently shown by us and 
others [I ,2,3]. 
In fact, there is a high concentration of glutathione (GSH) in the erythrocytes (approx. 2 rnM) compa- 
red with plasrna (approx. 10 FM), and in other cases GSH was even considered a converting agent 14, 
51. 
~ h a l l e n ~ e  experirnents are a useful tool for estimating the stability of cornplex compounds to tran- 
schelation processes [6]. Systernatic studies with GSH as a challenger were therefore carried out with 
a nurnber of "3+1" rnixed-ligand 9 9 m ~ ~  cornplexes of the general forrnula [ 9 9 m ~ c ~ ( ~ ~ ~ ) ( ~ ~ ) ]  (E 
= S, NMe). To investigate the influence of the structure of the tridentate as well as the rnonodentate 
ligands on the stability the following complexes were used. 
Table 1. General forrnula and nurnbering scherne of the "3+1" mixed-ligand 99m~c cornplexes 
General formula R-SH E = S  E=NMe 
1 a 1b 
Experimental 
Pre~aration of  com~lexes 
The 99m~c complexes were prepared by direct reduction of pertechnetate with stannous chloride in an 
optimized mixture of various amounts of the ligands and propylene glycol according to Seifert et al. [7, 
81. 
Approx, 150 - 200 MBq of the -TC pertechnetate eluate were added to 1 ml propylene glycol and 
filled up to 2 ml with a solution of 0.9 % sodium chloride. After mixing approx. 40 pg of the tridentate 
ligand (diluted in acetone or methanol), 0.5 mg of the monodentate ligand (diluted in 100 pI H20), 100 
MI 0.1 N NaOH and 20 PI stannous chloride solution (1 -0 - 2.0 mg SnCI2 dissolved in 5 ml 0.1 N HCI) 
were added and the reaction mixture was heated at 50 "C for 20 minutes. 
The complexes were purified by HPLC with a semipreparative PRP-1 column (Hamilton, 305 X 7 rnm, 
10 Pm, fiow rate 2.0 mWmin) using a linear gradient system (@nin]PhB): (5130),(10180), (10180) of H20 
0.1 % trifiuoroacetic acid (A) and acetonitrik? 0.1 % trifluoroacetic acid (B). The effluent from the co- 
lumn was monitored by y-detection and UV detection. After adding 200 p1 propylene glycol and remo- 
ving acetonitrik by vacuum evaporation, the separated neutralized complex fraction was stable for 
more than 8 h. 
Challenge experimnis 
For the challenge experimenl about 1 MBq of the HPLC-purified -TC complexes was diluted in 
0.1 M phosphate buffer (pH = 7.4 20 % propylene glycol) containing 1 mM or 10 PM solution of GSH 
to a final volume of 200 pl- The reaction mixture was incubated at 37 "C in a thermoshaker. After va- 
rious krngths of time the reaction products were analysed by HPLC. 
HPLC analyces 
HPLC ainaiyses were carried out with a PRP-3 column (Hamitton, 150 X 4 mm,lO Pm, fiow rate 1.0 
mtlmin) using a linear gradient System (t[minY%B): (5/0),(5/70), ( 1 0 4  of 10 mM phosphate buffer of 
pH = 7.4 (A) and acetonitnk (B). The effluent from the column was monitored by ydetection. 
Resuits and Discussion 
lnfluence of the nature of tridentate ligands 
Remarkable differences are observed between the complexes containing the tridentate ligand with E = 
S and the complexes containing the tridentate ligand with E = NMe. In all investigated cases the 
SNMeS complexes are much more stable to transchelation with glutathione than SSS complexes. 
Most of the so-called SSS complexes are so fast converted with GSH concentrations of 1 mM that the 
time course of conversion could not be followed and only the transchelation product is found after 1 - 2 
minutes. To compare the influence of the monodentate ligands we later studied these complexes with 
GSH concentrations of only 10 FM. 
Fig. 1. Time course of the conversion of the '%In mixed-ligand 9 9 m ~ ~  complexes l a l l  b and 2a/2b 
in the glutathione challenge 
2. lnfluence of the nature of monodentate ligands 
Variation of the monodentate ligand does not remarkabiy aiter the different kinetics of complexes with 
the E = S tridentate ligand versus E = NMe. When we compared the complexes with constant triden- 
tate ligand and varying monodentate Iigands for both types (E = S and E = NMe), we obssrved ex- 
actly the same tendency. The complexes with the monodentate ligand 2 and with the monodentate 
ligand 1 have almost the Same relatively high stability. The most stable of all investigated complexes 
was that with the monodentate ligand 7. All the other complexes are converted faster into the tran- 
schelation product. All these complexes have a nitrogen atom in the side chain of the monodentate 
ligand. This nitrogen atom is therefore assumed to have a destabilising effect. This effect was investi- 
gated by varying the spacer betvveen the nitrogen atom and the coordinated sulphur atom as well as 
the ability of this nitrogen to be protonated. 
For the complexes with the E = NMe tridentate ligand the challenge experiment was perforrned with 
an initial GSH concentration of 1 mM. After 120 min the GSH concentratiin in the reaction mixktre 
was still 0.85 mM + 0.04 and so that the GSH concentration was considered to be almost constant. 
The time course of the converting reaction therefore fits the equation for a pseudo first order reaction 
and the parameter k thus obtained is a direct measure of the stabiiii of the complex to ~nvers ion 
with GSH. 
For the complexes with the E = S tridentate ligand the challenge experiment was performed wjth an 
initial GSH concentration of 10 FM. In this case the time course of the converting reaction bk?cot'Ws a 
plateau. The reason for this behaviour seems to be the parallel autoxidaiion of the GStl so that *e 
GSH content during the challenge experiment cannot be considered to be constant for low GStl con- 
centrations. Unfortunateiy, we were not in a positiin to measure the glutattiine in Zhi chatlenw eX- 
periment because the detection iimit of the test System used was 25 PM. For these cornpk?xes the 
following equation was used to fit the time Courses (parameter not shown): 
GSH-Challenge of complexes with E= 
1107 
i 
0 20 40 80 80 1M) 120 140 160 180 
rnhutes after incubatii 
Fig. 2. Time Course of the conversion of the "3+ln mixed- ligand ""'TC complexes with E = NMe 
in the glutathione challenge with 1 mM GSH 
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Fig. 3. Time cource of the conversion of the 3+ln mixed-ligand *TC complexes with E = S 
in the glutaütione chaflenge with 10 FM GSH 
3. lnfluence of the nitrogen atom of the monodentate ligand 
4 , . , . , . , . , . , . , .  
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rninutes aiter incubation 
Fig. 4. Time Course of the conversion of the "311" mixed-ligand ""'TC complexes with E = NMe 
in the glutathione challenge with 1 mM GSH 
Interestingly, the compounds with the monodentate ligands 8b und 3b are converted the fastest. The- 
se compounds both have an ethylene spacer between the nitrogen atom and the coordinated sulphur 
atom. In Fig. 4 it is shown that the stability to GSH conversion increases with increasing spacer length 
between the technetium core and the nitrogen atom. But even with f i e  spacer carbon atoms the sta- 
bility of the complexes containing nitrogen in the monodentate lgand does not reach the stability of 
the complexes containing the monodentate ligands land 2. An exception in this range is compound 
4b where the nitrogen atom is an element of a morpholine ring system. This cornpound also has the 
ethylene spacer but it shows the same stability as the compounds lob, 11 b and 5b. fhis is not surpri- 
sing when the destabilizing effect of the nitrogen is explained by an electron- withdrawing(4) effect of 
the protonated nitrogen that weakens the metal-sulphur bond of the complex. Becauce all cornpounds 
except compound 4b have a pKa between 8.5 and 9.55 191, the nitrogen of those compounds should 
be protonated under our working conditions of pH = 7.4. Compound 4b has a pka of about 7.1, which 
means that the oxygen of the morpholine ring weakens the base strength of the nitrogen atorn and 
increases in this way the stability of the metal-sulphur bond compared to complexes 8b and 3b. 
The stabiliiy tendencies found can be summed up as follows: 
Complexes with the E = NMe tridentate ligand are much more stable than those with ffie E=S triden- 
tate ligand. 
A nitrogen atom in the monodentate ligand has a destabilizing effect, which can be explained by an 
-I-effect of the nitrogen on the complex core. 
Compounds with an ethylene spacer between the nitrogen atom and the coordinated sulphur atom are 
the fastest converted compounds. 
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47. ldentification of the Transchelation Product of "3+IcG Mixed-Ligand Technetium and 
Rhenium Complexes with Glutathione 
A. Gupta, S. Seifert, R. Syhre, B. Johannsen 
lntroduction 
The "3+ln mixed -1igand 9 9 " ~ c  complexes, developed for radiopharmaceutical application and proved 
to be stable in saline, phosphate buffer of pH 7.4 and in plasma, are shown to be subject to conversi- 
on with GSH into a more hydrophilic metabolite [3]. GSH, the most abundant sulphydryl compound in 
tissues, is present in almost all anirnal cells investigated in relaüvely high concentrations (0.5 mM to 
12 mM). It is quite reasonable to assume that the "3+1" mixed-ligand 99m~c complexes react with GSH 
in viv0 and in vitro forming the complex shown in Fig. 1 131. For some complexes this reaction has 
been proven [6,7]. 
To further support this explanation "3+lU mixed-ligand rhenium complexes as weil as the g 9 m ~ ~  com- 
plexes with varied tridentate ligands and GSH for a monodentate ligand were synthesized and compa- 
red with the product resulting from GSH challenge experiments. 
C O N H  - C H 2  COOH 
/NH2 
NH C O  GH, - CH,- H 
'COOH 
Fig. 1. General forrnula of the supposed transchelation product of the "3-i-1" mixed-ligand technetiurn 
or rhenium complexes (E = S or E = NMe) W'& glutathione 
Experimental 
Preparation of  [ßeO(SSS)(glutathione)] 
An equimolar amount of glutathione (50.9 mg, 0.166 mmol) diluted with acetonitriVwater (50150) and 
0.166 mmol tnethylamine (21 PI) were added to a stirred and refluxed solution of chioro(3-thiapentane- 
1,5dithiolato)oxorhenium(V) (65 mg, 0.166 mmot) in acetonitrile (10 rnlf[4]. Afier a period af 60 minu- 
tes the reaction rnixture was evaporated to dryness. The residue was again dissoivsrd in a mixture of 
acetonitrilelwater (50150) and the soluble Part separated from the insoluble residue. Then the coiuti- 
on was again evaporated to dryness and the residue washed with methanol. The residue was again 
dissolved in a mixture of acetonitrile I water and a soiid reddish brown powder was fo& by addition 
of diethyl ether. 
Preparation o f  [ReO(SNMeS)(glutaffiione)] 
The complex was prepared by ligand exchange, stariing from ä.ie gloconate precutsor ( 0.125 mmol) 
151 by adding a foutfoid molar excess of glutathione (150 rng, 0.5 mmdf dissohred in water. After the 
solution had tumed from blue to red the tridentate iigand dicsohred in water was adaeb in a molar 
ratio of 1:l (30.1 mg). After a period of 120 minutes the reaction mixtur@ was evaporated to daynecc. 
The residue was diccoived in water and punfied by liquid chromatqraphy over silica gel with a tnixtu- 
re of methanoVwater (80MO). The green fracüon was wllected and again evaporated ta dryness. T0 
compktefy remove the glutathione excess the residue was again dissofved in w te r  and punfied W 
HP= (semipreparative PRP-1 column, Iiamiiton, 305 X 7 mm, 10 Pm, flaw rate 2.0 mVmin u s i q  a 
iinear gradient System (@ninI/%B): f5/20),(f WW), (lW80) of EI& 0.1 % trifluosoacetic acid (A) and 
acetonitrile 0.1 % triRuoroacetic acid (B)). After purification the compiex was preipitated aS a grwn 
solid by siow evaporation of the mixture of methanMCliethykttter. 
Preparation of [ReO(SSS)(glutathione)] by GSH challenge of [ReO(SSS)(S-CH2CH2-N(CH&)] 
100 rng of glutathione were added to 13 rng of (0.026 rnrnol) [ReO(SSS)(S-CH2CH2-N(CH3)2)] dissol- 
ved in water. After cornplete ligand exchange the glutathione excess was rernoved by HPLC as de- 
scribed above. After evaporation of the solvent the residue was dissolved in a rnixture of acetonitri- 
lelwater and a solid reddish brown powder was forrned by addition of diethyl ether. 
Preparation of the n.c.a. complex [TcO(SSS)(Glutathione)] 
The 99m~c cornplexes were prepared by direct reduction of pertechnetate with stannous chloride in an 
optirnized rnixture of arnounts of the ligands and propylene glycol according to Seifert et al. [I, 23. 
Approx. 150 - 200 MBq of the 99m~c pertechnetate eluate were added to 1 rnl propylene glycol and 
filled up to 2 rnl with a solution of 0.9 % sodiurn chloride. After mixing approx.40 pg of the tridentate 
Iigand diluted in acetone, 0.5 rng of glutathione (diluted in 100 pI H20), 100 p1 0.1 N NaOH and 20 pl 
stannous chloride solution (1.0 - 2.0 rng SnC12 dissolved in 5 rnlO.l N HCI) were added and the reac- 
tion rnixture was heated at 50 "C for 20 rninutes. 
The cornplex were purified by HPLC as described above. 
HPLC analysis of the Tc and Re complexes 
HPLC analyses were carried out with a PRP-3 colurnn (Harnilton, 150 X 4 rnrn, 10 prn, flow rate 1.0 
rnürnin) using a linear gradient systern (t[rninyO/oB): (510),(5/70), (1Oli0) of 10 rnM phosphate buffer of 
pH = 7.4 (A) and acetonitrile (B). The effluent frorn the colurnn was rnonitored by y-detection. 
lnfrared spectroscopy of the Re complexes 
The cornplexes were cornpressed into KBr pellets and rneasured on a GARL ZElSS JENA infrared 
spectrometer against air. 
Capillary electrophoresis and UV spectroscopy of the Re complexes 
Capillary electrophoresis was petforrned using a HEWLETT PACKARD device equipped with a diode 
array UV detection systern. The analysis was perforrned with a non-coated silica capillary (24.5 crn, ID 
50 prn) in borate buffer (50 rnM, pH 9.3). 
' H  NMR 
The cornplexes were recorded in DMSO-d6 on an INOVA 400 spectrorneter. 
Fast atom bombardment mass spectrometry 
FAB+ rnass spectra of the Re cornplexes were recorded with a MAT 95 spectrorneter (Finnigan) by 
rnixing 1 pI sarnple solution with 5 p1 glycerol and bornbarding it with caesiurn atorns of low energy of 
about 150 eV at roorn ternperature. 
Results and Discussion 
The data in Table 1 show that the supposed challenge products with glutathione are available by a 
standard synthesis procedure for "3+lU rnixed-ligand rheniurn cornplexes. As shown for the SSS corn- 
plex, the cornplex corresponds to the cornplex resulting frorn the glutathione challenge of other "3+lK 
rheniurn cornplexes in terms of congnient UV, IR and NMR spectra. 
The "%IK 99"Tc cornplex with GSH was also obtained by the standard n.c.a. synthesis procedure and 
was shown to have the sarne retention time in the HPLC analysis as the above-characterized rheniurn 
cornplex as weil as the product resuiting frorn challenge experiments and the rnetaboiite resulting frorn 
in vitro incubation of "3+lK ""'TC rnixed-ligand cornplexes with whole blood. Furtherrnore, the ligand- 
exchange reactron leading to the GSH cornplex proved to be reversibk. lt was shown that after corn- 
plete tumover of the parent cornpound into the challenge product it was possible to reconstitute the 
parent cornpound by an excecs of the original monodentate ligand. 
Table 1. Chemical data of the "3+lK mixed-ligand rhenium com~lexes containing glutathione as 
- 
monodentate ligand 
I Re(SSS)(GSH) synthesis Re(SSS)(GSH) challenge Re(SNMeS)(GSH) synthesis 
Rf = 4.67min I Rf = 4.61 min I 
I HPCE: Rf = 11.9min I % = 12.3min I 
MS: 
659(48), 660(5), 661 (1 00)M+1, -------- ( 
662(1 0),663(11) I 
found: found: 
C,23.9 H,3.8 N,5.8 S,16.9 C,23.9 H,3.5 N4.5 S,13.7 
I I 
red powder red powder I 
found: 
C,26.4 H4.5 N,7.6 S,13.2 
Cl5H2,O7ReS3N&?H2O requires: 
C,26.0 H,4.36 N,8.0 S,13.8 
green powder 
vma~cm" (KBr): 
952.4(Re=O), 1526.9 (CO-NH), 
1650 (CO-NH), 1729.2(COOH), 
3247.4(NH), 3391.7 (OH) 
IR: 
v,~cm" (KB~): 




'H NMR in DMSO-DG [8]: 
signals of tridentate: 
2.25(2H), 3.02(2H),4.05(2H), 
4.29(2H) 
signals of monodentate: 
1.8011.89 (2H), 2.31 (2H) 
3.68(4H), 4.54(1 H) 8.34(1 H), 
v,,Jcm-' (KB~): 




signals of tridentate: 
2.23(2H), 3.02(2H),4.M(2H), 
4.29(2H) 
signals of monodentate: 
1.95(2H), 2.32(2H), 3,73(4H), 
4.59(1 H) 8.34(2H), 
signals of tndentate: 
2.59(2H), 3.53(2H),3.18(xH), 
3.24(CH3) 
signafs of rnonodentate: 
1.82,l .W (2H), 2.29(2H), 
3.67(4H), 4.51 (1 W), 8.31 (IH), 
8.4611 H) 
For solubility or synthetic reasons the complexes contain eittier 2 rnok waer or triituoroacetic acid aS 
shown by 'H , ' 3 ~  and "F NMR. 
The Wluoroacetic acid resuits from HPLC purification. 
The resultc show that the reaction of the 3 1 '  mixed-I'ind rfienium compiexes wjth GSH as well aS 
direct synthesis lead to a "3+1" rnixed-Kind rhenium complex with GSH as a monodentate ligand. 
$e formation of a metabolite of the Same sbucture can heretore be assumed for 5 1 '  mixed-ligand 
Tc compiexes in viv0 as weil as in challenge experirnents witb GSH. 
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48. Stability of "3+1" Mixed-Ligand 9 9 m ~ ~  Complexes In Vitro: Inhibition of the GSH in 
the Blood Results in a Stabilization of the Complexes In Vitro 
A. Gupta, S. Seifert, R. Syhre, B. Johannsen 
lntroduction 
When the "3+lW mixed-ligand 99"~c  ornplexes are incubated in blood, they are converted into hydro- 
philic products. If the tridentate ligand is SNMeS, oniy one product occurs, but with SSS as the tri- 
dentate ligand two products are found. Glutathione (GSH) is responsible for this conversion [I]. In 
challenge experiments of the "3+lU rnixed-ligand 9 9 m ~ ~  complexes against GSH, a relationship bet- 
ween the complex stability and the structure of the tridentate or rnonodentate ligand is elucidated. The 
supposed challenge products were synthesized with Re and chemicaliy characterized (see previous 
reports). 
Here we report on the incubation studies performed to elucidate the influence of the structure of the 
monodentate ligand on the in vitro stability of the complexes. Further we give a detailed description of 
the inhibition experirnents performed to support the GSH hypothesis. 
Table 1. General formula and numbering scherne of the "3+1" mixed-ligand m ~ c  omplexes 
I General formula R-SH I I I 
Experimental 
Preparation of complexes 
The ""'TC complexes were prepared by direct reduction of pertechnetate with stannous chloride in an 
optimized mixture of ligand amounts and propylene glycol according to Seifert et al. [2,3]. 
Approx. 150 - 200 MBq of [99m~c]pertechnetate w re added to 1 ml propylene glycol and filled up to 2 
ml with a solution of 0.9 % sodium chloride. After mixing approx.40 pg of the tridentate ligand (diluted 
with acetone or methanol), 0.5 mg of the rnonodentate ligand (diluted with 100 p1 H20), 100 pI 0.1 N 
NaOH and 20 pI stannous chloride solution (1.0 - 2.0 mg SnCI2 dissolved in 5 rnl 0.1 N HCI) were 
added and the reaction mixture was heated at 50 "C for 20 minutes. 
The complexes were purified by HPLC with a semi-preparative PRP-1 column (Hamilton, 305 X 7 
mm,lO pm, flow rate 2.0 ml/min), using a linear gradient system (t[minyO/aB): (5/30),(10180), (10180) of 
H20 0.1 % trifluoroacetic acid (A) and acetonitrile 0.1 % trifluoroacetic acid (B). The effluent from the 
column was monitored by ydetection and UV detection. After adding 200 pl propylene glycol and re- 
moving acetonitrile by vacuum evaporation, the separated neutralized complex fraction was stable for 
more than 8h. 
GSH inhibition 
For GSH-depletion experiments the whole blood was incubated with 2 % diethylmaleate (DEM) for 1 h 
before the complex was added [4, 51. After that time it was shown that the GSH content of the blood 
had decreased under the detection limit. 
GSH determination 
The GSH determination in whole blood was performed according to the procedure of Coutelle et al.[6, 
7, 81.50 pI of blood were haemolysed by addition of 100 p1 of water and deproteinized by further addi- 
tion of 50 pI metaphosphoric acid. After centrifugation for 5 min (10000g) the supernatant solution 
(125 pI) was diluted with 375 pI of buffer (phosphate buffer 0.05 M, EDTA 0.005 M pH = 7.4). This 
solution was analysed for GSH and GSSG, using the DTNB-GSSG reductase recycling procedure 
first reported by Owens and Belcher [9] and later modified by Tietze [I01 and Griffith [ I  I]. 
In vitro studies 
About 5 - 7 MBq of the ""'TC complexes in 0.1 M phosphate buffer pH = 7.4 / 20 % propylene glycol 
were incubated in 500 pI of whole blood or plasma at 37 "C. After the incubation time the blood is 
centrifuged and the supernatant plasma was analysed by HPLC. 
HPLC analyses 
HPLC analyses were carried out with a PRP-3 column (Hamilton, 150 X 4 mm, 10 Fm, flow rate 1.0 
ml/min) using a linear gradient system (t[miny%B): (5/0),(5/70), (10/70) of lOmM phosphate buffer of 
pH = 7.4 (A) and acetonitrile (B). The effluent from the colurnn was monitored by ydetection. 
Results and Discussion 
In vifro stabil@ of the complexes in blood 
For all complexes with the E = S tridentate ligand, no parent compound was detectable in the plasma 
part of whole blood after 1 - 2 minutes. It was therefore not possible to 0bse~e  diierences between 
the used monodentate ligands for this class of complexes. On the other hand these complexes as well 
as their metabolites show a tendency to label protein components of the plasma so that more than 
one metabolite peak occurs in the chrornatogram. Generally about 40 - 50 % of the acüvii in the 
blood sample are found in the plasma fraction. 
By contrast incubation in the blood of complexes with the E = NMe tridendate Iigand results in only 
one conversion product with the same retention time as the challenge product. The conversion is also 
much slower than that of complexes with the E = S tridentate ligand, so that it was possible to observe 
the time course for these complexes. 
Concerning the infiuence of the monodentate ligand on the stabiiii of the complexe in vitro incubation 
in whoie btood shows a similar tendency as the GSH challenge assays (see previous reports). That 
means that compiexes with nitrogen in the side chain of the monodentate ligand are less stable than 
those with an aromatic or aliphatic monodentate ligand (1 b, 2b). In the challenge experirnents as also 
in vitru the complex W'& dimethykystamine as a monodentate ligand is the compound that is conver- 
ted the fastest. There are rninor differentes in the time courses of the compiexes ob, 4b and 5b com- 
pared with the challenge experiments. As reasons for these differences in the whole blood, interaction 
with proteins and the various modes of transport of the complexes and their conversion products 
through the membrane of the erythrocytes may be assumed. 
I 
minuies after incubtion i 
I 
Fig. 1. Portion of parent complex of Tc species in plasma 
at various incubation time 
Depletion o f  GSH in whole the blood 
For the complexes 5a and 4b it could be shown that the depletion of GSH with DEM in the whole 
blood leads to a stabilization of the complex against conversion in the blood (Fig. 2). For control a 
blood sample was preincubated at room temperature without diethylmaleate (DEM) for the Same pe- 
riod of time as the sample with DEM. After preincubation the 9 9 m ~ ~  "3+1"complex was added. It was 
shown that after standing for about 4 h at 25 "C the GSH concentration in the blood was still 1.0 mM, 
whereas after 4 h incubation with DEM no GSH was detectable. In another control experiment it was 
* 
also shown that there is no reaction between our complexes and DEM (Fig. 2B). In Fig. 2D it is shown 
that in the whole rat blood preincubated for 4 h at 25 OC without DEM the complex 4b is converted into 
one more hydrophilic metabolite while no conversion occurs in the blood sampie preincubated for the 
Same period of time with DEM (Fig. 2C). 
Fig 2. HPLC Patterns of compound 4b. A. parent cornpound, B. after Wminutes incubation in rat 
plasma containing 2 % DEM, C. plasma part of Mole blood after 30 minutes incubation in thtfie 
whoie blood containing 2 % DEM, D. plasma pari of whole bfood affer 30 minlttes incubation 
in the whole blood. 
These results support the assumption that GSH is the converting agent in whole blood and is respon- 
sible for the instability of the "3+lU mixed-ligand complexes in vitro. The principle of the in vitro conver- 
sion seems to be similar to that of the GSH challenge experiments. 
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49. Reactivity of "3+1" 99mTc Compiexes to Proteins 
S. Seifert, A. Gupta, R. Syhre 
Introduction 
Mixed-ligand 3+1 complexes containing a tridentate dithiol and a monothiol exhibit reacüvity towards 
thiols. Ligand exchange with glutathione (GSH) is considered to be the main reason for the observed 
instability of the cornplexes in blood [I, 21. In vitro and in vivo studies of 3+1 %TC complexes have 
shown that structural difierences of the tridentate ligand as well as the rnonothiolato ligand influence 
the stability of these complexes in the blood and in the plasma. It was found that complexes with an 
S(NR)S configuration (R = Me, Et, Pr) of the tridentate ligand are much more stable than complexes 
with an SSS moiety [3]. Moreover, the stabil i  of the complexes decreases when the monodentate 
ligand contains an amino nitrogen in its side chain. Another important parameter for the stabil@ of 
these complexes with nitrogen in the side chain of the monothiolato ligand is the number of C atoms 
between the SH group and the nitrogen atom [4]. On the basis of systematic stability studies per- 
formed with a nurnber of 3+1 complexes possibilities of labelling SH-containing components of the 
blood with 9 9 m ~ ~  were investigated. 
Experimental 
Preparation of complexes. The %TC complexes were prepared by direct reduction of pertechnetate 
with stannous chloride in an optimized mixture of ligand amounts and propylene giycol (PG) and puri- 
fied by HPLC 1561. 
HPLC anabes. HPLC analyses were carried out with a PRP-3 column (Harniiton, 150 X 4 mm, 10 
pm, flow rate 1.0 mllmin) using a linear gradient System [t(min)l%B]: (5/0), (10/70), (5170) of 10 mM 
phosphate buffer (PBS) of pH 7.4 (A) and acetonitrile (B). For plasma and blood analyses a Supel- 
guard column (20 X 4.6 rnm, 10 pm, flow rate 1.0 rnVmin) was used with a linear gradient of 95 % A to 
40 % A in 15 min [A: isopropanoV0.1 % TFA (1 OIgO), B: isopropanoV0.1 % TFA (90/10)]. 
In vitro studies. HPLG-purified 9 9 m ~ ~  complexes were dicsolved in 0.1 M PBS of pH 7.4 containing 15 
% PG. In vitro incubation at 37" C was carried out in a thermoshaker for various lengths of time. 500pI 
samples of 0.1 M PBS, pH 7.4 containing the g S m ~ ~  complex and 2 - 3 mg rat or human albumin or 
globulin were used. For incubation in rat or human plasma, 50 - 100 pI of the OOmrc compiex solution 
(5 - 10 MBq) were added to a suspension of pre-washed erythrocytes as well as to heparinized whole 
blood. The reactions were stopped in an ice bath and the reaction products anaiysed by HPLC. 
Results and Discussion 
For all tested complexes a correlation was visible between the stabiiii to GSH and the in stal3ility 
in plasrna and blood. All complexes shown in Fig. 1 are unstable in the whoie b W  of rats and hu* 
mans. 
R-S E = S  E=N-Me 
In accordance with their high glutathione content, these solutions undergo, at various rates, a ligand- 
exchange reaction with GSH to yield the [ 9 9 m ~ ~ ~ ( ~ ~ ~ / ~ ~ ) ]  complex. While most of the investigated 
complexes are stable in plasma, the complexes 4a and 5a are converted. 
The following HPLC analyses were perFormed with a Supelguard column, which is recommended for 
the separation of proteins. The retention times of the ""'TC complexes 1 - 5 are shorter than those of 
the reaction products with plasma and blood proteins, which are eluted at the same times as the main 
components of the plasma (albumin and globulin) and blood (Rt values between 8 and 13 minutes). 
lncubation with plasma, albumin and globulin: 
The more stable complexes 1 - 3,4b and 5b do not undergo further reaction with plasma components 
(Fig. 2). However, complexes 4a and 5a react with albumin and one of the globulin fractions of the 
plasma (Fig. 3). It is remarkable that other plasma proteins eluted at 10 and 11 minutes are not la- 
belled. 
UV detection ydetection 
/ 
0 2 4 6 8 10 12 14 
Time (min) 
0 2 4 6 8 10 12 14 
T i  (mm) 
Rat albumin Complex 26 in rat albumin 
Fig. 2. HPLC patterns of the incubation of complex 2b with a 3 % rat albumin solution 
UV detection ydetection 
4a 
I 8  I d  
0 2 4 6 8 10 12 14 16 0 2 4 6 8 70 12 14 16 6 ' 2 ' 4 ' 6  8 10 12 14 16 
Tano (mmf T i  (lrin) Tme (mm) 
Rat plasma Complex [2a+GSH] in rat plasma Complex 4a in rat plasma 
Fig. 3. HPLC analyses of incubation samples of the complexes 4a and 5a with rat plasma. Complex 
5a was prepared in a challenge experiment of 2a with GSH; incubation time 30 minutes. 
The reaction is reversible. Adding an excess of another monothiol R-SH to the plasma solution results 
in the formation of the 3+1 complex with this monothiol (Ag. 4). The final product is eluted in the same 
retention time of 5.5 min as the complementary rhenium complex [ReO(SSS/RS)]. 
0 2 4 6 8 1 0 1 2 1 4  
Tm* (mn) 
5 min &er adding of R-SH 
Complex 4a 
- in rat plasma C / (>ks" 'u  / \s + .'-.H 
W 
R S H  crCO(SSs/R-S)] 
Fig. 4. Reaction of labelled albumin and globulin fractions with the monothiol R-SH yielding the 3+1 
complex [ g g m ~ c ~ ( ~ ~ ~ / ~ ~ ) ]  
The Same reversibility was found for the ligand-exchange reaction with GSH (Scheme 1). The original 
3+1 complex reacts with an excess of GSH to yield the 3+1 TcO(SES1GS) complex. The reaction 
product can be re-converted by adding a higher excess of the original mercaptide ligand F]. An equi- 
librium reaction obviously exists, depending on the concentration of monodentate ligand in the reac- 
tion solution. 
Scheme I. 
E = S,  N(CH3) 
M = Tc,  R e  
GSH 
The example shows that SH-containing Peptides are also able to substitute the mercaptide ligand in 
the 3+1 complex. 
Albumin from bovine Serum was also successfully labelled in this way. The labelling W.& complex 4a 
failed when rat plasma was inhibited by adding diethylmaleate (DEM) to the incubation solution. 
It is concluded that the unstable 3+1 complexes 4a and 5a can also form 3+1 complexes with proteins 
such as albumin or globulin. The proteins containing at least one free SH-group react as monodentate 
thiol ligands, substituting the dimethylcysteamine or glutathione ligand in the original complexes. 
lncubation with rat blood 
The incubation of complex 2b with the whole blood of rats results in the labelling of an unknown com- 
ponent of the blood which is eluted in HPLC after 10.4 minutes (Fig. 5). After centnkigation most of 
the radioactivity remains in the erythrocytes as an unchanged complex 2b [8]. 
Fig. 5. Reactions of the complexes 2a and 2b W*& rat b M  and pre-washed etythrocytes. 
A 2b in rat blood (supematant), f): 2a in a sucpension bf etytbrocytes, 
C: 2a in rat blood (supematant); 30 min incubation time 
The presence of the free cornplex 2b in the incubation solution, which is eluted after 2.5 minutes, con- 
firrns the higher stability of that type of complex. Only traces of the metabolization product 
[ 9 9 m ~ c ~ ( ~ ~ ~ e ~ / ~ ~ ) ]  (Sb) ar  found (R, = 0.7 rnin). It seerns that primarily the [ 9 9 m ~ c ~ ( ~ ~ ~ e ~ / ~ ~ ) ]  
cornplex is forrned, which immediately undergoes a ligand-exchange reaction with one of the compo- 
nents of the blood (Rt = 10.4 min) in a secondary step. The alburnin and globulin fractions as well as a 
third component (R, = 9.4 rnin) are not labelled. Complex 2a, however, reacts with alburnin and globu- 
lin after rnetabolization by GSH. 
When cornplex 2a is incubated with a suspension of pre-washed red blood cells, the Same component 
is labelled as in the whole blood. No free complex 2a is found in this solution. It is obviously com- 
pletely converted into complex 5a, which reacts with the unknown cornponent. As observed for com- 
plex 2b in the whole blood, the cornponent with Rt = 9.4 min is not labelled. 
In both cases the incubation solutions are red. Perhaps a protein released by haemolysis is labelled 
and serves as the rnonodentate ligand in the 3+1 complex formed. 
Conclusions 
Sorne of our 3+1 99m~c  cornplexes can react with the plasrna and blood proteins which replace the 
rnonodentate ligand in the cornplexes. 
The reversibiliiy of the reaction confirms that only the monothiol ligand is exchanged. 
All investigated 3+1 cornplexes are metabolized in the whole blood in vifro and in viv0 into GSH- 
containing complexes which are able to label a protein component of the blood. 
While the [ 9 9 m ~ c O ( ~ ~ ~ e ~ / ~ ~ ) ]  cornplex is stable in rat and human plasrna, the rnore unstable 
[ 9 9 m ~ c O ( ~ ~ ~ / ~ ~ ) ]  complex 5a as well as the [ 9 9 m T ~ O ( S S ~ / ~ ~ ~ ~ ) ]  cornplex 4a react with alburnin 
and globulin. 
The usefulness of this new labelling procedure for proteins and peptides should be exarnined. 
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50. An Effective Pre-Labelling Method for Amino Acids with Activated 
99mT~-MAG3 in Aqueous Solution 
T. Knieß, St. Noll, B. Noll, H. Spies 
lntroduction 
Mercaptoacetyltriglycine (MAG3) as an excellent 9 9 m ~ ~  chelator has suitable properties for being used 
as a bifunctional chelating agent (BFCA) since its carboxylic group is not necessary for complexation 
and is therefore available for coupling with biomolecules. Some time ago we described a new pre- 
labelling method for coupling Re- and Tc-MAG3 complexes to amines and nucleobases using O- 
(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium-tetrafluoroborate (TBTU) [I]. However, as this pro- 
cedure is limited to aprotic solvents we looked for a pre-labelling procedure with ""'TC- MAG^ in aque- 
ous media that can be applied to water-soluble compounds such as amino acids, peptides and oligo- 
nucleotides. Only a few Papers are known on this topic where the 9 9 m ~ ~ - ~ ~ ~ 3  complex was coupled 
to biomolecules when the method suffered from low yields [2,3,4]. 
Here we describe a pre-labelling method that makes use of a 99m~c-~~~3-ac t i va ted  ester for coupling 
to amino acids, esters and also a fatty acid in aqueous solution in good yields. 
Experimental 
General 
HPLC investigations were carried out with a WDAC C18 column, using a gradient of 0.01 M phos- 
phate buffer pH = 6.0 / acetonitrile at a flow rate of 1.0 mllmin. The 9 9 m ~ ~  compounds were determined 
by ydetection, impurities such as unreacted 2,3,5,6-tetrafluorophenol were detected by UV ad- 
sorbance at 230 nm. The purification of the intermediates was performed with cartridges for solid 
phase extraction RP 18 (LiChrolut, MERCK). 
Labelling of ''"'Tc-MAG~ and coupling to arnino acids and arnino esters (general procedure) 
103 MBq 9 9 m ~ ~ 0 4  generator eluate diluted with 2.0 ml water was added to a commercial MAG3 kit. 
After 30 minutes the solution was acidified with 100 pl 1.0 M HCI and the mixture was eluted On an 
activated RP 18 cartridge. The pure 9 9 m ~ ~ - ~ ~ ~ 3  fraction was re-eluted with 800 p1 acetonitrile. 20 mg 
2,3,5,6-tetrafluorophenol dissolved in 50 ml acetonitrile and 50 mg NI-(3-dimethyl-aminopropy1)-N- 
ethylcarbodiimide hydrochloride (EDC) dissoked in 100 p1 90 % acetonitrile were added to this solu- 
tion. After 30 minutes the mixture was diluted with 5.0 ml water and the active ester was separated by 
elution through an RP 18 cartridge. After washing with diethyl ether the product was removed from the 
cartridge with acetonitrile. The organic layer was removed in a stream of nitrogen and the residue was 
dissolved in 1.0 ml water. 4.0 mg of amino acid (amino ester) in 500 p1 phosphate buffer pH = 9.2 was 
added to this solution and after 30 minutes the product was purified by HPLC. The total reaction time 
was 2 hours and the product had an activii of 51 MBq (overall yield: 49 %). 
Results and Discussion 
The pre-labelling with '-TC-MAG~ in aqueous solution was canied out in the order described in Figure 
1. As a first step the activated ester of 9 9 m ~ ~ - ~ ~ ~ 3  was synthesized by reaction of the complex with 
2,3,5,6-tetrafluorophenol in 90 % acetonitrile. Because both tetrafiuorophenol and the coupling rea- 
gent EDC were used in great excecc over the Tc complex, the product had to be separated by soW- 
phace extraction and the unreacted tetrafluorophenylester removed by washing witb diethyl ether. In a 
second step the active ester was reacted wiäi the amino acid in alkaline soiution where the aet& 
ester bond was cleaved and the coupling to the amino group murred. 
EDC. TFP 
actonitrilelwater = 9:l 
30 min. RT 
4 arnino esier 1 
pi-asphate M e r  
PH 9.2 
30 min. RT 
Fig.1. Course of the coupling reaction of 9 9 m ~ ~ - ~ ~ ~ 3  with amino acids and esters 
The reaction steps and the purity of all intermediates were checked by HPLC. Figure 2 shows the 
radiochromatograms of the coupling to diglycine ethyl ester, starting from pure 9 9 m ~ ~ - ~ ~ ~ 3  (Fig.2a), 
the conversion into m~c-~~~3-tetrafluorophenyl ester (Fig.2b) and the final product 9 9 m ~ ~ - ~ ~ ~ 3  
diglycine ethyl ester (Fig2c). It is remarkable that no by-products are observed and the reactions are 
fully completed. The chromatogram of the 9 9 m ~ ~ - ~ ~ ~ 3  diglycine ethyl ester detected by UV ad- 
sorbance is represented in Fig2d, and some impurity by tetrafluorophenol with a retention time of 
15.85 min is visible. 
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Fig. 2b. m ~ ~ - ~ ~ ~ 3  tetrafluorophenyl ester 
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Fig. 2d. m ~ ~ - ~ ~ ~ 3  diglycine ethyl ester 
(UVchromatogram) 
~ j .  2. HPLC anaiyses of the coupling of *TC_MAG~ to digiycine ethyl ester, (MDAC C18, gradient 
0*0.3 M phocphate buffer pW = 6.0 / acetonitrile, 1.0 mVmin) 
Table 1 provides information on HPLC retention times and yields of products obtained by coupling 
some amino compounds to 9 9 m ~ ~ - ~ ~ ~ 3 .  The total yields were calculated by measuring the activity of 
the solution containing the product compared with the starting activity. The amino ester and the free 
amino acid Na-BOC-lysine reacted with similar results, the reaction with the free fatty acid showed 
some impurities and a lower yield. Attempts of coupling nucleoside derivatives such as cytidine or 
cytidine monophosphate failed. 
It can be summarized that the pre-labelling procedure is an advantageous method of coupling hydro- 
philic compounds such as amino acids or amino ester to 9 9 m ~ ~ - ~ ~ ~ 3  in aqueous solution. In the future 
this reaction is intended to be expanded to peptides and ~li~onucleo~des. ' 
Table 1. 9 9 m ~ ~ - ~ ~ G 3  coupled amino compounds, retention times and yields 
Amino compound 
glycine methyl ester 
Retention 
time 
1 1.24 min 
1 1.78 min 
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51. '%e-~abelling of an Endothelin Derivative 
B. Noll, L. ~inkelborg', H. ~i lger '  
'~chering AG 
The radioactive isotopes of rhenium, 18%e and ls8Fie, are of interest in nuclear medicine for therapeu- 
tical use because of their nuclear properties. The labelling of peptides with Re-188 is described by 
several authors. Guhlke et al. explored a somatostatin analogue for its potential as a locally/regionally 
administered radiotherapeutic agent targeting somatostatin-receptor- positive tumours [I]. Savavy et 
al. describe the labelling of small molecule peptides (7-amino acid analogue of bombesin) with an- 
tagonistic activities as potential radiotherapeutic agents [2]. Tc-labelled endothelin derivatives were 
characterized for imaging experimentally induced atherosclerosis in vivo [3]. 
The aim of our work was to investigate the labelling of endothelin derivatives with rhenium186/188 in 
analogy to technetium labelling. The compounds were labelled by means of 18%e(v) gluconate [4]. To 
optimize the conditions experiments were carried out, including variation of the amounts of the reac- 
tants and the reaction time. In analogy to the "TC labelling the ligand exchange reaction between the 
18%e(V) gluconate and the peptide Asp-Gly-Gly-Cys-Gly-CysPhe-(D-Trp)-Leu-Asp-lle-lle-T results 
in a product that contains two species, which are separable by HPLC [5]. 
Preparation and anaiysis 
1.0 mg peptide is disolved in 200 VI phosphate buffer solution pH 7.0 (SÖRENSEN) and stepwise 
added to the 18%e(v) gluconate solution. After 45 rnin the reaction mixture is analysed by HPLC (Eu- 
rosphere RP 18, 25014 mm, eluent A: 95 % 0.013 M phosphate buffer pH 7.4 / 5 % CH3CN, eluenf B: 
25 % 0.013 M phosphate buffer pH 7.4 I 75 % CH3CN, gradient elution: 5 min 80 % A, 5 rnin from 
80 % A to 75 % A, 20 rnin 75 % A to 72 % A Row: 1 ml I min, 5 rnin 100 % B, flow 1.5 ml I rnin). For the 
semipreparative separation a sample volume of 200 pI was injected and the peak fractions were sepa- 
r a t 4  and frozen in a refrigerator to prevent the occurrence of perrhenate by radiolysis. The prepara- 
tions took place under a nitrogen atmosphere, and a nitrogen stream was bubbled to all solutions. The 
HPLC analysis of the isolated isomers (cornplexes I and II) afier 24 h storage at -20 "C is shown in 
Fig.1. 
The reaction mixture was separated into l8%e gluconate (Rt 2.0 min, about 10 %), ' 8 6 ~ e 0 i  (Rt 
2.5 min, c5 %), 18%e endothelin complex I (Rt 22.0 min, about 15 %), 18%e endothelin complex II (Rt 
25.0 min, about 25 %). The residual activity remained on the column under this separation conditions 
and was eluted with acetonitrile. 
0 10 20 30 40 
Time (min) 
Fig. 1. The HPLC anafysis of the ceparated fractions after 24 h storage at -20°C using a 
f3-radioactivi detecfor. a) complex 1, b) complex il 
The stability of the18%e labelled endothelin to radiolytic effects is a prerequisite for the success of a 
possible therapeutical approach. The radiolysis was investigated without separating the 18%e labelled 
endothelin into its isomers. The labelling preparation was separated from hydrophilic components on a 
solid-phase LiCrolut column (Merck, RP-18 endcapped / 200 mg). The high ß-energy of the rhenium 
isotope initiated the radiolytic formation of perrhenate to up to 20 % within 5 h at room temperature. 
We found that storage in refrigerator at -20 or the addition of ascorbic acid to the preparaüons or the 
isolated fractions stabilize theT8%e labelled endothelin complexes so that no radiolysis occurs. The 
18%e endothelin complexes were stabil for over 24 h and useful for in viv0 animal studies. 
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52. Capillary Electrophoresis of 99"'T~ Radiopharmaceuticals: Quality Control and pK 
Determination at the Tracer Level 
R. Jankowsky, B. Noll, H. Spies, B. Johannsen 
lntroduction 
In radiophannaceutical practice, quality control of radiotracers is of importance. Although the majonty 
of analytical controls are done by thin-layer chomatography (TLC) and HPLC; the capillary electropho- 
resis (CE) as a micro-analytical technique becomes more and more relevant. Here we describe the 
construction of a y-ray sensitive detector for CE and its usage for the quality control of the 9 9 m ~ ~  radio- 
harmaceuticals ""'TC- MAG^, 9 9 m ~ ~ - ~ ~ ~ ~ ,  9 9 m - ~ ~ ~ ~ ,  9 9 m ~ ~ - ~ ~ ~ ~ ~ ,  9 9 m ~ ~ - ~ ~ ~ ~ ,  9 9 m ~ ~ - ~ ~ ~ ,  
BgmTc-EC, g m ~ c - ~ l  2, w m ~ c - ~ ~ ~  and ggm c-~etrofosmin. 
As a further application of CE, it can be used for the determination of pK values as important molecu- 
lar parameters which decisively influence the bioloyical behaviour of pharrnaceuticals [ I  - 31. In the 
present work, we report on the pK determination of Tc-MAG3 and 9 9 m ~ ~ - ~ ~  using the radio-CE. 
Experimental 
For measurements, a 3 D ~ ~  device (Hewlett-Packard, Waldbronn, Germany) was used. It was 
equipped with a y-ray sensitive flow detector consisting of a cylindric scintillation crystal. The sche- 
matic construction is given in Fig. 1. 
F Secondary electron 
C 
A 
E ~ead  collirnators 
Fig. 1. Schematic construction of the CE radiodetector. Lei3 sketch, arrangement of the detector at the 
CE device; A, capillary inlet; B, capillary; C, diode array detector; D, capillary outlet; E, high 
voltage suppfy; F, radioactivity detector. Right sketch, schematic construction of the detector. 
-TC radiophamiaceuticals were prepared according to instnictions with ~a99"rcO~ generator eluate 
or were purchaced readily from the University Hospital of the Dresden University of Technology, re- 
spectively. For ana&tkal CE runs, both conventional and pressure-modified capillary Zone electropho- 
resis were uced [4]. pK determinaüonc of -TC-MAG and T c - E C  were accomplished by rneasuring 
the relative e ~ o p h o r e t i ~ t  mobiiii depending on the running buffer pH 55 - 83. The mobiiiies were 
referred to the electrophoretrcal mobil@ of simukneously measured internal standards 143. 
ResuRs and Discussion 
ßadioactivity detector. The constructed radioactivity detector showed linear response over a broad 
activity range and a low offset. The detection cell volume was deterrnined to be 2.2 nl which ensures a 
high spatial resolution. However, due to the small detection cell volume, the detector possesses a 
rather low sensitivity. The lowest possible radioactivity arnount is expected to be roughiy 3 MBq 9 9 m ~ ~  
per 100 PI, depending on the amount of components in the sample. 
Quality control. 99m~c-~etrofosmin, 9 9 m ~ ~ - ~ 1  2 and 9 9 m ~ ~ - ~ ~ ~ l  showed cationic migration behaviour 
(Fig. 2). This is in accordance to the proposed complex charges [9]. 
Fig. 2. 
0 I 2 3 4 5 
Zeit (rnin) Zeit (min) 
Capillary zone electrophoresis of cationic and neutral -Tc radiopharmaceuticals. The dotted 
lines represent the extrapolated detection time of a neutral marker. Left sketch, cationic com- 
lexes; A, 99m~c-~etrofosrnin; B, 9 9 m ~ ~ ~ 1 2 ;  C, 9 D m ~ ~ - ~ ~ ~ ~ .  Right sketch, neutral complexes; Al 
FmTc-HMPAO; B, '%-ECD. 
For 9 9 m ~ ~ - ~ 1 2 ,  a complex mucture could be detected while ggm~c-~etrofosrnin and -Tc-MIBI deliv- 
ered single peaks. The migration times are different for the three cationic complexes showing the pos- 
sibility to analyze them simuitaneousiy. In case of neutral complexes, no separation can be achieved 
by capiliary zone electrophoresis (Fig. 2). They do not exhibit any electrophoretical mgration and are 
thus detected with the neutral marker. However, this result is in agrrrement with the propo& neutral 
complex structures [9]. For anionic complexes, it has to be distinguished htween complexes of high 
and low electrophoretical mobilii. The first are detectabie by conventionaf capiliary zone electrupho- 
resis, while the latter are oniy analyzabie by the presure-mod'ied capillarjr Zone electr horecis. 
-TC-EC, -TC-DTPA and -C-EHIDA can be considered as bw-mobile mmplexec. TheOI)OmTc-~~ 
and 9 9 m ~ c - ~ ~ ~ ~  omplexes exhibited single peaks in their electropherogramc showing tttat ~nif0rIn 
complex species are forrned (Fig. 3). 
I .  , . !. , , 8 , , , , . 8 , , , , . I 
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Fig. 3. Capillary Zone electrophoresis of anionic 9 9 m ~ ~  radiopharrnaceuticals. The dotted lines repre- 
sent the extrapolated detection time of a neutral rnarker. Left sketch, conventional capillary 
Zone electrophoresis mode; A, 9 9 m ~ ~ - ~ ~ ;  B, 9 9 m T ~ - ~ ~ ~ ~ ;  C, 9 9 m ~ ~ - ~ ~ ~ ~ ~ .  Right sketch, pres- 
sure-rnodified capillary zone electrophoresis rnode; A, 9 9 m ~ ~ - ~ ~ ~ 3 ;  B, 9 9 m ~ ~ - ~ ~ ~ ~ ;  C, 9 9 m ~ ~ -  
MDP. 
In contrast, the 9 9 m ~ ~ - ~ ~ ~ ~ ~  cornplex delivered a rather complicated peak Pattern giving rise to the 
assumption that a variety of cornplex species are forrned. For 9 9 m ~ ~ - ~ ~ ~ 3 ,  9 9 m ~ ~ - ~ ~ ~ ~  and '*TC- 
MDP, the pressure-rnodified capillary Zone electrophoresis was applied due to their high electrophore- 
tical rnobilities (Fig. 3). Rernarkably, 9 9 m ~ ~ - ~ ~ ~ 3  and 9 9 " ~ c - ~ ~ ~ ~  showed nearly identical migration 
tirnes which is obviously caused by the sirnilar charge-size ratio of the cornplexes. 9 4 " ~ c - ~ ~ ~  exhibits 
a broad peak, thus it can be assurned that several complex species with sirnilar properties are forrned. 
pK determination. 9 9 m ~ c - ~ ~ ~ 3  and 9 9 m ~ c - ~ ~  b a r  freeprotonable carboxyl groups [9], whose pK val- 
ues can be rneasured. For the determination of pK values, the cornplex structure-based therrnody- 
narnical equilibria constants of ligand deprotonations were ernployed to derive equations describing 
the relation between electrophoretical mobility and buffer pH [4]. The rneasured electrophoretical mo- 
bility cuwes of 9 9 m ~ ~ - ~ ~ ~ 3  and 9 9 m ~ c - ~ ~  are given in Fig. 3. 
Fi. 4. Elrtctrophoretical rnobility curves of -TC-MAG~ (left sketch) and -TC-EC (right sketch). 
The cuwe fitting using structure-bad themodynarn-mi equations are shown 
as insets, respectivefy. 
For both curves, sigmoidal decay properties could be obtained. The experimentally determined pK 
values are 4.22 and 2.90 for the 9 9 " ' ~ c - ~ ~ ~ 3  and ""'TC-EC complex, respectively. In case of ""'TC- 
MAG3, the value is higher than for carboxyl groups in comparable free peptides [10]. 9 9 m ~ c - ~ ~  bears 
two free carboxyl groups, which are obviously chemically identical. That can be assumed, since only 
one step was obtained in the electrophoretical mobility curve. However, for 9 9 " ' ~ c - ~ ~  the determined 
pK value is significantly increased comparing to the free cysteine [10], which could be due to the 
chemical modification of the ligand as well as to the metal complexation. 
In Summary, the CE equipped with a radioactivity detector proved to be a useful tool in both the analy- 
sis and the determination of pK values of 99m~c radiopharmaceuticals. Although few 9 9 m ~ ~  radiophar- 
maceuticals show similar migration features under the described conditions, variation of the running 
conditions should improve the Separation efficiency. Considering the pK determination, the radio-CE 
can be expected to become an essential tool in radiopharmaceutical research. Advantages are the 
small required sample amounts, possible automatization and very low running costs. 
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53. Some Additions to the Determination of log P and pK, Values by Using Reversed 
Phase HPLC 
R. Berger, H. Spies 
lntroduction 
As reported earlier, the lipophilicity (log P) andlor the ionization constants (pK,) of certain organic 
bases can be determined by using reversed phase HPLC [I, 21. 
A specific HPLC column (PRP-1) and elution system (acetonitrile/buffer) having a well-defined volume 
ratio are basic requirements for reliabiiii in achieving correspondence between the retention times of 
the tested compounds and their octanoüwater pattition coefficients (P or log P). The more structure- 
related the tested substances are, the better the lipophilicity values obtained by HPLC correspond to 
P. The lipophilicity values of heterogenous compounds can only be compared with each other by re- 
ferring to the chromatographic system used. Here we study the effects of deviations of the volume 
ratio in the elution system on the lipophilicity as weil as on the ionization Parameters of some organic 
bases and acids. 
Resutts and Discussion 
Amines: 
In Table 1 we compare the lipophilicity values of amines obtained by reversed phase HPLC, using 
various organic modifier (acetonitrile) to buffer ratios, with log P values taken from the literature and 
from the internet. (The amines are arranged according to increasing pK, values (cp. Table 2)). 
Table 1. Experimental lipophilicity values and log P data from the literature and the internet for 
some amines 
I I 1 Volume Ratio: Acetonitrile I Buffer A 
(2:i) log P=) - 
PHPLC log PHPLC log PHPLC 









I Collidine 1.88 2.45 1 Brucine 3 0.98 - - 
Benrylarnine 11.09 1.09 1.07 f 2.2 0.34 
*) mean value ; taken from I )  liierature [4] if not noti f i i  othenntise; 
'j WWW (h~llesc.syrres.cÖd-ecctkowexpdb-holi); 
') cakuiated by W (htpilfecc.syrres.conJ-ecclkowint.htm); mean values 
The Iipophiiicity cxwrstantc (P) obtained from retention times are denoted by the inciex HPLC (PHPLC)- A 
modlfication of äte volume ratio d acetonitrik to buffer from 3:l to 23 does not ecsentiatiy change the 
PHPLC values. 
These PHRC data diifer to some extent from the log P vaIues reported in the literature or internet. In 
the cace of congenerc of pymline the log PHPL~ values are much smaller than the log P values from 
the fiterohrre 13, 41. It is pssbly on a m n t  of a nitrogen atom in the aromalic fing of the referring 
examples that M interaction with fIfe SWonafy phase ~iyfst)rren&winylbenzene)] Js diminished 
and äle appropriate etentian times are thus reduced, 
dielectric constants srnaller than that of water weaken both acidic and basic groups, the pKa of an 
acidic group is raised and that of a basic group lowered [5]. 
For a nurnber of organic bases the pKa values frorn the literature and those determined by HPLC using 
two acetonitrile to buffer ratios are cornpared in Table 2. The pK, values were measured by potenti- 
ornetric titration in pure aqueous solution or extrapolated into this medium. The addition of the organic 
rnodifier to the buffer dirninishes the pK, value. Thus, the third colurnn contains the lowest pK, values. 
Table 2. pKa values of sorne arnines taken frorn the iiierature [6J and 
deterrnined by HPLC using two volurne ratios of acetonitrile to buffer 
Amine 1 P K ~  PKHPLC (23) PKHPLC (3:1) 












Based on these data, calibration curves were defined for conection of the measured values of further 
organic bases (Figs.1 and 2). 
Fig. 1. Calibration curve for corrections of ttre pKHptC values of ocganic bases 
(acetonitrilelbuffer = 3:1 (VIV)) 
Fig. 2. Calibration curve for corrections of the PKHPLC values of organic bases 
(acetonitrilelbuffer = 2:1 (VIV)) 
Both calibration curves show a similar trend. In Fig.1 the curve presents an approximately parallel shift 
(by an amount of 1.5) to the function pK, = PKHPLC (analogous to y = X). The curve in Fig. 2 is some- 
what steeper. In both examples the curves represent rather good correlations. 
In practice, the higher the proportion of acetonitrile in the eluant mixture, the shorter is the retention 
time af the solvent. A decrease in the proportion of the organic rnodiiier prolongs the retention time. In 
the above chromatographic system a change in the acetonitrile/buffer volume ratio from 3:1 to 2:1 
approximately doubles the retention time. A further change to 1:1 doubles it again. The continued re- 
duction of the organic modifier in the elution mixture while maintaining the chromatographic system 
makes therefore no sense, economically or practically. 
Organic acidss 
The above studies were extended to organic acids. The P&, and pKHPLC values of some organic acids 
are listed and plotted in Table 3 and Fig. 3. 
Table 3. P&, values of some organic acids taken from the Iiterature [6] and 
determined by HPLC, using a volume ratio of acetonitrilehuffer = 3:l 
Organic acid 1 P& P&PLC 







Fig. 3. Calibration curve for corriections of the pKHP~c values of organic acids 
(acetonitrilelbuffer = 3:1 (viv)) 
Appropriate trend programs using the above calibration curves make it possible to calculate pK,(„ from 
pKHPLC values for organic bases and organic acids. 
References 
Berger R., Fietz T., Glaser M. and Spies H. (1995) Determination of partition coefficients for coor- 
dination compounds by using HPLC. Annual Report 1995, Institute of Bioinorganic and Radio- 
pharmaceutical Chemistry, FZR-122, pp. 69-72. 
Berger R., Scheunemann M., Pietzsch H.-J., Noll B., Noll St., Hoepping A., Glaser M„ 
Fietz T., Spies H. and Johanncen B. (1995) pK, value determinations by HPLC of some Tc and 
Re complexes containing an ionizable group. Annual Report 1995, Institute of Bioinorganic and 
Radiopharrnaceutical Chemistry, FZR-122, pp. 73-79. 
Hansch C., Sammes P. G. and Taylor J. B. eds. (1990) Compmhensive Medicinal Chemistty, 
The Rational Design, Mechanistic Study & Therapeutic Application of Chemical Compounds, 
Vol. 6 (Cumulafive Subject Index & Drug Compendium), Pergamon Pr-, Oxford, p. 330. 
Leo A. J., Hansch C. and Elkins D. (1971) Partition coefficients and their wes. 
Chem. Rev. 71,525-61 6. 
Pagliara A., Testa B., Carrupt P. A., Jolliet P., Morin C., Morin D., Urien S., Tillement J. P. and 
Rihoux J. P. (1 998) Molecular properties and pharmacokinetic behavior of cetirizine, a trvimrionic 
H-1 -receptor antagonist. J. Med. Chem. &i,8%M63. 
Lide D. R. ed. (1992-1993) CRC Handbook of Chemistry and Physb.,. CRC Press, Tokyo, W. 8-37. 
Berger R., Friebe M., Pietzsch H.-J., Scheunemann M., Noll B., Fetz f ., Spies H. and dohannsen 
B. (1996) Lipophilicity and ionization properties of some amine-bearing tahnetium and rbenium 
" S I "  mixed-ligand chelates of the Same ligand structure. Annual R q r t  1996, InsihtG! of f3idn- 
organic and Radiopharrnaceutical Chemistry, FZR-165, pp. 43-47. 
54. Partition Coefficients for Steroidal Rhenium Coordination Compounds Determined 
by Using RP-HPLC 
R. Berger, F. Wüst, M. Reisgys, H. Spies 
Lipophilicity is an important Parameter in the design of ""'TC steroid hormone receptor-binding ligands 
able to image hormonedepending metabolic pathways of tumours [ I ,  2,3]. This also applies to steroid 
hormone complexes with rhenium as an inactive Surrogate of technetium. 
In order to determine the lipophilicity of steroid-derived Re complexes we used HPLC on a PRP-1 
column eluted by an acetonitrile to buffer mixture in a volume ratio of 3 to 1 [4]. Following a preliminary 
report [SI, we now publish all lipophilic data of steroid-derived Re complexes measured by us (Table 
1). Column a) exhibits lipophilicity values based on known octanoVwater partition coefficients (log P*) 
of aniline, benzene and bromobenzene as references [4,6]. 
It is anticipated that structure-related steroids will be better reference molecules for the determination 
of log P* of steroid complexes than the hitherto used aromatics aniline, benzene and bromobenzene. 
We therefore compare the above values with those obtained on the basis of some steroids for which 
log P& values are known as references. In column b) PHPLC data obtained by analogous calculations 
using the steroids 3,17 B-estradiol, testosterone and progesterone are shown. (Both series of values 
are based on the corresponding capacity factors which are listed in an additional column for compari- 
son.) 
The PHpLc values in column b) are generally larger by 1 - 2 orders of magnitude than those in column 
a). Because of the PRP-1 column matrix having aromatic properties, the results for steroids or steroi- 
da1 ligands of chelates have to be interpreted with particular care. An interaction between the sterically 
marked steroidal structures and the column matrix obviously does not take place as could be ex- 
pected. Presumably the functional groups of steroidal molecules are responsible for the relatively 
weak interaction with the column matrix, which is in a certain contrast to the behaviour concerning the 
partition between the phases of octanol and water. (In order to overcome this source of error as far as 
possible, the log PA values of above-mentioned steroids available in [7] are used to calculate the 
PHPLC: values as was described earlier [4].) 
A cornparicon of the lipophilic results obtained by using a) the aromatics and b) various steroids that 
are more structure-related to the chelates, revealed a certain correspondence. However, apart from 
the great difference between the values obtained by the two methods, the individual lipophilicity values 
are not sufficientfy influenced by structural changes of functional groups of the steroidal Re com- 
piexes, i.e. an indirect determination of P& by using the above-mentioned chromatographic system is 
not advisable. 
Table 1. PHPLC and log PHPLC values as well as the corresponding capacity factors (k') of several 
steroids and neutral rhenium complexes containing steroidal ligands [pH interVal5 - 9, n = 31, 
a) reference substances: aniline, benzene, bromobenzene, 









log P* 4.01 
Cm 
M 






log P& 3.87 
As already deduced in our last report 151, the following general rules are valid: 
7) Each formation of rhenium ~ T n p l e x ~  with basic steroidal structures such as 3,17 P-estradiol, tes- 
tosterone or progesterone has a growing lipophilicity as a consequence; however, the extent of the 
 hange in fipophiiicity depends on the selection of references. Besides, the lipophilicity of these com- 
plexes is increaced either by iengthening the carbn chain between the Re cf-ielate moiety or removing 
a hydrophilic group ac usuaf. 
2) For a deiinite steroid moiety the lipophilicity is increased depending on the coordination mode in the 
foitowing oräer: "&1" (Nos. 18; 19,27) > "3+1 " (Nos. 4,s; 12, 13; 24,251 > "carbonyl-thioether' (Nos. 
16; 17; 26). 
3) In äie "&tu Re C~Tnplex€?S, consMring äle trKientate ligand moiety, the &mphilicit)r growc in the 
faltowing order: "SN(GS-f3)S" (No. 11) < *SOS" (No. 12) "SSS" (No. 13). 
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55. Miscellaneous Results of Determining the Partition Coefficients and lonization 
Constants for Rhenium and Technetium Coordination Compounds by Using HPLC 
R. Berger, F. Wüst, A. ~ablotskaya', M. Friebe, H.-J. Pietzsch, M. Scheunernann, M. Reigys, 1. Spies, B. Johannsen 
Latvian Institute of Organic Chernistry, Riga, Latvia 
lntroduction 
In previous reports rneasurernents of the lipophilicity and ionization behaviour of various substituted 
TdRe complexes with "3+ln rnixed-ligand coordination priority were presented [I, 21. This article is 
dedicated to analogous rneasurernents of rnixed-ligand cornplexes with a) variations in the tridentate 
ligands SXS (X=N-Me, S, 0, N-Pyr) and rnonodentate ligands, to which b) a hydroxyl group or C) alkyl 
or aryl-silyl groups are substituted, d) which can be potentially bound to receptors as arnines with a 
protonable nitrogen [3] and e) Re tricarbonyl dithioether cornplexes, which can be linked to bio- 
rnolecules [4]. 
The deterrnination of lipophilicity resulting in apparent so-called log PHPLC values was performed by 
appiying an HPLC procedure involving a PRP-1 column eluted by an acetonitriletbuffer rnixture in a 
volume ratio of 3 to 1 [I]. lonization constants are rneasured as pKHPLC and subsequently corrected to 
the form pKa(cl by using calibration curves both for organic bases and acids 12, 5, 63. 
Resuits and Discussion 
The lipophilicity values of sorne rheniurn coordination cornpounds rnodified both in the tridentate and 
in the rnonodentate chelate unit substituted rnostly by hydroxyl groups are listed in Table 1. 
a)  Infiuence of the exchange of the central atom in the tridentate ligands: The lipophilicity values show 
a structural dependence as expected, i-e. as already discussed, the replacement of the central het- 
eroatom in the tridentate ligand increases PHPLC in the rank order N-Me C 0 I S [5, 7,8] (Nos. 1-3). In 
the case of embedding the central nitrogen atorn in a pyridine ring [S-N(pyr)-SI (No. 6), the PHPLC value 
is higher than the one with the S-S-S unit (No. 5). 
b) Effects of hydroxyl-groupcontaining substituents and the alkyl chain length in monodentate ligands: 
In general, ligands bearing hydroxyl substituents have the expected low PHPLC values. For instance, 
PHPL~ values decrease when the rnonodentate benzene ring (No. 8) is substituted in the para positition 
by oxygen-containing groups (Nos. 6, 7), among which the hydroxyl group has the greatest influence 
on diminishing PHPLC (NO. 6). 
Lengthening the N-alkyl side chain in the rnonodentate ligand increases the PHPIC value [5] (Nos. 3, 4). 
C) Infiuence of the introduction of silyl groups into the monodentate ligands: Table 2 lists "311" rhe- 
nium complexes in which the proton of the hydroxyl group is substituted by a silyl group. A drastic 
increase in lipophilicity is obsewed. Regardless of the involvement of silicon in the chelate structure, 
the usual obsewations of Iipophilic diierences in the tridentate chelate units having various central 
atoms (Nos. 1, 2) and lengthening c a h n  chains (Nos. 2, 3) remain unchanged. The cornplex with 
three phenyl residues bound to silicon represents a certain exception. The relatively high PHPLC value 
is a consequence of an intimate interaction with the arylic column matrix (No. 4). 
d) "3+1* R d i c  complexes beatjng protonable nitrogen: In cono'nuation of previous studies, the sug 
piementary lipophilicity and pK&) values relating to amine-group-bearing '311" rhenium and some 
technetium complexes are dispiayed in Table 3a and b. In particular, three novel monodentate Iigands 
consisting of structural units such as 1,4-diixa-8-azaspiro-N-2-mercaptoefhylen~ne, 4- 
piperidinone or a-dimethylamino acetic acid methylester [cp. structure moieties of Nos. 1, 2, 51 are 
included ii.i the determination. 
Table 1. Lipophilicity values of some "3i1" rhenium complexes (N-pyridine in 



















From these two compilations similar findings as earlier obtained [5] can W deduced, i.e. 
1) looking at the tridentate moiety and keeping the mon&ntate unit constant, growing P-C vaIueS 
can be observed in the following order [S-N(Me)-S] .: [S-N(Et)-S] - [S-S-SI C fS-N(Pr)-C]; 
2) for the compounds in Nos. 9, 10, greater Iipophilicity values of tfie Whnetium species {m imum 
about double the amount) can be assumed; 
3) directing attention to the DHPLC values (obtained at pH 7.4), the relatively highest amount of the 
PHPLC value can be observed in the case of the monodentate unit involving a ketone group; 
4) considering the pKa values, an increase depending on monodentate structural groups can be de- 
duced in the order of the typical groups: keto C ester < dioxa unit. 
Apart from that an evident difference between the pKa(c) values of technetium and rhenium complexes 
having the Same structure cannot be recognized. 
Table 3a. Lipophilicity values (PHPLC, DHPLC) and ionization constants (pKa(„) of "3+1" 
rhenium coordination compounds in continuation of previous results [5,9] 
Table 3b. Lipophilicity values (PHPLC, DHPLC) and ionization constants (pK,(,)) of "3+Iu rhenium and 




* M = Tc, Re; *) at pX 7.4; Pr = propyi. 
PHPLC log PHPLC 
Tc R e  Tc Re 
104 49 2.0170 1.6902 
46 29 1.6628 1.4624 
Structure 
s \ 8 / s / \ - u 3 3  
L - s  
r u  
R 
0 -230 c;x:  
F/- 
DHPLC*) log DHPLC*) 
Tc R e  Tc R e  
16 3 1.2041 0.4771 
35 21 1.5441 1.3222 
P 4 a  
Tc R e  
8.04 8.42 
7.07 7.06 
Additional structures of "3+1" technetium and rhenium complexes modified at the monodentate ligand 
and the corresponding PHPLC, DHPLC at pH 7.4 as well as pKdc) values are listed in Table 4 as a func- 
tion of the growing PHPLC values. 
Table 4. P, D (at pH 7.4) and pK,(„ values of special '3+1" rhenium and technetium 
complexes modified at the monodentate ligand bearing protonable amine nitrogen 
Structure DHPLC log DHPLC 
5 0.6990 
The following interdependences can be derived from Table 4: 
1) In complexes of the Same ligand structure those invobing technetium have a higher lipophilicity 
than those containing rhenium (cp. pair Nos. 5,6 and 10, 11). 
2) The D H P L ~  values increase with growing PHPLC and diminishing pK+). 
3) The smaller the pK& values, the higher are the DHPLC vaiues. 
4) Arrangement of oxygen in ß-position (eg. in the morpholine ring or within a chain) decreases the 
pK& because of its electron-withdrawing effect on the amine nitrogen (No. 9). 
This effect is negligible over a distance of three carbon atoms (Nos. 8,14,18,21). 
5) Lengthening the N-afkyl side chain in üte monodentate ligand from two to three carbon atoms 
increases the pKNcj values by about 0.3 units (Nos. 13, 17 and 16,20). 
Some supplementary structures of "&1" technetium and rhenium complexes modiied chiefiy at the 
tridentate Jigand and the corresponding PHPLC, DHPLC at PH 7.4 as weil as pK& values are listed in 
Table 5, 
Table 5. PHPLC, D H ~ ~ ~  (at pH 7.4) and pK,(,> values of special"3+lM rhenium and technetium 
complexes modified chiefly at the tridentate ligand 
Structur 
In contrast to the discussion on oxygen in ether bridges (Jabie 41, an interes'ting example ic Iisted in 
Table 5 under No. 3. An ether bridge in a chain containing anotfier nitrogen aiom bound through an 
ethylene bridge to the nitrogen of the tridentate ligand obviousiy resub in a pronounced decreace in 
the pK& value. The corresponding lipophilicity value at pH 7.4 grows reciprocaiiy. Pis can be -n 
from Nos. 1 and 2, an ethylene bridge between Wo nitro@ atoms, one of which represents the cen- 
trat atom of the tridentate ligand, has a remarkable inffuence on diminishing basicity. 
e) Re tricarbonyl dithioether complexes: The lipophilicity values as well ac the ionization wnstang of 
several rhenium tricarbonyl diioether complexes are lisied in Table 5. 
Table 6. The lipophilicity values (PHPLC, log PHPLC) and ionization constants (pK,(„) of carbonyl- 








The rhenium tricarbonyl dithioether complex (No.1) can be considered to be the parent compound 
from which the complexes (Nos. 2 - 6) with a relativeiy low lipophilicity derive. 
in complexes containing benzene rings the lipophilicity is enhanced to log P values greater than 3 
(Nos. 2, 31, while the OHICOOH-groupcontaining compounds, as expected, show log P values at 
about 1. In accordance with their varying ionization properties Nos. 2,3 behave as bases and the Nos. 
4, 5 as acids. That can also be deduced by comparing the columns containing the pKHPLC values, on 
the one hand, and the pK& values, on the other. In cases of an acid or base the measured values 
have to be corrected by subtracting or adding a definite amount [cp. 101. 
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56. lnfluence of Transport Conditions of the ["F]F Water Target on the ["F]FDG 
Synthesis 
St. Preusche, F. Füchtner, J. Steinbach 
lntroduction 
The Rossendorf PET cyclotron 'CYCLONE 1819' is equipped with a large-volume [ ' 8 ~ ] ~  water target 
irradiated volume - 1.5 ml). The [ 1 8 ~ ] ~ ~ ~  synthesis is based on a modified Nuclear Interface 
[18qFDG module. 
At the Rossendorf PET Center the PET cyclotron and the radiochemical laboratories are 500 meters 
apart. In case of the water target the distance is bridged by a pneumatic transport System. The 
principle of the transport of irradiated liquids is shown in Fig. 1. The irradiated liquid ['80]~201[18F]~ is 
transferred from the target to the loading unit of the pneumatc rabbit in a capillary tube 25 m in length, 
of 0.8 mm inner diameter (cyclotron site) and from the unloading unit to the ["F]FDG module in a 50 
m long tube (radiochemistry site). The 500 m distance is bridged by the pneumatic rabbit. The whole 
unloading procedure (E06 to BOS) takes about 10 minutes. 
Measwement 
of activiiy 
Fig. 1. Transport of irradiated liqiuds at the Rossendorf PET Center 
- principle - 
When we started our routine ["F]F produ?? in 1997, we observed Wo phenomena: 
- a relativeiy low Saturation yield of the [ F]F water target due to the reported data 
- a rapid decrease in the [l8FI~DG yield when a high level of activity was produced the day before. 
Investigations were carried out to determine the activity losses during transport and the factors 
influencing the ["F]FDG yield. 
Experimental 
AcfNiy losses during fransporf: 
The activii is measured oniy at ihe radiochemistry site (see Fig. 1) just before starting the 
synthesis. The decay-corrected target yield is the real target yield minus the activii losses of 
transport. To determine these losses we compared the activii of the unloading procedure described 
above (normal unjfading) with that measured after an addiional target and tube rinse and by direct 
unloading of the F]F water target into a measuring vessel, using a container for transport (see Fig. 
1, dotted line). T he lengih of the capillary tube in case of container transport was oniy 2 m. The 
Container was iransported by handcart. The aciivii was always measured in hot cell13. 
P*@FDG yield: 
We observed that the f8qF5G yield rapidly decreased when a high level of act ivi  was produced the 
day before. Sifver parlicbs from fhe target were NM out as ihe reason. This effect is mainly reported 
from GYCLONE 1819 facilitiec with targets ins& the yoke [I]. At our cycbtron the f 8 0 ] ~ 2 0 1 [ 1 8 ~ ~ -  
w&r target is placed outside ihe yoke and thus the beam cpot is larger and the power density tower. 
When we opened the target for a preventive change of the target and vacuum windows, the inner 
surface of the target was mostly clean. There were hardly any silver particles to be removed. 
Water drops remaining in the 75 m tube system (tubes and valves) after each unloading of the t 8 F ] ~  
water target could lead to the radiolysis effects in the tubes. This could be the reason for the low 
[ ' 8 ~ ] ~ ~ ~  yield on the next day. We performed a series of experiments with various tube materials to 
find the most suitable one in terms of a high [ ' 8 ~ ] ~ ~ ~  yield and minimum activity losses during 
transport. The following tube materials of 0.8 mm inner diameter were tested in one and a half years: 
silicone, teflon (PTFE), polyethylene (PE), PEEK and polypropylene (PP) [2]. 
Activity losses during transport 
The activity losses during transport can be described by the following equations: 
(L = average activity losses, A = average activity of index N = normal unloading, C = container 
unloading, R = normal unloading with an additional target and tube rinse). 
R1: Ac: - AR (differente less than 3 %) 
Nearly the Same activity was achieved by container unloading and the normal unloading with an 
additional target and tube rinse. This is an indication that the target was always completely unloaded. 
R2: LNVC - LN,R = (1 4 tO 17) % 
(14 to 17) % of the target yield are lost in the 75 m tube system. With our normal unloading procedure 
it is not possible to reduce the activity losses during transport. They depend on the length of the tube 
system and on the unloading principle. 
R3: The results R1 and R2 are largely independent of the tube materials, the irradiation parameters 
and the particular charges of enriched water (level of enrichment = 96 %, 95 %, 94 %, recycled 
enriched water with lower level) 
R4: The amount of activity that always remains in the via1 of the pneumatic rabbit was estimated to be 
less than 3.5 % of the transported activity. 
We also found that the vertical target position was not correct. To decrease the target pressure during 
the irradiation by increasing the gas expansion area above the water, the target was not completeiy 
filled. After correction of the vertical target position, the ion beam now touches the water compieteiy 
and the target yield and also the saturation yield have thus been increased. 
Properties of the tube materials in tems of transport of the water bohs ~ ~ ~ [ " W F D G  synthesis: 
Silicone: 
- due to the surface, high resistance to transport of the water bolus 
- transport time increased with the number of unloadings 
- for 25 m (target to the hot cell 0 at the cyclotron srte) transport time often much bnger than 5 
minutes 
- water bolus was split into several park 
Silicon tubes are unsuitable for our putpose. 
Polyethylene (PE): 
- dwe to low mechanical stabil'Q unsuitable for long distances 
- our experience in accordance with that of other research Centers. 
PE kibes are unsuitable for our porpose. 
Teflon (PTFE): 
- good properties for transporting the water bolos 
- low resistance to radiation: tubes became britüe and often broke at the Rheodyne vaiwe of 
target systern (entrance point of the activity into the tube) and in the FOG modukr, high risk of 
act~ated water squirting into the cyclotron vaut and the moduk! 
PTFE tubes are unsuitable for our purpose. 
PEEK: 
- results of transport of the water bolus not reproducible 
- sornetimes good, sornetirnes bad transport of the water bolus, reasons for this behavior not clear 
- no reliable transport of the water bolus 
PEEK tubes are unsuitable for our purpose. 
Polypropylene (PP): 
- very good properties for transporting the water bolus 
_ high resistance to radiation 
- FDG yield stable and sufficient 
PP tubes are the rnost suitable ones for our purpose. 
['*F~'FDG yield 
In addition to the use of the PP tubes, the activated water was rernoved frorn the 75 m tubes and the 
vaives placed inside the tube System by rinsing thern with deionized water after each unloading of the 
target. 
The PP tubes have been used since July 14, 1998. The results are surnmarized in Fig. 2: 
1. The absolute increase in the ["FIFDG yield is small but the standard deviation of the average 
[ "~FDG yield was reduced by a factor of two. 
2. Every two to four rnonths (see Fig. 2: 14 Jul. 98,6 Nov. 98, 22 Jan. 99) the tube systern is rinsed 
with the following procedure: rinse with 20 rnl acetone, 20 ml heptane, 20 ml acetone, 100 rnl 
deionized water, dry the tube systern with nitrogen for half an hour. This leads to an irnprovernent 
of the i ' 8 ~ ~ ~ ~  yield. 
, - 
41.1 % 4- 10.1 % 42.8 % 4- 5.7 % 8 
01.01.97 02.03.97 01.05.97 30.06.97 29.08.97 28.10.97 27.12.97 25.02.98 26.04.98 25.08.98 24.08.98 23.10.98 22.12.98 20.02.99 21.04.99 
time 
Fig. 2. ?*F]FDG yield over two and a haif years (not corrected for decay) 
[I] E&. IBA and K.U. Lewen (1998) IBA PET CYCLONE USERS, second workshop, Leuven, 
Beigiurn, Dec 10- 11. 
[2] Westera G. (1997), Universitätshospital Ziirich, Nukiearmedizin, private communicalion. 
57. lmprovements at the Rossendotf PET Cyclotron "CYCLONE 1819" 
St. Preusche, H. Roß 
Remote control for the azimuthal movement systems of the H- and D- ion sources 
lntroduction 
The Rossendorf CYCLONE 1819 is one of the first cyclotrons of the IBA CYCLONE 1819 series. In our 
version the dees with their stems are fixed to the upper part of the yoke. Ion source adjustments have 
to be carried out after each opening and closing of the yoke, both for radial and azimuthal directions. 
This is a disadvantage for the effective riunning of the cyclotron and for radiation protection. To 
overcome it we equipped the azimuthal movement systems of both ion sources with remote-controlled 
electric drives. Now the azimuthal positions of the ion sources can be optimized under real ion beam 
conditions. 
Technical solution and resuits 
Two 24 V DC motors including gear units were added to the transmission spindles of the azirnuthal 
movement systems of both ion sources (see Fig. 1). The 24 V power supply unit and the control 
buttons are placed close to the COntrol terminal of the cyclotron in the control room. 
The combination of radial and azimuthal movement of the ion sources causes their optimum 
positioning to the puller electrodes of the dees and thus maximizes the ion kam. After each opening 
and closing of the yoke the radial positions of the two ion sources are manually adjusted to the last 
operational positions with an accuracy of less than 0.3 mm. These radial positions are the resuk of our 
experience of operating of the CYCLONE 1819. 
We observed that during their lifetime the original sharp shapes of the slits of the ion sources and the 
puller electrodes are more and more burned out. These wear effects lead to losses in the ion beam. 
With our remote control for the azimuthal movement systems of both ion sources it is possible to 
adjust the azimuthal positions, if necessary, during particle acceleration to get maximum ion beam 
from the ion sources and at least on the targets. 
- 
Fig 1. Radial (I) and azirnuthal(2) movement Fig 2. Hydrauk cyclinder unit of the RF 
systems of the H and D- ion sources (patt of rough and fine tuning system (part of IBA 
IBA drawing 05.09.00.001) The arrow indi- drawing 05.09.26.000) The arrow i n d i -  
cates the position of the motor. tes the psition ssf ihe motor. 
Remote control for the RF rough tuning system 
lntroduction 
RF resonant tuning is by capacitive tuning. A pulse discriminator circuitry sends a signal which 
activates a DC rnotor on the cavity tuning drive mechanism. This mechanisrn consists of a tandern 
pair of small hydraulic cylinders, one for the rough and one for the fine tuning . 
We observed that the fine tuning system always moves to the lower limit switch under the influence of 
ternperature effects during Iong-time irradiation. To prevent RF instabilities when reaching the switch 
(reflected power inreases and the RF system shuts down), we equipped the rough tuning system with 
remote control to correct its position in a small range as a compensation of the fine tuning rnovement 
during the irradiation process. 
Technical solution and results 
The srnall hydraulic cylinder of the rough tuning systern was replaced by a 24 V DC motor including a 
gear unit and a transmission spindle (see Fig. 2). We used the Same 24 V power supply as used for 
the azirnuthal movement of the ion sources. 
The tuning plate inside the cyclotron only rnoves in one direction under the influence of temperature 
effects. These observed effects are indicated by the rnovement of the fine tuning system to the lower 
lirnit switch. For optimum resonance conditions we positioned the rough tuning systern so that the fine 
tuning system has nearly the full range of operation, starting from the cold cyclotron. When we reach 
the lower lirnit switch during long-time irradiation (the RF system is out of resonance and shuts down 
after a certain time) we can cornpensate the movement of the fine tuning system by remote-controlled 
moving of the rough tuning system in a srnall range. The RF system goes back to the resonant rnode 
and the irradiation can go ahead. 
Conclusion 
Both the remote control for the azimuthal movement Systems of the H and D- ion sources and the RF 
rough tuning system have improved the handling and reliability of our CYCLONE 1819. Ion source 
adjustments have been sirnplified and RF kining has becorne more stable in long-time irradiation. 
58. Operation of the Rossendorf PET Cyclotron "CYCLONE 1819" in 199811999 
St. Preusche, J. Steinbach 
lntroduction 
A detailed description of the Rossendorf PET cyclotron "CYCLONE 1819 facility and the 500 m long 
Radionuclide Transport System between the cyclotron and the radiochemicaVradiopharmaceutica1 
laboratories was given in [I] - [5]. Since we received the licence for routine operation in autumn 19?36, 
the cyclotron has worked in its predicted way with high reliability. 
Routine operation 
Our standard radionuclides in routine operation are v 8 F I ~ ,  [ 1 8 ~ ] ~ 2  and "C, which makes a few 
radiotracers and radiopharmaceuticals available. 
The Rossendorf PET Center uses the satellite concept and supplies clinics in Dresden, Gera, Jena, 
Suhl, Erfurt, Leipzig, Berlin and Bautzen (max. distance: 200 km) through Mallinckrodt Medical GmbH 
with the radiopharmaceutical [ 1 8 ~ ] ~ ~ ~ .  Do to this fact the need for f8FIFDG has grown remarkably (s. 
Figs. 1 and 2). 
The cyclotron runs 2 to 4 hours per day (Tuesdays to Fridays). Monday is the so-called service day 
both for the cyclotron and radiopharmacy. Table 1 gives an ove~iew of the 199811999 radionuclide 
production (01 January 1998 to 30 June1999) and typical irradiation condiions. The radionuclides ' 3 ~  
and 1 5 0  were produced to optimize the irradiation and extraction conditions and the 500 m on-line gas 
transport. 
Table 1. Radionuclide production in l998Il999 (01 January 1998 to 30 June1999) 
*)including pre-irradiations 
Fig. 1 shows the number of irradiations and Fig. 2 ihe total amount of activcity praduced in 1998 in 
comparison with 1997. 
Fig.1. Number of irradiations of radionuciides produced 
Fig. 2. Total amount of activity produced 
Investigations and improvements at the cyclotron 
- Remote control for the azimuthal movement systems of the H and D ion sources 
The azimuthal movement systems of the H- and D- ion sources were equipped with remote-controlled 
electric drives to optimize their azimuthal positions under real ion beam conditions in terms of 
maximum ion beam on the targets [6,8]. 
- Remofe control for the RF rough tuning system 
The RF rough tuning system was equipped with remote control to correct its position in a small range 
during long-time irradiation in terms of stabilization the RF tuning process [6, 81. 
- lnvestigations of tube material for effective transport of irradiated liquids 
Investigations were carried out to find the most suitable material for transport of the irradiated [ ' 8 ~ ] ~  
water target from the cyclotron to the pneumatic rabbit (cyclotron site, 25 m) and from the pneumatic 
rabbit to the f8F ]F~G module (radiochemistry site, 50 m). Tubes of silicone, polyethylene, teflon, 
PEEK and polypropylene were tested in terms of minimum activity losses during transport and their 
influence on a stable ['*F]FDG synthesis. Polypropylene tubes proved to be the most suitable ones 
[7,81. 
Maintenance and service 
In view of our many years of experience in operation and maintenance of accelerators in Rossendorf, 
no maintenance contract was concluded with BA. The CYCLONE 1819 staff are responsible for all 
maintenance work and Service of the cyclotron. 
Maintenance at the Open cyclotron and of the vacuum system is carried out annually in the first week 
of January and during two or three days in summer to: 
- rebuild and clean the ion sources 
- repiace parts of the acceleration system 
- check all parts inside the vacuum chamber 
- check the forevacuum and the oil diiusion pumps 
Several checks of the cyclotron subsystems are carried out on Mondays. 
Destroyed stripper foils were the main reason for venting and opening the cyclotron until the middle of 
1998. A new IBA stripper version with a higher area density and Ionger lifetime has been in use since 
then. Cyclotron openings as a result of destroyed strippers were reduced. 
The strippers are mostly replaced in the late afternoon. Until the first irradiation in the following 
moming there is enough time for pumping the vacuum chamber down. 
Unplanned turn-off periods: 
1998: no turn-offs 
1 999: March: four days 
- troubleshooting in the vacuum system to find a very small leak between the 
lower Part of the vacuum chamber and the yoke 
- compensated by additional irradiations on Mondays 
June/July: thirteen days 
- PLC communication processor destroyed by heavy storrn 
- intervention On site necessary by IBA and Siemens 
- test and repair of the PLC system at IBA site 
Once a year the CYCLONE 1819 facility is checked by the TÜV Sachsen organization (TÜV = 
Association for Technical Inspection) for § 76 of the German Radiation Protection Order. Until now 
there have been no objections to further operation of the cyclotron. 
Maintenance and service of the so-called peripheric facilities (ventilation, climatization facilities, etc.) is 
carried out by the ABB service firm. 
Radiation protection 
- Emission of radionuclides with the exhaust air 
Exhaust air monitoring for radionuclides is carried out by a Berthold exhaust air emission 
measurement facility both for the CYCLONE 18/9 and the U-120 cyclotron, which is still used for 
various application purposes except PET. The annual limits for the emission of radionuclides have 
been confirmed by our authority. Investigations of the emission of radionuclides by both cyclotrons 
showed that the emission resulting from the CYCLONE 1819 cyclotron is negligible. Table 2 gives an 
overview of the emission of radionuclides with the exhaust air and can be taken as an indication of the 
safe operation of the CYCLONE 1819 cyclotron. 
Table 2: Emission of radionuclides with the exhaust air resulting from 
operation of the CYCLONE 18/9 and U-120 cyclotrons 
1 01 January to 1 01 January to I 
I annual Iimit I I I 
4 1 ~ r  [Bua] 
"F [Bua] 
- E%posure to radiation of the cyclotron staff 
The cyclotron staff belong to the categoty A of occupational exposed persons. The everage exposure 
to radiation was 2.9 mSv in 1998, which is less than 6 % of the annual Iimit. In addition to the annual 
medical check-ups, there are quarterly measurementc of incorporation with the whole body Counter. 
Miscellaneous 
31 December 1998 
6.7E09 
4.8E09 
Since its foundation in 1996 on the initiative of out institut, the woridwide CYCLONE 18/9 & 1015 
USER COMMUNITY has worked as a forum of the CYCLONE 1819 and CYCLONE 1015 Users, 
exchanging experience of operation and maintenance of these types of IßA cyclotrons and the 
corresponding chemistry modules [2]. It is also very helpful in case of problems and failures to discuss 
methods and ways of troubleshooting. The second workshop of our user community took p i a ~  in 
Leuven, Belgium, in December 1998 [B]. 
30 June 1-$9!3 
1.6E09 
1.1 E09 71.4E10 3.4E09 
C [Bqla] 
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59. Sources of Radiation Exposure during FDG-PET Studies 
H. Linemann', E. Will, B. Beuthien-Baurnann', A. Wittrnüß', H. Schröder', H. Kutzner', 
A. Hauptmann2 
'TU Dresden, VKTA Rossendorf 
The airn of this study was to identify the main sources of radiation doses to the medical personnel 
during PET studies so as to rninirnize the radiation exposure in routine scanning. The tasks to be 
undertaken under radiation exposure in preparing and perforrning a PET study are syringe 
preparation, injection, blood sampling (only for quantitative studies) and handling of the patient alter 
injection of the radiopharmaceutical. The acquired radiation dose depends strongly on the work 
organization (distance and time) and on the shielding used. 
The effects on the radiation dose were studied by the various working steps with the shielding used in 
the Rossendorf PET Center. We focused our work on 2 - [ ' 8 F ] f l ~ ~ r ~ - 2 - d e s ~ ~ y - g 1 ~ ~ ~ ~ e  ([18F]FDG) 
studies since this is the most frequently used PET radiopharmaceutical. 
It is known, that radiation exposure during blood sampling is a major factor for the acquired dose per 
study [I]. We therefore designed a special rnovable radiation protection shield. 
In the literature the radiation dose for the PET personnel is indicated either as annual value over all 
studies [2] or as values for a part of the tasks [I, 31. Only limited information is available on hand dose 
values. 
Experimental 
The radiation exposure, personal dose and hand dose of the medical personnel were measured 
during the preparation and performance of [''FIFDG scans with the ECAT EXACT HR' PET camera 
(Siemens - CTI). 
The dosimeters used: 
- dosirneter L6 133 (gamma probe) (Berthold) to measure the radiation emitted by the patient, 
- personal digital dosimeter EDM 150A (Graetz) to obtain the body dose of the personnel. 
- LiF-thermoluminescent dosimeters (Harshaw). We used finger rings to determine the radiation 
dose during injection and detectors of 8 mm diameter were taped to the fingertips of each hand to 
measure the radiation dose during syringe preparation. 
The PET studies included dynamic brain scans with manual blood sarnpling (arteriaiized venous 
blood) as well as heart and whole body scans without blood sampling. The injected activiiies vafled 
between 260 and 370 MBq. 
The radiopharmaceutical 
for the day (max. 7 GBq) 
was transported and 
stored in a lead container 
of 3 cm wall thickness. The 
syringes containing the 
individual patient doses 
were prepared in a lead 
box with a window of 3 cm 
lead equivalent (Fig. 1). 
The syringes were handled 
with a special pair of tongs 
to minimize the radiation 
dose to the hands during 
preparation. During trans- 
port and injection the syr- 
inge was provided with a 
tungsten sytinge shield of 
8 mm wall thickness. 
A movable radiation shield 
(2 cm lead) was decigned - container for radiopharmaceubcal Fif. 2. ffadiabon shield wth hand hat- 
- pair of tongs for synnge preparation ~ng box for M o o d  sawing 
- sflnge shield for injection. 
(Fig. 2)" to protect the technologist from radiation emitted by the patient during manual blood 
sampling. It can be placed between the patient and the technologist on both sides of the bed. Another 
advantage is the possibility of mounting on this device a hand heating box for pseudo arterial blood 
sampling. 
ResuRs and Discussion 
Table 1 shows the results of the personal dose and hand dose measurements using protection 
devices. 
Table 1. Results of the personal dose and hand dose measurements 
Task Number of 













The detailed finger dose distribution values for the syringe preparation without and with using a pair of 
tongs are shown in Tables 2 and 3. The hand dose for the syringe preparation shown in Table 1 was 
derived from the mean of the highest finger dose values measured with the LiF dosimeters taped to 
the fingerüps (Table 3). 
Table 2. Highest finger doses for syringe preparation (manipulation without tongs, 1 technologist) 




The measurement of radiation exposure lateral to the unshielded patient thorax directly after injection 
of 340 MBq showed dose rates of 60 ySv1h and 20 pSvh for distances of 30 cm and 80 cm. 
W i i  the movable radiation shield placed betvveen the patient and the technologist, the radiation 
exposure of the technologist was reduced to 20% in comparison with the unshielded situation. 
To estimate the radiation risk, we have to compare the measured dose for one year with the dose 
limits for exposed personnel faccording to class A this means 50 mSv for the personal dose, 500 mSv 
for ihe hand dose). We acsume a frequency of 13 PET studiedweek and 52 working weekdyear. 




W i i  the above-mentioned number of studies per year and the measured values from Table 1, a 
personal äose of about 10 mSv1a will be obtained for a technoiogist performing ail tasks. This personal 
dose depends mainfy on #e time of close contact with the patients during b b d  sampling and patient 
handling. 
Carefui pianning of äIe PET procedure is required to avoid unnececsary radiatiin expsure. 
Highest finger doselsyringe preparation] 
r [ mSv1 I 
0.85 2.80 
Hand dose: 
The hand dose is mainly accumulated during syringe preparation. The use of a pair of tongs (left hand) 
reduced this dose to about 40% (Tables 2 and 3). For all these efforts the maximum permissible hand 
dose per year will be reached after preparation of 500 syringes. In PET facilities with a high patient 
throughput an automatic or remote-controlled filling device should therefor be used. 
Table 3. Highest finger doses for syringe preparation (manipulation with tongs, 3 technologists) 
Measurement 
Nr. 




Number of syringe 
preparations 
[ I ]  McCormick V. and Miklos J. (1 993) Radiation dose to positron emission tomography technologists 
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Highest finger dose/syringe preparation 
r [msvl I 
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COOPERATIVE RELATIONS AND JOINT PROJECTS 
In multidisciplinary research such as carried out by this Institute, collaboration, the sharing of 
advanced equipment and, above all, exchanges of ideas and information play an important role. 
Effective collaboration has been established with colleagues at universities, in research centres and 
hospitals. 
Dresden University of Technology has been a major partner in our cooperative relations. Cooperation 
with various groups in the Department of Chemistry and the Faculty of Medicine was again 
significantly extended last year. Common objects of radiopharmacological and medical research link 
the Institute with the Dresden University Hospital, above all with its Department of Nuclear Medicine 
(Prof. Franke). A joint team of staff members from both the Institute and the Clinic of Nuclear Medicine 
are currently working at the Rossendorf PET Centre. 
The lnstitute cooperates with the Department of Surgical Research (Prof. Schackert) on a project 
concerning gene therapy monitoring. The lnstitute of Analytical Chemistry (Prof. Salzer) plays not only 
an important Part in tracer research by performing analytical characterization (Dr. Scheller) but also 
cooperates in tumour research. 
Very effective cooperation exists with the Federal Material Research lnstitute in Berfin (Dr. Reck, Mr. 
Leibnitz), whose staff members carried out X-ray crystal structure analysis of new technetium and 
rhenium complexes. The lnstitute of Organic Chemistry (Dr. Seichter) of the Freiberg University of 
Mining & Technology also contributes to analysing coordination compounds. 
Our Institute is linked with the Institute of Pathology (Prof. Zwiener, Dr. Bauer) of Jena's Friedrich- 
Schiller University by long-standing fruitful cooperation on the pathophysiologiciil aspects of brain 
functions. 
In the field of PET tracers (steroid chemistry) the lnstitute works together with the Hans-Knöll- Institute 
for Natural Products Research, Jena (Prof. Hinnen, Dr. Kasch). 
The fruitful collaboration with the Paul Scherrer lnstifute (Prof. Schubiger) of Villigen, Switzeriand, 
which involves bioinorganic, radiochemical and biological topics, is much appreciated. PSI is also one 
of the main partners in the current BIOMED2 project on tumour-affine neuropeptides. 
Our long-standing cooperation with the "Demokritos" National Research Centre for Physical Sciences 
in Athens (Dr. Chiotellis) has been continued. Various joint projects on technetium and rhenium 
chemistry were dealt with. 
A field of cooperation with the Department of Pharmacy (Prof. Folkers, Prof. Wunderli-Ailenspach) of 
the Swiss Federal lnstitute of Technology Zurich (ETH Zürich) was the chemical and biological 
characterization of technetium and rhenium complexes. 
Based on PhD student and post doc visits, joint research into labelled steroids was carried out with the 
Departrnent of Chemistry (Prof. Katzenellenbogen) of the University of Illinois, Urbana. USA, and öle 
Division of Radiological Sciences (Prof. Welch) of the Washington UnivePsity Cchool of MAdicne, St. 
Louis, USA. 
Cooperation on a special subject concerning bioinorganic chemistry is in Progress with ASTA jkfedica 
Frankfurt (Prof. Kutscher, Dr. Bernd). 
In the field of supramolecular chemistry, successful cooperation was established with the Institute of 
Organic Chemistry and Biochemistry (Prof. Schmidtchen) of Technische Universität München and wiöl 
the Kekule Institute of Organic Chemistry and Biochemistry (Prof. Vögüe) of the UnNersiiy of bm. 
The identification of common objects in PET radiophamacy has led to coliaborative research wrth the 
Department of Nuclear Medicine (Prof. Georgi) of öle University of Leipzg. 
Effective cooperation also exists with the Riga Institute of Organic Chemistfy (Dr. Zablotskaya), Labia. 
Cooperation in PET tracer chemistry has been established with the Turku Medical PET Centre (Dr. 
Solin). 
The lnstitute works with the Bar-llan Universify in Ramat-Gan, Israel (Dr. G. Yadid), with the West 
Virginia University Morgantown, USA (Prof. H. Kuwabara), the PET Centre Aarhus, Denmark (Prof. A. 
Gjedde), the Birla Institute of Technology and Science, Pilani, lndia (Dr. P. Srinivas) on the 
biochemical aspects of radiotracer research. 
During a PhD student's visit, joint research on the serotonin transporter was carried out in cooperation 
with the Department of Biochemistry and Molecular Biology (Prof. Ganapathy, Prof. Leibach) of the 
Medical College of Georgia, Augusta, USA. 
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PSI Villingen, Switzerland 
September 22 - 25,1998 
S. Seifert 
ESRF Grenoble, France 
January 26 - February 3,1999 
J.-U. Künstler 
ESRF Grenoble, France 
January 26 - February 3,1999 
H. Spies 
Institut0 Tecnologico e NucIear Lissabon/Savavem, Portugat 
February 25 - 28,1999 
H.-J. Pietscch 
Karoiinska Institute Stcrckholm, Sweden 
May29-June 1,1999 
H. Spies 
Latvian Institute of Organic Synthesis, Riga, Latvia 
June 10 - 15,1999 
GUESTS 
Dr. A. Zablotskaya 
Latvian lnstitute of Organic Synthesis, Riga, Latvia 
May 3 - 24,1998 
M. Netter 
Universität Wien, Austria 
July 1 - October 31,1998 
Prof. Dr. H. Kuwabara 
West Virginia University, USA 
July 2 - September 25,1998 
J. Zaers 
Krebsforschungszentrurn Heidelberg 
August 14 - 17,1998 
0. Ublitz 
Krebsforschungszentrum Heidelberg 
August 14 - 17,1998 
Prof. Srivastava 
University Brookhaven, USA 
August 27 - 29,1998 
Dr. G. Byk 
Bar Ilan-University, Israel 
October 13 - 21,1998 
Prof. A. Nudelman 
Bar Ilan-University, Israel 
October 13 - 16,1998 
Dr. Knickrneier 
Universität Münster 
October 15 -1 7,1998 
Dr. Bauer 
Universität Jena 
November 9 - 13,1998 
B. Walther 
Universität Jena 
November 9 - 13,1998 
EI Sajed 
Universität Jena 
November 9 - 13,1998 
I. Benkovsky 
Slovak Institute of Metrology Bratislava, Slovak Republic 
January 14 - February 14,1999 
A. Alberti Rarnirez 
Centro de Isotopes, La Habana, Cuba 
April 1 - May 31,1999 
Dr. A. Zablotskaya 
Latvian Institute of Organic Synthesis, Riga, Latvia 
April 6 - May 7, 1999 
L. Patrico 
Institut0 Tecnologico e Nuclear Lissabon, Portugal 
May 1 - 4,1999 
I. Cantos 
Institut0 Tecnologico e Nuclear Lissabon, Portugal 
May 1 - 4,1999 
Prof. M. Mintas 
ETH Zurich 
June 4 - 6,1999 
Prof. Dr. C. Streffer 
Universität Essen 
June 11 -12,1999 
K. Chavatte 
University Brussels, Belgium 
June 20 - July 1,1999 
M. Vekeman 
University Brussels, Belgiurn 
June 20 - July 1,1999 
MEETINGS ORGANIZED 
PET Centre Workshop ,Die Anwendung der kinetischen Modellanalyse im klinischen PET (am 
Beispiel Hirn und Tumoren)" 
Dresden, February 18,1998. 
First meeting of the partners of the EU project: "Development of novel peptide based 
radiopharmaceuticals for in vivo receptor associated tumour diagnosis and therapy" 
Rossendorf, June 19,1998 
Gerrnan-Portuguese Workshop on Aspects of Radiotracer Research 
Rossendorf, May 3 - 4,1999 
OTHER ACTlVlTlES 
Chairman: Johannsen, B. 
(see also homepage http:\\w\ivw.nuklearmedizin.de) 
ActFtiües for the IAEA: 
Agency Research Agreemtne No. 8959 (CNS receptor irnaging agents) 
Johannsen, B. 
Two.rnonths fellowship training of Aiberti Ramirez, A., Cuba 
fsupervisor: Spies, H.) 
One-month fellowship training of Benkovksy, I, Siovak Republic 
(supervisor: Steinbach, J.) 
Consuttation on setup of PET centres in Prague and Bratislava 
Meeting with Dr. Vera Ruiz, Head of lndustrial Applications and Chemistry Section, to discuss the 
impkmentaüon of PET reference centres. 
Visits of scientists in the frame of network of fAEA from Pakistan Nuclear Research Centre and 
Peking Institute of Nuctear Research. 
V. SEMINARS 
TALKS OF VISITORS 
Prof. Dr. W. Jaroß und Dr. S. Gehrisch, Institut für Klinische Chemie und Laboratoriumsmedizin, 
Universitäts-Klinikum Carl Gustav Carus, Dresden 
Genetische Grundlagen von Herz-Kreislauf-Erkrankungen und Methoden der DNA- und RNA-Analytik. 
23.01. 1998. 
Prof. Dr. G. Folkers, Dept. Pharmazie, Eidgenössische Technische Hochschule Zürich 
Integrierte Ansätze zur rationalen Entwicklung von Gentherapeutika auf der Basis Nukleosid- 
prozessierender Proteine. 
24.04.1998. 
Dr. M. Glaser, Hammersmith Hospital London 
Neue bifunktionelle Chelatbildner für Technetium und Rhenium. 
28.04.1998. 
Dr. 0. Solin, National PET-Centre Turku, Finnland 
Fluorine-18 radiochemistry at the Turku PET Centre. 
30.04.1998. 
Prof. T. Kuwert, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen 
Stoiiwechseluntersuchungen an Hirntumoren. 
12.05. 1998. 
Prof. H. Kuwabara, West Virginia University, USA 
Clinical applications of F-DOPA-PET. 
27.07. 1998. 
Prof. C. Srivastava, Brookhaven National Laboratory, USA 
Research and production of medical radionuclides at Brookhaven National Laboratory. 
28.08. 1998. 
Prof. Vögtle, Universität Bonn 
Energie- und Elektronentransfer in Übergangsmetallen, Komplexchemie und Homocaiiiarenen und 
dendritische Diagnostika. 
18.09.1998. 
Prof. 0. Schober und Dr. M. Knickmeier, Westf. Wilhelms-Universität Münster 
Sympathische lnnetvation des Herzmuskels 
- Klinische Fragestellung und In-vivo-Darstellung 
- Radiochemie der Transmitter und Rezeptoren. 
16. 10. 1998. 
Dr. G. Byk, Bar-llan-Universität Israel 
Novel cationic lipids for gene delivety and gene therapy. 
19. 10. 1998. 
Herr Erler, Universitätsklinikum Dresden 
Einführung in die Versuchstie~ucht. 
28. 10.1998. 
Prof. M. Schwaiger, Nuklearmedizinische Klinik der TU München 
PET in der kardiologischen Forschung. 
20.1 1.1998. 
Prof. F. P. Schmidtchen, Technische Universiiät München 
Die Guanidine: Vielseitige Bausteine für Kataiysatoren und abiotische Wirte. 
23.11.1998. 
~ r o f .  T. Jones, Hammersmith Hospital London 
Einführung in PET - Prinzipien, Anwendungen, Probleme, Zukunft (Zentrumsseminar). 
04.02.1999. 
Prof. M. Schwaiger, Nuklearmedizinische Klinik der TU München 
PET: Körperfunktionen auf dem Bildschirm (Zentrumsseminar). 
18.02.1999. 
Dr. J. Steinbach, FZR 
Radiopharmazie am PET-Zentrum Rossendorf (Zentrumsseminar). 
04.03.1999. 
Prof. G. Vollmer, TU Dresden, Institut für Zoologie 
Horrnonabhängige Kanzerogenese des Endometriums - zur Bedeutung von Hormonen und 
Komponenten der extrazellulären Matrix. 
08.04.1999. 
Dr. V. Otto, Universitätsspital Zürich 
Das schwere Schädel-Hirn-Trauma in der Klinik und im Forschungslabor. 
07.05.1999. 
Prof. M. Mintas, Eidgenössische Hochschule Zürich 
Novel pyflmidines and pyrimidine derivatives of L-ascorbic acid: synthesis and biological evaluation. 
04.06.1999. 
Prof. Dr. Dr. h,c. Streffer, Universitätsklinikum Essen 
Hypoxie und Tumorstoffwechsel und ihr Einfluss auf die Strahlentherapie. 
1 1.06.1999. 
K. Chavatte und M. Vekeman, Freie Universität Brüssel 
-The bioevaiuation of radiolabelled neurotensin analogues 
-Synthesis and the pre-clinical evaluation of 2-I-tyrosine. 
21.06.1999. 
INTERNAL SEMINARS 1998J99 
U. Dintner (Hans-Knöll-Institut Jena) 
Synthese von 16a-Fluor-androst-5-en-3ß,l7ßdiol. 
14.05.98. 
H. Stephan 
Supramolekulare Rezeptoren zur Anionenerkennung, 
27-05-98. 
M. Reisgys 
Thioetherchelate, erfolgversprechende Kombination von TdRe und Biomolekiil. 
17.06.98. 
B. Beuthien-Baumann 
Stand der PET bei der Diagnostik von Mediastinal- und Lungen-Tumoren. 
07.07.98. 
M. Scheunemann 
Neue Rheniumkomplexe mit Affinität zu Serotonin- HTIA- und HT2A-ReZept~ren. 
19.08.98. 
M. Kretzschmar 
Die Autoradiographie - eine Methode zum Nachweis der Rezeptor- bzw. Transporter-Ligand-Bindung 
im Hirn und peripheren Gewebe verschiedener Tierspezies. 
16.09.98. 
J. Zessin 
"C-~ernmarkierung von aromatischen Heterocyclen. 
28.1 0.98. 
H. Spies, J. Kropp 
Vorstellung des Gemeinschafisprojekts Tc-Fettsäuren. 
13.1 1.98. 
R. üerger 
Bestimmung von Lipophilie- und pk-er ten für TdRe-Komplexe mit RP-HPLC. 
02.12.98. 
R. Jankowsky 
Strukturuntersuchungen an Peptid-Komplexen von Tc und Re. 
09.1 2.98. 
W. Seidel (Abt. FWKF) 
Freie Elektronen-Laserstrahlung: Prinzip und mögliche Anwendungen. 
17.03.99. 
H. Linemann 
Graphische Lösungen für das Kompartment-Model bei dynamischen PET-tfntersuchungen. 
7.04.99. 
T. Knieß 
Bifunktionelle Chelatagenzien im pre-Labelling von Biomolekülen mit ""'TC. 
10.06.99. 
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